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Abstract 
Various DNA viruses, including pox- and herpesviruses, express proteins which downregulate 
host MHC class I antigen expression as an immune evasion strategy. Previous studies into 
whether ASFV modulates expression of the porcine MHC class I molecule, SLA-I, have not 
provided a clear answer. In this thesis, the effect of African swine fever virus (ASFV) and the 
roles of two proteins, EP153R and CD2v, were investigated in the transcription, protein synthesis 
and expression of SLA-I at the surface of ASFV-infected cells. The expression and localisation of 
EP153R were also investigated. 
CD2v has previously been shown to bind mABp1, an actin binding adaptor protein implicated in 
vesicular transport. Higher expression of surface SLA-I was observed in macrophages infected 
with virulent isolates of ASFV than in cells infected with their ΔCD2v deletion mutants. Through 
binding to mABp1, CD2v may indirectly affect transport and cell surface expression of SLA-I. 
The C-type lectin domain of EP153R shows similarities to that of Clec2B, the ligand of NK cell 
activating receptor NKp80. Previous studies have suggested that EP153R inhibits up-regulation 
of SLA-I expression in response to stimulation with cytokines. Results presented here confirmed 
a reduction in up-regulation of surface SLA-I in porcine kidney cells stimulated with both 
PMA/ion and IFN-γ when transfected with EP153R from virulent ASFV isolate Benin 97/1, but 
not ASFV Georgia 2007/1. Localisation and processing studies revealed different patterns of 
EP153R expression in ASFV-infected and uninfected cells. In uninfected cells, the expressed 
protein localises to the ER with no surface expression detected. In ASFV-infected cells, both 
fully modified and deglycosylated forms of the expressed protein are smaller, and it is detected 
throughout the cytoplasm and at the cell surface. EP153R is probably processed by a virus-
encoded/induced enzyme and localisation and processing of the protein may be important for its 
function(s) during virus infection.   
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Chapter 1 
1 Introduction 78 
1.1. African swine fever 
1.1.1. History and geographical distribution  
African swine fever virus is the etiological agent of African swine fever, a haemorrhagic 
fever of swine, originating in east Africa and first described by Montgomery in 1921. Since 
its initial discovery and description, the disease has been shown to be endemic across east and 
west Africa. However, from the middle of the 20th century, outbreaks began to be reported 
from Europe, and later on from South America and the Caribbean. While most outbreaks 
have been eradicated, the disease remains endemic in Sardinia. Of particular current concern 
to authorities and pig farmers across Europe, however, is an outbreak which began in Georgia 
in 2007 and is continuing to spread north and west across the Caucasus region and into 
Europe, with outbreaks having been reported in Lithuania in January 2014, Poland in 
February 2014, Latvia in June 2014 and Estonia in September 2014 (Costard et al., 2013; 
OIE, 2014) (figure 1.1). The most virulent isolates of ASFV cause a mortality approaching 
100% within 5-10 days from onset of viremia (Dixon et al., 2008), and this is true of the 
current outbreak of the Georgia 2007/1 isolate (Blome et al., 2013). At present there is no 
effective treatment or vaccine, and the disease is controlled by a policy of quarantine and 
slaughter (Wilkinson, 1989). As such, ASF is economically devastating and a major threat to 
agriculture in the developing world (OIE, 2014) and a serious constraint for pig production 
wherever it occurs (Penrith, 2009).  
20 
 
  
Figure 1.1: Distribution of the current outbreak of ASFV Georgia 2007/1  
Distribution of ASF outbreaks with the current circulating isolate ASFV Georgia 2007/1 in the 
Caucus region and Europe from 1 September 2007 to 30 September 2014, showing resolved 
domestic (blue circles) and wild (green triangle) outbreaks and continuing domestic (red 
circles) and wild (orange triangles) outbreaks. 
(http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/Diseaseoutbreakmaps) 
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1.1.2. Hosts and pathogenesis 
ASFV is maintained in sylvatic cycle between its natural hosts, warthogs (Phacochoerus 
africanus) and bushpigs (Potamochoerus porcus) (Detray, 1963) and soft ticks of the genus 
Ornithodoros which inhabit their burrows. In these wild suids, the virus causes a persistent 
subclinical infection. However, in domestic swine (Sus scrofa domesticus) and wild boar (Sus 
scrofa), it causes disease ranging from chronic through to peracute (Wardley et al., 1983; 
Blome et al., 2013). Typical clinical signs of ASFV include pyrexia, loss of appetite, bloody 
diarrhoea and cyanosis of the ears, snout, lower limbs, rump and belly (Wardley et al., 1983; 
Wilkinson, 1989).   
Virus spread occurs either by direct contact with infected animals, or through the ticks that 
inhabit the burrows of wild suids. However, the virus is also resistant to changes in pH and 
high temperature (Plowright & Parker, 1967), and persists in the meat of infected animals or 
outside the host on fomites. While the majority of virus transmission occurs through direct 
contact, the spread of ASFV from Africa to other parts of the world is attributed to feeding 
contaminated waste food to pigs (Wilkinson, 1989). 
The virus is found throughout the tissues, lymph nodes, organs, bone marrow and blood of 
infected suid hosts, although, since viral particles are transported by blood, the virus found in 
many tissues may be a reflection of their blood content. However, virus titre is particularly 
high in the liver and in bone marrow, which serve as sites of viral replication and production 
(Plowright et al., 1968). Within these tissues, the virus replicates in cells of the mononuclear 
phagocyte system, and predominantly in macrophages and monocytes (Heuschele, 1967; 
Wardley & Wilkinson, 1978; Mebus, 1987; Pérez et al., 1994; Carrasco et al., 1996; Ramiro-
Ibáñez et al., 1997; Childerstone et al., 1998). The level of replication in macrophages seems 
to be a critical factor in ASFV virulence (Tulman & Rock, 2001). However, in later stages of 
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infection, other cell types such as hepatocytes, endothelial cells, neutrophils and epithelial 
cells can also be infected (Fernandez et al., 1992).  
1.1.3. Classification 
African swine fever virus is the only known DNA arbovirus and a member of the nucleo-
cytoplasmic large DNA virus super-family, along with Poxviridae, Iridoviridae, 
Phycodnaviridae, Mimiviridae and other giant virus families (Dixon et al., 2005; Iyer et al., 
2006). Formerly classified with the Iridoviridae based on its capsid morphology, ASFV was 
reclassified in 2001 (Salas, 1999; Dixon et al., 2000; Fauquet & Mayo, 2001) and is now the 
only known member of the family Asfarviridae in the genus Asfivirus, which occupies a 
separate clade between the Poxviridae and Iridoviridae (Raoult et al., 2004). 
1.1.4. Morphology  
The ASFV virion is approximately 200 nm in diameter, icosahedral in symmetry with a 
regular structure by electron microscopy (figure 1.2 and figure 1.3) and is composed of more 
than 50 polypeptides (Breese & DeBoer, 1967; Wardley et al., 1983; Carrascosa et al., 1984; 
Tulman et al., 2009). The viral particle consists of four concentric layers; an inner central 
nucleoid, a core shell, an inner membrane and an outer icosahedral capsid (figure 1.3 and 
figure 1.4-A) (Wardley et al., 1983; Carrascosa et al., 1984; Andres et al., 1997). 
Extracellular virus particles also acquire an external envelope on budding from the cell 
membrane (figure 1.3 and figure 1.4-B)(Breese & DeBoer, 1966).  
The icosahedral structure is formed of capsid protein p72 (also known as p73), which 
comprises around a third of the total protein mass of the viral particle. Structural proteins 
p150, p37, p34, and p14 comprise a further 25% (Andres et al., 1997). The structural 
organisation of the capsid has been estimated to comprise approximately 2000 capsomers 
organized into 12 pentamers and with the remainder as hexamers. The capsid structure 
23 
 
  
Figure 1.2: African swine fever virus morphology 1. 
African swine fever virus particles as they were first visualised by electron microscopy, 
showing complete (arrows) and incomplete virions in Epon embedded thin sections. 
Scale bar = 1 µm (after Breese & DeBoer, 1967). 
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Figure 1.3: African swine fever virus morphology 2. 
Graphic representation of the morphology of the ASFV virion, showing the genomic DNA within 
the nucleoid, the matrix shell, inner membrane (envelope), outer capsid and outer envelope. The 
virus particle is spherical to pleomorphic in shape and 175-215 nm in diameter. The viral capsid 
exhibits icosahedral symmetry (T=189-217), corresponding to 1892-2172 capsomers (Carrascosa et 
al., 1984). Image reproduced with permission from ViralZone, Swiss Institute of Bioinformatics. 
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Figure 1.4: African swine fever virus morphology 3.  
Electron micrographs of (A) an intracellular full ASFV particle and (B) an extracellular 
mature ASF virion. The different structural domains are indicated. Outer envelope (oe), 
capsid (ca), inner envelope (ie), core shell (cs) and nucleoid (nu). Scale bar = 50 nm. 
(C) The localization of different ASFV structural proteins inside ASFV as deduced 
from immunoelectron microscopy data and/or from EM studies with inducible ASFV 
recombinants (adapted from  Salas & Andrés, 2013). 
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requires approximately 12,000 structural protein subunits to construct a closed lattice (figure 
1.3) (Carrascosa et al., 1984).  
The inner envelope of the virion particle has been shown to derive from the ER of the 
infected cell by a mechanism not fully understood, but believed to result from the collapse of 
ER cisternae during the course of ASFV infection (Andres et al., 1998; Netherton & 
Wileman, 2013). Internal to the inner envelope is a core shell of approximately 30 nm which 
encloses the nucleoid. The core shell is comprised of proteins p150, p37, p34 and p14, which 
are derived from polyprotein pp220, and proteins p35 and p15 which are derived from 
polyprotein pp62 (figure 1.4-C) (Salas & Andrés, 2013). This characteristic of deriving 
structural proteins from polyproteins is not usually associated with DNA virus, but instead 
with positive-strand RNA viruses and retroviruses (Andres et al., 1997). The virion nucleoid 
is an electron dense structure of approximately 80 nm, which contains the viral genome and 
nucleoproteins. It also contains multi-subunit RNA polymerase, poly A polymerase, capping 
enzymes and early transcription factors which form the transcription machinery required for 
the early stage of the virus replication cycle (Salas, 1999). Other enzymes and factors 
packaged in the nucleoid are also thought to be required for initiating infection. 
1.1.5. Infection cycle 
The ASFV replication cycle is represented in figure 1.5, and the following sections describe 
the process in detail. 
1.1.5.1. Virus entry 
From early studies including electron microscopy to more recent publications, ASFV has 
been observed to enter both macrophages and tissue-culture cell lines such as Vero via 
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Figure 1.5: ASFV replication cycle. 
The ASFV virus particle enters the cell by (1) clathrin-mediated endocytosis or (2) 
macropinocytosis  and (3) enters the endosomal-lysosomal system. (4) It then exits through 
fusion of the viral envelope with the vesicle membrane and virus particles are directed to 
perinuclear regions through interaction between structural protein p54 and the dynein motors 
of the microtubule network. Early viral gene transcription begins in partially uncoated cores 
following entry of the core into the cytoplasm, using enzymes and factors packaged into the 
virus core, independently of host RNA polymerase. (5) Replication of viral DNA occurs in the 
cytoplasm, in perinuclear virus factories, although (6) early sub-genomic length fragments are 
produced in the nucleus. (7) New virions are assembled through wrapping of the nucleoprotein 
core by a single lipid bilayer on which the virus capsid is formed. (8) Fully assembled virus 
particles are transported to the cell surface by kinesin motor proteins of microtubules where 
(9) they exit by budding through the plasma membrane (10) and acquire an outer envelope 
(adapted from Lithgow, 2011; Netherton & Wileman, 2013) .  
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receptor-mediated endocytosis in a process dependent on dynamin and clathrin, as well as 
specific conditions of temperature and pH (Valdeira & Geraldes, 1985; Alcamí et al., 1989; 
Alcamí et al., 1990; Hernaez & Alonso, 2010; Alonso et al., 2013). Additionally, ASFV has 
been observed to enter macrophages and Vero cells via macropinocytosis in a transient, 
growth factor-induced, actin-dependent process. Delivery to the autophagosome is avoided 
(Mercer & Helenius, 2009; Basta et al., 2010; Sánchez et al., 2012b; Alonso et al., 2013). 
1.1.5.1. DNA replication 
Once ASFV virus particles have been internalised the inner envelope fuses with endosome 
membranes at an acidic pH and the viral core is released into to the cytoplasm of the host cell 
(Valdeira et al., 1998). Early viral gene transcription begins in partially uncoated cores 
following entry of the core into the cytoplasm, using enzymes and factors packaged into the 
virus core, independently of host RNA polymerase. The viral core is transported to the 
perinuclear region of the infected cell, where virus factories, the primary cytoplasmic sites of 
viral replication, form. This transport occurs via the microtubule network by means of an 
association of core protein p54 with dynein motors (Moura Nunes et al., 1975; Rojo et al., 
1999; Hernaez et al., 2006; Alonso et al., 2013; Netherton & Wileman, 2013). Viral DNA 
replication occurs in two stages, with early DNA replication occurring in the nucleus, where 
small DNA fragments are produced, followed by the majority of genomic replication 
occurring at a late stage in virus factories in the cytoplasm (Caeiro et al., 1990; Garcia-Beato 
et al., 1992; Rojo et al., 1999). The ASFV replication cycle generally follows the model of 
poxviruses in which head-to-head concatameric intermediates are produced in the cytoplasm 
and are resolved into unit length genomes containing terminal cross links (Caeiro et al., 1990; 
Rojo et al., 1999; Boyle & Traktman, 2009). However, the additional nuclear phase of ASFV 
replication is not shared with poxviruses. 
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1.1.5.2. Viral mRNA transcription 
Transcription of viral mRNA is carried out by enzymatic machinery encoded by the virus 
including a DNA-dependent RNA polymerase, giving rise to mature transcripts with capped 
5' ends and poly(A) tails at their 3' termini, similar to those of  eukaryotic mRNAs (Kuznar et 
al., 1980; Salas et al., 1981; Almazán et al., 1992). Twenty ASFV genes are currently 
considered to be involved in transcription and modification of viral mRNA, although the 
function of most of these has been postulated from comparative analysis with similar proteins 
of known function (Rodríguez & Salas, 2013). The temporal nature of transcription is tightly 
controlled both at the level of transcription initiation and mRNA degradation, with ASFV 
genes being classified as early, immediate early, intermediate or late, based on when within 
the viral replication cycle they are transcribed (Salas et al., 1986; Rodríguez et al., 1996). 
Early genes are transcribed shortly after infection and before viral DNA replication begins, 
from 2 to 6 hours post-infection (hpi), although their transcription may continue through to 
the late stage of replication. Immediate early genes are a subclass of early genes which are 
not transcribed beyond the start of viral DNA replication at around 6 hpi. Expression of 
intermediate genes begins from 4 to 6 hpi, when early gene expression is at a maximum, and 
decreases from 8 hpi. Intermediate genes are thought to act as a switch for the start of DNA 
replication, while late genes are those expressed after the initiation of viral DNA replication, 
beginning when intermediate gene expression is at a peak from 8 hpi, reaching a maximum at 
12 to 16 hpi and then gradually decreasing (Salas et al., 1986).  
1.1.5.1. Subversion of host protein translation machinery 
In order to ensure synthesis of viral proteins essential to replication, ASFV takes control of 
host protein synthesis machinery by affecting both the activity of translational initiation 
factors and their localisation within an infected cell (Sánchez et al., 2012a), with an 
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associated and progressive reduction in host protein synthesis affecting 65% of cellular 
proteins. This culminates in a 92% shut-down of cellular synthesis of affected host proteins 
by 14 hpi in porcine alveolar macrophages, and up to 77% by 16 hpi in Vero cells (Tabarés et 
al., 1980; Rodríguez et al., 2001).  
Eukaryotic initiation factors (eIFs) such as eIF2 are involved in initiating translation through 
recruitment of ribosomes to mRNA. Phosphorylation of the eIF2α subunit inhibits eIF2 
activity and this acts as a key control point to regulate global protein synthesis. ASFV-
encoded protein DP71L contains a protein phosphatase 1 (PP1) binding site motif, and has 
been shown to interact with PP1, causing dephosphorylation of eIF2α (Rivera  et al., 2007; 
Zhang et al., 2010). Levels of phosphorylated eIF2α decrease early in ASFV infection and 
remain undetectable throughout the course of infection, ensuring that synthesis of ASFV 
proteins continues uninterrupted (Sánchez et al., 2012a). Interruption of host protein 
synthesis is advantageous both in terms of limiting the energy and resources of the cellular 
protein synthesis machinery to proteins essential for the replication of ASFV, and also to 
prevent the expression of host proteins involved in immune evasion of ASFV infection. This 
is achieved through the relocalisation of eIFs, ribosomes and mitochondria to the sites of viral 
replication in an area adjacent to, but not overlapping with, the site of viral assembly as 
determined by the presence of structural protein p72 (Rojo et al., 1998; Castelló et al., 2009).  
Despite the subversion of host protein synthesis, Rodriguez, et al. (2001), using high-
resolution two-dimensional gel electrophoresis, identified 16 proteins expressed in porcine 
alveolar macrophages and 48 proteins in Vero cells which were up-regulated on infection 
with ASFV.  
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1.1.5.2. Host organelle rearrangement 
Closely associated with the subversion of host protein synthesis machinery is the 
rearrangement of host cell organelles during infection with ASFV. The relocation of 
ribosomes and mitochondria to sites of virus replication was discussed in the preceding 
section. However, these are not the only organelles to be affected. ASFV is closely associated 
with the microtubule network during all stages of its infection cycle, an association most 
strikingly demonstrated in the location of virus factories at the microtubule organising centre 
(MTOC), with a surrounding vimentin cage in tissue culture cells (Netherton & Wileman, 
2013).  
The nucleolus and nuclear envelope break down early in Vero cells infected with tissue-
culture adapted isolate ASFV BA71V, with some nuclear membrane components 
redistributed to the cytoplasm. Additionally, host RNA polymerase II is inactivated, which 
has implications for viral control of host cell components essential for cellular transcription 
and replication (Ballester et al., 2011).  
Proteins encoded by ASFV multigene family 110 with KDEL ER retention motifs are 
predicted to cause redistribution of ER resident proteins, which may in turn lead to the 
relocation of ER membranes to the virus factories in preparation for their role in virus 
envelopment (Netherton et al., 2004). In addition to the ER, the Golgi and the trans-Golgi 
network are also disrupted by infection with ASFV (McCrossan et al., 2001; Netherton et al., 
2006). The disruption of these components has implications for the secretion of host proteins 
from infected cells, including pro-inflammatory cytokines, as well as transport to the cell 
surface of major histocompatibility complex (MHC) class I molecules loaded with viral 
peptides for presentation to cytotoxic T-lymphocytes. Netherton et al. (2006) confirmed that 
infection with ASFV BA71V slowed delivery of experimental marker vesicular stomatitis 
32 
 
virus G-protein to the surface of Vero cells, or caused an accumulation within the cytoplasm, 
suggesting that the vesicular transport system is disrupted in ASFV-infected cells. However, 
while transport may be slowed, disruption is not complete as transport of MHC class II 
(Gonzalez-Juarrero et al., 1992a; Lithgow et al., 2014), cell surface markers CD45, CD203a 
and CD163 (Lithgow et al., 2014) and MHC class I (Gonzalez-Juarrero et al., 1992a; Vallée 
et al., 2001; Netherton et al., 2006; Hurtado et al., 2011) to the cell surface has been shown to 
continue throughout ASFV infection. 
1.1.5.3. Morphogenesis 
Assembly of ASFV virions occurs in the virus factories, beginning with the formation of 
precursor single lipid bilayer structures derived from cisternae of the ER modified by 
mechanisms as yet unknown (Andres et al., 1998; Hawes et al., 2008; Salas & Andrés, 2013). 
The capsid is progressively assembled on the convex face of viral membranes in regular 
layers of virus protein p72, arranged in a hexagonal pattern that develops into polyhedral 
forms with virus protein B438L required to form vertices of the capsid and virus protein 
B602L acting as a chaperone (Cobbold & Wileman, 1998; Epifano et al., 2006). The core 
shell is formed at the same time as the capsid, underneath the concave face of the viral 
membrane. This core shell is formed from the myristoylated proteolytic products of 
polyproteins pp220 and pp62, with the myristoyl moiety acting as a membrane-anchoring 
signal to bind the developing core shell to the inner viral envelope (Andrés et al., 2002). The 
formation of the nucleoid is the final stage of virion morphogenesis, and involves the 
condensation of viral nuclear material, and packaging at a single vertex into the assembled 
empty virion particles (Brookes et al., 1996; Brookes et al., 1998).  
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1.1.5.4. Egress and budding 
Once the virion particles have been assembled they are transported to the plasma membrane 
via the microtubule network, with structural protein EP120R essential for this process. At the 
plasma membrane newly formed virions bud from the surface of infected cells from 
microtubular projection (Andrés et al., 2001; Netherton & Wileman, 2013). In a similar 
manner to vaccinia virus (VACV), ASFV has been shown to stimulate the polymerisation of 
actin at the cell surface. A localised nucleation of actin is induced and the ASFV particles 
then project out at the tip of filopodia-like protrusions, in which actin is arranged in long 
unbranched parallel arrays. These actin structures are likely to be involved in viral release or 
cell-to-cell spread. However, a key difference between these actin projections induced by 
ASFV and by VACV is that the ASFV particles are intracellular, while VACV particles are 
external (Jouvenet et al., 2006). 
1.2. Host immune response to viral infection 
1.2.1. Recognition of pathogens by the innate immune system 
Throughout evolution organisms have evolved mechanisms to respond to infection with 
pathogens such as viruses. In response, viruses have also evolved mechanisms to evade host 
immune systems, including both innate and adaptive immunity, in an ongoing competition 
between virus and host. The innate defence system detects the presence of pathogens within a 
host cell through pathogen-associated molecular patterns (PAMPs); molecular features which 
are unique to pathogens and would not normally be present in a host cell. PAMPs are 
detected by pattern-recognition receptors (PRRs) which, for the most part, are expressed by 
immune cells such as macrophages, neutrophils and dendritic cells. These immune cells in 
turn release cytokines and chemokines to induce an inflammatory response (figure 1.6). PRRs 
stimulated by infection by a dsDNA virus such as ASFV include the Toll-like receptors
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Figure 1.6: Activation of the interferon response triggered by the detection of viral 
pathogen-associated molecular patterns.  
All of the pattern-recognition receptors (PRRs) initiate signalling pathways that converge at the 
activation of the transcription factors interferon (IFN)-regulatory factor 3 (IRF3), IRF7 and/or 
nuclear factor-κB (NFκB); this leads to the expression of IFN-β. IFN-β then initiates an antiviral 
effector programme in the infected cell and neighbouring cells, which involves the expression of 
numerous IFN-stimulated genes (ISGs). Some of the ISGs shown here, such as RIG-I (retinoic-
acid-inducible gene I), MDA5 (melanoma differentiation-associated gene 5), DAI (DNA-
dependent activator of IRFs), some microRNAs and the TRIM (tripartite motif-containing) 
family of proteins, are involved in the amplification and regulation of the interferon response. 
Other ISGs shown here, such as 2′5′-oligoadenylate synthetase (OAS) and ribonuclease L 
(RNaseL), interferon-inducible dsRNA-dependent protein kinase (PKR), myxovirus resistance 
(Mx) protein, adenosine deaminase RNA-specific (ADAR) and apolipoprotein B mRNA-editing 
enzyme, catalytic polypeptide 3 (APOBEC3), are involved in antiviral mechanisms that interfere 
with the life cycle of individual viruses. OAS and PKR are further activated by double-stranded 
RNA (dsRNA). IFNAR1, interferon-α receptor; IPS1; IFNB-promoter stimulator 1; ISG15, 
interferon-stimulated protein of 15 kDa; MD2, myeloid differentiation protein 2; PPP, 5′ 
triphosphate; ssRNA, single-stranded RNA; STAT, signal transducer and activator of 
transcription; TLR, Toll-like receptor (from Bowie & Unterholzner, 2008). 
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(TLRs), which are an evolutionarily ancient host defence system. The TLRs were first 
discovered in Drosophila, and the human and pig genomes encode ten TLRs, each of which 
recognises a different type of PAMP. Between them, TLR receptors are capable of 
recognising PAMPs from Gram-positive and -negative bacteria, fungi and viruses. The 
nucleic-acid-sensing TLR-7, TLR-8 and TLR-9, signal uniquely through MyD88, which 
activates interferon regulatory factors (IRFs) to induce production of anti-viral type I 
interferons (IFNs), IFN-α and IFN-β. Additionally, TLR-3 induces the interferon response 
through a MyD88-independent pathway by recruiting adaptor protein TRIF (Takeda & Akira, 
2005).  
Since the major PAMP of viral infection is viral nucleic acids, which may be structurally 
similar to host nucleic acids, tight control of nucleic acid PAMP recognition is crucial 
(Yoneyama & Fujita, 2010). Viruses with a dsDNA genome such as ASFV are usually 
detected by TLR-3, which recognises dsRNA and TLR-9, which recognises DNA with 
unmethylated CpG motifs such as viral genomic DNA. Both TLR-3 and TLR-9 are expressed 
within endosomes, where host nucleic acids would not be expected to be located (Bowie & 
Unterholzner, 2008; O'Neill & Bowie, 2010; Yamamoto & Takeda, 2010).  
The RIG-I-like receptor (RLR) family have been shown to be activated by both DNA and 
RNA viruses (O'Neill & Bowie, 2010), and while more commonly associated with 
recognition of RNA viruses, dsRNA produced by the transcription of genomic DNA from 
DNA viruses may also be detected by interferon-inducible dsRNA-dependent protein kinase 
(PKR), melanoma differentiation-associated gene 5 (MDA5) and/or the retinoic-acid-
inducible gene I (RIG-I) pathway (Bowie & Unterholzner, 2008; Brennan & Bowie, 2010; 
O'Neill & Bowie, 2010; Yamamoto & Takeda, 2010). Cytosolic DNA sensors have also been 
identified which are activated by viral DNA present in the cytoplasm and thus not detected by 
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TLR-9. One such sensor, DNA-dependent activator of IRFs (DAI) has been shown to interact 
directly with TBK1 and IRF-3, causing activation of IRF-3 (Bowie & Unterholzner, 2008; 
Brennan & Bowie, 2010; O'Neill & Bowie, 2010; Yoneyama & Fujita, 2010). This class of 
PRRs is one of only three, together with RIG-like receptors (which detect RNA viruses) and 
other cytosolic dsDNA sensors such as stimulator of interferon genes (STING), which are 
expressed by non-immune cells (Kawai & Akira, 2010; Abe et al., 2013). 
The signalling pathways activated by the detection of PAMPs by PRRs are outlined in figure 
1.6, but all cumulate in the activation of transcription factors NFκB, IRF3 and/or IRF7, which 
then translocate to the nucleus and induce the transcription of genes for pro-inflammatory 
cytokines such as IFN-β, TNF-α, IL-1β and IL-6 (Brennan & Bowie, 2010; Yamamoto & 
Takeda, 2010; Yoneyama & Fujita, 2010). From the wide range of pro-inflammatory 
cytokines induced by the innate immune system, viral infections in particular induce the 
production of interferons, which are the major cytokines involved in the antiviral response 
mounted by the host immune system (Sadler & Williams, 2008; O'Neill & Bowie, 2010; 
Yoneyama & Fujita, 2010).  
1.2.2. The antiviral response 
The antiviral response, triggered by the secretion of type I interferons, is part of the innate 
immune response to viral infection and is the means by which response to infection can be 
amplified and spread to surrounding uninfected cells. Type I interferons interact with cell 
surface receptors, which results in activation of intracellular signalling via the JAK-STAT 
pathway (figure 1.7). In this pathway Janus kinases JAK1 and TYK2 phosphorylate signal 
transducer activator of transcription (STAT) molecules at specific tyrosine residues. The 
STAT molecules then join with DNA-binding subunit, IRF-9 to form a transcription activator 
known as IFN-stimulated gene factor 3 (ISGF3). ISGF3 translocates to the nucleus, where it  
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Figure 1.7: Type I and II interferon receptor signalling  
Type I and type II interferons bind to receptors at the cell surface. The type I IFN receptor is 
composed of two subunits, IFNAR1 and IFNAR2, which are associated with TYK2 and JAK1, 
respectively. The type II IFN receptor is also composed of two subunits, IFNGR1 and IFNGR2, 
which are associated with JAK1 and JAK2, respectively. Activation of the JAKs that are 
associated with the type I IFN receptor results in tyrosine phosphorylation of STAT2 and STAT1; 
this leads to the formation of the ISGF3 complex, composed of STAT1–STAT2–IRF9. This 
complex translocates to the nucleus and binds IFN-stimulated response elements (ISREs) in DNA 
to initiate gene transcription. Both type I and type II IFNs also induce the formation of STAT1–
STAT1 homodimers that translocate to the nucleus and bind GAS (IFN-gamma-activated site) 
elements that are present in the promoter of certain ISGs, thereby initiating the transcription of 
these genes. The consensus GAS element and ISRE sequences are shown (adapted  from Platanias, 
2005). 
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activates the transcription of hundreds of interferon-stimulated genes (ISGs) encoding 
molecules involved in the inhibition of viral gene expression, regulation of post-
transcriptional events, the degradation of viral nucleic acids, inhibition of post-translational 
modification or catalysis of cytoskeletal remodelling to induce apoptosis (Sadler & Williams, 
2008; Yoneyama & Fujita, 2010; Yan & Chen, 2012). Importantly for long-term immunity 
against viral infection, interferons secreted by immune cells such as macrophages or dendritic 
cells (DCs) also regulate the priming of adaptive immunity, which includes the maturation of 
DCs, activation of natural killer (NK) cells and the differentiation of cytotoxic T lymphocytes 
(Bowie & Unterholzner, 2008; Yoneyama & Fujita, 2010).  
1.2.3. Antigen presentation by the major histocompatibility complex  
Another important mechanism in host evasion of viral infection is the major 
histocompatibility complex (MHC). There are two types of MHC molecule; class I and class 
II, which are expressed at the cell surface and present peptide fragments to either CD8+ or 
CD4+ lymphocytes respectively in mice and humans. Detection of antigenic peptides of “non-
self” origin presented by MHC class I induces the killing of infected cells by CD8+ cytotoxic 
T-lymphocytes (CTLs), while the presentation of antigenic peptides on MHC class II 
molecules to CD4+ helper T-lymphocytes triggers the release of cytokines including IFN-γ to 
mediate the anti-viral response and the recruitment of other lymphoid cells. In pigs, however, 
the distinction between CD8+ and CD4+ lymphocytes is not as clear-cut since it has been 
proposed that the population of classical CD8+ CTLs may be low, with CD8 instead mainly 
expressed on the surface of NK cells, natural killer T-cells, a subset of γδ T-cells and memory 
helper T-cells. Additionally, double-positive CD8+CD4+ T-cells have been identified in swine 
(Yang & Parkhouse, 1997; Zuckermann, 1999; Denyer et al., 2006; Takamatsu et al., 2013).  
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The major histocompatibility complex forms a bridge between innate and adaptive immunity; 
with other members of the innate immune system it plays a vital part of the first line of 
defence against infection. However, like other molecules of both the adaptive and innate 
immune systems such as T-cell, B-cell and NK cell receptors, the MHC is both polygenic and 
polymorphic and recognised by polymorphic receptors on lymphocytes. Within each 
individual, a number of different MHC class I and MHC class II genes encode a unique panel 
of MHC molecules with a range of peptide-binding specificities. In addition, multiple 
variants of each gene exist within the population as a whole (Janeway et al., 2001). Most of 
the variability within MHC molecules is found in the peptide-binding groove of both MHC 
class I and class II, with protein polymorphisms allowing variations in the anchor residues to 
which peptides dock. This enables the binding, and thus presentation, of a wide variety of 
antigenic peptides to T-cells (Neefjes et al., 2011). 
MHC class II molecules are primarily expressed by professional antigen presenting cells 
(APCs) such as macrophages and B-cells, and particularly DCs. The heterodimeric molecule 
is composed of transmembrane α‑ and β‑chains which are assembled with the invariant chain 
(Ii) in the ER. The Ii–MHC class II complex is then transported to a late endosomal 
compartment, named the MHC class II compartment (MIIC). In this compartment, Ii is 
digested, leaving a small residual fragment (class II‑associated Ii peptide (CLIP)) in the 
peptide-binding groove. This maintains the MHC class II molecule in an inactive form. 
Proteins ingested from the lymphatic system by professional APCs enter the endocytic 
pathway, where they are degraded and enter the MIIC for loading onto the MHC class II 
molecule. These peptides are exchanged for the CLIP fragment and the MHC class II 
molecule is then transported to the plasma membrane either via tubules emanating from MIIC 
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or by direct fusion of MIIC to the plasma membrane, where its peptide cargo is presented to 
CD4+ T-cells (Neefjes et al., 2011; van Kasteren et al., 2014). 
The MHC class I complex is composed of a heavy chain transmembrane protein with three 
immunoglobulin-like extracellular domains, α1, α2 and α3, which are non-covalently bound 
to soluble protein β2-microglobulin. The peptide binding groove is formed by the α1 and α2 
domains, while the α3 domain contains the binding site for the CD8+ T cell receptor (Hulpke 
& Tampé, 2013) (figure 1.8). Cytoplasmic protein products are degraded by the 26S 
proteasome into peptide fragments of 8-10 amino acid, which is the size required for the 
transporter associated with antigen presentation (TAP) to then transport them into the lumen 
of the ER (Sijts & Kloetzel, 2011). Within the lumen, peptides may be further trimmed at 
their N termini by the ER aminopeptidase associated with antigen presentation, and then 
loaded onto the MHC class I molecule. Peptide loading is mediated by tapasin, calreticulin 
and ERp57, which maintain the MHC class I molecule in a stable conformation until peptide 
loading is achieved. Once loaded, the MHC class I/peptide complex becomes stable without 
chaperone proteins, is released from the ER and moves through the Golgi to the cell surface 
via the vesicular transport system. The MHC class I complex with loaded peptide remains 
stable at the cell surface for 4 to 18 hours, dependent on cell type (Vossen et al., 2002; 
Petersen et al., 2003; Hansen & Bouvier, 2009). At the cell surface, peptides presented by the 
MHC class I molecule are recognised by receptors on CTLs as either “self” or “non-self” 
proteins. If the peptides are recognised as “non-self”, the CTL will respond by transferring 
cytolytic granules containing enzymes to destroy the infected cell (figure 1.9).  For the most 
part, cytosolic proteins processed and subsequently presented as peptides by MHC class I are 
defective ribosomal products (DRiPs), incorrectly processed or folded polypeptides which are 
rapidly delivered to the 26S/20S proteasome complex. The advantage of these newly-
processed polypeptides being rapidly fed into the MHC class I antigen processing pathway is  
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Figure 1.8: MHC class I complex. 
The MHC class I complex, showing heavy chain α1 and α2 domains 
forming the peptide loading groove (loaded with antigenic peptide), the 
α3 domain with T-cell binding site and light chain β2-microglobulin. 
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Figure 1.9: The presentation of intracellular antigenic peptides by MHC class I 
molecules.  
Cytosolic proteins are degraded by the proteasome and the resulting peptides translocated 
via transporter associated with antigen presentation (TAP) into the endoplasmic reticulum 
(ER) lumen and loaded onto MHC class I molecules. Peptide–MHC class I complexes are 
released from the ER and transported via the Golgi to the plasma membrane for antigen 
presentation to CD8+ T-cells. β2m = β2-microglobulin; ERAD = ER-associated protein 
degradation; TCR = T cell receptor (after Neefjes et al., 2011). 
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that any viral peptides will be similarly processed soon after protein translation, which leads 
to the early detection of viral infection (Hulpke & Tampé, 2013). The up-regulation of the 
MHC class I presentation pathway of APCs by IFN-γ is one of the antiviral responses 
described in Chapter 1.2.1 which are induced upon viral infection. Upon IFN-γ stimulation, 
the multiple subunit 20S proteasome, which is the catalytic constitutive core of the 26S 
proteasome, is replaced by the subunits β1i/LMP2, β2i/MECL-1 and β5i/LMP7 to form the 
immunoproteasome (Pamer & Cresswell, 1998; Sijts & Kloetzel, 2011). Two of these three 
subunits, LMP2 and LMP7, are encoded next to the TAP subunits, suggesting that the 
proteasome, which was initially thought to only play a role in cellular housekeeping by 
degrading non-functional or unnecessary proteins, has evolved to have functions closely 
linked to antigen presentation (Pamer & Cresswell, 1998; Früh & Yang, 1999). Early 
investigations concluded that the role of the immunoproteasome was to tailor peptide 
production to MHC class I specificity (Früh & Yang, 1999). However, current theory is that 
the immunoproteasome simply processes the proteins targeted to it more efficiently and 
quickly than the 20S proteasome (Neefjes et al., 2011; Sijts & Kloetzel, 2011). Since the 
supply of peptides to MHC class I molecules is the rate-limiting step in the antigen 
presentation pathway, a more rapid production of peptides allowed by the 
immunoproteasome means a faster delivery of antigenic peptides to the surface of infected 
cells to induce a response from CTLs (Neefjes et al., 2011).  
1.2.3.1. T-cell response to MHC class I antigen presentation 
MHC class I molecules are present on the surface of all nucleated cells and present peptides 
to CTLs. The peptides being presented are recognised by polymorphic receptors on the 
surface of CTLs and the MHC class I molecules themselves are recognised by CD8 co-
receptors. The pairing of CD8 co-receptors to MHC class I and CD4 co-receptors to MHC 
class II ensures the correct T-cell response to antigen presentation. As a CTL encounters an 
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infected cell presenting viral antigens on its surface which match its MHC class I binding 
groove, the CTL will be triggered to release perforin from secretory vesicles by local 
exocytosis at the point of contact with the target cell. However, given the broad 
polymorphism of MHC class I and the range of peptides which they are capable of binding, 
this response will have a very narrow focus and not be capable of efficiently clearing the site 
of infection of infected cells. To trigger a more effective response at the site of infection, 
when pathogen-derived peptides are presented to naïve CD8+ CTLs by infected cells, the 
CTLs become activated and start proliferating. In around 4 days, antigen-specific CD8+ CTLs 
will migrate to the site of infection, recognise the antigenic peptides presented by infected 
cells and mount an attack on infected cells in the area. At the same time, the inflammatory 
response induces the production of IFN-γ, which in turn induces immunoproteasomes within 
infected cells to increase the generation of antigenic peptides for presentation on their surface 
within the infected area. This process greatly enhances the potential for clearing the infection 
(Alberts et al., 2002). 
1.2.3.2. Porcine swine leukocyte antigen I 
Named after the white blood cells on which they were first discovered, MHC class I 
molecules in humans are termed human leukocyte antigen (HLA). The genes for HLA are 
located on chromosome 6, and the classical MHC class I genes are formed of three loci 
encoding gene products designated HLA-A, HLA-B and HLA-C (Fagoaga, 2007). Similarly, 
swine MHC molecules are designated swine leukocyte antigen (SLA). The MHC complex is 
one of the most gene-dense regions of the genome of most mammalian species, and the SLA 
complex, located on chromosome 7 of the swine genome, is no exception. However, in 
swine, the SLA complex spans the centromere, which is a characteristic not yet observed in 
any other mammals. It is also the smallest MHC complex seen among mammals. The swine 
SLA complex codes for seven classical MHC class I genes, although of these, only SLA-1, 
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SLA-2 and SLA-3 are constitutively expressed while the others are pseudogenes. SLA-1, 
SLA-2 and SLA-3 share a greater degree of homology to each other than do the genes of the 
HLA class I complex; the eight exons of the classical SLA-I genes share a high degree of 
similarity in their coding regions between different genes. This reduced diversity in the SLA 
complex is further reflected in the number of alleles encoded by the SLA-I complex. While 
over 2000  HLA-A, -B and -C alleles have been identified, only 116 have been discovered for 
SLA-1, SLA-2 and SLA-3, combining into just 28 haplotypes (Lunney et al., 2009). 
The swine immune system displays other differences to those of other mammals. While, as 
expected, SLA class II is expressed on B-cells and macrophages, there is also preferential 
expression of SLA class II on CD8+ T-cells, as well as the existence of CD4+CD8+ T-cell 
subsets. Additionally, swine endothelial cells express SLA-I, and also up-regulate expression 
of SLA class II in response to IFN-γ. SLA-I is found on both differentiated and 
undifferentiated bone marrow cells of monocyte origin, but these express low levels of SLA 
class II (Lunney et al., 2009).  
1.2.4. Viral modulation of MHC class I antigen presentation 
Viruses have evolved various mechanisms to downregulate presentation of viral peptides by 
MHC class I molecules in order to avoid infected cells being detected by CTLs. However, 
expression of MHC class I on the cell surface inhibits NK cell activation, which means that 
viruses must use a two-pronged strategy to avoid detection by the immune system; first 
preventing presentation of viral peptides by MHC class I, and also preventing NK cells from 
being activated by a lack of MHC class I molecules at the cell surface (“missing self”). 
Dictated by the size of viral genomes and replication via a more error-prone RNA polymerase 
compared to DNA polymerase, viruses have evolved two evasion strategies; escape of 
immune detection by mutation of the viral genome and interference with MHC class I antigen 
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presentation and NK cell killing by specific mechanisms. The first strategy, escape by 
mutation, is frequently employed by RNA viruses which have higher mutation rates and 
limited coding capacity for immune evasion proteins. Mutations in amino acid sequences 
flanking peptide epitopes which would be presented on MHC class I molecules prevent 
processing of the epitope by the proteasome, and mutations within epitopes will prevent their 
recognition by CTLs when presented by MHC class I molecules (Früh et al., 1997; Oldstone, 
1997).  
The second strategy is generally used by DNA viruses with large genomes, although there are 
exceptions such as the Nef and Vpu gene products HIV-1 (Schwartz et al., 1996; Kerkau et 
al., 1997; Vossen et al., 2002), and involves encoding specific immunomodulatory proteins 
which interfere with the MHC class I antigen presentation pathway (Früh et al., 1997; Alcamí 
& Koszinowski, 2000). This viral modulation of MHC class I antigen presentation may occur 
at any number of points on the pathway from interference with peptide processing by the 
proteasome to recycling of MHC class I molecules from the cell surface and targeting them 
for degradation within lysosomes (figure 1.10). Epstein-Barr virus (EBV) protein EBNA-1, 
which is the only viral protein expressed during the latent stage of infection, contains repeats 
which have been shown to prevent antigen presentation if fused to other antigens, preventing 
the generation of epitopes by the proteasome. Human cytomegalovirus (HCMV) protein 
UL83 results in phosphorylation of several HCMV proteins, which may prevent these 
proteins from entering the proteasomal degradation pathway (Früh et al., 1997; Alcamí & 
Koszinowski, 2000; Tortorella et al., 2000; Vossen et al., 2002). Herpes simplex virus (HSV) 
protein ICP47, HCMV proteins US6, EBV protein EBNA-1 and cowpox virus (CPXV) 
protein CPXV12 all inhibit transport of viral peptides into the ER via TAP, either through 
direct inhibition of TAP itself or of ATP binding to TAP 
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Figure 1.10: Viral evasion of MHC class I antigen presentation.  
Proteasomal processing inhibitors, such as Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1), 
escape processing by the proteasome. TAP function inhibitors, such as herpes simplex virus (HSV) 
protein ICP47 and human cytomegalovirus (HCMV) protein US6, block peptide and ATP binding, 
respectively. Herpesvirus protein UL49.5 and EBV protein BNLF2a also inhibit TAP-mediated 
peptide transport. Tapasin function inhibitors, such as HCMV protein US3 and adenovirus protein 
E3-19K, inhibit the peptide optimization and recruiting functions of tapasin, respectively. ER 
retainers or retrievers of MHC class I molecules, such as adenovirus protein E3-19K and cowpox 
virus protein 203 (CPXV203) retain MHC class I molecules in the ER. ER-associated degradation 
inducers, such as HCMV proteins US2 and US11 and mouse herpesvirus 68 (MHV68) protein mK3, 
target MHC class I molecules for proteasomal degradation. Sorters, such as murine CMV proteins 
gp48 and HIV-1 protein Nef, divert the trafficking of MHC class I molecules from the Golgi to a 
lysosomal compartment. Finally, the Kaposi’s sarcoma-associated virus (KSHV) proteins kK3 and 
kK5 induce rapid endocytosis of cell surface MHC class I molecules, leading to lysosomal 
degradation (after Hansen & Bouvier, 2009). 
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(Lehner & Cresswell, 1996; Früh et al., 1997; Alcamí & Koszinowski, 2000; Tortorella et al., 
2000; Alzhanova et al., 2009; Hansen & Bouvier, 2009; Wilkinson & Lehner, 2009). Proteins 
U2 and U11 of HCMV and the protein product of murine cytomegalovirus (MCMV) gene 
m06 target MHC class I molecules in the ER for degradation respectively by the proteasome 
or lysosome (Früh et al., 1997; Tortorella et al., 2000; Vossen et al., 2002). Karposi’s 
sarcoma-associated herpesvirus (KSHV) K3 and K5 proteins interfere with the final stages of 
MHC class I expression and remove MHC class I molecules from the surface of the cell 
(Vossen et al., 2002; Petersen et al., 2003).  
Some proteins target a number of points of MHC class I antigen presentation, such as murine 
γ-herpesvirus 68 (MHV-68) protein MK3 which ubiquitinates the cytoplasmic tails of MHC 
class I heavy chain molecules and targets them for destruction by the proteasome, and also 
causes degradation of tapasin and TAP2 (Boname et al., 2004). An alternative strategy 
employed by HCMV is to encode a number of proteins, US2, US3, US6, US11 and UL18, 
which all target different points of the antigen presentation pathway (Tortorella et al., 2000; 
Petersen et al., 2003). Other viral proteins only target particular MHC class I molecules, such 
as HIV-1 protein Nef, which causes the internalisation of HLA-A and -B and sequestration of 
these molecules in the trans-Golgi network, but has a far lesser effect on the expression of 
HLA-C and -E. This means that viral peptide presentation is reduced, but MHC class I 
molecules are still presented on the cell surface, allowing HIV-1-infected cells to escape lysis 
by NK cells (Schwartz et al., 1996; Petersen et al., 2003). Of particular interest is adenovirus 
protein E19, which was the first viral protein to be discovered with an MHC class I inhibitory 
function, and as such has been extensively studied over the intervening 30 years. E19 
displaces β2-microglobulin from the MHC class I complex and causes retention of the heavy 
chain in the ER by means of retention motifs in its cytoplasmic tail, thus inhibiting surface 
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Table 1.1: Summary of previous research into effect of ASFV on host cell SLA-I expression. 
Four in vitro studies are available in the literature in which the effect of ASFV infection on SLA-I 
expression in porcine primary cells or cell culture lines is investigated. The results are highly variable 
with no clear pattern of the effect of ASFV infection on SLA-I expression emerging. This may be due 
to the range of cells and virus isolates used, as well as the time points at which SLA-I expression was 
measured and differences in experimental techniques. The cell type and ASFV isolate used in each 
study, as well as other treatments applied, are listed along with whether there was a subsequent 
increase (up), decrease (down) or no change (unchanged) in SLA-I expression relative to uninfected 
cells. 
Paper Cells ASFV 
isolate 
Other 
treatments 
Surface 
SLA-I 
Total  
SLA-I 
González-Juarrero et al.  
1992b 
Porcine PBMC NH/P68 none down unchanged 
 
 L60 none down unchanged 
 
 DR-II none up unchanged 
Vallée et al. 2001 Porcine aortic 
endothelial cells 
(PAECs) 
Malawi Lil 
20-1 
none unchanged  
 
 Malawi Lil 
20-1 
IFN-α unchanged 
(stimulation 
overcome) 
 
Netherton et al. 2006 Porcine PBMC (cc pigs) 
Malawi Lil 
20-1 
none down up 
 
Porcine PBMC 
(dd pigs) 
Malawi Lil 
20-1 
none up up 
Hurtado et al. 2011 Raw BA71V 
ΔEP153R 
no 
reinsertion 
of EP153R 
up up 
 
Raw BA71V 
ΔEP153R 
EP153R 
transfected 
back in  
unchanged  
 
EP153R-
transfected 
IPAM 
EP153R 
gene from 
BA71V 
none down  
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expression of MHC class I (Burgert & Kvist, 1985; Burgert et al., 1987; Cox et al., 1991; 
Bennett et al., 1999). This method of MHC class I inhibition is also employed by HCMV 
protein US3 (Misaghi et al., 2004). 
1.2.5.  MHC class I modulation by ASFV 
The effect of ASFV on MHC class I antigen presentation has been investigated previously, 
but these investigations have not been comprehensive and the results have been neither 
conclusive nor congruent, as demonstrated in table 1.1. Early in vivo studies of spleen tissue 
from pigs infected with virulent isolate ASFV Lisbon 60 (L60) and moderately virulent 
isolate ASFV Dominican Republic 1978 (DR-II) found that in conjunction with an overall 
decrease in the number of macrophages in this tissue, there was also an overall decrease in 
staining for SLA-I in the red pulp of spleens from animals infected with ASFV L60 and 
DR-II at 3 days post-infection (dpi) (Gonzalez-Juarrero et al., 1992a). Within our own 
laboratory, recent confocal microscopy of tissue sections from spleens of animals infected 
with current outbreak isolate ASFV Georgia 2007/1 revealed an increase in SLA-I levels in 
the red pulp of infected spleen at earlier times post-infection, but that this decreased to levels 
below those seen in uninfected tissue at 3 dpi (L. Goatley (TPI), unpublished data). 
González-Juarrero et al. (1992a) observed a pronounced decrease in SLA-I expression in the 
red pulp from animals infected with ASFV L60 at 4 dpi. On examination of tissue at higher 
magnification, they observed that among cells expressing ASFV antigen, SLA-I expression in 
some matched that of uninfected cells, while in others, either very little or no SLA-I 
expression could be detected. However, in the spleen of pigs infected with ASFV DR-II they 
observed an increase in SLA-I expression from 4 dpi to above the levels of uninfected 
animals (Gonzalez-Juarrero et al., 1992a).   
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In an in vitro study in the same year, cultured porcine peripheral blood mononuclear cells 
(PBMC) were infected with ASFV L60, DR-II or naturally attenuated non-haemadsorbing 
isolate NH/P68. In cells infected with ASFV L60 and NH/P68 at an infection rate of >90%, 
surface expression of SLA-I as determined by flow cytometry was seen to decrease at 8 and 
12 hpi relative to uninfected cells, but expression increased on the surface of cells infected 
with ASFV DR-II at 8 hpi, subsequently reducing to a similar level to uninfected cells by 12 
hpi. However, an analysis by immunoblotting revealed no significant difference in total 
SLA-I levels in cells infected by these same three ASFV isolates and uninfected cells at any 
time point from 4 to 24 hpi (Gonzalez-Juarrero et al., 1992b). 
Although in pigs ASFV primarily infects monocyte/macrophages, by 6-7 dpi analysis of 
tissues from pigs infected with various virulent isolates of ASFV has revealed infection of 
endothelial cells within the kidney and liver (Gómez-Villamandos et al., 1995; Ramiro-
Ibáñez et al., 1996). In in vitro cell culture, the presence of viral protein VP30 has been 
detected from 4-18 hpi in porcine aortic endothelial cells (PAECs) and bush pig endothelial 
cells (PBECs) infected with virulent isolate ASFV Malawi Lil 20-1, indicating that the virus 
can also replicate within vascular endothelial cells (Vallée et al., 2001). Investigations into 
the effect of infection with ASFV Malawi Lil 20-1 on the expression of SLA-I on the surface 
of PAECs as detected by flow cytometry revealed no difference in levels of expression 
between infected and uninfected cells. However, when PAECs were stimulated with IFN-α, a 
subsequent increase in SLA-I expression was observed in uninfected cells but not in cells first 
stimulated with IFN-α and then infected with ASFV, suggesting that this isolate of ASFV can 
interfere with IFN-α activation of endothelial cells (Vallée et al., 2001). 
Minipigs with specific SLA-I haplotypes have been bred as a tool for investigation into the 
role of the major histocompatibility complex in organ rejection after xenotransplantation. The 
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three minipig strains developed are designated aa, cc and dd (Sachs et al., 1976). Most pigs, 
including dd minipigs, inoculated with attenuated isolate ASFV OURT88/3 are resistant to 
subsequent infection by homologous virulent isolate OURT88/1, and show no increase in 
circulating CD8+ lymphocytes on infection with OURT88/1 (Boinas, 1994; Oura et al., 2005; 
King et al., 2011).  However, cc pigs subjected to the same regimen of infection either 
contracted acute ASFV or developed viremia in addition to an increase in circulating CD8+ 
cells (Oura et al., 2005). In an investigation into the effect of ASFV infection on transport of 
proteins to the cell surface, Netherton et al. (2006) infected PBMC from cc and dd minipigs 
with ASFV Malawi Lil 20-1 and analysed both internal and surface SLA-I expression by 
flow cytometry. The study revealed a moderate 1.15-fold increase in total SLA-I in ASFV-
infected cells from cc minipigs, but an almost three-fold increase in expression in infected 
cells from dd minipigs. Perhaps more importantly, these changes in total expression did not 
correlate with changes in surface expression of SLA-I. Surface expression of SLA-I in 
infected cells from dd minipigs was double that of uninfected cells, but decreased by half in 
infected cells from cc minipigs. Additionally, when analysing surface expression as a 
proportion of total SLA-I expression, there was a decrease in the percentage of total SLA-I 
represented on the surface of cells from both types of pigs when infected with ASFV. In 
terms of actual numbers, the mean fluorescent intensity (MFI) of total SLA-I detected in 
uninfected cells from cc pigs was nearly five times higher than in dd pigs, and twice as high 
in ASFV-infected cells (Netherton et al., 2006). This higher measure of MFI may mean that 
cells from cc pigs express more SLA-I molecules than dd pigs. However, this may be simply 
due to differing levels of efficiency of the anti-SLA-I antibody binding between the two 
SLA-I haplotypes. 
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1.2.6. "Missing self" and NK cell activation 
Natural killer (NK) cells are immune cells which probably developed in response to viral 
evasion of host MHC class I antigen presentation. They express both activating (stimulatory) 
and inhibitory receptors on their surfaces, with dynamic balance between the signalling 
cascades of both types of receptor controlling their activation Activating receptors on NK 
cells bind to ligands on the surface of APCs, and unless the activating signalling cascades are 
countermanded by an inhibitory signal, activation of the NK cell will trigger cytolysis of the 
cell to which the receptors of the NK cell are bound, as well as secretion of pro-inflammatory 
cytokines, including interferons. Inhibitory NK cell receptors bind to MHC class I molecules, 
and so the presence of MHC class I molecules on the surface of cells prevents NK cell 
activation (figure 1.11-A). However, if virus infection causes down-regulation of MHC 
class I molecules on the surface of a cell, no inhibitory signal will be given to NK cells and 
cytolysis of infected cells will result (figure 1.11-B). This is known as the “missing self” 
response, and is the means by which infected host cells with a compromised MHC class I 
antigen presentation pathway may still be targeted for destruction by a lack of “self” peptides 
presented at the cell surface.  
NK cell activation can also be triggered even if expression of MHC class I molecules at the 
surface of infected cells is not be inhibited. Viral infection may induce cells to express co-
activating ligands at their surface which amplify the activating signal and stimulate the 
activation of a bound NK cell despite the expression of MHC class I molecules as an 
inhibitory ligand (figure 1.11-C) (Lanier, 1998; Sawicki et al., 2001; Natarajan et al., 2002; 
Yokoyama & Plougastel, 2003; Jonjic et al., 2008; Topham & Hewitt, 2009; Lakshmikanth et 
al., 2011; Miletić et al., 2013). 
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Figure 1.11: The balance of inhibitory and stimulatory signals received by a natural killer 
cell determines the outcome of interactions with target cells. 
A) Normal target cells are protected from killing by natural killer (NK) cells when signals 
delivered by stimulatory (activating) ligands are balanced by inhibitory signals delivered by 
self MHC class I molecules. B) If, however, a target cell loses expression of self MHC class I 
molecules as a result of infection, then the activating signals delivered by the target cell are 
unopposed, resulting in NK-cell activation and target-cell lysis (known as “missing-self” 
recognition). C) Infection might also induce expression of stimulatory ligands such that 
constitutive inhibition delivered by inhibitory receptors is overcome (known as induced-self 
recognition). In many contexts, it is probable that both missing-self and induced-self 
recognition operate simultaneously to provide NK cells with the maximal ability to 
discriminate between normal cells and transformed or infected target cells (adapted from 
Raulet & Vance, 2006). 
B 
A 
C 
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NK cell receptor proteins fall into two categories: immunoglobulin-like receptors and C-type 
lectin-like receptors, classified on the basis of their extracellular domain (Natarajan et al., 
2002; Miletić et al., 2013). The C-type lectin-like family of NK receptors are homo- or 
heterodimeric type II transmembrane glycoproteins with an extracellular C-type lectin-like 
domain (CTLD) (Weis et al., 1998; Cummings & McEver, 2009; Lakshmikanth et al., 2011). 
This sub-family of C-type lectin proteins, discussed further in Chapter 1.3.3.1, is unique in 
that their CTLDs bind proteins rather than carbohydrates (Sawicki et al., 2001; Zelensky & 
Gready, 2005). 
1.3. ASFV genome 
The size of the ASFV genome varies from around 170 to 193 kbp, depending on the isolate, 
and is composed of an A/T-rich single molecule of linear double-stranded DNA encoding 
between 151 and 167 open reading frames (ORFs) (Yáñez et al., 1995; Chapman et al., 2008; 
Dixon et al., 2013). As represented in figure 1.12, the ORFs are closely spaced along the 
genome and read from both forward and reverse strands, with no apparent bias for coding of 
genes on either strand (Dixon et al., 2013). Both termini of the genome are covalently closed 
by imperfectly-paired hairpin loops in two flip-flop forms that are inverted and 
complementary to each other, flanked by inverted arrays of different tandem repeats 
(González et al., 1986; Dixon et al., 1990). The central region of the genome is highly 
conserved and contains the 110 ORFs present as only a single copy across all isolates. The 
regions of greatest variation are at the left and right ends of the genome, with most variation 
between isolates resulting from insertions or deletion of genes from within six multi gene 
families (MGFs), MGF100, MGF110, MGF300, MGF360, MGF530 and the p22 family, 
which contain the remaining 40-57 ORFs (Chapman et al., 2008). 
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Figure 1.12: Genome map of ASFV.  
Genome map of ASFV isolate Georgia 2007/1, indicating (predicted) gene function or membership of 
MGFs by colour and with arrows indicating the size and direction in which protein-coding regions are 
transcribed. Grey indicates ORFs encoding structural proteins, pink indicates ORFs encoding proteins 
involved in evading the host defences, turquoise, blue, green, brown and mauve indicate members of 
multigene families, ORFs encoding proteins with other predicted functions are shown in yellow and 
ORFs encoding proteins of unknown function are shown in white. Red text indicates ORFs whose 
deletion reduces virus virulence. Genes of particular interest to this thesis, EP153R and EP402R are both 
coloured pink (as predicted immune evasion proteins) and their position highlighted by a red asterisk (*) 
(adapted from Dixon et al., 2013). 
* 
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Table 1.2: Genes encoded by ASFV which have been demonstrated to or are predicted to be involved 
in host immune evasion (adapted from Dixon et al., 2004; Dixon et al., 2013) 
 
ASFV genes involved in modulating host cell function or immune response  Gene name 
Bcl-2 apoptosis inhibitor A179L 
IAP apoptosis inhibitor A224L 
IκB homolog and inhibitor of calcineurin phosphatase A238L 
ERV 1 like. Involved in redox metabolism  B119L 
Geranyl pyrophosphate synthase B318L 
Phosphoprotein binds to ribonucleoprotein-K CP204L 
Nudix hydrolase D250R 
Similar to HSV ICP34.5 neurovirulence factor  DP71L (l14L) 
C-type lectin like. Inhibits apoptosis, modulates MHC class I. EP153R 
CD2 like. Causes haemadsorbtion to infected cells. EP402R 
Ubiquitin conjugating enzyme I215L 
Inhibition of Toll-like receptor 3 I329L 
Suppresses host interferon response MGF 360/530 
Nif S like QP383R 
Serine protein kinase R298L 
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1.3.1. ASFV proteins involved in host cell interactions 
Of the 150 to 167 ORFs encoded by ASFV, many encode proteins which are not essential for 
virus replication in cells, but are important for replication and transmission in vivo, including 
those predicted to interfere with the host’s defence system (Dixon et al., 2004; Tulman et al., 
2009). The functions and mechanisms of the majority of these proteins remains unknown, but 
some ASFV proteins have been identified and characterised which modulate cellular 
processes of the host, including the immune system. Some of these proteins are discussed in 
other sections of this chapter, and all proteins known to be involved in host cell-virus 
interaction are listed in table 1.2. However, a number of proteins of particular interest or 
relevance for this thesis are highlighted here. 
1.3.1.1. Proteins involved in the inhibition of apoptosis 
The triggering of apoptosis in infected cells is a common response to viral infection and can 
limit virus replication. This mechanism of cell death is controlled by a cascade of 
intracellular signalling events culminating in the activation of caspases, which are archetypal 
proteases existing as inactive zymogens. Proteolytic processing activates caspases, which in 
turn cleave various cellular proteins, leading to the induction of apoptosis within the cell 
(Elmore, 2007; Best, 2008; Portugal et al., 2009). 
ASFV infection has been shown to trigger activation of caspase-3 in Vero cells at about 
2 hpi, coincident with internalisation of virus particles into the cytoplasm and uncoating of 
the core, and independent of viral replication and protein synthesis (Carrascosa et al., 2002). 
However, apoptosis, as defined by fragmentation of cellular DNA, membrane blebbing and 
the formation of apoptotic bodies, is not seen in Vero cells or porcine macrophages infected 
with ASFV until 12-16 hpi. From 12-16 hpi, small numbers of cells begin to show signs of 
apoptosis, but these cells remain in the minority until 18-24 hpi by which stage viral 
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replication is complete. Further, caspases were found not to play an essential role in apoptosis 
during ASFV infection (Portugal et al., 2009). This suggests that ASFV exerts a tight control 
over apoptosis of the infected cell until it has time to complete replication, and spread of 
newly formed virions may be enhanced by the destruction of the cell containing them 
(Carrascosa et al., 2002; Portugal et al., 2009).  
Bcl-2 is an integral inner mitochondrial membrane protein which interferes with programmed 
cell death (Vaux et al., 1988; Hockenbery et al., 1990).The ASFV gene A179L expresses a 
homologue of Bcl-2, 5-HL (p21), which has been shown to inhibit apoptotic cell death and 
has been proposed to transiently modulate the survival of infected macrophages to allow viral 
replication to occur (Afonso et al., 1996; Brun et al., 1996; Revilla et al., 1997).  
Inhibitors of apoptosis (IAP) proteins are a family of proteins involved in regulating cell 
death, immunity, inflammation, cell cycle and migration. These were first identified in 
baculovirus genomes and shown to suppress host-induced apoptosis and cell death during 
viral infection (Crook et al., 1993; Birnbaum et al., 1994). ASFV protein A224L is a 
structural protein homologue of IAP, which modulates the proteolytic processing of 
caspase-3 in addition to the activation of NFκB (Chacon et al., 1995; Nogal et al., 2001; 
Rodriguez et al., 2002). 
Protein EP153R is also predicted to inhibit apoptosis, and this is discussed in Chapter 
1.3.3.3.2. 
1.3.1.2. Proteins involved in the evasion of the host immune system 
Since ASFV primarily infects macrophages, which play a key role in activating and 
orchestrating the innate and adaptive immune response of the host, by modulating the 
function of these cells ASFV can influence activation of both branches of the host immune 
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response. Also, since ASFV, like poxviruses, encodes its own RNA polymerase and does not 
require that of the host for gene transcription, it can interfere with transcription of immune 
response genes within the cells it infects without affecting its own replication cycle (Tulman 
& Rock, 2001; Dixon et al., 2004).   
The outcome of cell death versus cell survival depends on a balance of immune stimulatory 
signals through NFκB and apoptotic signals (Rodriguez et al., 2002), which means that the 
viral proteins involved in the regulation of apoptosis and inhibition of host immune response 
need to work in symphony. Expressed from the early stages of infection, ASFV protein 
A238L was first flagged up for study because it contains ankyrin repeats in its central region 
similar to those of IκB, an inhibitor which binds host NFκB transcription factor. It was 
subsequently confirmed that A238L acts as a homologue of IκB and inhibits activation of 
NFκB in response to virus infection (see Chapter 1.2.1) (Powell et al., 1996; Revilla et al., 
1998; Dixon et al., 2004). Like many ASFV proteins, A238L has more than one discovered 
function. Through use of a yeast two-hybrid system to identify host proteins binding to 
A238L, it was discovered that A238L binds to the catalytic subunit of calcineurin, which is a 
serine threonine protein phosphatase. A238L inhibits the phosphatase activity of calcineurin 
and thus inhibits dephosphorylation of substrates of calcineurin, including the nuclear factor 
of activated T-cells (NFAT) transcription factor family, which is present in several cell types. 
This prevents translocation of NFAT to the nucleus and transcriptional activation of genes 
including several cytokines (Miskin et al., 1998; Dixon et al., 2004). Additionally, A238L 
inhibits transcriptional activation of host immunomodulatory genes via various transcription 
factors, including NFκB, by interacting with the N-terminus of transcriptional co-activator 
p300/CBP (Granja et al., 2008). Thus, ASFV is able to suppress both the innate immune 
response early in infection through inhibition of transcription factors NFκB and NFAT, but 
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later in infection, as discussed in the preceding section, expression of A224L inhibits 
apoptosis through the activation of NFκB (Rodriguez et al., 2002). 
The multigene families within the ASFV genome have also been implicated in host immune 
evasion. Multigene families 360 and 530 are necessary for efficient virus replication in 
macrophages, although not in tissue-culture adapted isolates, and infection with virus isolates 
lacking these multigene families induces early cell death in macrophages (Zsak et al., 2001). 
This implies that the genes within these families play a role in cell tropism and cell survival 
in macrophages. These same two multigene families have also been implicated in inhibiting 
the interferon response induced by ASFV infection (Afonso et al., 2004). 
1.3.2. Viral protein CD2v  
1.3.2.1. Host cell adhesion molecule CD2 
CD2 is a glycoprotein expressed on the surface of all peripheral blood T-lymphocytes and 
some NK cells that mediates adhesion between T-lymphocytes and cells expressing the 
ligand of CD2, CD58. This interaction is important in forming and stabilising the interaction 
of the T-cell receptor with MHC complex on APCs. CD2 has been implicated in signal 
transduction resulting in T-cell activation, and also in haemadsorption of erythrocytes to T-
lymphocytes (Sewell et al., 1986; Moingeon et al., 1989). The cytoplasmic domain of CD2 
contains a high proportion of proline residues and has been shown to bind CD58 and play an 
active role in T-cell activation, while the extracellular region shares primary structural 
characteristics with the immunoglobulin superfamily (Sewell et al., 1986; Moingeon et al., 
1989; Rodríguez et al., 1993). The binding of CD2 on the surface of cytotoxic T-lymphocytes 
(CTLs) and CD58 on the surface of antigen-presenting cells has also been shown to facilitate 
recognition by the CTL of foreign antigens presented by MHC class II molecules (Moingeon 
et al., 1989; Koyasu et al., 1990). 
62 
 
1.3.2.2. ASFV-encoded CD2 homologue, CD2v 
CD2v is encoded by the gene EP402R, located centrally on the ASFV genome (figure 1.12), 
and is transcribed late in the ASFV replication cycle. It is a type I transmembrane 
glycoprotein which shares a number of similarities with host CD2. Host CD2 and viral CD2v 
share two predicted immunoglobulin superfamily (IgSF) domains in the extracellular region, 
four conserved cysteine residues which form two intramolecular disulphide bonds and 
conserved aromatic residues (Rodríguez et al., 1993). The EP402R gene expresses a full-
length uncleaved protein of 105 to 110 kDa as well as an N-terminal fragment of 63 kDa 
containing the extracellular domain and a C-terminal fragment of 26 kDa. When CD2v is 
expressed with N- and C-terminal epitope tags, full length and/or the 63 kDa fragment with 
the N-terminal tag is observed at the cell surface, localised to virus factories and co-localises 
with markers for the Golgi. Full length and/or the 26 kDa fragment of CD2v with a 
C-terminal tag is observed to be expressed throughout the cytoplasm and also located in 
membrane vesicles (Goatley & Dixon, 2011). The N-terminal fragment is responsible for 
haemadsorption (see Chapter 1.3.2.3.1) while the C-terminal fragment is predicted to be 
involved in modulating vesicular transport through interaction with host protein mAbp1 (see 
Chapter 1.3.2.3.2) (Kay-Jackson et al., 2004; Goatley & Dixon, 2011). Deletion of the 
EP402R gene from the genome of virulent isolate ASFV Malawi Lil 20-1 did not reduce 
mortality in infected pigs, but caused a delay in the onset of viremia and virus dissemination 
to tissues (Borca et al., 1998). 
1.3.2.3. Functions 
To date, four functions of CD2v have been described: 
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1.3.2.3.1 Haemadsorption  
The formation of “rosettes” of erythrocytes around macrophages infected with ASFV is a 
well-documented characteristic of infection by the virus (Malmquist & Hay, 1960; Quintero 
et al., 1986; Sierra et al., 1991; Rodríguez et al., 1993; Carrasco et al., 1996). CD2v, and in 
particular its N-terminal extracellular region, has been shown to be responsible for this 
haemadsorption, although its ligand has yet to be identified (Rodríguez et al., 1993; Borca et 
al., 1998; Goatley & Dixon, 2011). It is theorised that the haemadsorption of erythrocytes to 
infected macrophages allows the budding of newly-formed virions into pits on the surface of 
erythrocytes, and thus assists in the dissemination of the virus around the body of infected 
animals (Sierra et al., 1991). 
1.3.2.3.2 Binding to mAbp1 
The cytoplasmic tail of CD2v contains proline-rich repeats and this region of CD2v has been 
shown to bind to host protein mammalian actin-binding protein 1 (mAbp1, also known as 
SH3P7 and HIP55) within virus factories in ASFV-infected cells (Kay-Jackson et al., 2004). 
mAbp1 is an adaptor protein associated with actin filaments and plays a role in various 
elements of transport and signalling within host cells involving the cytoskeleton. It localises 
both with Golgi marker β-COP and at the cell surface in structures resembling ruffles or 
lamellipodia (Larbolette et al., 1999; Fucini et al., 2002; Song et al., 2013). mAbp1 plays a 
role in ER-to-Golgi vesicular transport by limiting the interaction between nascent vesicles at 
the Golgi and scission machinery, preventing premature release or translocation of these 
vesicles during protein loading (Larbolette et al., 1999; Fucini et al., 2002; Stamnes, 2002). It 
is also believed to recruit the actin cytoskeleton to the dynamin-restricted neck of clathrin 
coated pits, where actin can apply the force required to detach the clathrin-coated vesicle 
from the plasma membrane (Song et al., 2013). While CD2v localises both with markers for 
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the Golgi and at the cell surface, it has only been shown to localise with mAbp1 in the Golgi, 
and as such, the binding of CD2v to mAbp1 has been postulated to be involved in the 
modulation of protein transport to the surface of ASFV-infected cells (Kay-Jackson et al., 
2004). 
1.3.2.3.3 Inhibition of lymphocyte proliferation 
Infection with both virulent and avirulent strains of ASFV has been shown to cause a 
decrease in proliferation of lymphocytes in vitro (González et al., 1990; Canals et al., 1992; 
Childerstone et al., 1998). On infection of PBMC with a ΔCD2v deletion mutant of ASFV 
Malawi Lil 20-1, the 90-95% reduction in T-lymphocyte proliferation observed in cells 
infected with wild-type ASFV Malawi Lil 20-1 was abrogated, indicating that CD2v plays a 
role in the down-regulation of lymphocyte proliferation in response to mitogens (Borca et al., 
1998). While lymphocytes have been shown not to be infected by ASFV, a reduction in their 
proliferation means fewer B- and T-lymphocytes available to respond to antigen-presenting 
cells signalling their infection. One proposed mechanism for this function of CD2v is that a 
secreted form of CD2v could mimic or compete with host CD2 (Borca et al., 1998). Goatley 
and Dixon (2011) considered that since the N-terminal fragment of CD2v does not contain a 
transmembrane domain, it may be secreted from cells. However, they were unable to detect a 
secreted form of the protein on analysis of supernatants from infected cells (Goatley & 
Dixon, 2011). Alternatively, CD2v could bind CD58 and either sequester it or render it 
inactive on the cell surface, preventing it from interacting with CD2 on the surface of T-
lymphocytes. Either mechanism would prevent the activation of T-lymphocytes through 
binding CD58 (Borca et al., 1998; Childerstone et al., 1998). 
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1.3.2.3.4 CD2v increases virus uptake across tick gut 
Boinas (1994) showed that a non-haemadsorbing isolate of ASFV, NH/P68, did not replicate 
to a high titre in infected ticks, possibly due to inactivation of CD2v or other mutations in the 
genome. This lead Rowlands et al. (2009) to investigate the role of EP153R and the 
extracellular region of CD2v in replication of ASFV within ticks. They used wild-type ASFV 
NH/P68, which has disrupted ORFs EP402R (encoding CD2v) and EP153R, and two 
recombinants in which a modified ORF for CD2v (with intact extracellular domain but 
truncated cytoplasmic domain) or a modified ORF for CD2v plus the entire ORF for EP153R 
were restored (see Chapter 2.3 for further details on ASFV NH/P68 and the recombinants 
used). They showed that the extracellular domain of CD2v enhances virus replication in ticks 
by increasing virus uptake across the gut of the tick vector, Ornithodoros erraticus. The 
mechanism for this is not clear, although as described in Chapter 1.3.3.3.1, CD2v is essential 
for adhesion of ASFV virions to erythrocytes. It has been suggested that these adsorbed 
ASFV virions may be phagocytosed along with erythrocytes into the midgut epithelial cells 
of ticks (Kleiboeker et al., 1999; Rowlands et al., 2009). 
1.3.3. Viral protein EP153R  
1.3.3.1. C-type lectins, including NK cell receptors  
C-type lectins are a group of glycan-binding proteins including collectins, selectins, 
endocytic receptors, and proteoglycans. They have similar carbohydrate-recognition domains 
that bind Ca2+ and mediate specific functions (Drickamer, 1988; Cummings & McEver, 
2009), and also act as effectors in signal transduction pathways (Neilan et al., 1999). A set of 
receptors found on NK and other immune cells forms a family of C-type lectin proteins that 
are evolutionarily divergent, since they have lost critical CTLR residues for carbohydrate 
binding (Zelensky & Gready, 2005). These function as receptors to either activate or inhibit 
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immune responses by binding proteins rather than carbohydrates. In humans, these proteins 
are represented by the NK complex proteins, including CD69 and CD94, and in mice, by the 
Ly49 group of proteins. Both NK complex and Ly49 proteins are disulphide-bonded, type II, 
homodimeric transmembrane proteins with protein-binding CTLDs (Weis et al., 1998; 
Natarajan et al., 2002; Cummings & McEver, 2009). 
1.3.3.2. The ASFV C-type lectin protein, EP153R 
EP153R is a gene centrally located on the ASFV genome, directly downstream from the gene 
for CD2v, EP402R, and codes for a type II transmembrane protein with a C-type lectin 
domain (Yáñez et al., 1995; Neilan et al., 1999; Galindo et al., 2000). The predicted 
unmodified size of EP153R is ∼18ikDa, with experimentally determined sizes of ∼18ikDa 
unmodified and ∼50ikDa glycosylated product using a transcription/translation assay 
(Galindo et al., 2000). The N-terminal region is short and hydrophilic, with a hydrophobic 
transmembrane domain and a hydrophilic extracellular region containing the C-type lectin 
domain. The gene is conserved across all ASFV isolates, although it is disrupted in non-
haemadsorbing isolates NH/P68 and OURT88/3. The level of variability of the sequence of 
EP153R, and the extracellular domain of CD2v, is greater than seen in other well-
characterised non-essential ASFV genes (Neilan et al., 1999; Chapman et al., 2008; 
Chapman et al., 2011) (see Chapter 3.1.1 for further details).  
Reports differ as to whether the gene is expressed only at late, or at early and late stages of 
infection; using Northern blot analysis, Neilan et al. (1999) showed an inhibition of RNA 
transcription of the EP153R ORF in the presence of cytosine arabinoside, indicating 
expression late in the infection cycle. Galindo et al. (2000) used the same method plus 
primer extension analysis to map the 5’ end of the transcript, and found both immediate-early 
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and late-stage transcripts for EP153R. In addition, Galindo et al. (2000) detected expression 
of EP153R by Western blot from 6 to 22 hpi in Vero cells infected with ASFV BA71V.  
Deletion of the EP153R ORF from the genome of virulent isolates has no noticeable effect 
on virulence or replication of the virus, although conservation of the gene across isolates 
suggests an important role for the protein in ASFV infection; possibly within its natural hosts 
rather than domestic swine (Neilan et al., 1999; Galindo et al., 2000).  
1.3.3.3. Functions 
To date, three functions of EP153R have been reported: 
1.3.3.3.1 Haemadsorption  
CD2v has been shown to be required for the haemadsorption of erythrocytes around infected 
macrophages (Rodríguez et al., 1993; Borca et al., 1998). However, a reduction in both the 
number of rosettes and of erythrocytes per rosette has been reported when various cell lines 
were infected with ASFV BA71V ΔEP153R in the presence of erythrocytes, compared to 
cells infected with wild-type BA71V. From these results it was proposed that EP153R may 
act as a stabilising molecule in the interaction between CD2v on the surface of infected cells 
and its ligand in erythrocytes (Galindo et al., 2000). 
1.3.3.3.2 Inhibition of apoptosis 
As discussed in Chapter 1.3.1, the ASFV genome codes for proteins involved in the 
inhibition of host-induced apoptosis of infected cells. EP153R has also been implicated in 
this role, by means of inhibiting the proteolysis of caspase-3 from its 32 kDa precursor to its 
17 kDa active form. Infection of Vero cells with an ASFV BA71V ΔEP153R deletion mutant 
resulted in an approximately 2-fold increase in caspase-3 activity, and a resultant increase in 
cell death of infected cells (Hurtado et al., 2004). 
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1.3.3.3.3 Modulation of MHC class I antigen presentation 
The effect of ASFV infection on expression of the porcine MHC class I homologue, SLA-I, 
is described in Chapter 1.2.5. Hurtado et al. (2011) used flow cytometry to show that 
expression of MHC class I at the surface of IPAM (porcine macrophage-derived cells) or 
Jurkat (human leukaemia T-cell line) cells stably transfected with EP153R and stimulated 
with PMA and ionomycin was significantly lower than in cells which were untransfected or 
transfected with a control plasmid. Through further transfections of IPAM and Jurkat cells 
with EP153R-derived constructs, they also showed that the extracellular region of EP153R 
alone can modulate MHC class I surface expression, and that the Arg133 residue and the five 
C-terminal amino acids of this region are critical to modulation. There are two highly 
conserved Ile-Cys residues four amino acids from the C-terminal end of EP153R, and the 
Arg133 residue is part of an RGD motif, of which only the Arg133 residue is highly conserved 
across isolates (figure 3.2).  
To test whether the down-regulation of MHC class I expression seen in transfected cells was 
also the case in infected cells, Hurtado et al. (2011) went on to transfect Raw (murine 
macrophage) cells with EP153R or a control plasmid and then infect the cells with deletion 
mutant ASFV BA71V ΔEP153R. In infected cells concurrently transfected with EP153R, 
surface SLA-I expression remained at the basal levels of control cells in response to 
infection. In comparison, expression was upregulated in response to infection in cells 
transfected with the control plasmid. Infection of IPAM cells with virulent isolate ASFV E70 
or an E70 ΔEP153R deletion mutant revealed higher levels of surface SLA-I expression in 
cells infected with the deletion mutant. Further, in IPAM cells transfected with EP153R-
specific siRNA and infected with virulent ASFV isolate Uganda 59, an increase in surface 
SLA-I expression was seen over infected cells which were untransfected or transfected with 
a control plasmid. 
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This study by Hurtado et al. (2011) used a variety of methods, cell lines and virus isolates to 
identify that EP153R plays a role in modulation of surface MHC class I expression. They 
also showed that the C-type lectin domain and certain residues within it are critical to this 
function, and proposed that EP153R binds directly to SLA-I based on protein modelling 
(discussed in Chapter 3). However, the stage of the MHC class I presentation pathway which 
is effected, the cellular location of SLA-I modulation, or how EP153R affects this 
modulation beyond binding to SLA-I were not elucidated, giving scope to further research 
into the mechanism of action of EP153R. 
1.4. Aims of the project  
A greater understanding of the mechanisms employed by ASFV in manipulating the host 
immune system, and in particular the virus factors involved, is of crucial importance to the 
development of rationally designed vaccines and anti-virals. Previous work investigating the 
role of ASFV in the modulation of host MHC class I has revealed that there are still a number 
of questions to be answered before the process is fully understood. To this end the objectives 
of this project are:  
1. To expand on the knowledge of the effect of various isolates of ASFV on host MHC 
class I at all stages of expression from translation through to vesicular transport and 
surface expression. 
2. To investigate the role of EP153R in the modulation of MHC class I expression 
through further characterisation of the expression of this protein in ASFV-infected 
and uninfected cells. 
3. To investigate the role of CD2v in the modulation of MHC class I expression. This 
was undertaken due to the predicted role of CD2v in modulating protein transport and 
proposed interaction with EP153R.  
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Chapter 2 
2 Materials and Methods 
2.1. Solutions  
2.1.1. Cell culture media and reagents 
The following media were used for cell culture: 
Vero cell cultures: Dulbecco’s modified Eagle’s medium plus HEPES (DMEM) (The 
Pirbright Institute Central Services Unit (TPI-CSU); Gibco-Life Technologies, USA or 
Sigma-Aldrich, USA), 10% (v/v) foetal calf serum (FCS) (Lonza, Switzerland or Sigma-
Aldrich), 100 standard international (SI) units.ml-1 penicillin, 100 μg.ml-1 streptomycin.  
Max cell cultures: Iscove's Modified Dulbecco's Medium (IMDM) (Gibco), 10% (v/v) FCS 
(Lonza or Sigma-Aldrich), 100 SI units.ml-1 penicillin, 100 μg.ml-1streptomycin. 
Porcine bone marrow derived macrophage (BMDM): Earle’s saline (TPI-CSU or Gibco), 
15% (v/v) porcine serum (Biosera, France), 150 SI units.ml-1 penicillin, 150 μg.ml-1 
streptomycin.   
Peripheral blood mononuclear cells (PBMC) cell cultures: DMEM (TPI-CSU, Gibco or 
Sigma-Aldrich), 30% (v/v) porcine serum (Biosera), 100 SI units.ml-1 penicillin, 100 μg.ml-1 
streptomycin.  
Versene-trypsin (TPI-CSU or Lonza, Switzerland): 136 mM NaCl, 5.3 mM KCl, 5.5 mM 
NaHCO3, 0.02% (w/v) trypsin, 0.01% (w/v) versene (EDTA), 0.1% (w/v) phenol red. 
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Phosphate buffered saline (TPI-CSU, Lonza, Gibco or Sigma-Aldrich): 138 mM NaCl, 2.7 
mM KCl, 1.47 mM KH2PO4, and 9.67 mM Na2HPO4, with or without 6.8 mM CaCl2.2H2O 
0.49 mM MgCl2.6H2O at pH 7.5. 
BMDM wash buffer: PBS (TPI-CSU, Lonza, Gibco or Sigma-Aldrich), 1% (v/v) FCS (Lonza 
or Sigma-Aldrich), 100 SI units.ml-1 penicillin, 100 μg.ml-1streptomycin. 
2.1.2. SDS-PAGE solutions 
The following solutions were used in SDS-PAGE gel electrophoresis and Western blotting.  
12% Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) resolving 
gel: 12% (v/v) acrylamide/bis-acrylamide (ratio 29:1), 300 mM Tris-HCL pH 8.8, 0.1% (w/v) 
SDS, 0.1% (w/v) ammonium persulphate (APS), 0.15% (v/v) tetramethylethylenediamine 
(Temed). 
4% SDS-PAGE stacking gel: 4% (v/v) acrylamide/bis-acrylamide (ratio 29:1), 375 mM Tris-
HCL pH 8.8, 0.1% (w/v) SDS, 0.1% (w/v) APS, 0.15% (v/v) Temed. 
SDS-PAGE running buffer: 25 nM Tris, 190 mM glycine, 0.37% (w/v) SDS. 
Western blot transfer buffer: 50% SDS-PAGE running buffer, 20% (v/v) methanol. 
Western blot wash buffer: 0.2% Tween-20 (v/v) in PBS. 
Western blot blocking buffer: 5% skimmed milk powder (w/v) and 0.2% Tween-20 (v/v) in 
PBS. 
SDS-PAGE lysis/loading buffer (6x): 45% glycerol (v/v), 8% SDS (w/v), 23% β2-
mercaptoethanol (v/v), 23% 1M Tris (pH 6.8) (v/v), 0.001% Bromophenol blue (w/v). 
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Table 2.1: Primary antibodies used for detection of proteins by immunofluorescence (IF), Western blot (WB), flow cytometry (Flow) and 
immunoprecipitation (IP). 
      Dilution (1:x) 
Against Manufacturer Clone/ref Species  Clonality Isotype IF WB Flow IP 
ASFV VP30 (purified) TPI C18 mouse mono IgG1 500 - 1000 - 
ASFV VP30 (TC) TPI C18 mouse mono IgG1 10 - - - 
ASFV VP54/J13L TPI J13L rabbit poly - 1000 - - - 
ASFV VP72 (purified) TPI 4H3 mouse mono IgG2a 500 - - - 
ASFV VP72 (TC) TPI 4H3 mouse mono IgG2a 20 - 20 - 
Bovine isotype control TPI CC39 mouse mono IgG1 5 - - - 
CD203a TPI C4 mouse mono IgG1 4 - - - 
ER TPI PDI mouse mono IgG1 1000 - - - 
ER TPI ERp57 rabbit poly - 200 - - - 
FLAG-tag Cell Signalling Technology 2368 rabbit poly - 800 1000 - - 
FLAG-tag Acris 29E4.G7.H11 mouse mono IgG2a 1000 5000 - - 
Golgi BD Transduction Laboratories GM130 mouse mono IgG1 500 - - - 
Golgi TPI β cop rabbit poly - 200 
 
- - 
HA-tag Roche 3F10 rat mono IgG1 2000 2000 2000 - 
HA-tag Bioss 12CA5 mouse mono Alexa Fluor 488 
conjugation 400 - 400 - 
HLA-A,B,C Biolegend W6/32 mouse mono IgG2a 100 - 100 - 
SLA-I TPI 2.27.3a mouse mono IgG1 2 - 2 - 
SLA-I BioRad AbD Serotec JM1E3 mouse mono IgG1 100 - 100 100 
SLA-I:FITC BioRad AbD Serotec JM1E3 mouse mono FITC 
conjugation 100 - 100 - 
V5-tag BioRad AbD Serotec SV5-Pk1 mouse mono IgG2a 500 1000 - 100-500 
γ-tubulin Sigma GTU-88 mouse mono IgG1 - 10000 - - 
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TritonX-100 lysis buffer (for radiolabelling experiments): 50mM Tris-HCl (pH 7.4), 150 mM 
NaCl, 1% TritonX-100 (v/v), 1% Protease Inhibitor Cocktail (Sigma-Aldrich). 
Coomassie blue stain solution: 0.1% Coomassie Brilliant Blue R-250 (w/v), 50% methanol, 
10% acetic acid. 
Coomassie blue destain solution: 40% methanol, 10% acetic acid. 
2.1.3. Agarose gel electrophoresis solutions 
The following solutions were used for agarose gel electrophoresis: 
TAE (50x): 2 M Tris, 5.7% acetic acid (v/v), 7.5 mM EDTA at pH 7.0. 
Gel loading buffer (10x): 30% glycerol (v/v), 0.25% Orange G (w/v). 
Agarose gel: 1.5% agarose (w/v) in 1x TAE, 0.5 g.ml-1 ethidium bromide. 
2.1.4. Antibodies for Western blot, immunofluorescence, flow cytometry 
and immunoprecipitation 
A list of antibodies used in the experiments described in this thesis, and their dilutions, are 
given in table 2.1. 
2.2. Cell lines 
2.2.1. Tissue culture cells lines 
Vero cells are derived from African green monkey (Circopithecus aethiops) kidney cells 
(European Collection of Cell Cultures reference 84113001) and were maintained in DMEM 
media. Max cells are derived from dd haplotype minipig kidney cells (Pauly et al., 1995) and 
74 
 
were maintained in IMDM. Instituto Biologico Renale Swine-2 (IB-RS2) cells are derived 
from porcine kidney cells (Laude, 1978) and were maintained in DMEM. 
Cells were cultured in T175 cm2 and T75 cm2 flasks to maintain cell lines. For use in 
experiments cells were cultured in 6-, 12-, 24- or 96-well tissue culture microtitre plates 
(Nunc, Denmark) and incubated at 37 °C in the presence of 5% CO2. Cells were passaged in 
a ratio of 1:20 for general cell line maintenance, and in ratios of 1:4 to 1:10 for experimental 
work depending on the level of confluence required. Cells were passaged by removing the 
medium and washing three times in versene-trypsin. The cells were incubated in 5 ml of 
versene-trypsin at 37ºC for 5 min, after which the flask was agitated until the cells detached. 
10 ml of medium was then added to T175 cm2 or 5 ml to T75 cm2 flasks and the cell 
suspension pipetted several times to break up cell clumps. An appropriate amount of the cell 
suspension was then transferred to a new flask with fresh medium and incubated at 37°C. 
2.2.2. Primary porcine cells 
2.2.2.1. Preparation of porcine bone marrow derived macrophages  
Porcine bone marrow derived macrophages (BMDM) were obtained from piglet femur bones 
(outbred large white/landrace cross; 7-10 kg; 4 weeks old, supplied to TPI). Bones were 
stripped of connective tissue and crushed, then agitated at 37˚C for 90 min in BMDM wash 
buffer. Bone fragments were removed by passing the suspension through muslin. The cells 
were pelleted by centrifugation at 400 x g for 5 min and washed once in BMDM wash buffer. 
For growing and titrating new virus stocks, cells were resuspended in Earle’s saline at a 
concentration of 1.6 x 107 cells.ml-1 and cultured for 5 days at 37˚C with 5% CO2. For all 
other experimental work, BMDM were separated from erythrocytes and other contaminants 
as follows in Chapter 2.2.2.2. 
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2.2.2.2. Separation of BMDM  
BMDM cells obtained from piglet femur bones were pelleted by centrifugation at 400 x g for 
5 min. Cells were then resuspended in sterile Ca2+Mg2+ free PBS and overlaid onto an equal 
volume of 1077 Histopaque (Sigma-Aldrich, USA). After centrifugation at 400 x g for 30 
min, buffy coat cells were removed into Ca2+Mg2+ free PBS. Cells were pelleted by 
centrifugation at 350 x g for 3 min, then the supernatant discarded and the cells washed a 
further three times by resuspending the pellet in Ca2+Mg2+ free PBS and centrifuging for 3 
min at 350 x g. Cells were resuspended in Earle’s medium and cultured at 5 x 106 cells.ml-1 in 
appropriate tissue culture microtitre plates for 5 days at 37˚C with 5% CO2. 
2.2.2.3. Preparation of porcine peripheral blood mononuclear cells 
Blood was collected from piglets (outbred large white/landrace cross; 7-10 kg; 4 weeks old, 
supplied to TPI) into 50ml Falcon tubes containing 5% heparin. An equal volume of sterile 
6% (w/v) Dextran (Sigma-Aldrich, USA) in 0.85% (w/v) saline solution (TPI-CSU) was 
added to blood before incubation at 38°C in a water bath for approximately 30 min (until 
sedimentation of erythrocytes). The supernatant was removed and the PBMC pelleted by 
centrifugation at 450 x g for 4 min. Cells were washed twice in Ca2+Mg2+ free PBS, after 
which any remaining erythrocytes were lysed by incubating with 10 ml 1x RBC Lysis Buffer 
(Santa Cruz Biotechnology, USA) on ice for 5 min. The cells were washed a further 3 times 
with Ca2+Mg2+ free PBS before being resuspended in DMEM plus 30% porcine serum, 100 
SI units.ml-1 penicillin and 100 μg.ml-1 streptomycin, and cultured at 5 x 106 cells.ml-1 in 
appropriate tissue culture microtitre plates overnight at 37˚C with 5% CO2. The following 
day, the medium was changed to remove non-adherent cells and the cells cultured for a 
further 4 days at 37˚C with 5% CO2. 
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2.3. Virus genotypes and isolates used 
The isolates of ASFV used in this project are summarised in table 2.2. For three isolates of 
ASFV, deletion mutants were used with either the E402R gene deleted (Benin 97/1 and 
Malawi Lil 20-1) or both E402R and EP153R (BA71V). These deletion mutants were 
prepared as part of previous studies (L. Goatley (TPI), unpublished; Borca et al., 1998; 
Abrams & Dixon, 2012) by standard recombination methods which completely abrogated the 
function of these genes. The recombinants of naturally attenuated field isolate ASFV NH/P68 
were constructed by gene re-insertion and bear further description. NH/P68 is non-
haemadsorbing attenuated field isolate, and has a large deletion of multigene family members 
from MGF360 and MGF530 compared to virulent strains of ASFV. It also contains 
frameshift mutations in the ORFs of EP402R (encoding CD2v) and EP153R. Within the ORF 
of EP153R, a single base pair deletion at position 49 introduces a stop codon in to the coding 
sequence at position 58. This mutation also introduces a second start codon 120 bp 
downstream from the first, coding for a peptide of 113 amino acids. However, this second 
start codon is unlikely to be effectively transcribed as it does not have a characterised 
promoter sequence. The first frameshift mutation in the ORF of EP402R is at position 85, and 
introduces a stop codon 5 bp further downstream for a total ORF length of 90 bp. A further 
two single base pair deletions are located at positions 798 and 963, with the final deletion 
introducing a stop codon at position 976. A second start codon at position 59 would encode a 
peptide of 304 amino acids up to the stop codon introduced by the frameshift mutation at 
position 963, truncated at both the C- and N-terminal ends, and with an altered sequence of 
the 55 amino acids at the C-terminal end (Rowlands et al., 2009). 
While investigating the molecular basis of virulence and haemadsorption in virulent isolates 
of ASFV, Duarte (2000) produced two recombinants of NH/P68, named Rec 4 and Rec 34. 
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Table 2.2: Isolates of ASFV used in this project, including origin of virus, year and country 
of isolation and reference. 
ASFV isolate Origin Genotype Year Country Reference 
Attenuated Uganda  Tissue culture X 1965 Uganda  (Hess et al., 1965)  
BA71V  Tissue culture I 1971 Spain (Enjuanes et al., 
1976) 
BA71V 
ΔCD2v/ΔEP153R 
Recombinant I 2012 Spain (Abrams & Dixon, 
2012) 
Benin 97/1 Domestic pig I 1997 Benin (Chapman et al., 
2008) 
Benin 97/1 ΔCD2v Recombinant  I 2007 Benin L. Goatley (TPI), 
unpublished. 
Georgia Domestic pig II 2007 Georgia (Chapman et al., 
2011) 
Malawi Lil 20-1 Tick VIII 1983 Malawi (Haresnape & 
Wilkinson, 1989) 
Malawi Lil 20-1ΔCD2v Recombinant  VIII 1998 Malawi (Borca et al., 1998) 
Malawi Lil 20-1 ::CD2v Recombinant  VIII 1998 Malawi (Borca et al., 1998) 
NH/P68 Domestic pig I 1957/ 
1960 
Portugal (Vigário et al., 1974) 
NH/P68 Rec 34 Recombinant  I 2000 Portugal (Duarte, 2000) 
NH/P68 Rec 4 Recombinant  I 2000 Portugal (Duarte, 2000) 
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Figure 2.1: EP153R and EP402R open reading frames in NH/P68 and recombinants. 
Comparison of EP153R and EP402R open reading frames from ASFV isolates BA71V, NH/P68 
parental, NH/P68 Rec 34 and NHP68 Rec 4 viruses. (A) Predicted open reading frames (ORFs) from 
the genome region encoding EP153R and EP402R. (A-D) show these from the BA71V, NH/P68, 
Rec 34 and Rec 4 viruses, respectively. Boxes indicate ORFs. White boxes represent signal peptides 
and transmembrane coding domains. The start and stop positions of ORFs relative to those in the 
parental HAD BA71V isolate are numbered above the ORFs. The position of nucleotide deletions is 
indicated below ORFs. Black boxes in the ORFs of NH/P68, Rec 34 and Rec 4 illustrate the regions 
from which the deduced amino acid sequences have no homology with those encoded by BA71V 
isolate (adapted from Rowlands et al., 2009). 
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As demonstrated in figure 2.1, in both these recombinants the EP402R gene has a restored 
start codon, extracellular domain and transmembrane domain but retains the frameshift 
mutation in the cytoplasmic domain such that a protein with a 67 amino acid truncation and 
an altered sequence of the 55 amino acids at the C-terminal end would be expressed. 
Additionally, in Rec 4 an intact EP153R gene is restored whereas in Rec 34 the sequence for 
the EP153R gene is the same as in NH/P68. This set of recombinant NHP68 isolates, one 
with EP153R disrupted (NH/P68 Rec 34) and the other with an intact EP153R gene restored 
(NH/P68 Rec 4), were used as a proxy wild type (NH/P68 Rec 4) and EP153R deletion 
mutant (NH/P68 Rec 34) to evaluate the effect of EP153R on MHC class I modulation by 
ASFV as described in Chapter 4. Parental NH/P68, as a double CD2v and EP153R deletion 
mutant, was used as a further control in the investigations. 
2.4. Growth, maintenance and titration of virus stocks 
2.4.1. Growth of virus stocks  
 
For all non-tissue-culture adapted isolates, BMDM were cultured in T175 cm2 flasks for three 
days before inoculation with an isolate of ASFV. For ASFV BA71V and attenuated Uganda, 
Vero or IB-RS2 cells respectively were cultured overnight in T175 cm2 flasks before 
inoculation. The flasks were then incubated at 37°C in the presence of 5% CO2 for 3-5 days. 
The contents of the flask were then transferred to a 50 ml Falcon tube and centrifuged at 
4200 x g for 10 min. The supernatant was transferred to a fresh Falcon tube for short term 
storage (< 2 months) at 4°C or long term storage at -80°C.  
2.4.2. Filtration of virus stocks  
To separate virus particles from smaller molecules such as cytokines present in the media of 
infected cell culture supernatant, the supernatant prepared as described in Chapter 2.4.1 was 
passed through a 1,000,000 molecular weight cut-off (MWCO) PES Vivaspin filter spin column 
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(Satorius Stedim, France). As these filters are not sterile, they were washed with ethanol prior to 
use. 15 ml of 70% ethanol was added, shaken to coat the inside of the column, and then 
centrifuged at 4200 x g for 2 min. This was followed by a second wash of 15 ml sterile PBS, 
centrifuged at 4200 x g for 5 min. Virus was added in volumes of 20ml and the columns 
centrifuged at 4200 x g for 1 hour or until the volume in the top half of the column had been 
reduced by at least half. The concentrated filtered virus stock was transferred directly to a 50 ml 
Falcon if greater than 2ml, or diluted in 5-10 ml of sterile PBS prior to transfer if less than 2 ml. 
If further virus was to be filtered, the column was re-filled with 20 ml and the process repeated to 
a total of 40 ml per column. Stocks of greater than 40 ml were split over multiple columns. Once 
all virus has been filtered and transferred, columns were rinsed with 2-5 ml sterile PBS and the 
wash also transferred to the Falcon tube with the filtered virus. 
2.4.3. Titration of virus stocks by immunofluorescence  
BMDM were seeded into 96 well tissue culture microtitre plates (Nunc) in 100 μl of media 
containing 1 x 107 cells.ml-1 and cultured for three days. A ten-fold virus dilution series from 
10-1 to 10-8 was prepared in appropriate cell culture media. After removal of the media from 
the cells in the culture plate, the dilution series was applied to the cells at 100 μl per well. 
Fresh media was applied to uninfected cells as negative control. The plates were incubated at 
37°C in the presence of 5% CO2 for three days. Cells were fixed in 4% paraformaldehyde 
(PFA) and infected cells evaluated by indirect immunofluorescence. 25 μl of primary 
antibody against ASFV protein VP30 (clone C18, TPI) (table 2.1) diluted in PBS was added 
per well and incubated for 30 min at room temperature with shaking. After two washes in 
PBS, 25 μl of Alexa Fluor anti-mouse 488 (Life Technologies, USA) secondary antibody 
diluted in PBS was added to each well and incubated as previously. Infected cells were 
identified by fluorescence of VP30 under inverted microscope, and virus titres estimated 
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using the Spearman-Karber formula. Titres were expressed as log10 50% infectious units per 
ml (IU50.ml-1) 
2.5. RNA and DNA methods 
2.5.1. RNA extraction 
RNA was extracted from BMDM using an RNeasy Mini Kit (Qiagen, Netherlands) as per the 
manufacturer’s instructions. BMDM were directly lysed on 6-well microtitre tissue culture 
plates and the lysate homogenised by vortexing and pipetting up and down. The on-column 
DNA digestion step was omitted. The final elution step was carried out with 30 μl of RNase-
free water and the RNA stored at -20°C until DNase digestion, and then stored at -80°C long-
term.  
DNA digestion was performed with a TURBO DNA-Free Kit (Ambion-Life Technologies, 
USA) following manufacturers guidelines either immediately after RNA extraction or after 
short-term storage at -20°C. 
RNA was quantified using a NanoDrop 8000 UV-Vis Spectrophotometer (Thermo Scientific, 
USA).  
2.5.2. cDNA first strand synthesis 
Reverse transcription of mRNA was performed using oligo(dT) primers with either 
Superscript III First Strand Synthesis SuperMix (Invitrogen-Life Technologies, USA) or First 
Strand cDNA Synthesis Kit (Thermo Scientific). The cDNA product of reverse transcription 
was analysed by NanoDrop spectrophotometer and diluted to 100 ng.μl-1. cDNA was stored 
at -20°C until analysis by quantitative reverse transcriptase PCR (qRT-PCR). 
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Table 2.3: Primers used in conventional and qRT-PCR amplification reactions, including incorporated restriction sites, stop and start codons and epitope tags. 
Name Features Sequence 
qRT-PCR 
β2m qPCR fwd    AGAAGATGAACGCGGAGCAG 
β2m qPCR rev  TGCCGGTTAGTGGTCTCGAT 
GAPDH qPCR fwd  TCAACGACCACTTTGTCAAGC  
GAPDH qPCR rev  TGGTGGTCCAGGGGCTCTTA 
SLA-I qPCR fwd  GCGAGGCCGGGTCTCACACC 
SLA-I qPCR new short rev  TGAACGAGGACCTGCGCT 
Cloning EP153R from ASFV Georgia into expression vectors pcDNA3 and pTriEx with and without cognate ASFV promoter 
EP153R C-HA rev XhoI HA tag stop GCGCCTCGAGTTAAGCGTAATCTGGAACATCGTATGGGTATTTACTACAAATATATAATAAACT  
EP153R C-V5 rev XhoI stop V5 tag GCGCCTCGAGTTAGGTGGAGTCCAATCCCAGCAAAGGGTTTGGGATCGGCTTTCCTTTACTACAAAT
ATATAATAAACT 
EP153R N-HA fwd BamHI start HA tag GCGCGGATCCATGTACCCATACGATGTTCCAGATTACGCTTTTTCTAACAAAAAGTACATCGG 
EP153R N-V5 fwd BamHI start V5 tag GCGCGGATCCATGGGAAAGCCGATCCCAAACCCTTTGCTGGGATTGGACTCCACCTTTTCTAACAAA
AAGTACATCGG 
EP153R stop rev XhoI stop GCGCCTCGAGTTATTTACTACAAATATATAATAAACT 
EP153R start fwd PstI start GCGCCTGCAGATGTTTTCTAACAAAAAGTACATCGGT 
EP153R stop rev (2) HindIII stop GCGCA’AGCTTTTATTTACTACAAATATATAATAAACT  
EP153R-FLAG ASFV rev XhoI FLAG tag stop GCGCCTCGAGTTACTTATCGTCGTCATCCTTGTAATCTTTACTACAAATATATAATAAACT  
FLAG-EP153R ASFV fwd BamHI start FLAG tag GCGCGGATCCATGGATTACAAGGATGACGACGATAAGTTTTCTAACAAAAAGTACATCGG 
EP153R prom fwd  BamHI GCGCGGATCCGATAGTACAGAAGGTAAAC 
EP153R prom fwd HindIII GCGCAAGCTTGATAGTACAGAAGGTAAAC 
EP153R prom rev (2) BamHI GCGCGGATCCGATTAATTTTGTGTTATATATT 
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Name Features Sequence 
Changing epitope tags on codon-optimised EP153R clones purchased from Eurofins 
EP153R-V5(pig) fwd BamHI start GCGCGGATCCATGTTCTCCAACAAGAAATACATTGGACT 
EP153R-V5(pig) rev XhoI stop V5 tag GCGCCTCGAGTTAGGTGGAGTCCAATCCCAGCAAAGGGTTTGGGATCGGCTTTCCAGCGTAATCTGG
AACATCGT    
EP153R(pig) fwd  AAGAAATACATTGGACTGAT 
EP153R(pig) rev  AGCGTAATCTGGAACATCGT 
EP153R(pig) 5′ mut fwd  TTGACGACTATTCCATCCTG 
V5-EP153R(pig) fwd BamHI start V5 tag  GCGCGGATCCATGGGAAAGCCGATC 
V5-EP153R(pig) rev HindIII stop GCGCAAGCTTTTACTTGCTGCATATG 
EP153R(pig)-HA-AA fwd BamHI start GCGCGGATCCATGTTCTCCAACGCCG 
EP153R(pig)-HA-RR fwd BamHI start GCGCGGATCCATGTTCTCCAACCGCC 
EP153R(pig)-HA rev HindIII stop HA tag  GCGCAAGCTTTTAAGCGTAATCTGGA 
Sequencing 
EP153R int fwd  TGCCCTAAAGATTGGGTTGGATA 
EP153R int rev  TATCCAACCCAATCTTTAGGGCA 
EP153R(pig) int fwd  GTTGGTTACAATAACGTGTG 
EP153R(pig) int rev  CATTGTTGTAGTTCTTCTCC 
EP153R(pig) fwd  AAGAAATACATTGGACTGAT 
EP153R(pig) rev  AGCGTAATCTGGAACATCGT 
EP153R(pig) 5′ mut fwd  TTGACGACTATTCCATCCTG 
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2.5.3. Quantitative (real time) PCR 
Full details on setup and optimisation of the qRT-PCR reactions performed in this thesis, 
including primer design, are given in Chapter 5.2.1.1. Briefly, a 25 μl or 20 μl qPCR reaction 
was set up containing cDNA template obtained in Chapter 2.5.2, primers for SLA-I, GAPDH 
or β2M (as listed in table 2.3 and described table 5.2) and either SYBR GreenER qPCR 
SuperMix Universal (Invitrogen-Life Technologies, USA) and SYBR Select Master Mix 
(Applied Biosystems- Life Technologies, USA) and run in a Stratagene Mx3005P instrument 
(Agilent Technologies, USA).  
2.5.4. DNA amplification, extraction and analysis 
2.5.4.1. Polymerase Chain Reactions (PCR) 
For most PCR amplifications (see below for exceptions) Platinum Blue PCR SuperMix 
(Invitrogen-Life Technologies) was used in 25 μl reaction volumes with 1 µM of forward and 
reverse primer (table 2.3), and a variable amount of template DNA (typically 50-100 ng). 
For high-fidelity amplification of gene templates for cloning, AccuPrime Pfx DNA 
polymerase with proofreading 3’ to 5’ exonuclease activity was used in 25 μl reaction 
volumes with 1 µM of forward and reverse primer (table 2.3), and a variable amount of 
template DNA (typically 50-100 ng). 
A typical reaction included initial denaturation by heating at 95 ˚C for 2 min, followed by 35 
cycles of amplification with the following conditions: denaturing 30 s at 95°C, annealing 60 s 
at 60°C; extension 60 s at 72°C (for Platinum Blue PCR SuperMix) or 68°C (for AccuPrime 
Pfx) followed by a final extension of 10 min at the appropriate extension temperature and an 
indefinite hold at 10°C. Amplifications were carried out using Eppendorf MasterCycler or 
Nexus thermal cyclers. Following PCR, samples were stored at 4 ˚C or immediately analysed 
on an agarose gel.  
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All primers were purchased from Sigma-Aldrich and are listed in (table 2.3) 
2.5.4.2. Agarose gel electrophoresis  
DNA samples to be analysed by gel electrophoresis were run on 1.5% agarose/TAE gels 
containing ethidium bromide (0.5 g.ml-1), and separated at 150 V for ~30 min. Platinum Blue 
Supermix DNA polymerase contains a loading buffer in its formulation, and so DNA samples 
amplified with this polymerase could be directly loaded onto gels, while samples amplified 
with AccuPrime Pfx were mixed with gel loading buffer before loading. DNA fragments 
were visualised using a GeneDoc gel viewer (Bio-Rad, USA) and imaged using Quantity One 
(v4.1.0) software (Bio-Rad). The size of the DNA fragments was estimated with 100 bp or 
1 kbp molecular weight ladders (Biogene, UK).  
2.5.4.3. DNA extraction from agarose gels 
Where required, bands were excised from agarose gels and the DNA extracted and purified 
using a GFX Gel Band Purification Kit (GE Healthcare, UK), following the manufacturer’s 
instructions, with elution into 30 μl dH2O. 
2.5.5. Cloning virus genes into expression vectors 
2.5.5.1. Amplification, digestion and ligation of target genes 
Viral genes were either cloned into expression vectors as described below or purchased 
directly from Eurofins (Luxembourg). Synthetic EP153R genes from Eurofins were ordered 
so as to be codon optimised for expression in porcine cells and to include epitope tags. These 
genes were delivered cloned into the company’s own backbone vector, pEX-A. Once 
received, the synthetic genes were cloned into pTriEx-1.1 as described below. 
Viral genomic DNA was extracted from BMDM cell culture infected with ASFV Georgia 
2007 using a QIAamp Viral RNA Mini Kit (Qiagen) according to manufacturer’s 
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instructions. The DNA was amplified by PCR using AccuPrime Pfx DNA polymerase and 
appropriate primers for EP153R (table 2.3). Sequences encoding epitope tags were included 
as required in the primer sequences so that these tags were directly incorporated by PCR, 
along with restriction endonuclease (RE) digestion sites at the 3′ end of forward primer and 5′ 
end of reverse primers to allow cloning of amplified fragments into expression vectors. 
Both the amplified target gene DNA and either pcDNA3 or pTriEx-1.1 expression vector 
were digested with appropriate REs and then ligated in a 1:3 molar ratio with T4 Ligase (New 
England Biolabs (NEB), USA or Thermo Scientific) following the manufacturer’s 
recommendations.  
2.5.5.2. Transformation of chemically competent cells 
Competent E.coli XL-Blue cells were removed from storage at -80°C, rapidly defrosted, and 
dispensed into 50 μl volumes on ice. 5 μl of the ligation reaction was added to each aliquot of 
cells and incubated on ice for 30 min. The cells were then heat-shocked at 42°C for 1 min 
before being placed back on ice for 5 min. 500 μl of antibiotic-free SOC media was added to 
the cells and the cultures incubated with shaking at 37°C for 1 hour to initiate growth. 100 μl 
of the transformed culture was spread on LB agar plates supplemented with ampicillin 
(100 μg.ml-1) and incubated at 37°C overnight.  
Single colonies were selected and analysed for presence of the correct gene insert by PCR 
prior to small scale plasmid preparation of a 10 ml overnight culture using a QIAprep Spin 
Miniprep Kit (Qiagen) following manufacturer’s instructions. Minipreps were checked for 
the correct insert by digestion and PCR, then large-scale plasmid preparations of 100 ml or 
200 ml overnight cultures were performed using a Plasmid Midi Kit or Plasmid Maxi Kit 
(Qiagen), respectively.  
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2.5.5.3. Plasmid DNA sequencing 
Cloned plasmid DNA was prepared for sequencing using a BigDye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems-Life Technologies). 500 ng of DNA was made up to 
10 μl in nuclease-free dH2O and denatured at 95°C for 5 min. 1.88 μl of denatured DNA was 
combined with 1 μl of primer (table 2.3) at 1.6 nmol, 0.25 μl BigDye Terminator v3.1 Ready 
Reaction Mix, 1.88 μl 5X Sequencing Buffer and 5.37 μl nuclease-free dH2O. The 
sequencing reaction was then amplified on a PCR thermocycler with the following 
programme: initial denaturation by heating at 96 ˚C for 1 min followed by 25 cycles of 
denaturing 10 s at 96°C, annealing 5 s at 50°C and extension 4 min at 60°C. The amplified 
DNA was then ethanol washed and submitted to the sequencing department at The Pirbright 
Institute where samples were run on an ABI 3730 DNA Analyzer (Applied Biosystems-Life 
Technologies). 
2.6. Protein methods 
2.6.1. Protein expression methods 
To express proteins encoded by plasmid constructs, monolayers of mammalian cell cultures 
were transfected using TransIT-LT1 (Mirus, USA) following manufacturer’s instructions. 
After incubation the transfection reaction, containing the transfection reagent, plasmid DNA 
and serum-free media, was added drop-wise to the media in microtitre cell culture plates and 
incubated at 37°C for 4-6 hours. Media was then changed, and if appropriate, the cells were 
infected with ASFV for expression of genes under their cognate ASFV promoter (see Chapter 
6.2.1). Transfected cells were incubated for 18-24 hours at 37°C and 5% CO2. 
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2.6.2. Protein analysis methods 
2.6.2.1. SDS-PAGE  
Proteins from cell lysates or immunoprecipitates (see Chapter 2.6.2.7.2) were separated by 
size by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). 12% resolving 
polyacrylamide gels were overlaid with 4% stacking gel (see Chapter 2.1.2). Cells were 
washed in PBS before being lysed and harvested by addition of 1x SDS-PAGE lysis/loading 
buffer directly to the monolayer in microtitre plates. Proteins within the lysates were then 
denatured by heating to 96°C for 5 minutes, and nuclear material disrupted by passing 
samples through a 26 gauge needle 5 times. 30-40 μl of sample was then loaded onto the gel 
along with ECL Full-Range Rainbow Molecular Weight Marker (Amersham-GE Healthcare, 
UK) and run in SDS-PAGE running buffer at 150 V for approximately 1 hour, or until the 
loading buffer ran off the end of the gel, using a Mini Protean II system (Bio-Rad). 
2.6.2.2. Western Blot  
Where appropriate, following SDS-PAGE, proteins were detected by Western blotting using 
antibodies specific to the protein of interest or its epitope tag (table 2.1) and an HRP 
conjugated secondary antibody (Dako-Agilent Technologies, USA). The gels from the SDS-
PAGE were assembled with a nitrocellulose membrane in a Mini Protean II slab cell Western 
blot apparatus (Bio-Rad). The cassette was then submerged in Western blot transfer buffer 
and 100 V applied for >1 hour. The nitrocellulose membrane was then removed and 
incubated in blocking buffer before incubation with primary, followed by HRP-conjugated 
secondary antibodies diluted in blocking buffer. All incubations were performed with 
agitation either for 1 hour at room temperature or at 4°C overnight, with four washes in wash 
buffer between each stage. Chemiluminescence detection was performed by incubating the 
membranes for 1-2 min at room temperature with LumiGLO chemiluminescent substrate 
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solution (Cell Signalling Technologies, USA). The membranes were then immediately 
exposed to X-ray film and the film developed. 
2.6.2.3. Investigating deglycosylation and post-translational modifications 
To investigate post-translational modifications of proteins, transfected cell cultures were 
treated with 1 µg.ml-1 of tunicamycin (Sigma-Aldrich) when the media was changed on the 
transfection reaction (see Chapter 2.6.1) and the cells incubated overnight at 37°C. 
Alternatively, after the overnight incubation of the transfection reaction, the cells were 
harvested in Glycoprotein Denaturing Buffer (NEB) instead of SDS-PAGE lysis/loading 
buffer and treated with EndoH or PNGaseF endoglycosidase enzymes (NEB) according to the 
manufacturer’s instructions. The treated cell lysates were then run on SDS-PAGE gels and 
analysed by Western blot as described in Chapters 2.6.2.1 and 2.6.2.2. 
2.6.2.4. Indirect immunofluorescence (confocal microscopy) 
Cells were seeded onto 13 mm coverslips in 24 well microtitre tissue culture plates prior to 
transfection, infection or other relevant treatment. At the experiment end point, cells were 
fixed for 20 minutes in 4% PFA, washed twice in PBS then either stored at 4°C for up to two 
weeks or immediately stained for immunofluorescence. 
Cells to be stained internally were permeabilised with 0.2% TritonX-100 for 5 min at room 
temperature. To prevent non-specific antibody binding, samples were incubated for 5 min in 
PBS + 0.2% bovine serum albumin (BSA) prior to incubation with primary antibodies, 
followed by Alexa Fluor (Life Technologies) secondary antibodies diluted in PBS + 0.2% 
BSA (table 2.1). 100 - 150 μl of diluted antibody was added to a coverslip within the well of 
the tissue culture plate and incubated with agitation for 30 min at room temperature. Three 5 
min washes in PBS containing 0.2% BSA were performed after each antibody incubation. 
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Finally, coverslips were rinsed in dH20 and mounted onto slides with Vectasheild containing 
DAPI (Vector Laboratories, USA), and sealed using nail varnish. Slides were viewed on a 
Leica TCSSP2 confocal microscope.  
2.6.2.5. Flow cytometry 
BMDM to be analysed by flow cytometry were washed twice in PBS, fixed for 20 minutes in 
4% PFA then washed twice more in PBS. The cells were harvested using Non-Enzymatic 
Cell Dissociation Solution (Sigma-Aldrich) and washed three times in MACSQuant Running 
Buffer (Miltenyi Biotech, Germany). Cell culture lines were washed twice in PBS, harvested 
in versene-trypsin, washed a further three times in PBS, fixed for 20 minutes in 4% PFA then 
washed twice more with MACSQuant Running Buffer. Cells were resuspended in 
MACSQuant Running Buffer + 0.2% BSA as a blocking buffer and plated out onto round-
bottom 96-well plates, with technical triplicates for each sample, for staining. 
Between each step in the staining process, cells were pelleted by centrifugation at 400 x g and 
the supernatant removed by a single flicking movement of the inverted plate. Cells to be 
stained internally were permeabilised with 0.2% TritonX-100 for 5 min at room temperature. 
25 μl of primary antibody (table 2.1) diluted in PBS + 0.2% BSA were added to each relevant 
well and incubated at 4°C for 20 min. After incubation, wells were topped up with 150 μl 
MACSQuant Running Buffer and the cells were pelleted by centrifugation, followed by two 
further washes in MACSQuant Running Buffer. Incubation with Alexa Fluor (Life 
Technologies) secondary antibodies was performed in the same manner. Finally, cells were 
resuspended in 150 μl MACSQuant Running Buffer and run on a MACSQuant Analyzer, 
with automatic compensation for spectral overlap performed where necessary.  
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Figure 2.2: Gating strategy for evaluating SLA-I expression in ASFV-infected BMDM.  
Flow cytometry analysis gating strategy for obtaining SLA-I expression values from ASFV-infected 
monocyte/macrophages stained for viral protein VP30 with an Alexa Fluor 647 secondary antibody, 
and for SLA-I with an Alexa Fluor 488 secondary antibody. First, the population of monocytes is 
gated (A), and from this gated population, ASFV-infected cells are identified by positive expression 
of viral protein VP30 (B). Values below gate names are percentages of the total population in the plot 
represented by each gate. 
A B 
92 
 
For BMDM experiments, gating for the macrophage/monocyte population was applied as 
demonstrated in figure 2.2-A. In tissue culture cell line samples, dead cells/cellular  debris 
were excluded by gating as shown in figure 2.2-A , and side scatter signal width versus area 
used to identify and gate for single cells. Both BMDM and tissue culture cells in ASFV 
infection studies were labelled for ASFV protein VP30 as a marker of infection. To gate 
results for cells infected with ASFV, first a “VP30 negative” gate, as shown in figure 2.2-B, 
was drawn to contain all the cells in the control sample labelled with secondary antibody only 
on the channel detecting labelling for VP30. In this sample, no positive labelling for ASFV 
would be expected. Next, this gate was applied to a sample of cells exposed to infection with 
ASFV, to confirm that the gate correctly identified the population within the sample in which 
no labelling for VP30 was detected (uninfected cells). A “VP30 positive” gate, as shown in 
figure 2.2-B, was then drawn to contain the population of cells which were positively labelled 
for VP30 on the channel detecting labelling for VP30. The gates were then applied to all 
samples in the experiment and individually checked to ensure that the gates correctly 
identified the populations of infected and uninfected cells in each. If necessary, slight 
adjustments to the gates were made as required. Data was then analysed and results were 
interpreted using FCS Express v3 (De Novo Software, USA) or FlowJo v10 (Tree Star Inc., 
USA). 
2.6.2.6. Conjugation of primary antibodies with secondary fluorophores using 
the Zenon system 
For certain immunofluorescence and flow cytometry applications it was desirable to use pre-
conjugated primary and secondary antibodies, mainly to allow concurrent staining with two 
different antibodies of the same host species and isotype. In these cases, Zenon Antibody 
Labeling Kits (Invitrogen-Life Technologies) were used following manufacturer’s 
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instructions. Staining was then carried out as per Chapters 2.6.2.4 and 2.6.2.5, but with only 
one antibody incubation step. 
2.6.2.7. [35S] radiolabelling and autoradiography 
BMDM were matured in 6-well microtitre tissue culture dishes and treated as required, then 
starved by the removal of growth media and incubation for 1 hour in cysteine/methionine-
free media. Cells were then radiolabelled by the addition of 1.5 MBq.ml-1 EXPRE35S35S 
Protein Labeling Mix [35S] (Perkin Elmer, USA) for an appropriate time. Cell lysates were 
harvested in 250 μl TritonX-100 lysis buffer and either analysed immediately or stored 
at -20°C.  
2.6.2.7.1 Scintillation counting 
20 mm diameter glass microfibre discs (Whatman-GE Healthcare, UK) were pre-soaked in 
10% trichloroacetic acid (TCA) and allowed to dry. 20 μl of radiolabelled lysate was dropped 
onto the discs and proteins were precipitated by incubation in 20% TCA on ice for 45 min 
with agitation. The discs were then washed in 95% ethanol on ice for 15 min, dried and 
placed in OptiPhase Supermix Cocktail (Perkin Elmer, USA). Incorporation of [35S]-
cysteine/methionine was measured on a LS6500 Multi-Purpose Scintillation Counter 
(Beckman Coulter, USA). These scintillation counts were used as the basis to dilute all 
radiolabelled cell lysates from a single experiment to the same total protein concentration in 
TritonX-100 lysis buffer (standardised radiolabelled cell lysates).  
2.6.2.7.2  Immunoprecipitation 
180 μl of standardised radiolabelled cell lysates were homogenised with a pipette filter tip, 
then tumbled at 4°C overnight with primary antibody (table 2.1). 50 μl of immobilized 
recombinant Protein G resin beads (Generon, UK) were added and the lysates tumbled at 4°C 
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for a further hour. The beads were washed three times by adding 200 μl of ice-cold 
TritonX-100 lysis buffer, mixing thoroughly and incubating on ice for 3 min. Beads were 
pelleted between each wash step by pulsing at 12 000 rpm in a benchtop microfuge. After 
washing, beads were resuspended in 50 μl of 2x SDS-PAGE lysis/loading buffer and mixed 
thoroughly.  
2.6.2.7.3 SDS-PAGE and detection of radiolabelled proteins 
Radiolabelled immunoprecipitate/Protein G bead mix samples as prepared in Chapter 
2.6.2.7.2 were boiled at 100°C for 10 min, the beads spun down by pulsing at 12 000 rpm in a 
benchtop microfuge and 40 μl of the supernatant loaded onto a 12% SDS-PAGE gel as in 
Chapter 2.6.2.1. Gels for detection of immunoprecipitated radiolabelled protein were 
incubated for 1 hour in 1M Na-salicylate in the dark before washing and vacuum drying onto 
filter paper. The dried gels were then exposed to X-ray film in a cassette at -80°C for 5-7 
days before films were developed.  
The remaining 50 μl of standardised radiolabelled cell lysate was used to investigate total 
protein staining by running the samples on 12% SDS-PAGE gels in the same manner as the 
immunoprecipitated samples. The gels were then incubated in Coomassie blue stain for 
1 hour, followed by destain overnight, then vacuum dried onto filter paper and the bands 
photographed.   
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Chapter 3 
3 Bioinformatic Analysis of Viral Protein EP153R 
3.1. Introduction 
3.1.1. ASFV proteins EP153R and CD2v 
The ORFs EP402R and EP153R are located adjacent to each other on the ASFV genome and 
encode proteins CD2v and EP153R. While more detailed descriptions of the structure and 
function of both proteins and their location on the genome are provided in Chapter 1.3.2 and 
1.3.3, briefly, EP153R is a type II transmembrane protein with a C-type lectin domain 
(CTLD) similar to those of the NK cell receptor family (Yáñez et al., 1995; Neilan et al., 
1999; Galindo et al., 2000), and has been associated with inhibition of host-induced apoptosis 
(Revilla et al., 1997; Hurtado et al., 2004), augmenting haemadsorption in association with 
CD2v (Galindo et al., 2000), and modulation of the MHC class I antigen presentation 
pathway (Hurtado et al., 2011). Neilan et al. (1999) found that EP153R was encoded by all 
the ASFV isolates which they examined, but in non-haemadsorbing isolates ASFV 
OURT88/3 and NH/P68, the gene has been shown to be interrupted (Chapman et al., 2008; 
Rowlands et al., 2009). Genome analysis across ASFV isolates has shown that the genes for 
CD2v and EP153R are among the most divergent of the ASFV genome, with identity ranging 
from 43% to 100% at the nucleotide level, and 55% to 100% at the amino acid level. This is 
in contrast to more highly conserved proteins encoded by the ASFV genome, such as A104R, 
a histone-like structural protein which has 99 to 100% amino acid identity between ASFV 
isolates (Chapman et al., 2008; Chapman et al., 2011). Explorations into the regions of 
EP153R which remain conserved and those which are divergent form part of the 
bioinformatic investigations discussed within this chapter. 
96 
 
CD2v is a type I transmembrane protein which shares two predicted Ig superfamily (IgSF) 
domains with host protein CD2. CD2v has been shown to be essential for the haemadsorption 
of erythrocytes around ASFV-infected monocytes and macrophages, and has been linked to 
increased virus dissemination (Quintero et al., 1986; Rodríguez et al., 1993; Borca et al., 
1998). A functional EP402R gene has also been shown to be required for the inhibition of 
bystander lymphocyte proliferation in infected PBMC cultures (Borca et al., 1998) and to 
enhance replication of ASFV in infected ticks (Rowlands et al., 2009). Proline-rich repeats in 
the cytoplasmic region of CD2v bind mAbp1, a cytoplasmic adaptor protein involved in 
vesicular transport (Larbolette et al., 1999; Kay-Jackson et al., 2004).  
As stated above, EP153R has been implicated in modulating expression of the porcine MHC 
class I molecule, SLA-I (Hurtado et al., 2011). One of the main focuses of the work covered 
in this thesis is to expand on the results of Hurtado et al. (2011). CD2v is also under 
investigation as an ASFV protein which may potentially exert an effect on the cell surface 
expression of host proteins (see Chapter 4). Since CD2v has already been studied and several 
of its functions and their mechanisms elucidated (Rodríguez et al., 1993; Borca et al., 1998; 
Kay-Jackson et al., 2004; Rowlands et al., 2009; Goatley & Dixon, 2011), this chapter will 
focus on bioinformatic analysis of EP153R in order to find information which may be helpful 
in expounding both its function and mechanisms of action.  
3.1.2. C-type lectin proteins sharing homology with EP153R 
A range of host- and virus-encoded proteins with CTLDs share some amino acid sequence 
similarity with EP153R. Most of these function in cell-cell interactions, particularly involving 
cells of the immune system (Holland et al., 1984; Bettler et al., 1989; Chan & Takei, 1989; 
Houchins et al., 1991; Smith et al., 1991; López-Cabrera et al., 1993; Chang et al., 1995; 
Neilan et al., 1999; Afonso et al., 2000; Galindo et al., 2000; Perdiguero  et al., 2008; 
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Hurtado et al., 2011; Sackstein, 2011). While investigating the function of EP153R, Neilan et 
al. (1999), Galindo et al. (2000), Yáñez et al. (1995) and Hurtado et al. (2011) all performed 
homology searches which yielded a range of C-type lectin proteins encoded by poxviruses 
and mammalian hosts with sequence similarities to EP153R. These proteins are listed in table 
3.1, along with their known functions. One common feature of all these proteins is that their 
CTLD belongs to the NK cell receptor subfamily of C-type lectins. 
As described in Chapter 1.2.6 and demonstrated in figure 1.11, receptors on NK cells bind to 
MHC class I complex molecules as they present peptides on the surface of nucleated cells, 
and this binding prevents activation of the NK cells. The absence of MHC class I molecules 
on the cell surface due to viral inhibition of expression by a viral protein triggers the “missing 
self” response, in which the NK cell is activated and releases cytotoxic proteins contained 
within secretory lysosomes which destroy the infected cell (Topham & Hewitt, 2009; 
Lakshmikanth et al., 2011). Based on this interaction between NK cell receptors and MHC 
class I molecules, Hurtado et al. (2011) modelled a 3D structure for EP153R based on its 
similarity to human CD69, human CD94 and murine Ly49A; all NK cell receptors with a 
CTLD. The ligand of CD69 has not yet been identified (Marzio et al., 1997; Bartel et al., 
2013), but it has not been associated with MHC class I complex binding. The heavy chain of 
MHC class I has been shown to bind directly with a heterodimer of CD94 and NKG2, and 
homodimers of Ly49A (Moretta et al., 1997; Ryan & Seaman, 1997; Lanier, 1998; 
Matsumoto et al., 2001; Bartel et al., 2013). The Ly49 complex of NK cell receptor proteins 
is most commonly identified in rodents, with different strains of mice encoding varying 
numbers of up to 31 different Ly49 genes (Schenkel et al., 2013). In contrast, a single Ly49 
gene has been identified in pigs (Gagnier et al., 2003). From their modelling of EP153R 
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Table 3.1: Summary of proteins reported in literature as having sequence similarity to EP153R. 
A list of the C-type lectin proteins encoded by poxviruses and mammalian hosts generated from 
homology searches for proteins with sequence similarities to EP153R as performed by Neilan et al. 
(1999), Galindo et al. (2000), Yáñez et al. (1995) and Hurtado et al. (2011) as part of their 
investigations into the function of EP153R. The UniProtKB accession numbers and reported functions 
of each protein are also listed. 
Protein Encoded 
by 
Function UniProtKB 
reference  
Reference 
A34 VACV Determinant in the protein composition of 
the vaccinia virus extracellular envelope. 
P24761 (Smith et al., 1991; 
Galindo et al., 2000; 
Perdiguero  et al., 
2008) 
A40 VACV Predicted to bind to the surface of immune 
cells and modulates the ability of NK cells 
to kill VACV infected cells. 
P21063 (Neilan et al., 1999; 
Galindo et al., 2000; 
Jarmin, 2009) 
Asgr1 Rat Mediates the endocytosis of plasma 
glycoproteins. 
P02706 (Holland et al., 1984; 
Neilan et al., 1999; 
Galindo et al., 2000) 
CD44 Human, 
mouse 
Mediates cell-cell and cell-matrix 
interactions through an affinity for 
hyaluronic acid and other possible ligands; 
involved in cell migration. 
P16070, 
P15379  
(Galindo et al., 2000; 
Sackstein, 2011) 
CD69 Human, 
mouse, pig 
Lymphocyte proliferation and signal 
transmitting receptor in lymphocytes, NK 
cells and platelets. 
Q07108, 
P37217,  
Q8SPX1 
(López-Cabrera et al., 
1993; Neilan et al., 
1999; Galindo et al., 
2000; Hurtado et al., 
2011) 
CD94 Human Receptor for the recognition of MHC class 
I HLA-E molecules by NK cells and some 
cytotoxic T-cells. Forms heterodimer with 
NKG2. 
Q13241 (Chang et al., 1995; 
Hurtado et al., 2011) 
Fcer2 Mouse Regulation of IgE production and 
differentiation of B-cells. 
P20693 (Bettler et al., 1989; 
Neilan et al., 1999) 
FPV008, 
FPV253 
Fowlpox Unknown. P14370 (Neilan et al., 1999; 
Afonso et al., 2000) 
Ly49A Mouse Inhibitory NK cell receptor binding MHC 
class I H-2d alleles. 
P20937 (Chan & Takei, 1989; 
Hurtado et al., 2011) 
NKG2-A Human Receptor for the recognition of MHC class 
I HLA-E molecules by NK cells and some 
cytotoxic T-cells. Forms heterodimer with 
CD94. 
P26715 (Houchins et al., 1991; 
Neilan et al., 1999; 
Hurtado et al., 2011) 
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against these proteins, Hurtado et al. (2011) predict that EP153R may form a homodimer and 
bind directly with MHC class I molecules. This model is discussed further in Chapter 3.2.4.  
While previous work has identified host and viral proteins with sequence similarities to 
EP153R, little has been done beyond Hurtado et al.’s (2011) structural modelling to reconcile 
the CTLD of EP153R with the identified functions of the protein, or to elucidate the 
mechanisms by which it acts. As a prelude to conducting investigations into the mechanism 
of action of EP153R, bioinformatic studies were conducted to obtain as much information as 
possible about the protein. Online tools and databases were used to identify functional motifs 
and post-translational modifications. A BLAST search of both the entire protein and its 
CTLD were conducted to find additional proteins which share sequence similarity with 
EP153R to those previously identified. Both previously and newly identified proteins were 
then analysed for conserved motifs, amino acid sequences were aligned and percentage 
identities established to rank levels of similarity, and their functions compared to those 
already identified for EP153R. Alignments were also performed on the amino acid sequence 
of EP153R encoded by various isolates of ASFV to find conserved regions and identify 
domains which may be essential for EP153R function. The results suggest an alternative 
model for the function of EP153R as an inhibitor of NK cell activation in addition to 
functions previously described (Revilla et al., 1997; Galindo et al., 2000; Hurtado et al., 
2004; Hurtado et al., 2011) as well as proposing a mechanism for the previously described 
function of augmenting haemadsorption.  
3.2. Results 
3.2.1. Domain searches and post-translational modifications 
The amino acid sequences of all the host and viral proteins analysed were obtained in FASTA 
format from the European Bioinformatics Institute (EBI) UniProtKB database 
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(www.uniprot.org/uniprot/) or The National Center for Biotechnology Information (NCBI) 
GenBank (http://www.ncbi.nlm.nih.gov/genbank/). If available, sequences from the Swiss-
Prot section of the UniProtKB database, which are manually annotated and reviewed, were 
selected instead of sequences from the TrEMBL section, which are automatically annotated 
and not reviewed. The accession numbers of EP153R encoded by thirteen isolates of ASFV, 
the genotype to which they belong and whether the amino acid sequences were obtained from 
the Swiss-Prot or TrEMBL database, are listed in table 3.2. 
A search for functional domains within EP153R encoded by ASFV Georgia 2007/1 and 
ASFV BA71V was conducted using the InterProScan tool on the EBI website 
(www.ebi.ac.uk/interpro/), and figure 3.1 shows the results of this search, with each line 
representing the results from different predictive models provided by the member databases 
of the InterPro consortium. It has previously been reported that EP153R contains a CTLD of 
the NK cell receptor subfamily, and the InterProScan search confirmed these findings. The 
search also identified a region similar to equine herpesvirus-1 (EHV-1) protein UL-45, a type 
II transmembrane viral protein nonessential for EHV-1 growth in vitro, but deletion of which 
reduces replication efficiency and virus release (Oettler et al., 2001). 
Predicted glycosylation sites are listed among the protein characteristics in the EBI 
UniProtKB/Swiss-Prot database. EP153R contains seven or eight predicted asparagine-linked 
glycosylation sites within its extracellular domain, depending on the isolate. Predicted 
phosphorylation sites were identified using the NetPhos 2.0 Server from the Technical 
University of Denmark (http://www.cbs.dtu.dk/services/NetPhos). The results varied across 
isolates with one serine-linked and five tyrosine-linked predicted phosphorylation sites in 
EP153R from ASFV Georgia 2007/1, two serine-linked and seven tyrosine-linked in EP153R
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Table 3.2: UniProtKB accession numbers of ASFV C-type lectin EP153R from different isolates. 
Accession numbers of ASFV C-type lectin protein EP153R encoded by thirteen isolates of ASFV, 
their genotype based on sequencing of structural protein VP72 and whether the sequences are from 
the Swiss-Prot database (manually reviewed and annotated) or the TrEMBL database (non-reviewed 
and automatically annotated). 
Encoded by Accession 
number  
Genotype Obtained from  
BA71V Q65150 I UniProtKB/Swiss-Prot 
Georgia 2007/1 E0WMJ5 II UniProtKB/TrEMBL 
Warthog P0CA65 XIX UniProtKB/Swiss-Prot 
Kenya P0CA63 VIII UniProtKB/Swiss-Prot 
Tengani 62 O89337 V UniProtKB/TrEMBL 
Malawi Lil 20-1 P0CA64 VIII UniProtKB/Swiss-Prot 
Pretoriuskop O89335 XX UniProtKB/Swiss-Prot 
Warmbaths AY261365.1 III GenBank (entire genome) 
Mkuzi AY261362.1 II GenBank (entire genome) 
Benin 97/1 A9JL06 I UniProtKB/TrEMBL 
Lisbon 60 Q8JSP0 I UniProtKB/TrEMBL 
OURT88/3 A9JLS3 I UniProtKB/TrEMBL 
NH/P68 Q8JSP2 I UniProtKB/TrEMBL 
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Figure 3.1: Domain search within the full amino acid sequence of EP153R.  
Full amino acid sequence of EP153R from A) ASFV Georgia 2007/1 and B) ASFV BA71V 
analysed for the presence of known domains using the InterProScan tool of the European 
Molecular Biology Laboratory - European Bioinformatics Institute website. Each line and 
different colour represents the results from different predictive models provided by the member 
databases of the InterPro consortium. 
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from ASFV Malawi Lil 20-1 and three serine-linked and four tyrosine-linked in EP153R 
from ASFV BA71V.  
A search for sites of potential cleavage by protease action within EP153R encoded by ASFV 
Georgia 2007/1 was conducted using the Peptide Cutter tool on the Swiss Institute of 
Bioinformatics website (http://web.expasy.org/peptide_cutter) and the PROSPER tool from 
the Whisstock Laboratory in the Department of Biochemistry and Molecular Biology at 
Monash University, Australia (http://lightning.med.monash.edu.au/PROSPER). Searches 
were performed without filters against the full range of proteases and their cleavage sites 
contained within the databases of these search tools. While the list of proteases is too long to 
practically be reproduced here, no predicted unique protease cleavage sites were identified at 
the N-terminal end of EP153R encoded by ASFV Georgia 2007/1. The relevance of the 
search for N-terminal protease cleavage sites will be described in Chapter 6. 
3.2.2. Comparison of EP153R between isolates of ASFV 
An alignment of the full amino acid sequences of EP153R from thirteen ASFV isolates, 
representing seven genotypes, was performed using the AlignX tool of Vector NTI Advance 
11.5.3 software (Life Technologies, USA) to identify conserved regions. The isolates selected 
for this alignment included the virulent strain currently circulating in the Russian federation 
and Trans Caucasus region, Georgia 2007/1, virulent isolates Benin 97/1 and 
Malawi Lil 20-1, the tissue-culture adapted isolate BA71V and naturally attenuated field 
isolate NH/P68. With the exception of ASFV attenuated Uganda, for which no complete 
sequence is yet available, the isolates listed above are all those used in the ASFV infection 
experiments described within this thesis. The results of the alignment, depicted in figure 3.2, 
highlight the divergent and conserved regions of EP153R. The degree of divergence between 
isolates is considerable, with an amino acid identity ranging from 54.9% identity between 
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        EP153R-BA71V    (1) MYFKKKYIGLIDKN-CEKKILDDSSTIKICYILIGILIGTNMITLIYNFIFWDNYIKCYR 
      EP153R-Georgia    (1) MFSNKKYIGLINKKEGLKKKIDDYS-----ILIIGILIGTNILSLIINIIGEINKPICYQ 
      EP153R-Warthog    (1) MFSNKKYIGLINKKEGLKKKIDDYS-----ILIIGILIGTNILSLIINIIGEINKPICYQ 
        EP153R-Kenya    (1) MFLNKKYPSLIEKK------MDDLMTLKFCYLIITFLIITNIFSLAIN-IWGGGDMIDRQ 
    EP153R-Tengani62    (1) MFSNKKYPSLIEKK------MDDLMTLKFCYIIIAILIMTNIFSLVVN-IWGGG---DRQ 
       EP153R-Malawi    (1) MFSNKKYIGLIDKY-CEKKILDDSSTIKICYILIGILIGTNMITLIYNFIFWENYITCNQ 
EP153R-Pretorisuskop    (1) MYFKKKYIGLIDKN-CEKKILDDCTTIKICYILIGILIGTNMITLIYNFIFWDHYMTCNK 
    EP153R-Warmbaths    (1) MYFKKKYIGLIDKN-CEKKILDDCTTIKICYILIGILIGTNMITLIYNFIFWDHYMTCNK 
        EP153R-Mkuzi    (1) MYFKKKYIGLIDKN-CEKKILDDSSTIKICYILIGILIGTNMITLIYNFIFWDNYIKCYR 
      EP153R-Benin97    (1) MYFKKKYIGLIDKN-CEKKILDDSSTIKICYILIGILIGTNMITLIYNFIFWDNYIKCYR 
          EP153R_L60    (1) MYFKKKYIGLIDKN-CEKKILDDSSTIKICYILIGILIGTNMITLIYNFIFWDNYIKCYR 
     EP153R-OurT88_3    (1) -----------------------------------------MITLIYNFIFWDNYIKCYR 
       EP1535_NH/P68    (1) -----------------------------------------MITLIYNFIFWDNYIKCYR 
           Consensus    (1) MY  KKYIGLIDK  CEKKILDD STIKICYILIGILIGTNMITLIYNFIFWDNYI CYR 
 
        EP153R-BA71V   (60) NNDKMFYCPNDWVGYNNICYYFSNGSFSKNYTAASNFCRQLN-GTLANNDTNLL------ 
      EP153R-Georgia   (56) NDDKIFYCPKDWVGYNNVCYYFGNE-E-KNYNNASNYCKQLN-STLTNNNTILVNLTKTL 
      EP153R-Warthog   (56) NNDKIFYCPKDWVGYNNVCYYFSND-NGNNYTTADNKCKQLNNSTLANNLTDLLNLTSFL 
        EP153R-Kenya   (54) SCENIFYCPKDWVGYNNACYYFSNN--NKNYTDANNYCKNSHNSTLANNDTKLLNLTKLL 
    EP153R-Tengani62   (51) SYENVFYCPKDWVGYNNACYYFSND--MKNYTEASNYCKNLYNSTIVNNNTNIVNLTKTL 
       EP153R-Malawi   (60) K-DKTFYCPKDWVGYNNVCYYFGND--EKNYNNASNYCKQLN-STLTNNNTNLVNLTKTL 
EP153R-Pretorisuskop   (60) K-DKMFYCPKDWVGYNNVCYYFNND--SKNYTTATNSCKQLN-STLANNDTNLL------ 
    EP153R-Warmbaths   (60) K-DKMFYCPKDWVGYNNVCYYFSNDSFTKNYTYASNSCKKIN-STLANNDTNLL------ 
        EP153R-Mkuzi   (60) NNDKMFYCPNDWVGYNNVCYYFSNGSFFKNYTDANNYCKKIN-STLANNDTNLL------ 
      EP153R-Benin97   (60) NNDKMFYCPNDWVGYNNICYYFSNGSFSKNYTAASNFCRQLN-GTLANNDTNLL------ 
          EP153R_L60   (60) NNDKMFYCPNDWVGYNNICYYFSNGSFSKNYTAASNFCRQLN-GTLANNDTNLL------ 
     EP153R-OurT88_3   (20) NNDKMFYCPNDWVGYNNICYYFSNGSFSKNYTAASNFCRQLN-GTLANNDTNLL------ 
       EP1535_NH/P68   (20) NNDKMFYCPNDWVGYNNICYYFSNGSFSKNYTAASNFCRQLN-GTLANNDTNLL------ 
           Consensus   (61) NNDKMFYCPKDWVGYNNVCYYFSN SFSKNYT ASNFCKQLN STLANNDTNLL     L      
 
        EP153R-BA71V  (113) NLTKIYNNQSMYWVNN------TVILRGDNKYSQ-KVNY-TDLLFICGK 
      EP153R-Georgia  (113) NLTKTYNHESNYWVNYSLIKNESVLLRDSGY---YKKQKHVSLLYICSK 
      EP153R-Warthog  (115) NLTKLYHHHSHYWVNYSLNNNYSVPLIDSKYNLNRKKSHYTDLLFICSK 
        EP153R-Kenya  (112) NLSKLYYNDSTYWVKYSLPKNKAVTLRNSTYKYD-RVKY-TETFFICSN 
    EP153R-Tengani62  (109) NLTKIYNHESNYWVNYSLINNESLTLRDSNFPSSGKRTY-IDLLYICSI 
       EP153R-Malawi  (116) NLTKTYNHESNYWVNYSLIKNESVLLRNSGYYKKQKHVS---LLYICSK 
EP153R-Pretorisuskop  (110) NLTKVYHHDKLYWVNYSLNDNFSLSLR-NSTYEK-RSKY-LPLLFICSK 
    EP153R-Warmbaths  (112) NLIKVYNNVSEYWVNN------TVTLRGDHKYINKQNNCNTEFLFICSR 
        EP153R-Mkuzi  (113) SLTKIYNNQSMYWVNN------TVALRGDSVYAQRKVNN-SDLLFICSK 
      EP153R-Benin97  (113) NLTKIYNNQSMYWVNN------TVILRGDNKYSQ-KVNY-TDLLFICGK 
          EP153R_L60  (113) NLTKIYNNQSMYWVNN------TVILRGDNKYSQ-KVNY-TDLLSICGK 
     EP153R-OurT88_3   (73) NLTKIYNNQSMYWVNN------TVILRGDNKYSQ-KVNY-TDLLFICGK 
       EP1535_NH/P68   (73) NLTKIYNNQSMYWVNN------TVILRGDNKYSQ-KVNY-TDLLFICGK 
           Consensus  (121) NLTKIYNN SMYWVNN      TVILRGD  YSQ KVNY TDLLFICSK 
Figure 3.2: Amino acid sequence alignment of EP153R across various isolates of ASFV. 
The full amino acid sequences of EP153R from various isolates of ASFV were aligned using the 
AlignX tool of Vector NTI. Regions of identity across all isolates are represented as X, conserved 
regions as X, similar regions as X and weakly similar as X. The major regions of interest are depicted, 
showing X  the C-type lectin domain, X  the transmembrane region, X  the putative di-lysine ER 
retention motifs, X  the RGD cell adhesion motif and X  the region of highest similarity to host NK cell 
receptor ligand Clec2B. 
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ASFV Warmbaths and Georgia 2007/1, to 79.7% identity between ASFV Warthog and 
Georgia 2007/1 (Chapman et al., 2011) to 100% identical between ASFV BA71V and 
Benin 97/1 (Chapman et al., 2008). A highly conserved region was identified at the start of 
the CTLD, which also shows a high level of similarity to regions in other NK cell receptor C-
type lectin proteins, and the C-type lectin subfamily 2 (Clec2) in particular (outlined in green 
in figure 3.2) (see Chapter 3.2.3). The region is 19 amino acids in length, spanning residues 
66-84 in EP153R from most ASFV isolates investigated and contains a CP motif at position 
68-69. CP motifs have been implicated in protein-haem interactions in various mammalian 
haem-binding proteins (Lathrop & Timko, 1993; Li et al., 2011). Other conserved regions 
within EP153R include a set of three di-lysine motifs just downstream from the amino 
terminus at Lys5-Lys6, Lys13-Lys14 and Lys18-Lys20 (outlined in orange in figure 3.2) which 
had previously been identified as putative ER retention motifs (Neilan et al., 1999; Hurtado et 
al., 2004), although the Lys13-Lys14 motif is not conserved across isolates.  
3.2.3. Homology searches for EP153R 
3.2.3.1. BLAST search for proteins sharing homology with EP153R 
The full amino acid sequence of EP153R encoded by ASFV Georgia 2007/1, as well as the 
CTLD (amino acids 65 to 125) were entered into the protein basic local alignment search tool 
(blastp) of the National Center for Biotechnology Information 
(www.ncbi.nlm.nih.gov/BLAST), with a search condition to ignore results from the ASFV 
taxon. Previous homology searches described in literature have identified a similarity 
between EP153R and CD69, a lymphocyte proliferation and signal transmitting receptor 
expressed on the surface of lymphocytes, NK cells and platelets (López-Cabrera et al., 1993; 
Neilan et al., 1999; Galindo et al., 2000; Hurtado et al., 2011). CD69 is also known as 
Clec2C, and is a member of the Clec2 subfamily. BLAST searches conducted in this study 
for proteins with similarities to full-length EP153R and the CTLD of EP153R identified 
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    EP153R_Georgia   (57) DDKIFYCPKDWVGYNNVCYYFGNEEKNYNNASNYCKQLNSTLTNNNTILVNLTKTLNLTKTYNHE 
       CLC2B_HUMAN   (29) RDSQSLCPYDWIGFQNKCYYFSKEEGDWNSSKYNCS-----TQHADLTIIDNIEEMNFLRRYKCS 
        CLEC2B_PIG   (65) QNAPYFCPDNWIGFQDKCYYFSKEEKNWNSSKDSCL-----SENADLVLISTPEEMQFLKRYKCT 
       CLC2A_HUMAN   (52) HAKPVACSGDWLGVRDKCFYFSDDTRNWTASKIFCS-----LQKAELAQIDTQEDMEFLKRYAGT 
CLEC2C(CD69)_HUMAN   (79) DSHVSSCSEDWVGYQRKCYFISTVKRSWTSAQNACS-----EHGATLAVIDSEKDMNFLKRYAGR 
  CLEC2C(CD69)_PIG   (79) NMHVSSCPDDWIGYQTKCYFISKKTKNWTLAQSFCSK----HHGATLALLESKEDMVFLKQHVGR 
       CLC2D_HUMAN   (69) VCLQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCD-----SQDADLAQVESFQELNFLLRYKGP 
        CLEC2D_Pig   (75) YIRYVTCPKGWIGFGSKCFYFSEDAKNWTVSQMFCV-----SLEAHLAQFETEEELKFLKRYKGP 
         Consensus   (79)     SACPDDWIGFQ KCYYFS D KNWTSSQ FCS     S  ADLALIDS EEMNFLKRYKGg 
 
    EP153R_Georgia  (122) SNYWVNYSLIK-------------N---------ESVLLRDSGYYKKQKHVSLLYICSK----- 
       CLC2B_HUMAN   (89) SDHWIGLKMAK-NRTGQWVDGATFTKSFGMRGSEGCAYLSDDGAATARCYTERKWICRKRIH-- 
        CLEC2B_PIG  (125) SDHWIHP--G--SQTKPWTERSTLNHWLTTKENEVCPYLNEDGIATARCYTERKWICKKK---- 
       CLC2A_HUMAN  (112) DMHWIGLSRKQ-GDSWKWTNGTTFNGWFEIIGNGSFAFLSADGVHSSRGFIDIKWICSKPKYFL 
CLEC2C(CD69)_HUMAN  (139) EEHWVGLKKEP-GHPWKWSNGKEFNNWFNVTGSDKCVFLKNTEVSSMECEKNLYWICNKPYK-- 
  CLEC2C(CD69)_PIG  (140) AEHWIGLKNED-GQTWKWSNGKEFNNWFKLTGSKNCPFLNSTEVGSMECEKNLHWICSKSSI-- 
       CLC2D_HUMAN  (129) SDHWIGLSREQ-GQPWKWINGTEWTRQFPILGAGECAYLNDKGASSARHYTERKWICSKSDIHV 
        CLEC2D_Pig  (135) SDHWIGLSRESPHHVWRWTDNTEYNASFVIRGVGECAYLNDIGVSSARTYTDRNWICTFFLTSF 
         Consensus  (144) SDHWIGLSRE  G TWKWTNGTEFN WF I GS  CAYLND GVSSARCYTERKWICSK    h  
Figure 3.3: Amino acid sequence alignment of EP153R Georgia 2007/1 and members of the 
Clec2 subfamily. 
Alignment of the full amino acid sequences of EP153R from ASFV Georgia 2007/1 versus the human 
and porcine members of the Clec2 subfamily of NK cell receptor C-type lectins, as determined by the 
alignment tool of Vector NTI software. Regions of identity across all isolates are represented as X, 
conserved regions as X, similar regions as X and weakly similar as X. Residues identified as 
conserved across NK cell receptor C-type lectins by Weis et al. (1998) are shown with magenta 
highlighting (X) in the consensus sequence, and a WIGF motif found to be conserved across the Clec2 
family but not in other NK cell receptor C-type lectins is outlined in red X  . 
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CD69, along with other members of the Clec2 subfamily, which also contains Clec2A 
(keratinocyte-associated C-type lectin (KACL)), Clec2B (activation-induced C-type lectin 
(AICL)), and Clec2D (lectin-like transcript 1 (LLT1)). Clec2A and Clec2B are cell surface 
ligands of activating NK cell receptors NKp65 and NKp80 respectively, Clec2D is the ligand 
of inhibitory NK cell receptor NKRP1A, while no ligand has yet been identified for Clec2C 
(CD69) (Marzio et al., 1997; Welte et al., 2006; Bartel et al., 2013).  
An amino acid alignment was performed of all four members of the Clec2 subfamily from 
humans and swine (with the exception of porcine Clec2A, for which no sequence was 
available in UniProt or GenBank) with the full length sequence of EP153R from ASFV 
Georgia 2007/1 using the AlignX tool of Vector NTI. This alignment, shown in figure 3.3, 
revealed that some residues previously identified as being conserved across NK cell receptor 
C-type lectins (Weis et al., 1998) are also conserved in EP153R from ASFV Georgia 2007/1 
and the Clec2 family, particularly cysteine residues Cys63, Cys74, Cys91and Cys156 which are 
likely to be involved in formation of the characteristic disulphide bridges at the bases of the 
double-loop structures of the C-type lectin fold of EP153R (Zelensky & Gready, 2005). The 
full range of residues conserved across NK cell receptor C-type lectin proteins identified by 
Weis et al. (1998) in EP153R and the Clec2B family are highlighted in magenta in the 
consensus sequence at the bottom of figure 3.3. An additional conserved WIGF motif, 
outlined in red in figure 3.3, was identified in the region of highest similarity between the 
Clec2 proteins and EP153R at the start of the CTLD, just beyond the transmembrane domain, 
although no reference to a motif with this sequence was found in the literature.  
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Table 3.3: Sequence alignments of EP153R and the Clec2 subfamily of NK cell receptor C-type 
lectins.  
Results of amino acid sequence alignments of A) the entire sequence of EP153R encoded by ASFV 
Georgia 2007/1 and ASFV BA71V versus the entire amino acid sequences of members of the Clec2 
subfamily of NK cell receptor C-type lectins from humans and swine and B) The C-type lectin 
domains of EP153R encoded by ASFV Georgia 2007/1 and ASFV BA71V versus the CTLD of 
members of the Clec2 subfamily of NK cell receptor C-type lectins from humans and swine showing 
percentage sequence identity, as determined by as determined by the percentage identity matrix of 
EMBL-EBI Clustal Omega multiple sequence alignment tool.. 
A) Entire 
protein 
Clec2 gene 
Alternative 
name 
UniProtKB 
reference Organism 
Sequence 
identity 
EP153R 
Georgia 
(%) 
Sequence 
identity 
EP153R 
BA71V 
(%) 
Mean 
sequence 
identity 
values 
Clec2B AICL Q92478 human 28.23 29.31 28.77 
Clec2C CD69 Q07108 human 23.84 23.49 23.67 
Clec2D LLT1 K7GP34 pig 19.86 26.39 23.13 
Clec2A KACL Q6UVW9 human 22.14 23.62 22.88 
Clec2D LLT1 Q9UHP7 human 22.92 22.30 22.61 
Clec2C CD69 Q8SPX1 pig 23.18 21.48 22.33 
Clec2B AICL H2F097 pig 21.97 21.80 21.89 
 
B) C-type 
lectin 
domain 
Clec2 gene 
Alternative 
name 
UniProtKB 
reference Organism 
Sequence 
identity 
EP153R 
Georgia 
(%) 
Sequence 
identity 
EP153R 
BA71V 
(%) 
Mean 
sequence 
identity 
values 
Clec2D LLT1 K7GP34 pig 25.77 33.33 29.55 
Clec2C CD69 Q07108 human 26.80 30.00 28.40 
Clec2D LLT1 Q9UHP7 human 26.80 30.00 28.40 
Clec2B AICL Q92478 human 27.84 28.89 28.37 
Clec2B AICL H2F097 pig 27.66 27.59 27.63 
Clec2C CD69 Q8SPX1 pig 23.71 27.47 25.59 
Clec2A KACL Q6UVW9 human 21.65 28.89 25.27 
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Percentage sequence identity scores for full length EP153R from ASFV Georgia 2007/1 and 
BA71V versus each of the members of the Clec2 family (table 3.3-A), as well as against the 
CTLD for each as shown in figure 3.3 (table 3.3-B), were calculated using the Clustal Omega 
multiple sequence alignment tool from The European Molecular Biology Laboratory-
European Bioinformatics Institute (EMBL-EBI) (http://www.ebi.ac.uk/Tools/msa/clustalo/). 
Mean sequence identity values of the scores from EP153R from ASFV Georgia 2007/1 and 
BA71V were also calculated. Table 3.3-A shows that the Clec2 family member with the 
highest full-length amino acid sequence identity to EP153R by mean score is human Clec2B 
at 28.77%. When comparing the region of highest similarity (the CTLD domain), the Clec2 
family member with highest sequence identity compared to the mean score for EP153R is 
porcine Clec2D at 29.55% (table 3.3-B). However, the individual scores for Clec2D versus 
EP153R from ASFV Georgia 2007/1 (25.77%) and from ASFV BA71V (33.33%) show 
variability in EP153R identity between the different ASFV isolates. The score for both 
human and porcine Clec2B are more consistent in comparison to EP153R from either isolate. 
Human Clec2B shows 27.84% sequence identity to EP153R from ASFV Georgia 2007/1 and 
28.89% identity to EP153R from ASFV BA71V while porcine Clec2B shows 27.66% 
sequence identity to EP153R from ASFV Georgia 2007/1 and 27.59% identity to EP153R 
from ASFV BA71V. Mean sequence identity scores for EP153R from both isolates also 
placed human Clec2C (CD69) highly in the identity rankings, with mean identity scores of 
23.67% for full-length CD69 and 28.40% for the CTLD domain. 
Clec2B, the cell surface ligand of activating NK cell receptor NKp80, is expressed on the 
surface of macrophages, granulocytes and TLR-stimulated monocytes. The binding of 
Clec2B to its NK cell receptor NKp80 stimulates an effector response which promotes the
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Figure 3.4: NKp80 stimulates effector responses of NK cells.  
TNF-α and IFN-γ production is induced by the interaction of NKp80 and Clec2B in an 
activating cross-talk between NK cells and monocytes in the presence of inflammatory 
cytokines. Clec2B is transported to surface from the ER in monokine-activated NK 
cells, leading to NKp80-dependent cytotoxic response in resting NK cells (adapted 
from Bartel et al., 2013). 
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production of inflammatory cytokines TNF-α and IFN-γ (figure 3.4). These cytokines then 
activate cross-talk between NK cells and monocytes. Clec2B is also stored within the ER of 
NK cells, but upon activation this sequestered Clec2B is transported to the surface, rendering 
activated NK cells susceptible to NKp80-mediated cytolysis from other bystander NK cells 
(Marzio et al., 1997; Bartel et al., 2013).  
Clec2D is the ligand of inhibitory NK cell receptor NKRP1A and is expressed on the surface 
of T- and B-lymphocytes and NK cells (Boles et al., 1999). Binding of this ligand/receptor 
pair inhibits production of IFN-γ and cytolysis, thus impairing NK cell responses towards B-
cells (Bartel et al., 2013). Since Clec2D is not expressed on macrophages, it seems unlikely 
that ASFV has evolved to express EP153R to inhibit the function of Clec2D. The ligand of 
Clec2C (CD69) has not yet been identified (Marzio et al., 1997; Bartel et al., 2013), which 
would make speculation on the function of an ASFV homologue of Clec2C more difficult. As 
such, further investigations into the relationship between EP153R and proteins of the Clec2 
family have focussed on Clec2B. 
3.2.3.2. Investigating sequence similarity between EP153R and NK cell receptor 
C-type lectins  
Having determined that Clec2B had the highest full sequence identity to EP153R of the Clec2 
subfamily and seemed the best candidate for comparisons to EP153R, this protein was added 
to the ten NK cell receptor C-type lectins previously identified as having similarity to 
EP153R (table 3.1). The amino acid sequences of these eleven proteins were aligned with the 
sequences of EP153R encoded by ASFV BA71V and ASFV Georgia 2007/1, using the 
AlignX tool of Vector NTI. Figure 3.5-A shows only a 100 amino acid section of this 
alignment of full-length proteins, covering the CTLDs of each, starting at the Asp62 residue 
located five residues upstream of the conserved CP motif at the beginning of the CTLD
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  EP153R_Ba71V_Clec(1) DKMFYCPNDWVGYNNICYYFSNGSFSKNYTAASNFCRQLNGTLANN------DTNLLNLTKIYNNQSMYWVNNTVILRG------DNK 
EP153R_Georgia_Clec(1) DKIFYCPKDWVGYNNVCYYFGNE--EKNYNNASNYCKQLNSTLTNNNTILVNLTKTLNLTKTYNHESNYWVNYSLIKNES-VLLRDSG 
   CLC2B_HUMAN_Clec(1) DSQSLCPYDWIGFQNKCYYFSKEEGDWNSSKYNCSTQHADLTIIDN------IEEMNFLRR-YKCSSDHWIGLKMAKNRT-GQWVDGA 
    CLEC2B_PIG_Clec(1) NAPYFCPDNWIGFQDKCYYFSKEEKNWNSSKDSCLSENADLVLIST------PEEMQFLKR-YKCTSDHWIHPGSQTKP----WTERS 
    CD69_human_Clec(1) SHVSSCSEDWVGYQRKCYFISTVKRSWTSAQNACSEHGATLAVIDS------EKDMNFLKR-YAGREEHWVGLKKEPGHP-WKWSNGK 
      A40_VACV_Clec(1) YIREDCPTDWISYNNKCIHLSTDRKTWEEGRNTCKALNPNSDLIKI-------ETPNELSFLRSLRRGYWVGESEILNQT-TPYNFIA 
        FPV008_Clec(1) YFSKVCPDEWIGYNSKCYYFTINETNWNDSKKLCDVMDSSLIRFDN------IETLNFVSR--YGKGSYWIDINQNRKIP-GINFSLY 
    CD69_mouse_Clec(1) HHVATCKNEWISYKRTCYFFSTTTKSWALAQRSCSEDAATLAVIDS------EKDMTFLKR-YSGELEHWIGLKNEANQT-WKWANGK 
      CD69_pig_Clec(1) MHVSSCPDDWIGYQTKCYFISKKTKNWTLAQSFCSKHHGATLALLES-----KEDMVFLKQ-HVGRAEHWIGLKNEDGQT-WKWSNGK 
   Fcer2_mouse_Clec(1) TACNICPKNWLHFQQKCYYFGKGSKQWIQARFACSDLQGRLVSIHS------QKEQDFLMQ-HINKKDSWIGLQDLNMEGEFVWSDGS 
  NKG2-A_human_Clec(1) RHCGHCPEEWITYSNSCYYIGKERRTWEESLLACTSKNSSLLSIDN------EEEMKFLSI--I-SPSSWIGVFRNSSHHPWVTMNGL 
     Asgr1_rat_Clec(1) SERICCPINWVEYEGSCYWFSSSVKPWTEADKYCQLENAHLVVVTS------WEEQRFVQQ-HMGPLNTWIGLTDQNGPWKWVDGTDY 
      A34_VACV_Clec(1) LMPSACANGWIQYDKHCYLDTNIKMSTDNAVYQCRKLRARLPRPDT---------RHLRVLFSIFYKDYWVSLKKTNDKWLDINNDKD 
      Ly49_pig_Clec(1) NTGHLNEGHLSCWRGNFYYFTTKNQDWSKCKETCKNYASSLLKIDD-------NDELIFLQSQIYQNFYWIGLSFNEMESKWKWIDNS 
    CD94_human_Clec(1) SDCCSCQEKWVGYRCNCYFISSEQKTWNESRHLCASQKSSLLQLQN---------TDELDFMSSSQQFYWIGLSYSEEHTAWLWENGS 
    Ly49_mouse_Clec(1) HTGRGDKVY WFCYGMKCYYFVMDRKTWSGCKQACQSSSLSLLKIDD-------EDELKFLQLVVPSDSCWVGLSYDNKKKDWAWIDNR 
    CD44_MOUSE_Clec(3) ASTVHSKSHAAAQKQNNWIWSWFGNSQSTTQTQEPTTSATTALMTT--------PETPPKRQEAQNWFSWLFQPSESKSHLHTTTKMP 
    CD44_HUMAN_Clec(1) IFYTFSTVHPIPDEDSPWITDSTDRIPATTLMSTSATATETATKRQ---------ETW-----D--WFSWLFLPSESKNHLHTTTQMA 
          Consensus         CP DWIGYQ  CYYFS   KSW  A  SC    A LLLI          D  FL   Y     YWIGL        W WDDDD 
Figure 3.5: Amino acid sequence alignment of EP153R Georgia 2007/1 and BA71V with 
NK cell receptor C-type lectins. 
Sequence alignment of EP153R encoded by ASFV Georgia 2007/1 and BA71V with NK cell 
receptor C-type lectins identified as similar in the literature and by homology search, aligning 
A) whole protein sequences and B) 100 amino acids of the CTLD, using the alignment tool of 
Vector NTI software. Regions of identity across all isolates are represented as X, conserved 
regions as X, similar regions as X and weakly similar as X. Residues identified as conserved 
across NK cell receptor C-type lectins by Weis et al. (1998) are shown with magenta 
highlighting (X) in the consensus sequence. 
A 
B 
  EP153R_Ba71V    (62) DKMFYCPNDWVGYNNICYYFSNGSFSKNYTAASNFCRQLNGTLANN------DTNLLNLTKIYNNQSMYWVNNTVILRG--------- 
EP153R_Georgia    (58) DKIFYCPKDWVGYNNVCYYFGNE--EKNYNNASNYCKQLNSTLTNNNTILVNLTKTLNLTKTYNHESNYWVNYSLIKNES-------- 
   CLC2B_HUMAN    (30) DSQSLCPYDWIGFQNKCYYFSKEEGDWNSSKYNCSTQHADLTIIDN-------IEEMNFLRRYKCSSDHWIGLKMAKNRTGQWVDGAT 
    CLEC2B_PIG    (66) NAPYFCPDNWIGFQDKCYYFSKEEKNWNSSKDSCLSENADLVLIST-------PEEMQFLKRYKCTSDHWIHPGSQTKP---WTERST 
      A40_VACV    (51) YIREDCPTDWISYNNKCIHLSTDRKTWEEGRNTCKALNPNSDLIKI-------ETPNELSFLRSLRRGYWVGESEILNQTTPYNFIAK 
        FPV008    (44) YFSKVCPDEWIGYNSKCYYFTINETNWNDSKKLCDVMDSSLIRFDN-------IETLNFVSRYG-KGSYWIDINQNRKIP-----GIN 
    CD69_human    (80) SHVSSCSEDWVGYQRKCYFISTVKRSWTSAQNACSEHGATLAVIDS-------EKDMNFLKRYAGREEHWVGLKKEPGHPWKWSNGKE 
    CD69_mouse    (80) HHVATCKNEWISYKRTCYFFSTTTKSWALAQRSCSEDAATLAVIDS-------EKDMTFLKRYSGELEHWIGLKNEANQTWKWANGKE 
      CD69_pig    (80) MHVSSCPDDWIGYQTKCYFISKKTKNWTLAQSFCSKHHGATLALLE------SKEDMVFLKQHVGRAEHWIGLKNEDGQTWKWSNGKE 
    CD94_human    (56) SDCCSCQEKWVGYRCNCYFISSEQKTWNESRHLCASQKSSLLQLQN---------TDELDFMSSSQQFYWIGLSYSEEHTAWLWENGS 
  NKG2-A_human   (114) RHCGHCPEEWITYSNSCYYIGKERRTWEESLLACTSKNSSLLSIDN---------EEEMKFLSIISPSSWIGVFRNSSHHPWVTMNGL 
      A34_VACV    (42) LMPSACANGWIQYDKHCYLDTNIKMSTDNAVYQCRKLRARLPRPDT---------RHLRVLFSIFYKDYWVSLKKTNDKWLDINNDKD 
      Ly49_pig   (134) NTGHLNEGHLSCWRGNFYYFTTKNQDWSKCKETCKNYASSLLKIDD-------NDELIFLQSQIYQNFYWIGLSFNEMESKWKWIDNS 
   Fcer2_mouse   (181) TACNICPKNWLHFQQKCYYFGKGSKQWIQARFACSDLQGRLVSIHS-------QKEQDFLMQHINKKDSWIGLQDLNMEGEFVWSDGS 
    Ly49_mouse   (134) HTGRGDKVYWFCYGMKCYYFVMDRKTWSGCKQACQSSSLSLLKIDD-------EDELKFLQLVVPSDSCWVGLSYDNKKKDWAWIDNR 
     Asgr1_rat   (148) SERICCPINWVEYEGSCYWFSSSVKPWTEADKYCQLENAHLVVVTS-------WEEQRFVQQHMGPLNTWIGLTDQNGPWKWVDGTDY 
    CD44_MOUSE   (293) KSHLHTTTKMPGTESNTNPTGWEPNEENEDETDTYPSFSGSGIDDDEDFISSTIATTPRVSARTEDNQDWTQWKPNHSNPEVLLQTTT 
    CD44_HUMAN   (255) KNHLHTTTQMAGTSSNTISAGWEPNEENEDERDRHLSFSGSGIDDDEDFISSTISTTPRAFDHTKQNQDWTQWNPSHSNPEVLLQTTT 
DDDDDConsensus              CP DWIGYQ  CYYFS E K W  A   C    A LLLID          EL FL  Y     YWIGL              L 
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Table 3.4: Alignments of EP153R and NK cell receptor C-type lectins with sequence similarity to EP153R. 
Results of amino acid sequence alignments of A) the entire sequence of EP153R encoded by ASFV Georgia 2007/1 and ASFV BA71V versus the entire 
amino acid sequences of Clec2B and the NK cell receptor C-type lectins listed in  table 3.1, and B) The C-type lectin domains of EP153R encoded by ASFV 
Georgia 2007/1 and ASFV BA71V versus the CTLD of members of the NK cell receptor C-type lectins, as shown in figure 3.5-B showing percentage 
sequence identity, as determined by the percentage identity matrix of EMBL-EBI Clustal Omega multiple sequence alignment tool. 
A) Entire 
protein Genome 
EP153R 
Georgia 
Identity (%) 
EP153R 
BA71V 
Identity (%) 
Mean values 
Identity (%) 
Clec2B human 31.71 32.14 31.93 
FPV008 fowlpox virus 26.12 24.11 25.12 
Clec2B pig 24.81 24.58 24.70 
A40 vaccinia virus 25.64 22.73 24.19 
CD94 human 21.37 21.55 21.46 
CD69 mouse 24.32 17.46 20.89 
CD69 human 25.00 16.67 20.84 
A34 vaccinia virus 20.43 21.19 20.81 
CD69 pig 22.97 18.25 20.61 
CD44 mouse 18.45 21.28 19.87 
Ly49 mouse 16.89 21.83 19.36 
CD44 human 16.83 18.48 17.66 
Asgr1 rat 15.60 19.42 17.51 
NKG2-A human 17.73 17.16 17.45 
Fcer2 mouse 15.86 17.46 16.66 
Ly49 pig 14.77 16.78 15.78 
B) C-type 
lectin 
domain Genome 
EP153R 
Georgia 
Identity (%) 
EP153R 
BA71V 
Identity (%) 
Mean values 
Identity (%) 
FPV008 fowlpox virus 31.94 28.79 30.37 
CD69 human 26.03 34.33 30.18 
Clec2B pig 30.00 29.69 29.85 
A40 vaccinia virus 30.00 29.41 29.71 
Clec2B human 30.14 28.36 29.25 
CD69 pig 23.29 31.34 27.32 
A34 vaccinia virus 22.73 29.69 26.21 
Asgr1 rat 25.35 25.76 25.56 
CD69 mouse 23.29 26.87 25.08 
Fcer2 mouse 22.22 25.00 23.61 
CD94 human 25.71 21.21 23.46 
NKG2-A human 20.00 21.21 20.61 
Ly49 mouse 19.18 17.91 18.55 
Ly49 pig 15.07 13.43 14.25 
CD44 mouse 11.76 15.00 13.38 
CD44 human 8.82 15.00 11.91 
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in EP153R. Based on the alignment depicted in figure 3.5-A, just these 100 amino acids of 
each protein, with the first residue of each being the one aligned with the Asp62 of EP153R, 
were aligned again in the same manner as the full-length protein sequences to produce the 
alignment depicted in figure 3.5-B. The residue number where this 100 amino acid sequence 
began for each protein is listed after the protein name in figure 3.5-A. In both figure 3.5-A 
and figure 3.5-B, residues identified by Weis et al. (1998) to be conserved across NK cell 
C-type lectins are highlighted in magenta in the consensus sequence at the bottom of the 
alignment. 
Both the full length proteins and the 100 amino acid CTLDs as depicted in figure 3.5-B were 
compared to EP153R encoded by both ASFV Georgia 2007/1 and ASFV BA71V using the 
Clustal Omega multiple sequence alignment tool to obtain percentage sequence identity 
scores. These scores were then averaged to obtain a mean score of the identity between the 
two ASFV isolates. As listed in table 3.4-A, the highest identity for the full-length proteins is 
between EP153R and human Clec2B at 31.93%, followed by fowlpox virus FPV008 at 
25.12% and porcine Clec2B at 24.70%. The lowest identity score observed was between 
EP153R and porcine Ly49 at 15.78%. When comparing the regions of highest similarity as 
identified by the sequence alignment in figure 3.5-B, the protein with the highest identity 
score to the mean across EP153R from ASFV Georgia 2007/1 and BA71V was fowlpox virus 
protein FPV008 at 30.37%. The next closest were human CD69 at 30.18% and porcine 
Clec2B at 29.85%. The function of FPV008 is currently unknown, which rules out 
speculations into the function of EP153R based on that of the fowlpox protein. Vaccinia virus 
C-type lectin protein A40 had the fourth highest identity score to the mean score for EP153R 
for both the full-length (24.19%) and CTLD (29.71%) rankings, but the function of this 
protein is also currently unknown. This comparison of all the proteins identified in the 
literature as possessing amino acid similarities to EP153R confirms the results of the 
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comparison with the Clec2 family of proteins; protein Clec2B ranked consistently at the top 
of identity comparisons with EP153R from ASFV Georgia 2007/1 and BA71V, and since its 
function and structure are known, it appears to be the protein most likely to offer insight into 
the function and structure of EP153R. 
3.2.4. Modelling of EP153R and examination of motifs shared by EP153R 
and NK cell receptor C-type lectins 
A predicted model of EP153R from ASFV Georgia 2007/1 was built using the SWISS-
MODEL automated protein structure homology-modelling server 
(http://swissmodel.expasy.org/, Arnold et al., 2006; Guex et al., 2009; Kiefer et al., 2009; 
Biasini et al., 2014). This model was based by the server on a template of mouse C-type 
lectin-related protein Clec2i (Protein Data Bank (PDB) reference 3rs1.1, UniprotKB 
accession number Q9WVF9); the protein of highest homology for which a crystal structure 
was available. Clec2i is a murine NK cell C-type lectin protein which functions as a ligand 
for NK cell activation receptor NKR-P1F and forms dimers in crystal structure resembling 
those of human CD69 (Skálová et al., 2012). Figure 3.6 represents the alignment of EP153R 
and Clec2i produced by the SWISS-MODEL server in preparation for modelling. The Clec2i 
residues in figure 3.6 with arrow-shaped and rectangular frames are the β-sheets and 
α-helices of this protein respectively. The coloured residues in the sequence of EP153R 
represents the region which has been successfully aligned with Clec2i and can thus be 
modelled based on this template. From this alignment, it can be seen that the cytoplasmic 
region and the start of the extracellular domain of EP153R share no homology with the 
template protein, meaning that only the CTLD of EP153R could be successfully modelled. 
The results of the modelling performed by the SWISS-MODEL automated protein structure 
homology-modelling server (figure 3.7-B) were then compared to the SWISS-MODEL 
Repository
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Figure 3.6: Alignment of EP153R with template for SWISS-MODEL structure.  
In preparation for structural modelling, EP153R from ASFV Georgia 2007/1 was automatically 
matched with murine Clec2i as the protein with highest homology for which a crystal structure was 
available, and the amino acid sequences of the two proteins was aligned. EP153R is labelled as 
“Model_01”, and Clec2i as “3rs1.1.A”. The coloured sequence of EP153R is the extent of the 
protein which could be matched to Clec2i, and represents the CTLD of the protein. Clec2i residues 
within arrow-shaped frames represent β-sheets, which rectangular frames represent α-helices. 
From this alignment, the SWISS-MODEL automated protein structure homology-modelling server 
(http://swissmodel.expasy.org/) was able to build a predicted structural model of EP153R. 
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  A 
B 
Figure 3.7: Predicted models of EP153R and Clec2B with conserved motifs.  
SWISS-MODEL protein structure models of A) human Clec2B from the SWISS-MODEL 
repository (UniProtKB accession number Q92478) showing WIGL motif (red), WIGF motif 
(magenta) and CP motif (green) and B) EP153R from ASFV Georgia 2007/1 as modelled by 
the SWISS-MODEL automated protein structure homology-modelling server based on a  
murine Clec2i template (PDB reference 3rs1, UniprotKB accession number Q9WVF9), with 
WVNY motif (red), WVGY motif (magenta), and CP motif (green). Models are angled to best 
show locations of key motifs. 
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Figure 3.8: Model of EP153R as a homodimer 
binding SLA-I 
A) Structural model for EP153R-SLA I interaction as 
predicted by Hurtado et al. (2011). Ribbon-plot 
representation of the relative position of the two 
proteins. The groove domain (yellow/orange) of the 
SLA-I heavy chain model comes into contact with the 
lectin domains (blue and green) of the EP153R dimer 
(after Hurtado et al., 2011). B) The CTLD of EP153R 
from ASFV Georgia 2007/1 as modelled in figure 
3.7-B oriented to show similarity to the green 
extracellular domain of EP153R in (A).  
SLA-I 
EP153R 
dimer 
A 
B 
EP153R 
extracellular 
region 
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(http://swissmodel.expasy.org/repository/, Kopp & Schwede, 2004; Kiefer et al., 2009) 
predicted structure of human Clec2B (UniprotKB accession number Q92478), as shown in 
figure 3.7-A. The CP motifs of both proteins are highlighted in green, the WIGL motif of 
Clec2B and WVNY motif of EP153R in red and the WIGF motif of Clec2B and WVGY 
motif of EP153R in magenta. Side chains of these potential key residues are included in the 
model to allow further evaluation of similarities and differences in structure.  
As discussed in the introduction to this chapter, Hurtado et al. (2011) based their model of 
EP153R on the structures of human CD69, human CD94 and murine Ly49A, and propose 
that is exists as a homodimer with the extracellular domains interacting with the antigen 
binding site of SLA-I (figure 3.8-A). A comparison of the extracellular domain of EP153R as 
modelled by Hurtado et al. (2011) and as modelled by SWISS-MODEL based on Clec2i 
(figure 3.8-B) shows an overall similarity in structure, although Hurtado et al. have identified 
two extra β-sheets in the region which shows limited structure in the Clec2i-based model.  
The NK cell receptor C-type lectin family of proteins all exist as homo- or heterodimers 
(Sawicki et al., 2001; Natarajan et al., 2002; Bartel et al., 2013). As such, it is not 
unreasonable to propose that EP153R also forms a homodimer. However, the results of 
EP153R expression studies, which will be discussed in detail in Chapter 6.2, indicated that 
EP153R is unstable when expressed in transiently transfected uninfected cell culture lines. 
This would suggest that EP153R does not form a homodimer, but instead potentially 
dimerises with another host or viral protein to confer stability. Clec2B, the NK cell receptor 
C-type lectin with highest similarity to EP153R, is not expressed in Max and Vero cells, 
which are the cell lines in which EP153R expression studies were carried out. However, the 
tropism of ASFV in natural infections is to infect macrophages which do express Clec2B at 
their surface. It is therefore possible that EP153R performs an immune evasion function by 
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A 
Clec2i 
dimer 
EP153R  
C-type lectin 
domain Clec2B 
B 
Figure 3.9: Model of murine Clec2i homodimer and predicted model of EP153R-
Clec2B heterodimer 
SWISS-MODEL protein structure models of A) murine Clec2i from the SWISS-MODEL 
repository (PDB reference 3rs1, UniprotKB accession number Q9WVF9) in homodimer 
form. B) The CTLD of EP153R from ASFV Georgia 2007/1 as modelled in figure 3.7-B 
and human Clec2B (UniProtKB accession number Q92478) in a predicted heterodimer 
based on the homodimer of murine Clec2i. 
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forming a heterodimer with Clec2B. Based on the homodimer of Clec2i (figure 3.9-A), the 
structure of the CTLD of EP153R modelled on Clec2i (figure 3.7-B) was aligned with the 
model of Clec2B (figure 3.7-A) to investigate whether it was feasible for a heterodimer of 
EP153R and Clec2B to form (figure 3.9-B). While this model of EP153R only includes the 
CTLD domain and not the transmembrane or cytoplasmic regions, the predicted structure of 
such a heterodimer does not preclude the dimerisation of EP153R and Clec2B. 
3.3. Discussion 
EP153R has previously been identified as one of the more divergent proteins encoded by the 
ASFV genome (Chapman et al., 2008; Chapman et al., 2011). Alignments of EP153R 
encoded by thirteen isolates of ASFV have revealed that the regions of highest homology are 
also the regions where potential functional domains have been identified, including a series of 
di-lysine repeats at Lys5-Lys6, Lys13-Lys14 and Lys18-Lys20. The di-lysine repeats will be 
discussed more fully in Chapter 6.2.1.2 while this chapter covers what has been determined 
about the CTLD of EP153R by bioinformatic analysis. The CTLD of EP153R has been 
identified as being similar to NK cell receptor type CTLDs. Mean sequence identity scores 
between the full length amino acid sequences of EP153R from ASFV Georgia 2007/1 and 
BA71V compared with the full length amino acid sequence of NK cell receptor sub-family 
member Clec2B showed 28.77% identity (table 3.3-A), while a comparison of the CTLDs of 
these same proteins showed 28.37% amino acid sequence identity (table 3.3-B). Clec2B, also 
known as AICL, is the host cell surface ligand of activating NK cell receptor NKp80 (Bartel 
et al., 2013).  
Previously published work on EP153R has identified a variety of functions of EP153R and 
postulated a variety of mechanisms by which it may carry out these functions (Neilan et al., 
1999; Galindo et al., 2000; Hurtado et al., 2004; Hurtado et al., 2011). Despite the different 
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conclusions drawn by these studies, they all recognise that the CTLD of EP153R is likely to 
be crucial in its function, and identify the CTLD as belonging to the NK cell receptor 
subfamily. As described in Chapter 1.3.3.1, these are an evolutionarily divergent group of 
C-type lectins found on NK and other immune cells which have lost critical CTLD residues 
for carbohydrate binding, and function as receptors to either activate or inhibit immune 
responses by binding proteins rather than carbohydrates (Zelensky & Gready, 2005). This 
subgroup of C-type lectins are type II transmembrane protein which form disulphide-linked 
dimers, with pairs of cysteine residues within the extracellular domain believed to form intra-
chain disulphide bonds (Yokoyama & Plougastel, 2003). Members of this subgroup include 
NK complex proteins, such as CD94, NKG2, Ly49 and CD69, all of which have been 
previously identified as sharing sequence similarity with EP153R (Neilan et al., 1999; 
Galindo et al., 2000; Hurtado et al., 2011).  
At the start of the CTLD of EP153R is a CP motif which is highly conserved across all 
isolates investigated (figure 3.2). Cys-Pro, followed by a hydrophobic residue, usually 
phenylalanine, is a reported haem-binding motif, although the CP motif is the only absolutely 
conserved sequence and most critical for haem binding (McCoubrey et al., 1997; Hira et al., 
2007). In haemadsorbing isolates of ASFV such as ASFV Georgia 2007/1 and 
Malawi Lil 20-1, the CP motif of EP153R is followed by a lysine residue (CPK) which, while 
not as strongly hydrophobic as phenylalanine, contains three methylene groups within its side 
chain which confer significant hydrophobic character. In isolates of ASFV which do not 
express functional CD2v the haemadsorption function is completely abrogated, and so any 
augmentation of this function by EP153R is void. In these non-haemadsorbing isolates such 
as ASFV NH/P68 and OURT88/3, the partially hydrophobic lysine residue downstream from 
the CP motif is replaced by a neutral asparagine residue (CPN). However, the gene for 
EP153R is interrupted in these isolates and intact proteins are not expressed. Interestingly, 
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observations from this project and other members of the ASFV Group report that ASFV 
Benin 97/1, which does have intact genes for CD2v and EP153R, but has the neutral 
asparagine residue downstream from the CP motif in EP153R, is more weakly 
haemadsorbing in vitro than other virulent ASFV isolates (D. Chapman, L. Goatley (TPI), 
personal communication). The predicted model of EP153R in figure 3.7-B is incomplete in 
that it shows only the CTLD and lacks the cytoplasmic domain, and is also displayed as a 
monomer while NK cell receptor C-type lectins take the form of homo- or heterodimers 
(Yokoyama & Plougastel, 2003; Bartel et al., 2013). However, even though a full structural 
model is not available, the CP motif (depicted in green in figure 3.7-B) appears to be located 
on the surface of the protein structure where it would be accessible for haem-binding 
functions. This conserved CP motif may, therefore, play a role in EP153R’s reported 
augmentation of the haemadsorption function of CD2v (Galindo et al., 2000). 
A motif conserved across CTLDs is the WIGL motif located within the β2 strand. While its 
function has not been fully elucidated, there is speculation that it may help to stabilise the 
core of the domain (Zelensky & Gready, 2005). A WIGL motif was identified in the Clec2 
subfamily of  NK cell receptor C-type lectins analysed (figure 3.3), but this motif was not 
conserved in EP153R, which usually has either WVNY or WVNN instead, depending on the 
isolate (figure 3.2). Examination of the location of the WIGL motif (depicted in red in figure 
3.7-A) within the structural model of Clec2B revealed that it is located within the centre of 
the protein, optimally placed for conferring stability. However, the model of the CTLD of 
EP153R shows that unlike in Clec2B, the corresponding WVNY motif (depicted in red in 
figure 3.7-B) is not located within a β-sheet, but instead a more exposed coil structure, and as 
such does not appear to be well-positioned for playing a part in protein stability. However, 
Hurtado et al.’s (2011) model of EP153R does show β-sheets in this region, and the addition 
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of these to the model may result in the WVNY motif being located in the centre of a more 
structured region of the protein. 
A WIGF consensus sequence was identified further upstream from the WIGL motif, although 
only the W and G residues were conserved across all NK cell receptor proteins and EP153R. 
This motif is depicted in magenta in both the models of EP153R (figure 3.7-A) and Clec2i 
(figure 3.7-B). While similar in sequence to the WIGL motif, no reference to WIGF motifs 
could be found in the literature or protein domain/motif databases.  
Also identified as conserved across EP153R and the NK cell C-type lectins were a range of 
cysteine residues, a well-defined feature of C-type lectins, which are predicted to form intra-
chain disulphide bonds involved in stability of the protein (Weis et al., 1998; Yokoyama & 
Plougastel, 2003). The locations of the conserved cysteine residues can be seen in the 
consensus sequences of figure 3.3 and figure 3.5, among the conserved residues highlighted 
in magenta. 
While a range of functions have been predicted for EP153R (Neilan et al., 1999; Galindo et 
al., 2000; Hurtado et al., 2004; Hurtado et al., 2011), only one of these studies has postulated 
a mechanism for EP153R function and connected this mechanism to the CTLD. As described 
in Chapter 1.3.3.3.3, Hurtado et al. (2011) found that EP153R, and in particular its CTLD, 
modulates the cell surface expression of MHC class I, and suggested that this was probably 
through interference with the correct configuration of the MHC class I complex in the plasma 
membrane.  
Hurtado et al. (2011) constructed a model of a homodimer of EP153R binding directly to the 
MHC class I complex in a similar manner to CD94/NKG2 or Ly49, with the CTLD of 
dimerised EP153R exposed and interacting within the antigen binding groove of the MHC 
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class I molecule. They based their model of EP153R on the crystallographic coordinates of 
human CD69, human CD94 and murine Ly49, which are publicly available. In structural 
modelling of EP153R in this project using the SWISS-MODEL automated protein structure 
homology-modelling server, the model of the CTLD of EP153R was based on Clec2i, a 
murine NK cell C-type lectin protein which forms dimers in crystal structure resembling 
those of human CD69 (Skálová et al., 2012). However, Ly49 and CD94/NKG2 are expressed 
on the surface of NK cells and bind to MHC class I complexes expressed on the surface of 
other nucleated cells. Since ASFV does not infect NK cells, but instead macrophages and 
other cells of the monocyte line (Heuschele, 1967; Wardley & Wilkinson, 1978; Mebus, 
1987; Pérez et al., 1994; Carrasco et al., 1996; Ramiro-Ibáñez et al., 1997; Childerstone et 
al., 1998), EP153R would not be expressed on the surface of NK cells and as such, it is 
difficult to conceptualise how EP153R expressed on monocytes would bind to MHC class I 
molecules on the surface of the same cell type, or to what end. Porcine MHC class I 
molecules have previously been seen to associate with internal viral particles by electron 
microscopy using monoclonal antibody and immunogold labelling (M. González-Juarrero, 
1988, unpublished data, cited in Gonzalez-Juarrero et al., 1992b). This implies that there may 
be viral a protein(s) which binds directly to MHC class I molecules, but this does not seem 
likely to be EP153R. 
While CD94/NKG2 and Ly49 bind to MHC class I molecules, other proteins identified as 
sharing similarity to EP153R, such as the Clec2 subfamily of NK cell receptor C-type lectins, 
do not, but are instead expressed on the surface of host cells including monocytes and 
macrophages, and function as ligands of activating or inhibiting NK cell receptors (Welte et 
al., 2006; Bartel et al., 2013). Viral proteins which play a role in evasion of the NK cell 
immune response include, for example, proteins encoded by the cytomegaloviruses which 
interfere with ligands for activating NK cell receptors (reviewed in Jonjic et al., 2008). 
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Further examples and brief reviews are given in Chapter 7.5. Given the cell tropism of ASFV 
and the similarity between EP153R and Clec2B, which is a ligand of activating NK cell 
receptor NKp80, it seems more likely that EP153R functions to interfere with cell-surface 
ligands of NK cell receptor proteins, either abrogating the function of Clec2B by binding to it 
in a heterodimer, or in direct competition with Clec2B as a homodimer or heterodimer with 
another, as yet unidentified, ASFV protein, in order to attenuate the activation of NK cells by 
ASFV infection.  
3.4. Conclusion 
Bioinformatic analysis of ASFV protein EP153R has revealed a high level of divergence 
across isolates, but the presence of highly conserved regions containing di-lysine repeats and 
a CTLD identified as having 28% amino acid sequence identity to Clec2B, a host cell surface 
ligand of activating NK cell receptor NKp80. Also conserved within the CTLD is a putative 
haem-binding CP motif which may play a role in augmenting the haemadsorption function of 
ASFV protein CD2v. Hurtado et al. (2011) proposed that EP153R forms a homodimer which 
binds directly to SLA-I. Based on the similarity of EP153R to Clec2B an alternative model is 
proposed in which EP153R forms a heterodimer with Clec2B to abrogate the function of 
Clec2B in ASFV-infected cells. This model and the putative function of the dilysine repeats 
will be further discussed in Chapter 6. 
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Chapter 4 
4 Investigating the Effect of ASFV Infection, and ASFV 
Proteins EP153R and CD2v, On Expression of SLA-I 
4.1. Introduction 
4.1.1. Viral modulation of MHC class I antigen presentation 
The major histocompatibility complex functions as a sentinel of the immune system by 
presenting cellular peptides on the plasma membrane to be scanned by T-cell receptors. 
Peptides of foreign origin presented by MHC class I molecules and detected by CD8+ 
cytotoxic T-lymphocytes trigger cytolysis of the infected cell. Peptides presented by MHC 
class II molecules and detected by CD4+ helper T-cells trigger the release of pro-
inflammatory cytokines and the proliferation/differentiation of T- and B-cells (Cresswell, 
1994; Neefjes et al., 2011; van Kasteren et al., 2014). This process is discussed in greater 
detail in Chapter 1.2.3 but briefly, in MHC class I antigen presentation, misfolded proteins of 
either host or pathogen origin in the cytosol are ubiquitinated, which marks them for 
degradation by the proteasome into peptides of 8-10 amino acids. These peptides are 
transported via transporter protein TAP into the lumen of the ER where they are loaded onto 
MHC class I molecules; heterodimers comprised of heavy chain MHC class I and light chain 
β2-microglobulin (β2M), in a process mediated by chaperone proteins tapasin, calreticulin 
and ERp57. These chaperone proteins maintain the MHC class I molecule in a stable 
conformation until peptide loading is achieved. Once loaded, the MHC class I/peptide 
complex is released from the ER and moves through the Golgi to the cell surface via the 
vesicular transport system. MHC class I molecules loaded with an antigenic peptide will 
remain stable at the cell surface for 4 to 18 hours, dependent on cell type, with the differences 
in internalisation rates between cell types being poorly understood (Lehner & Cresswell, 
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1996; Pamer & Cresswell, 1998; Hansen & Bouvier, 2009; Neefjes et al., 2011; Sijts & 
Kloetzel, 2011; Hulpke & Tampé, 2013; van Kasteren et al., 2014). At the cell surface, 
peptides presented by the MHC class I molecule are recognised by receptors on CTLs as 
being of either “self” or “non-self” origin. If the peptides are recognised as “non-self”, the 
CTL will then respond by releasing perforin and enzymes to destroy the infected cell.  
In order to avoid host-mediated killing of infected cells by CTLs, viruses have evolved 
various mechanisms to downregulate presentation of viral peptides by MHC class I. DNA 
viruses encode a range of immunomodulatory proteins which interfere with the MHC class I 
antigen presentation pathway. The first viral protein to be described with this function was 
adenovirus protein E19, which works by displacing β2M from the MHC class I complex and 
retaining the heavy chain in the ER by means of retention motifs in its cytoplasmic tail 
(Burgert & Kvist, 1985; Burgert et al., 1987; Cox et al., 1991; Bennett et al., 1999). HSV, 
HCMV, EBV and CPXV all encode proteins which inhibit transport of viral peptides into the 
ER via TAP, either through direct inhibition of TAP itself or of ATP binding to TAP (Lehner 
& Cresswell, 1996; Früh et al., 1997; Tortorella et al., 2000; Alzhanova et al., 2009; Hansen 
& Bouvier, 2009; Wilkinson & Lehner, 2009). Other examples include proteins encoded by 
the cytomegalovirus family which target MHC class I molecules for degradation by the 
proteasome or lysosomes (Früh et al., 1997; Tortorella et al., 2000; Vossen et al., 2002) and  
KSHV proteins K3 and K5 which interfere with the final stages of MHC class I expression 
and target MHC class I molecules for endocytosis (Vossen et al., 2002; Petersen et al., 2003). 
Further examples and more details on viral evasion of the host MHC class I antigen 
presentation pathway are given in Chapter 1.2.4. 
While the effect of ASFV on MHC class I antigen presentation has been investigated 
previously, as demonstrated in table 1.1 and discussed in Chapter 1.2.5, these studies have 
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not been comprehensive and have yielded different results depending on ASFV isolate and 
cell type studied. Additionally, none of these studies used more than one cell type or 
compared the effect of more than two ASFV isolates when investigating ASFV-induced 
changes in SLA-I expression.  
As outlined in the project aims (Chapter 1.4), an ASFV protein, EP153R, has been implicated 
in immune evasion of ASFV infection via the modulation of SLA-I expression (Hurtado et 
al., 2011) (see Chapter 1.3.3.3.3). The aim of this project was to expand on the work of 
Hurtado et al. by elucidating the mechanism by which EP153R, and potentially other virus 
proteins, affects this modulation. In this chapter, the effect of infection with various ASFV 
isolates and deletion mutants on host cell surface expression of SLA-I is investigated. 
Initially, conditions for maturation of bone marrow derived macrophages (BMDM) and 
ASFV infection time were established for optimal SLA-I expression and the effect of ASFV 
infection on host protein synthesis was determined.  
4.2. Results 
4.2.1. Analysis of BMDM maturation times for optimum SLA-I expression 
Virulent isolates of ASFV infect cells of the monocyte/macrophage lineage, which means 
that primary cell cultures must be used for investigations into these isolates. Macrophages can 
be harvested from the lungs (alveolar macrophages), blood (PBMC) or bone marrow 
(BMDM) of pigs. Of these three types of macrophage, BMDM are the type most readily 
harvested in quantities required for carrying out experiments such as flow cytometry where 
larger numbers of cells are required, particularly if multiple isolates of ASFV are being used 
for infection.  
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Bone marrow derived macrophages require a period of maturation in order to increase 
susceptibility to infection with ASFV, and SLA-I expression in porcine macrophages changes 
over the course of time spent in culture (Gonzalez-Juarrero et al., 1992b; McCullough et al., 
1997). BMDM were harvested from porcine bone marrow and purified as described in 
Chapter 2.2.2.1 and 2.2.2.2, then seeded into microtitre plates and matured for a range of 
days. At 24 hours prior to harvest from the microtitre plates, cells were either left untreated or 
stimulated with recombinant porcine IFN-γ (R&D Systems, USA) at 0.25 μg.ml-1. On 
harvesting, cells were fixed in 4% PFA and cells for internal labelling were permeabilised 
with 0.2% TritonX-100. Technical triplicates were labelled for SLA-I and surface and 
internal expression were measured by flow cytometry as described in Chapter 2.6.2.5 with 
gating applied for monocytes/macrophages. Expression of surface and intracellular SLA-I in 
BMDM stimulated with IFN-γ and untreated cells all peaked at five days’ maturation, with a 
decline in surface SLA-I levels on day 6 in both stimulated and untreated cells (figure 4.1). 
Five days was selected as the optimal maturation time for maximum expression of SLA-I in 
BMDM, and optimisation studies continued with investigations into induced changes in 
SLA-I expression by infection with ASFV. 
4.2.2. Establishing optimal infection time for evaluating changes in SLA-I 
expression  
In order to most effectively evaluate changes in SLA-I expression induced by ASFV 
infection of BMDM, it was necessary to establish the point in the infection cycle where 
differences in SLA-I expression between treatments were most clearly defined. Given that the 
replication cycle of ASFV takes 12-24 hours with apoptosis of infected cells observed from 
around 12-16 hpi (Portugal et al., 2009; Tulman et al., 2009), surface SLA-I expression was 
measured up to 16 hpi. BMDM were matured for five days, then infected with naturally 
attenuated field isolate ASFV NH/P68 and two NH/P68 recombinant isolates, NH/P68 Rec 4
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Figure 4.1: Determining the optimal maturation of BMDM for SLA-I expression.  
BMDM were extracted from bone marrow, separated with Histopaque and plated in 6-well cell 
culture microtitre plates. At 24 hours prior to harvest, half the cells were stimulated with IFN-γ 
(0.25 μg.ml-1). Post-harvest, the cells were fixed, permeabilised as required and labelled with anti-
SLA-I antibody followed by isotype-specific Alexa Fluor 488 secondary antibody. Expression of 
SLA-I was measured by flow cytometry with gating for monocytes/macrophages. Data are from a 
single experiment in this preliminary study. No statistical analysis was performed.  
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Figure 4.2: Establishing the optimal stage of ASFV infection for measuring changes in SLA-I 
expression.  
Matured BMDM were infected with ASFV NH/P68 parental, NH/P68 Rec 4 or NH/P68 Rec 34 
(MOI = 2) or stimulated with IFN-γ (0.25 μg.ml-1) and mean fluorescent intensity of surface SLA-I 
expression evaluated over a 16 hour time course. Cells were fixed and surface labelled with anti-
SLA-I antibody followed by isotype-specific Alexa Fluor 488 secondary antibody. Infected cells 
were also labelled with an antibody against viral protein VP30 followed by isotype-specific Alexa 
Fluor 647 secondary antibody as a marker of infection. Median fluorescent intensity of SLA-I was 
measured by flow cytometry with gating for monocytes/macrophages, plus gating for expression of 
VP30 in infected cells, in order to establish the time point where differentiation of SLA-I expression 
between treatments is optimal. Data are from a single experiment in this preliminary study. No 
statistical analysis was performed. 
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and NH/P68 Rec 34 (Duarte, 2000; Rowlands et al., 2009) (described in detail in Chapter 
2.3) at MOI = 2, or stimulated with recombinant porcine IFN-γ at 0.25 μg.ml-1 over a 16 hour 
time course. Cells at each time point were fixed in 4% PFA, harvested, labelled for SLA-I 
and ASFV protein VP30, then analysed by flow cytometry. Gating for macrophages and 
ASFV infection as determined by positive expression of viral protein VP30 was applied and 
changes in SLA-I expression as a result of infection with each ASFV isolate or stimulation 
with IFN-γ were evaluated across all time points. For all treatments, SLA-I expression on the 
cell surface increased across the time course, culminating in maximum differentiation 
between treatments at 16 hpi when the experiment terminated (figure 4.2). The greatest 
increases in surface SLA-I were seen in response to stimulation with IFN-γ (mean fold-
change = 3.1) and infection with ASFV NH/P68 (mean fold-change = 2.5), with infection 
with ASFV NH/P68 Rec 34 and ASFV NH/P68 Rec 4 inducing mean fold-changes of 1.7 and 
1.3 respectively over 4 to 16 hours hpi, and expression in mock-infected cells showing a 
mean fold-change of 1.4. 
4.2.3. Effect of ASFV infection on total cellular protein synthesis 
Before focusing investigations onto the effects of ASFV infection specifically on SLA-I 
expression, a baseline of the effect of ASFV infection on global protein expression within the 
experimental system was established. Primary porcine BMDM were either mock-infected, 
infected with ASFV Benin 97/1 at MOI = 2 or stimulated with recombinant porcine IFN-γ at 
0.25 μg.ml-1 for 16 hours, and then radiolabelled with EXPRE35S35S Protein Labeling 
Mix [35S] (Perkin Elmer, USA) at 1.5 MBq.ml-1, as described in Chapter 2.6.2.7. 
Incorporation of [35S]-cysteine/methionine was measured by scintillation counter, as per 
Chapter 2.6.2.7.1. Changes in cellular protein synthesis at 16 hpi, as measured by the amount 
of [35S]-cysteine/methionine incorporated into newly-synthesised protein, were measured and 
analysed by repeated measures one-way ANOVA. In cells stimulated with IFN-γ measures of 
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total cellular protein synthesis at 16 hpi were 26.9% higher (p = 0.0067) than in untreated 
cells over the time course, while in cells infected with ASFV Benin 97/1, cellular protein 
synthesis levels were 21.3% lower (p = 0.0383) compared to those of untreated cells (figure 
4.3).  
ASFV leads to apoptosis of infected cells from around 12-16 hpi (Portugal et al., 2009), and 
in this experiment both ASFV infection and treatment with IFN-γ were seen to lead to a 
decrease in cell counts by 16 hours, as determined by flow cytometry (figure 4.4). A lower 
cell count in infected samples would result in decreased incorporation of [35S] as fewer cells 
would be available to take up the [35S]-cysteine/methionine. To evaluate this, total cell counts 
obtained from four experiments where BMDM were infected with ASFV Benin 97/1 at 
MOI = 2 or stimulated with recombinant porcine IFN-γ at 0.25 μg.ml-1 for 16 hours were 
analysed by flow cytometry with gating for monocytes/macrophages. Both ASFV infection 
and IFN-γ treatment led to an approximately 30% reduction from the mean initial cell count 
across all treatments (figure 4.4). To factor in the influence exerted by the reduction in cell 
numbers when evaluating cellular protein synthesis as measured by incorporated [35S], mean 
scintillation count data was normalised to mean cell counts for each treatment (figure 4.5). 
When protein synthesis rates are normalised to cell counts, the results demonstrate that the 
decrease in cellular protein synthesis seen in cells infected with ASFV Benin 97/1 can be 
attributed to a decrease in cell numbers. Between 4 hpi and 16 hpi the change in [35S] 
incorporation per cell increased by 11%, although a decrease was observed between 12 hpi 
and 16 hpi. Stimulation with IFN-γ resulted in a 20% increase in [35S] incorporation per cell 
over the time-course. With optimal conditions established for measuring SLA-I expression in 
ASFV-infected BMDM by flow cytometry, investigations could begin into the effect of 
ASFV on the expression of SLA-I at the surface of infected cells. 
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Figure 4.3: Effect of ASFV infection and cytokine stimulation on total cellular proteins levels.  
BMDM were infected with ASFV Benin 97/1 (MOI = 2) or stimulated with IFN-γ (0.25 μg.ml-1) and  
changes in total cellular protein levels over 16 hours were measured by scintillation counter as 
counts per minute (CPM) of incorporated [35S]-cysteine/methionine, with CPM values normalised to 
those of mock infected cells. Error bars5 depict standard deviation. Replicates per time point: 6 hpi, 
n = 3; 8 hpi, n = 4; 12 hpi, n = 4; 16 hpi, n = 8. Data were collected over five experiments. Results 
were analysed by repeated measures one-way ANOVA. 
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Figure 4.4: Effect of ASFV infection and cytokine stimulation on total cell counts.  
BMDM seeded at 5 x 106 cells per well in 6-well cell culture plates and matured for five days  were 
infected with ASFV Benin 97/1 (MOI = 2) or stimulated with IFN-γ (0.25 μg.ml-1) and counts of live 
macrophages  measured across 16 hours by flow cytometry. Error bars depict standard deviation. 
Replicates per time point: n = 4. Data were collected over four experiments and results were 
analysed by repeated measures one-way ANOVA. 
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Figure 4.5: Effect of ASFV infection and cytokine stimulation on total cellular proteins 
synthesis levels normalised to total cell counts.  
Combination of the data presented in figure 4.3 and figure 4.4 to demonstrate the relationship 
between total cellular protein levels over 16 hours as measured by scintillation count as counts per 
minute (CPM) of incorporated [35S]-cysteine/methionine in relation to counts of live macrophages  
measured across 16 hours by flow cytometry. Mean scintillation count values for each time point 
were normalised to mean cell counts for each time point. 
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4.2.4. Measuring changes in surface expression of SLA-I induced by infection of 
BMDM with various isolates of ASFV 
Shortly after this project investigating ASFV membrane proteins with potential immune 
evasion functions began, Hurtado et al. (2011) implicated ASFV C-type lectin protein 
EP153R in the modulation of host MHC class I expression, reporting that EP153R was able 
to prevent an up-regulation of SLA-I expression in response to both ASFV infection and 
stimulation by PMA/ionomycin. The suggested mechanism for this modulation was direct 
binding of EP153R to MHC class I, as demonstrated in a proposed structural model (see 
Chapter 3.2.4, figure 3.8), although the authors did not determine at which stage of the MHC 
class I antigen presentation pathway this viral protein exerts its influence. The decision was 
made to focus this project on EP153R and further evaluate these published results.  
Naturally attenuated field isolate ASFV NH/P68 contains frame-shift mutations which 
abrogate the expression of EP153R as well as CD2v, the product of the EP402R gene 
immediately downstream from EP153R. As described in detail in Chapter 2.3, two 
recombinants of this isolate, ASFV NH/P68 Rec 4 and NH/P68 Rec 34, express a modified 
form of CD2v with the cytoplasmic domain containing a 67 amino acid truncation and an 
altered sequence of the 55 amino acids at the C-terminal end. ASFV NH/P68 Rec 4 also 
expresses intact wild-type EP153R whereas in ASFV NH/P68 Rec34 the EP153R gene has 
the same interruption as in parental NH/P68 (figure 2.1). These parental and recombinant 
viruses were used in a preliminary experiment to investigate the effect of EP153R on SLA-I 
expression during ASFV infection. BMDM were cultured for 5 days, then infected with 
ASFV NH/P68 and recombinants NH/P68 Rec 4 and NH/P68 Rec 34 at MOI = 2, mock-
infected or stimulated with recombinant porcine IFN-γ at 0.25 μg.ml-1 for 16 hours. Cells 
were then fixed in 4% PFA, harvested, and technical triplicates of each sample surface-
labelled with antibodies against viral protein VP30 and SLA-I. Surface expression of SLA-I 
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Figure 4.6: Effect of infection with ASFV isolate NH/P68 and recombinants on 
surface SLA-I expression.  
BMDM from four animals were infected with attenuated field isolate ASFV NH/P68 and 
recombinants NH/P68 Rec 4 and Rec 34 at MOI = 2 and median fluorescent intensity 
(MFI) of surface SLA-I expression evaluated at 16 hours post infection. MFI values were 
normalised to mock-infected values. Cells were fixed and surface labelled with anti-SLA-I 
antibody followed by isotype-specific Alexa Fluor 488 secondary antibody. Infected cells 
were also labelled with an antibody against viral protein VP30 followed by isotype-specific 
Alexa Fluor 647 secondary antibody as a marker of infection. Median fluorescent intensity 
of SLA-I was measured by flow cytometry with gating for monocytes/macrophages, plus 
gating for expression of VP30 in infected cells. (*) indicates significantly different 
expression between isolates by repeated measures one-way ANOVA. Error bars depict 
standard deviation. Replicates per treatment: n = 4, except infection with ASFV NH/P68 
Rec 4, where n = 3. Data were collected over four experiments.  
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Table 4.1: Analysis of the effect of ASFV infection on surface SLA-I expression in BMDM 
infected with ASFV NH/P68 and recombinants. 
Tukey’s multiple comparisons test one-way ANOVA of SLA-I expression in ASFV-infected BMDM 
relative to mock as measured by flow cytometry with gating for infected macrophage/monocytes only, 
with comparisons of all isolates and treatments to mock, and within-isolate comparison of parental 
and mutant strains. 
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Summary Adjusted P 
Value 
Mock vs. NH/P68 parental -0.247 -0.562 to 0.069 ns 0.1724 
Mock vs. NH/P68 Rec 34 0.189 -0.126 to 0.504 ns 0.3867 
Mock vs. NH/P68 Rec 4 0.256 -0.084 to 0.597 ns 0.1997 
NH/P68 parental vs. NH/P68 Rec 34 0.436 0.120 to 0.751 ** 0.0034 
NH/P68 parental vs. NH/P68 Rec 4 0.503 0.162 to 0.843 ** 0.0016 
NH/P68 Rec 34 vs. NH/P68 Rec 4 0.067 -0.274 to 0.408 ns 0.9521 
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in infected cells was analysed by flow cytometry with gating for live macrophages and 
infected cells as determined by expression of VP30. This experiment was performed four 
times with cells from four different animals, and the results, as shown in figure 4.6, were 
analysed by repeated measures one-way ANOVA (table 4.1). SLA-I expression was not 
observed to be significantly different from the mock-infected treatment in cells infected with 
ASFV NH/P68 (mean fold-change = 1.25 ± 0.31), NH/P68 Rec 34 (mean fold-
change = 0.81 ± 0.34) or NH/P68 Rec 4 (mean fold-change = 0.74 ± 0.36), However, 
expression was significantly lower in cells infected with ASFV NH/P68 Rec 34 (p = 0.0034) 
and NH/P68 Rec 4 (p = 0.0016) than infected with parental NH/P68.  
EP153R is expressed in ASFV NH/P68 Rec 4 and not in NH/P68 Rec 34, but no significant 
difference was seen between SLA-I expression in BMDM infected with ASFV 
NH/P68 Rec 4 or NH/P68 Rec 34, suggesting that EP153R expression did not affect levels of 
SLA-I surface expression in these recombinant virus isolates. However, infection with ASFV 
NH/P68 lead to significantly higher levels of surface SLA-I expression than NH/P68 Rec 4 
and NH/P68 Rec 34, both of which expressed truncated/modified CD2v. Based on these 
initial results, it appeared that CD2v may exert more of an influence on SLA-I expression 
than EP153R. Consequently, in further infection experiments virulent isolates ASFV Benin 
97/1 and Malawi Lil 20-1 and their ΔCD2v deletion mutants plus Malawi Lil 20-1 ::CD2v 
revertant were included in addition to parental NH/P68 and its recombinants in order to 
evaluate the effect of ASFV protein CD2v on surface SLA-I expression.  
Ten further experiments were performed, making a total of 13, in which BMDM were 
cultured for 5 days and then infected with ASFV NH/P68 and recombinants NH/P68 Rec 4 
and NH/P68 Rec 34, Benin 97/1 and ASFV Benin 97/1 ΔCD2v, Malawi Lil 20-1, 
Malawi Lil 20-1 ΔCD2v and Malawi Lil 20-1 ::CD2v at MOI = 2, mock-infected or 
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Figure 4.7: Effect of ASFV infection with various isolates on surface SLA-I expression.  
BMDM were infected with attenuated field isolate ASFV NH/P68 and recombinants NH/P68 Rec 4 
and NH/P68 Rec 34 or virulent isolates Benin 97/1 and Malawi Lil 20-1 and their ΔCD2v deletion 
mutants/revertants at MOI = 2, or stimulated with IFN-γ (0.25 μg.ml-1) and median fluorescent 
intensity of surface SLA-I expression evaluated at 16 hours post infection. Cells were fixed and 
surface labelled with anti-SLA-I antibody followed by isotype-specific Alexa Fluor 488 secondary 
antibody. Infected cells were also labelled with an antibody against viral protein VP30 followed by 
isotype-specific Alexa Fluor 647 secondary antibody as a marker of infection. Median fluorescent 
intensity of SLA-I was measured by flow cytometry with gating for monocytes/macrophages, plus 
gating for expression of VP30 in infected cells, (*) indicates samples with significantly different 
relative SLA-I expression from mock by one-way ANOVA, while (*) indicates significantly 
different within-isolate SLA-I expression. (A) Data represented as a min to max box and whiskers 
plot to show variations in patterns of SLA-I surface expression by ASFV isolate and (B) data 
represented as an XY plot of technical triplicate values from individual pigs to show variability in 
results by animal. Each specific colour/shape combination represents one of 13 animals from which 
BMDM were obtained. Error bars depict standard deviation. Replicates per treatment: Mock-
infected, n = 13; NH/P68, n = 8; NH/P68 Rec 34, n = 9; NH/P68 Rec 4, n = 8; Benin 97/1, n = 8; 
Benin 97/1 ΔCD2v, n = 7; Malawi Lil 20-1, n = 7; Malawi Lil 20-1 ΔCD2v, n = 7; Malawi Lil 20-1 
rev, n = 7; IFN-γ, n = 12. Data were collected over 13 experiments. 
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Table 4.2: Analysis of the effect of ASFV infection on surface SLA-I expression in BMDM in 
cells infected with ASFV NH/P68, Benin 97/1, Malawi Lil 20-1 and recombinants. 
Tukey’s multiple comparisons test one-way ANOVA of SLA-I expression in ASFV-infected BMDM 
relative to mock as measured by flow cytometry with gating for infected macrophage/monocytes only, 
with comparisons of all isolates and treatments to mock, and within-isolate comparison of parental 
and mutant strains. 
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Summary Adjusted P 
Value 
Mock vs. NH/P68 parental -0.299 -0.875 to 0.277 ns 0.8187 
Mock vs. NH/P68 Rec 34 -0.114 -0.689 to 0.462 ns 0.9998 
Mock vs. NH/P68 Rec 4 -0.317 -0.915 to 0.281 ns 0.7990 
Mock vs. Benin 97/1 -1.959 -2.557 to -1.361 **** < 0.0001 
Mock vs. Benin 97/1 ∆CD2v -0.484 -1.109 to 0.141 ns 0.2897 
Mock vs. Malawi Lil 20-1 -0.936 -1.561 to -0.311 *** 0.0001 
Mock vs. Malawi Lil 20-1 ∆CD2v -0.766 -1.391 to -0.141 ** 0.0046 
Mock vs. Malawi Lil 20-1 rev -0.767 -1.392 to -0.142 ** 0.0045 
Mock vs. IFN-γ -1.661 -2.190 to -1.133 **** < 0.0001 
NH/P68 parental vs. NH/P68 Rec 34 0.185 -0.459 to 0.829 ns 0.9958 
NH/P68 parental vs. NH/P68 Rec 4 -0.018 -0.682 to 0.645 ns > 0.9999 
NH/P68 Rec 34 vs. NH/P68 Rec 4 -0.204 -0.867 to 0.460 ns 0.9932 
Benin 97/1 vs. Benin 97/1 ∆CD2v 1.475 0.769 to 2.182 **** < 0.0001 
Malawi Lil 20-1 vs. Malawi Lil 20-1 
∆CD2v 
0.170 -0.560 to 0.900 ns 0.9992 
Malawi Lil 20-1 vs. Malawi Lil 20-1 rev 0.169 -0.561 to 0.899 ns 0.9992 
Malawi Lil 20-1 ∆CD2v vs. Malawi Lil 
20-1 rev 
-0.001 -0.731 to 0.729 ns > 0.9999 
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stimulated with recombinant porcine IFN-γ at 0.25 μg.ml-1 for 16 hours. The number of wells 
of microtitre plates which could be seeded with BMDM depended on the quantity of cells 
available after processing, meaning that not every experiment contained all isolates of ASFV, 
but each isolate was used in at least seven experiments. Cells were fixed in 4% PFA, 
harvested and surface-labelled with antibodies against viral protein VP30 and SLA-I. Surface 
expression of SLA-I in infected cells was analysed by flow cytometry with gating for live 
macrophages and infected cells as determined by expression of VP30. Results were analysed 
by repeated measures one-way ANOVA (table 4.2).  
An increase in the number of replicates changed the results of infection with ASFV NH/P68 
and its recombinants so that no significant difference was seen in surface SLA-I expression 
between mock-infected BMDM and cells infected with ASFV NH/P68 (mean fold-
change = 1.3 ± 0.40), NH/P68 Rec 4 (mean fold-change = 1.3 ± 0.60) or NH/P68 Rec 34 
(mean fold-change = 1.1 ± 0.48) (figure 4.7-A). All of the virulent isolates except ASFV 
Benin 97/1 ΔCD2v (mean fold-change = 1.5 ± 0.48) led to a significant up-regulation in 
surface SLA-I compared with mock-infected cells (figure 4.7-A), with the highest up-
regulation seen in cells infected with ASFV Benin 97/1 (mean fold-change = 3.0 ± 1.0; 
p < 0.0001). Infection with ASFV Malawi Lil 20-1 caused a mean fold-change of 1.9 ± 0.69 
(p = 0.0003), ASFV Malawi Lil 20-1 ΔCD2v a mean fold-change of 1.8 ± 0.61 (p = 0.0089) 
and Malawi Lil 20-1 ::CD2v a mean fold-change of 1.8 ± 0.48 (p = 0.0087) over surface 
SLA-I expression in mock-infected cells. Stimulation with IFN-γ induced significantly 
greater expression of surface SLA-I than mock-infected cells (mean fold-change = 2.8 ± 1.4; 
p < 0.0001). ASFV Benin 97/1 and ASFV Benin 97/1 ΔCD2v demonstrated a significant 
difference in surface SLA-I expression between them, with expression of SLA-I on ASFV 
Benin 97/1-infected cells double that of cells infected with ASFV Benin 97/1 ΔCD2v 
(p < 0.0001) (table 4.2). 
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These experiments were carried out in primary cells, with the full range of data points in 
figure 4.7-A representing cells from 13 different animals. Each pig varied slightly in age, 
weight, state of health, and, since they were outbred animals, genetic makeup. As such, the 
strength of immune response differed between each animal, as demonstrated by the large 
margin of error seen for the effect of IFN-γ stimulation on SLA-I expression. To demonstrate 
the high variability in response between animals, figure 4.7-B presents the same data as in 
figure 4.7-A, but represented as results from individual animals. Each set of three symbols 
represents technical triplicates within a single sample, and each different colour/shape symbol 
represents the data from a different pig. As mentioned above, due to the varying quantity of 
cells available after processing, not every experiment contained all isolates of ASFV and so 
some symbol/colour combinations are not seen across all samples. However, each ASFV 
isolate was used in at least seven experiments.  
The greatest variation by animal is seen in the IFN-γ-treated cells. For example, Animal 1 
demonstrates a 6-fold up-regulation in surface SLA-I expression in response to IFN-γ 
stimulation, while in Animal 2 SLA-I expression is reduced almost to zero (figure 4.7-B). 
These two examples are outliers in the response to IFN-γ stimulation, but serve to illustrate 
the wide variation in response by animal, thought to be dependent on the state of activation of 
the animal’s immune system when it was sacrificed. It is interesting to note, however, that the 
responses to infection with ASFV NH/P68 and its recombinant isolates in Animals 1 and 2 
are not outliers but fall within the more tightly grouped range of responses to these viruses.  
Across the range of responses in individual animals, for some animals all responses are raised 
and at the top end of the range of responses for each treatment, such as Animal 11 (figure 
4.7-B). For other animals, such as Animal 12, there is very little response above that of mock-
infected cells across all treatments. For yet others, such as Animal 5, the within-animal 
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responses are more variable, with some falling high in the grouping for a particular treatment 
(e.g. figure 4.7-B: Animal 5; NH/P68 Rec 4) and others falling low in the grouping  (e.g. 
figure 4.7-B: Animal 5; Benin 97/1 ΔCD2v). However, throughout the study results from 
technical replicates were always very closely matched regardless of the treatments used. 
While infection with ASFV was observed to modulate surface SLA-I expression in these 
experiments, it could not be concluded whether changes were a direct result of viral infection 
or due to an induced inflammatory response as a result of infection. 
4.2.5. Differentiating between the direct effect of ASFV infection and of 
cytokines produced as a result of infection on SLA-I expression 
In order to establish whether changes seen in SLA-I expression following infection with 
ASFV are a direct effect of virus within infected BMDM or a bystander effect due to 
cytokines released as a result of infection, two methods were employed. Firstly, the data from 
the experiments in Chapter 4.2.4 was interrogated again to obtain values for the expression of 
SLA-I on the surfaces of uninfected cells (as determined by gating for no positive expression 
of viral protein VP30) within cell populations exposed to virus. For the majority of 
treatments, very little to no response is seen in surface SLA-I expression in uninfected cells 
within a treatment exposed to ASFV and no significant up-regulation of surface SLA-I 
relative to mock-infected levels was detected by repeated measures one-way ANOVA. The 
only significant change was observed in VP30-negative cells within cell populations infected 
with ASFV Benin 97/1, which displayed a mean fold-change of 1.8 ± 1.2 in surface 
expression of SLA-I (p < 0.0001) (figure 4.8, table 4.3), although the high standard deviation 
imparts low confidence in this result and the change in SLA-I expression is lower than the 
mean fold-change of 3.0 ± 1.0 seen in VP30-positive cells within the same ASFV Benin 
97/1-infected cell populations (Chapter 4.2.5). 
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Figure 4.8: Effect of ASFV infection on surface SLA-I expression in neighbouring uninfected 
cells within an infected population.  
BMDM were infected with various isolates of ASFV at MOI = 2, or stimulated with IFN-γ 
(0.25 μg.ml-1) and median fluorescent intensity of surface SLA-I expression evaluated at 16 hours 
post infection. Cells were fixed and surface labelled with anti-SLA-I antibody followed by isotype-
specific Alexa Fluor 488 secondary antibody. Infected cells were also labelled with an antibody 
against viral protein VP30 followed by isotype-specific Alexa Fluor 647 secondary antibody as a 
marker of infection. Median fluorescent intensity of SLA-I was measured by flow cytometry with 
gating for monocytes/macrophages, plus gating for expression of VP30 in infected cells. (*) 
indicates samples with significantly different relative SLA-I expression from mock by one-way 
ANOVA, while (*) indicates significantly different within-isolate SLA-I expression. Error bars 
depict standard deviation. Replicates per treatment: Mock-infected, n = 10; NH/P68, n = 6; NH/P68 
Rec 34, n = 6; NH/P68 Rec 4, n = 5; Benin 97/1, n = 5; Benin 97/1 ΔCD2v, n = 4; Malawi Lil 20-1, 
n = 7; Malawi Lil 20-1 ΔCD2v, n = 4; Malawi Lil 20-1 rev, n = 4; IFN-γ, n = 7. Data were collected 
over 10 experiments. 
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Table 4.3: Analysis of the effect of ASFV infection on surface SLA-I expression in neighbouring 
uninfected cells within an infected population.  
Tukey’s multiple comparisons test one-way ANOVA of SLA-I expression in uninfected cells with a 
population of BMDM, as measured by flow cytometry with gating for uninfected 
macrophage/monocytes only, with comparisons of all isolates and treatments to mock, and within-
isolate comparison of parental and mutant strains. 
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Summary Adjusted P 
Value 
Mock vs. NH/P68 parental -0.119 -0.619 to 0.381 ns 0.9989 
Mock vs. NH/P68 Rec 34 0.344 -0.156 to 0.844 ns 0.4544 
Mock vs. NH/P68 Rec 4 0.349 -0.179 to 0.877 ns 0.5124 
Mock vs. Benin 97/1 -0.821 -1.349 to -0.294 **** < 0.0001 
Mock vs. Benin 97/1 ∆CD2v 0.048 -0.519 to 0.614 ns > 0.9999 
Mock vs. Malawi Lil 20-1 -0.122 -0.689 to 0.445 ns 0.9995 
Mock vs. Malawi Lil 20-1 ∆CD2v 0.078 -0.489 to 0.644 ns > 0.9999 
Mock vs. Malawi Lil 20-1 rev 0.003 -0.564 to 0.569 ns > 0.9999 
Mock vs. IFN-γ -1.701 -2.180 to -1.222 **** < 0.0001 
NH/P68 parental vs. NH/P68 Rec 34 0.463 -0.071 to 0.998 ns 0.1518 
NH/P68 parental vs. NH/P68 Rec 4 0.468 -0.092 to 1.029 ns 0.1898 
NH/P68 Rec 34 vs. NH/P68 Rec 4 0.005 -0.555 to 0.566 ns > 0.9999 
Benin 97/1 vs. Benin 97/1 ∆CD2v 0.869 0.248 to 1.490 *** 0.0006 
Malawi Lil 20-1 vs. Malawi Lil 20-1 
∆CD2v 
0.199 -0.455 to 0.854 ns 0.9931 
Malawi Lil 20-1 vs. Malawi Lil 20-1 rev 0.124 -0.530 to 0.779 ns 0.9998 
Malawi Lil 20-1 ∆CD2v vs. Malawi Lil 
20-1 rev 
-0.075 -0.730 to 0.580 ns > 0.9999 
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In a further analysis of whether changes in SLA-I expression observed in infected cells were 
due to bystander effects of host cell cytokines or other factors released in response to ASFV 
infection, the SLA-I expression response of cells treated with media conditioned by ASFV 
infection was measured. Media was harvested at 16 hpi from virus-infected and IFN-γ-
stimulated cells from the experiments described in Chapter 4.2.4 and filtered through a 
1,000,000 mwco Vivaspin column (Sartorius Stedim Biotech, Germany) to remove virus. 
These columns have been shown to retain virus within the upper chamber, while cytokines 
have a low molecular weight and are expected to move with the media through the filter into 
the lower chamber. This virus-depleted conditioned media was then added to fresh matured 
BMDM and incubated for 16 hours before the cells were harvested, labelled for surface 
SLA-I and analysed by flow cytometry in the same manner as the infected cells in Chapter 
4.2.4. No expression of VP30 was detected, confirming that depletion of virus was effective. 
The results from this experiment showed that the conditioned media exerted an influence on 
surface SLA-I expression, although not in complete accordance with the changes observed 
following infection of BMDM with the corresponding ASFV isolate (figure 4.9). Significant 
up-regulation of SLA-I expression from mock-treated cells, as analysed by repeated measures 
one-way ANOVA, was observed in cells treated with conditioned media from infections with 
ASFV Benin 97/1 (mean fold-change = 2.2 ± 1.2; p < 0.0001) and ASFV Malawi Lil 20-1 
(mean fold-change = 2.4 ± 0.74; p < 0.0001) and also from cells stimulated with IFN-γ (mean 
fold-change = 2.4 ± 0.82; p < 0.0001) (table 4.4). When compared with the up-regulation of 
surface SLA-I expression in ASFV-infected cells, conditioned media from infections with 
ASFV Benin 97/1 induce a lower increase in surface SLA-I expression than cells infected 
with the virus (mean fold-change = 3.0 ± 1.0), while conditioned media from infections with 
ASFV Malawi Lil 20-1 induced a higher up-regulation than infected cells
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Figure 4.9: Effect of conditioned media from ASFV infections on surface SLA-I expression.  
BMDM were treated with virus-depleted conditioned media harvested from cells infected with 
various isolates of ASFV at MOI = 2, or stimulated with IFN-γ (0.25 μg.ml-1), and median 
fluorescent intensity of surface SLA-I expression evaluated at 16 hours post infection. Cells were 
fixed and surface labelled with anti-SLA-I antibody followed by isotype-specific Alexa Fluor 488 
secondary antibody. Infected cells were also labelled with an antibody against viral protein VP30 
followed by isotype-specific Alexa Fluor 647 secondary antibody as a marker of infection. Median 
fluorescent intensity of SLA-I was measured by flow cytometry with gating for 
monocytes/macrophages, plus gating for expression of VP30 in infected cells. (*) indicates samples 
with significantly different relative SLA-I expression from mock by one-way ANOVA, while (*) 
indicates significantly different within-isolate SLA-I expression. Error bars depict standard 
deviation. Replicates per treatment: Mock-infected, n = 9; NH/P68, n = 4; NH/P68 Rec 34, n = 4; 
NH/P68 Rec 4, n = 4; Benin 97/1, n = 3; Benin 97/1 ΔCD2v, n = 3; Malawi Lil 20-1, n = 3; Malawi 
Lil 20-1 ΔCD2v, n = 3; Malawi Lil 20-1 rev, n = 3; IFN-γ, n = 6. Data were collected over nine 
experiments. 
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Table 4.4: Analysis of the effect of conditioned media from ASFV infections on surface SLA-I 
expression.  
Tukey’s multiple comparisons test one-way ANOVA of SLA-I expression in BMDM treated with 
virus-depleted conditioned media harvested from cells infected with various isolates of ASFV, as 
measured by flow cytometry with gating for macrophages/monocytes, with comparisons of all isolates 
and treatments to mock, and within-isolate comparison of parental and mutant strains. 
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Summary Adjusted P 
Value 
Mock vs. NH/P68 parental -0.094 -0.686 to 0.497 ns > 0.9999 
Mock vs. NH/P68 Rec 4 -0.323 -0.914 to 0.269 ns 0.7580 
Mock vs. NH/P68 Rec 34 0.030 -0.562 to 0.621 ns > 0.9999 
Mock vs. Benin 97/1 -1.176 -1.832 to -0.520 **** < 0.0001 
Mock vs. Benin 97/1 ∆CD2v -0.497 -1.153 to 0.159 ns 0.3110 
Mock vs. Malawi Lil 20-1 -1.408 -2.064 to -0.752 **** < 0.0001 
Mock vs. Malawi Lil 20-1 ∆CD2v -0.414 -1.070 to 0.242 ns 0.5743 
Mock vs. Malawi Lil 20-1 rev -0.501 -1.157 to 0.155 ns 0.2988 
Mock vs. IFN-γ -1.402 -1.920 to -0.883 **** < 0.0001 
NH/P68 parental vs. NH/P68 Rec 4 -0.228 -0.924 to 0.468 ns 0.9876 
NH/P68 parental vs. NH/P68 Rec 34 0.124 -0.572 to 0.820 ns 0.9999 
NH/P68 Rec 4 vs. NH/P68 Rec 34 0.352 -0.343 to 1.048 ns 0.8287 
Benin 97/1 vs. Benin 97/1 ∆CD2v 0.679 -0.125 to 1.482 ns 0.1758 
Malawi Lil 20-1 vs. Malawi Lil 20-1 
∆CD2v 0.993 0.190 to 1.797 ** 0.0044 
Malawi Lil 20-1 vs. Malawi Lil 20-1 rev 0.907 0.103 to 1.710 * 0.0143 
Malawi Lil 20-1 ∆CD2v vs. Malawi Lil 
20-1 rev -0.087 -0.890 to 0.717 ns > 0.9999 
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(mean fold-change = 1.9 ± 0.7). There was no significant difference in up-regulation of 
surface SLA-I between cells treated with conditioned media from infections with ASFV 
NH/P68 and its recombinants, or between cells treated with conditioned media from 
infections with ASFV Benin 97/1 and Benin 97/1 ΔCD2v. However, conditioned media from 
infections with wild-type virulent isolate ASFV Malawi Lil 20-1 induced a significantly 
higher up-regulation of surface SLA-I than its recombinants ASFV Malawi Lil 20-1 ΔCD2v 
(p = 0.0044) and ASFV Malawi Lil 20-1 ::CD2v (p = 0.0143) (table 4.4). 
The results from the preceding sections provide an evaluation of the effect of ASFV infection 
on SLA-I expression in BMDM. However, previous studies into changes in SLA-I expression 
induced by ASFV (Gonzalez-Juarrero et al., 1992b; Netherton et al., 2006) were not 
performed on BMDM, but were performed using macrophages matured from peripheral 
blood mononuclear cells (PBMC). 
4.2.6. Measuring changes in surface expression of SLA-I induced by infection of 
PBMC with various isolates of ASFV 
To compare the effect of ASFV infection on SLA-I expressed at the surface of bone marrow- 
and blood-derived macrophages, PBMC were obtained as described in Chapter 2.2.2.3, 
matured for 5 days and then infected with ASFV NH/P68, NH/P68 Rec 4, NH/P68 Rec 34, 
Benin 97/1, Benin 97/1 ΔCD2v, Malawi Lil 20-1,  Malawi Lil 20-1 ΔCD2v and Malawi Lil 
20-1 ::CD2v at MOI = 2, mock-infected or stimulated with recombinant porcine IFN-γ at 
0.25 μg.ml-1 for 16 hours. Changes in surface SLA-I expression were measured by flow 
cytometry with gating for infected macrophages/monocytes and the results analysed by 
repeated measures one-way ANOVA (figure 4.10). No significant up-regulation of surface 
SLA-I from mock-infected cells was seen in response to stimulation with IFN-γ (mean fold-
change = 1.7 ± 0.38). Infection with ASFV Benin 97/1 and ASFV NH/P68 Rec 34 induced 
significant mean fold-changes of 1.9 ± 0.26 (p = 0.0204) and 1.8 ± 1.0 (p = 0.0256) in surface 
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Figure 4.10: Effect of ASFV infection with various isolates on surface SLA-I expression in 
PBMC.  
Matured PBMC were infected with various isolates of ASFV at MOI = 2, or stimulated with IFN-γ 
(0.25 μg.ml-1) and median fluorescent intensity of surface SLA-I expression evaluated at 16 hours 
post infection. Cells were fixed and surface labelled with anti-SLA-I antibody followed by isotype-
specific Alexa Fluor 488 secondary antibody. Infected cells were also labelled with an antibody 
against viral protein VP30 followed by isotype-specific Alexa Fluor 647 secondary antibody as a 
marker of infection. Median fluorescent intensity of SLA-I was measured by flow cytometry with 
gating for monocytes/macrophages, plus gating for expression of VP30 in infected cells. (*) 
indicates samples with significantly different relative SLA-I expression from mock by one-way 
ANOVA. (A) Data represented as a min to max box and whiskers plot to show variations in patterns 
of SLA-I surface expression by ASFV isolate and (B) data represented as an XY plot of technical 
triplicate values from individual pigs to show variability in results by animal. Each specific 
colour/shape combination represents one of six animals from which PBMC were obtained. Error 
bars depict standard deviation. Replicates per treatment: Mock-infected, n = 7; NH/P68, n = 6; 
NH/P68 Rec 34, n = 6; NH/P68 Rec 4, n = 4; Benin 97/1, n = 5; Benin 97/1 ΔCD2v, n = 5; Malawi 
Lil 20-1, n = 3; Malawi Lil 20-1 ΔCD2v, n = 7; Malawi Lil 20-1 rev, n = 8; IFN-γ, n = 5. Data were 
collected over seven experiments. 
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Table 4.5: Analysis of the effect of ASFV infection on surface SLA-I expression in PBMC.  
Tukey’s multiple comparisons test one-way ANOVA of SLA-I expression in ASFV-infected PBMC 
relative to mock as measured by flow cytometry with gating for live infected cells only, with 
comparisons of all isolates and treatments to mock, and within-isolate comparison of parental and 
mutant strains. 
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Summary Adjusted P 
Value 
Mock vs. NH/P68 parental -0.559 -1.290 to 0.172 ns 0.3002 
Mock vs. NH/P68 Rec 4 -1.213 -2.008 to -0.419 *** 0.0001 
Mock vs. NH/P68 Rec 34 -0.783 -1.514 to -0.052 * 0.0256 
Mock vs. Benin 97/1 -0.869 -1.663 to -0.074 * 0.0204 
Mock vs. Benin 97/1 ∆CD2v -0.371 -1.147 to 0.405 ns 0.8744 
Mock vs. Malawi Lil 20-1 -0.249 -1.121 to 0.623 ns 0.9956 
Mock vs. Malawi Lil 20-1 ∆CD2v -0.335 -1.044 to 0.374 ns 0.8819 
Mock vs. Malawi Lil 20-1 rev -0.453 -1.152 to 0.247 ns 0.5429 
Mock vs. IFN-γ -0.732 -1.508 to 0.044 ns 0.082 
NH/P68 parental vs. NH/P68 Rec 4 -0.655 -1.477 to 0.169 ns 0.2481 
NH/P68 parental vs. NH/P68 Rec 34 -0.224 -0.986 to 0.538 ns 0.9946 
NH/P68 Rec 4 vs. NH/P68 Rec 34 0.431 -0.392 to 1.254 ns 0.803 
Benin 97/1 vs. Benin 97/1 ∆CD2v 0.498 -0.365 to 1.361 ns 0.6981 
Malawi Lil 20-1 vs. Malawi Lil 20-1 
∆CD2v -0.086 -0.966 to 0.794 ns > 0.9999 
Malawi Lil 20-1 vs. Malawi Lil 20-1 rev -0.204 -1.076 to 0.668 ns 0.9991 
Malawi Lil 20-1 ∆CD2v vs. Malawi Lil 
20-1 rev -0.118 -0.827 to 0.591 ns > 0.9999 
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SLA-I respectively. However, the highest up-regulation in induction of surface SLA-I 
expression was in response to infection with ASFV NH/P68 Rec 4, with a mean fold-change 
of 2.2 ± 0.74 (p > 0.005) compared to mock-infected cells (figure 4.10-A, table 4.5). These 
results are in contrast to those obtained in BMDM when infected with ASFV NH/P68 Rec 4 
(mean fold-change = 1.3 ± 0.60), ASFV Benin 97/1 (mean fold-change = 3.0 ± 1.0) and 
ASFV NH/P68 Rec 34 (mean fold-change = 1.1 ± 0.48) (figure 4.7).  
In the same manner as in figure 4.7-B, the data in figure 4.10-A is represented again in figure 
4.10-B as results from individual animals in order to demonstrate the high variability in 
response between animals. Each set of three symbols represents technical triplicates within a 
single sample, and each different colour/shape symbol represents the data from a different 
pig. Again, due to numbers of cells obtained after processing, not every ASFV isolate was 
used to infect the cells obtained from every animal, meaning some symbol/colour 
combinations are not seen across all samples. As in BMDM, there is a high variation in 
results between animals with some animals demonstrating a down-regulation in surface 
SLA-I expression across infections with all ASFV isolates coupled to an up-regulation in 
SLA-I in response to stimulation with IFN-γ (figure 4.10-B: Animal 14), in some animals 
there was a uniform level of up-regulation across all treatments (figure 4.10-B: Animal 18), 
while in others there was an up-regulation of surface SLA-I in response to infection with 
ASFV Benin 97/1 but no change in expression across any other treatments (figure 4.10-B: 
Animal 16). Only one animal provided both PBMC and BMDM to allow direct comparison 
of response across cell types, and the changes in surface SLA-I expression for each treatment 
in both cell sets are consistent (figure 4.7-B, figure 4.10-B: Animal 12). As for the 
experiments with BMDM, results between technical replicates in PBMC were highly 
consistent. 
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The high level of variability in modulation of surface SLA-I expression between isolates of 
ASFV, cell type and animal from which cells were obtained highlighted the need to 
investigate the effect of viral proteins EP153R and CD2v in isolation from other viral 
proteins, and also in established cells line which are more homogeneous in terms of maturity 
and activation than primary macrophages. Additionally, revertant recombinant isolates with 
intact CD2v restored were only available for ASFV Malawi Lil 20-1, but not Benin 97/1 or 
NH/P68. 
4.2.7. Changes in expression of HLA class I in Vero cells infected with ASFV 
BA71V and ASFV BA71V ΔEP153R/ΔCD2v  
In studies with wild type and deletion mutant viruses, revertant recombinant viruses are 
commonly used as controls to confirm that any observed effect between the parental and 
recombinant isolates is due to the deleted gene/s. Where a revertant recombinant virus is not 
available, it is possible to use exogenous expression through transfection with an expression 
construct containing the gene of interest prior to infection of cells with the deletion mutant. 
Primary macrophage cultures have low transfection efficiency compared to many established 
cells lines, which limits the possibility of further investigating the effect of EP153R by means 
of transfecting the gene into BMDM infected with ΔEP153R field isolates ASFV NH/P68 or 
ASFV NH/P68 Rec 34.  
Since Vero cell cultures have a higher transfection efficiency, a deletion mutant of the tissue 
culture adapted isolate ASFV BA71V with the EP153R and EP402R genes deleted 
(ΔEP153R/ΔCD2v) (Abrams & Dixon, 2012) was used to infect Vero cells alongside wild-
type ASFV BA71V to evaluate the effect of deletion of these genes on expression of the 
primate homologue of SLA-I, HLA class I. Cells were also stimulated with porcine or human 
recombinant IFN-γ at 0.25 μg.ml-1 for 16-24 hours as an HLA class I up-regulation control. 
Cells were then harvested, fixed in 4% PFA and technical triplicates labelled for HLA class I 
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Figure 4.11: Effect of ASFV infection on surface HLA class I expression in Vero cells.  
Vero (green monkey kidney) cells were infected with tissue-culture adapted strain ASFV 
BA71V or deletion mutant BA71V ΔEP153R/ΔCD2v at MOI = 2, or stimulated with IFN-γ 
(0.25 μg.ml-1) and median fluorescent intensity of surface HLA class I expression relative to 
mock-infected evaluated at 16-24 hours post infection. Cells were fixed and surface labelled 
with anti-HLA antibody followed by isotype-specific Alexa Fluor 488 secondary antibody. 
Infected cells were also labelled with an antibody against viral protein VP30 followed by 
isotype-specific Alexa Fluor 647 secondary antibody as a marker of infection. Median 
fluorescent intensity of SLA-I was measured by flow cytometry with gating for single cells, 
plus gating for expression of VP30 in infected cells. Error bars depict standard deviation. 
Replicates per treatment: Mock-infected, n = 3; BA71V, n = 8; BA71V ΔEP153R/ΔCD2v, 
n = 3; IFN-γ, n = 2. Data were collected over three experiments 
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Table 4.6: Analysis of the effect of ASFV infection on surface HLA class I expression in Vero 
cells.  
Tukey’s multiple comparisons test one-way ANOVA of HLA class I expression in Vero cells infected 
with ASFV BA71V and BA71V ΔEP153R/ΔCD2v, relative to mock as measured by flow cytometry 
with gating for single infected cells only, with comparisons of both isolates and treatments to mock, 
and within-isolate comparison of parental and mutant strains. 
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Summary Adjusted P 
Value 
Mock vs. BA71V 0.054 -0.282 to 0.391 ns 0.9709 
Mock vs. BA71V ΔEP153R/ΔCD2v 0.223 -0.114 to 0.559 ns 0.2921 
Mock vs. IFN-γ 0.193 -0.183 to 0.569 ns 0.5119 
BA71V vs. BA71V ΔEP153R/ΔCD2v 0.168 -0.168 to 0.504 ns 0.5317 
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and viral protein VP30. Expression of HLA class I was measured by flow cytometry with 
gating for single infected cells, as determined by detection of VP30. Results were analysed by 
repeated measures one-way ANOVA of HLA class I expression relative to mock-infected 
cells. No significant difference was seen in surface HLA class I expression between cells 
infected with ASFV BA71V wild-type (mean fold-change = 0.95 ± 0.42) or deletion mutant 
ASFV BA71V ΔEP153R/ΔCD2v (mean fold-change = 0.78 ± 0.26), or cells stimulated with 
IFN-γ (mean fold-change = 0.81 ± 0.06) (figure 4.11, table 4.6). As no difference in induced 
HLA class I expression was observed between the two virus isolates, and the apparent 
resistance of Vero cells to stimulation of HLA class I by IFN-γ, the planned second stage of 
this experiment, transient transfection of Vero cells with EP153R and CD2v using expression 
vector constructs described in Chapter 6.2.1.1 combined with infection with ASFV BA71V 
ΔEP153R/ΔCD2v, was not carried out.  
4.2.8. Visualising surface expression of SLA-I in cells BMDM infected with 
ASFV 
Complimentary to the evaluation of changes in levels of detected SLA-I on the surface of 
cells by flow cytometry, immunofluorescence allows visualisation of the relative localisation 
of SLA-I on the surface and in the cytoplasm of uninfected cells and cells infected with 
ASFV. BMDM were seeded onto coverslips and matured for 5 days before being mock 
infected (figure 4.12-A,B,C) or infected with ASFV Benin 97/1 at MOI = 4  (figure 
4.12-D,E,F) for 16 hours. Cells were fixed in 4% PFA and either permeabilised with 0.2% 
TritonX-100 (figure 4.12-A,B,D,E) for internal labelling or surface labelled (figure 4.12-C,F) 
for cellular markers for the ER (figure 4.12-A,D), Golgi (figure 4.12-B,E), and mature 
macrophage surface marker CD203a (figure 4.12-C,F). Cells infected with ASFV Benin 97/1 
were also labelled for viral protein VP72 as a marker of infection (figure 4.12-D,E,F).  
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A 
B 
C 
Figure 4.12: Localisation of SLA-I in 
infected and uninfected BMDM 
BMDM were seeded onto 13 mm coverslips 
and matured for 5 days before being (A-C) 
mock-infected or (D-F) infected with ASFV 
Benin 97/1 at MOI = 4. At 16 hpi samples 
were fixed and either (A,B,D,E) permeabilised 
with 0.2% TritonX-100 or (C,F) surface 
labelled with anti-SLA-I antibody (shown in 
green) followed by isotype-specific Alexa 
Fluor 488 secondary antibody. Cells were also 
labelled with antibodies against cellular 
markers for the ER (ERp60), Golgi (β-COP) or 
macrophage surface marker CD203a (all 
shown in red) followed by species- or isotype-
specific Alexa Fluor 568 secondary antibody. 
Infected cells were also labelled with an 
antibody against viral protein VP72 followed 
by isotype-specific Alexa Fluor 647 secondary 
antibody as a marker of infection (shown in 
white). Coverslips were mounted with 
Vectashield plus DAPI nuclear stain (shown in 
blue). Cells infected with ASFV are indicated 
with arrows (D-F). 
163 
 
 
F 
E 
D 
164 
 
SLA-I did not localise to the ER in either uninfected (figure 4.12-A) or ASFV-infected (figure 
4.12-D) cells. Some degree of localisation of intracellular SLA-I to the marker for the Golgi 
was observed in uninfected cells (figure 4.12-B), but not in ASFV-infected cells (figure 
4.12-E). SLA-I was expressed on the surface of uninfected (figure 4.12-C) and ASFV-infected 
(figure 4.12-F) cells, as demonstrated by co-localisation with mature macrophage surface 
marker CD203a. Across all cells and treatments labelling for cytoplasmic and surface SLA-I is 
highly variable between cells, with both uninfected and ASFV-infected cells showing both high 
and low levels of SLA-I expression.  
4.3. Discussion 
4.3.1. Optimisation of experimental conditions for evaluation of SLA-I expression 
Monocytes harvested from pig bone marrow must mature in vitro before they become 
susceptible to ASFV infection or respond to cytokine stimulation. Maturation of monocytes, as 
determined by up-regulation of marker of mature macrophages CD203a, has been 
demonstrated to correlate with increased susceptibility of these cells to ASFV infection 
(McCullough et al., 1999; Sanchez-Torres et al., 2003). Surface SLA-I expression had been 
shown to peak at days 3-4 of maturation in PBMC, with a dramatic decrease in surface 
expression by day six (Gonzalez-Juarrero et al., 1992b). The data presented in this chapter, 
obtained by tracking the expression of total and surface SLA-I in BMDM over six days of 
maturation post-harvest, showed that peak levels of SLA-I expression are observed after five 
days of maturation of BMDM in culture (figure 4.1). This time point was chosen, whenever 
possible, for analysis of BMDM cells in all experiments described within this thesis. 
Similarly, the effect of viral infection on SLA-I expression was tracked across a time course to 
determine the time point at which maximum differences between uninfected and ASFV-
infected treatments were observed. SLA-I levels in ASFV-infected and IFN-γ-stimulated 
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BMDM were seen to rise steadily from shortly after infection until 16 hpi, with maximum 
differentiation between treatments at 16 hpi (figure 4.2). Measurements were not taken after 
this point as cell death was observed to be high from 16-24 hours. Based on these results, all 
experiments on the effect of ASFV on BMDMs were performed on cells at 16 hpi, or time 
courses up to 16 hpi. 
In addition to determining the optimal time points for expression of the protein of interest, 
when evaluating the targeted and specific effect of a viral protein on host cells it is also 
important to consider the overall effect of the virus on host cell protein translation, synthesis 
and transport. Measures of changes in total protein synthesis as measured by incorporation of 
[35S]-cysteine/methionine revealed that host protein synthesis decreased from around 12 hpi in 
cells infected with ASFV Benin or Benin ΔCD2v, but increased in cells stimulated with IFN-γ 
(figure 4.3). However, ASFV infection triggers apoptosis at 12-16 hpi and high levels of cell 
death are observed from 16-24 hpi (Portugal et al., 2009; Tulman et al., 2009) and stimulation 
with IFN-γ was also observed in these experiments to cause some cell death by 16 hours post-
treatment (figure 4.4). On normalisation of protein synthesis data in figure 4.3 to the cell 
number data in figure 4.4 it was shown that protein synthesis rate per cell infected with ASFV 
remained fairly constant, with an increase from 4-12 hpi, and a slight decrease from 12-16 hpi, 
while synthesis per cell increased from 8-16 hours in cells stimulated with IFN-γ. Previous 
work on tissue-culture adapted strains of ASFV in Vero cells have shown that down-regulation 
of host protein synthesis begins almost immediately following infection, and becomes more 
pronounced from 8 to 12 hours post-infection (Tabarés et al., 1980; Rodríguez et al., 2001). 
However, other studies have shown expression of various host proteins, including pro-
inflammatory cytokines (Gómez del Moral et al., 1999; Gil et al., 2008), MHC class II 
(Gonzalez-Juarrero et al., 1992a; Lithgow et al., 2014), cell surface markers CD45, CD203a 
and CD163 (Lithgow et al., 2014) and MHC class I (Gonzalez-Juarrero et al., 1992a; Vallée et 
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al., 2001; Netherton et al., 2006; Hurtado et al., 2011) continue throughout infection and that 
some ASFV proteins such as DP71L enhance expression of some host genes (Zhang et al., 
2010). Thus, any down-regulation of expression of a particular protein such as SLA-I observed 
in subsequent experiments would need to be further scrutinised to determine whether this 
down-regulation was specific or the result of an overall decrease in protein synthesis and 
transport as a result of ASFV infection. However, any up-regulation observed could be 
assumed to be a targeted effect of viral infection, and such up-regulations may even potentially 
be under-represented if specific upward modulation was in competition with an overall 
downward modulation.  
4.3.2. Effect of ASFV infection on expression of SLA-I 
Previous work by Hurtado et al. (2011) reported that viral protein EP153R prevents up-
regulation of MHC class I at the surface of cytokine-stimulated or ASFV-infected IPAM 
(porcine macrophage-derived cells) or Jurkat (human leukaemia T-cell line) cells. However, in 
order to reconcile the results of Hurtado et al.’s study with the conflicting results of other 
studies into the effect of ASFV on MHC class I expression, it was decided to first examine the 
effect of virus infection on MHC class I expression, making use of ASFV isolates with 
mutations or deletions in genes EP153R or EP402R.  
Infection of BMDM with ASFV isolates Benin 97/1, Malawi Lil 20-1 and NH/P68, as well as 
mutants of these isolates with ΔCD2v (EP402R) and ΔEP153R deletions, interruptions and 
insertions, resulted in a range of levels of SLA-I surface expression, from no significant change 
relative to mock-infected cells in BMDM infected with ASFV NH/P68 or recombinants ASFV 
NH/P68 Rec 34 and NH/P68 Rec 4 to a three-fold up-regulation in BMDM infected with 
ASFV Benin 97/1 (figure 4.7-A). There was no universal effect of infection on surface SLA-I 
expression across all treatments and the level of SLA-I up-regulation was observed to depend 
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on the ASFV isolate infecting the cells. Figure 4.7-B also demonstrates the high level of 
variation in results between BMDM derived from different animals as well as between virus 
isolates. Only in infection with ASFV Benin 97/1 was a significant difference seen between 
infection with the wild-type isolate and the ΔCD2v deletion mutant. No difference was 
observed between surface SLA-I expression in cells infected with ASFV NH/P86, with an 
interrupted EP402R gene and ASFV NH/P86 Rec 4 and NH/P86 Rec 34 with a partially 
restored EP402R gene encoding a modified and truncated form of CD2v, while a significant 
difference was seen between the wild-type isolate and ΔCD2v deletion mutant of ASFV Benin 
97/1. This may be due to the abrogation of the proline-rich repeats within the cytoplasmic tail 
of wild-type CD2v in ASFV NH/P86 Rec 4 and NH/P86 Rec 34. The proline-rich repeats of 
CD2v have been shown to bind to mammalian actin-binding protein 1 (mAbp1) within virus 
factories in the Golgi region (Kay-Jackson et al., 2004). mAbp1 is an adaptor protein which 
links antigen receptor signalling to components of the cytoskeleton through association with 
actin filaments and is predicted to interact with transport vesicles while they are loaded at the 
Golgi, preventing premature release before these vesicles are correctly loaded with proteins for 
transport to the cell surface (Larbolette et al., 1999). The proposed function of CD2v when 
bound to mAbp1 is the modulation of protein transport to the surface of ASFV-infected cells 
(Kay-Jackson et al., 2004), meaning that transport of all proteins, including SLA-I, may be 
affected by the deletion of EP402R gene or the abrogation of the function of  its cytoplasmic 
region. This would not, however, explain why no difference in surface SLA-I expression is 
observed between cells infected with ASFV Malawi Lil 20-1 and Malawi Lil 20-1 ::CD2v, 
which both express intact CD2v, and ASFV Malawi Lil 20-1 ΔCD2v. 
Investigation into the effect of ASFV infection on SLA-I expression at the surface of bystander 
cells found that a significant up-regulation from mock-infected cells was induced only in 
uninfected cells within treatments infected with ASFV Benin 97/1 (figure 4.8). For all other 
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virus isolates no significant increase in surface SLA-I expression was induced in bystander 
cells. The results were similar when BMDM were treated with conditioned media harvested 
from ASFV infections; no significant increase in surface SLA-I expression was observed when 
cells were treated with conditioned media from infections with ASFV NH/P68 and its 
recombinants, ASFV Benin 97/1 ΔCD2v, ASFV Malawi Lil 20-1 ΔCD2v or ASFV 
Malawi Lil 20-1 ::CD2v. However, conditioned media from infections with ASFV Benin 97/1 
and ASFV Malawi Lil 20-1 wild-type isolates did induce significant increases in surface SLA-I 
expression. As with the direct effect of ASFV-infection, there was no universally induced 
change in surface SLA-I expression in response to cytokines released as a result of infection 
with ASFV in uninfected cells. Only infection of cells with wild-type virulent isolates ASFV 
Benin 97/1 and Malawi Lil 20-1 induced any bystander effect on SLA-I expression. However, 
of the isolates which did not induce a bystander effect, ASFV NH/P68 Rec 4 and ASFV 
NH/P68 Rec 34 encode a modified gene for CD2v, and ASFV Malawi Lil 20-1 ::CD2v 
encodes an intact gene for CD2v. Thus it seems unlikely that expression of CD2v is a 
significant factor in this difference between the observed bystander effect on surface SLA-I 
exerted by cytokines released in response to infection with wild-type virulent isolates and the 
non-virulent and mutant isolates. 
Macrophages are the primary producers of pro-inflammatory cytokine such as IFN-α, IFN-β, 
TNF-α, interleukin (IL)-1, IL-6 and IL-8 (Murtaugh et al., 1996; Gil et al., 2008) and while the 
production of IFN-γ is more often associated with NK cells and T-lymphocytes, there is 
evidence to suggest it is also produced by macrophages (Munder et al., 1998; Frucht et al., 
2001). Of the pro-inflammatory cytokines produced by macrophages, IFN-γ, IFN-α and TNF-α 
induce up-regulation of MHC class I (Ljunggren & Anderson, 1998; Früh & Yang, 1999; 
Zhou, 2009). However, ASFV has been demonstrated to be able to suppress the response of 
infected cells to stimulation with interferons and pro-inflammatory cytokines, either directly or 
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indirectly. Alveolar macrophages infected with ASFV Malawi Lil 20-1, OURT88/1 and 
OURT88/3 did not produce TNF-α or IL1 in response to stimulation either with 
lipopolysaccharide (LPS) or with IFN-γ (Whittall & Parkhouse, 1997). Similarly, up-regulation 
of IFN-α and TNF-α were suppressed in PMA-stimulated macrophage populations infected 
with ASFV Malawi Lil 20-1 and OURT88/1, both at the levels of mRNA transcription and 
secretion of these cytokines as detected by ELISA (Powell et al., 1996). Correia et al. (2012) 
used a luciferase reporter gene assay to demonstrate that ASFV infection inhibits IFN-β 
expression in an NFκB-independent manner, and Fishbourne et al. (2013) found no change in 
IFN-γ secretion as detected by ELISA in PBMC infected with either ASFV OURT88/3 or 
Benin 97/1 as compared to mock-infected cells.  
Infection rates averaged around 50% across all experiments, and so sufficient cytokines should 
have been released by infected cells in both the bystander cell and conditioned media 
experiments to induce an effect on uninfected cells. However, the only significant changes in 
SLA-I expression observed to be induced by cytokines via bystander effect or conditioned 
media resulted from cytokines induced by infection with ASFV Benin 97/1 and ASFV 
Malawi Lil 20-1. These results of the bystander cells and conditioned media experiments 
suggest that changes in surface SLA-I expression cannot be fully attributed to cytokines 
released as a result of infection with ASFV, which correlates to the previous studies discussed 
above which indicate that IFN-γ is not induced by infection with ASFV. Multigene family 
MGF360/530 genes have been shown to down-regulate induction of type I interferons and 
induction is only observed on infection with ASFV isolates such as OURT88/3 which lack 
these multigene family genes (Afonso et al., 2004; A.L. Reis (TPI), unpublished data). 
In the preceding paragraphs, it has been proposed that: while CD2v may exert an influence on 
surface SLA-I expression, it is likely to be an indirect influence via an effect on protein 
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transport; that pro-inflammatory cytokines released as a result of infection with some, but not 
all, ASFV isolates do appear to modulate surface SLA-I expression in uninfected cells; and that 
neither of these factors fully explain the variation seen in the level of SLA-I modulation 
observed between isolates. An alternative influencing factor may be the differences between 
the left variable genome regions of the three wild-type isolates. Naturally attenuated field 
isolate ASFV NH/P68 and its recombinants contain a large deletion in their left variable 
genome regions, which includes several members of multigene families MGF 360 and MGF 
505/530 which are encoded by ASFV Benin 97/1 and/or ASFV Malawi Lil 20-1, namely MGF 
360-6L, MGF 360-10L, MGF 360-11L, MGF 360-12L, MGF 360-13L, MGF 360-14L, MGF 
360-21L, MGF 360-22L, MGF 505-1R, MGF 505-2R and MGF 505-6R. ASFV NH/P68 
contains gene MGF 505-8R which is not encoded by ASFV Benin 97/1 and ASFV 
Malawi Lil 20-1. The genomes of virulent isolates ASFV Benin 97/1 and ASFV 
Malawi Lil 20-1 (including their ΔCD2v mutants) also contain variable genes within MGF 360 
and MGF 505/530. The genome of ASFV Benin 97/1 contains genes MGF 360-1L, MGF 360-
2L MGF 360-19R and MGF 505-6R which are lacking in the genome of ASFV 
Malawi Lil 20-1, while genes MGF 360-21R and MGF 360-22R are present in the left variable 
genome region of ASFV Malawi Lil 20-1 but absent in ASFV Benin 97/1 (Chapman et al., 
2008). The functions of most ASFV genes are still unknown, and this extends to the multigene 
families, with none of the functions of the above genes having been conclusively elucidated 
(Dixon et al., 2013). However, Afonso et al. (2004) showed that ASFV multigene family genes 
MGF 360 and MGF 505/530 inhibit a range of host genes involved in the interferon response, 
and that while no detectable IFN-α activity was observed in cells infected with virulent isolate 
ASFV Pretoriuskop/96/4 (Pr4), some activity was detected in cells infected with an ASFV Pr4 
ΔMGF360/530 deletion mutant at 24 hpi. Thus, genes from MGF 360 and MGF 505/530 may 
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indirectly prevent induction of SLA-I expression through down-regulation of type I and type III 
interferons.  
The results of investigations into modulation of SLA-I surface expression in PBMC by 
infection with ASFV also yielded ambiguous results, with a high degree of both between- 
isolate (figure 4.10-A) and between-animal (figure 4.10-B) variation in the results. Levels of 
SLA-I up-regulation were lower than that seen in BMDM, however, and in only three 
treatments; infection with ASFV NH/P68 Rec 34, NH/P68 Rec 4 and Benin 97/1, was a 
significant up-regulation of surface SLA-I expression observed relative to mock-infected cells 
(figure 4.10). Stimulation with IFN-γ did not significantly up-regulate surface SLA-I 
expression in PBMC. The differences observed between the results obtained from PBMC and 
BMDM may be due to the relative maturity of the cells, since BMDM are less mature than 
PBMC and even despite the 5 days maturation time in culture, may lack mechanisms to 
regulate cytokine response found in more mature macrophages such as PBMC. Additionally, 
infection of Vero cells with ASFV BA71V and deletion mutant ASFV BA71V 
ΔEP153R/ΔCD2v did not result in any changes in surface MHC class I expression relative to 
mock-infected cells (figure 4.11). This further highlights that when investigating the effect of 
ASFV infection on any host system, results obtained are likely to be highly specific to the 
individual animal from which primary cells were harvested, virus isolate and cell type tested. 
Flow cytometry provides a means by which quantitative measures may be taken of changes in 
expression of both host and viral proteins in response to infection. However, it does not provide 
any information on changes in the relative localisation of host and viral proteins within an 
infected cell. Confocal microscopy provided the means to investigate whether infection with 
ASFV induced any changes in the localisation of SLA-I within infected cells. In both ASFV-
infected and uninfected BMDM, labelling for SLA-I within the cytoplasm and at the plasma 
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membrane varied by cell, suggesting variable expression by cell. The relative localisation of 
SLA-I to cell surface marker of mature macrophages CD203a and ER marker ERp60 did not 
change between ASFV-infected and uninfected cells. The only difference observed was 
between SLA-I and marker for the Golgi, β-COP. In uninfected cells, SLA-I appears to localise 
to some extent with the Golgi, while this is not the case in infected cells. As reported by 
Netherton et al. (2006) and reviewed in Netherton & Wileman (2013), ASFV infection causes 
redistribution of components of the secretory pathway, most notably the trans-Golgi network. 
Thus the lack of localisation of the Golgi and SLA-I observed in figure 4.12 may be due to 
disruption of the Golgi in ASFV-infected cells. However, overall, ASFV infection does not 
appear to affect the localisation of SLA-I in infected cells. 
The experimental system described in this chapter was constructed with a view to evaluating 
the effect of ASFV infection on SLA-I expression, and further, elucidating the role of viral 
proteins CD2v and C-type lectin EP153R in any modulation seen. Unfortunately, it did not 
prove possible to shed any light on the involvement of EP153R in SLA-I modulation from 
these experiments. One conclusion which can be drawn from Chapters 4.2.4 and 4.2.5, 
however, is that viral protein CD2v is likely to play a role, either directly or indirectly, in the 
modulation of surface SLA-I expression. 
Given that SLA-I expression on the surface of cells infected with ASFV isolates expressing 
wild-type CD2v is higher than in cells infected with ΔCD2v deletion mutants or a isolates 
encoding a modified form of CD2v, it appears that CD2v exerts an influence on SLA-I 
expression. However, in light of the probable role of CD2v in maintaining vesicular transport 
in infected cells, this influence seems likely to be a generalised effect on all proteins which 
enter the vesicular transport system, and not targeted specifically at SLA-I. 
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4.4. Conclusions 
Changes in expression of SLA-I at the surface of host cells infected with ASFV differs by 
isolate and by type of cell infected, although the localisation of SLA-I remains unaffected by 
infection with the exception of abrogation of localisation to the Golgi in ASFV-infected cells. 
In cells where surface SLA-I is up-regulated, the change in expression cannot be conclusively 
shown to be directly influenced by expression of viral protein CD2v or caused by cytokines 
associated with ASFV infection. CD2v does appear to play a role in SLA-I up-regulation, but 
this may be a generalised effect of CD2v on protein transport through the vesicular system. No 
evidence was obtained on the role of EP153R in SLA-I modulation in ASFV-infected cells. 
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Chapter 5 
5 Investigating the Effect of ASFV Infection on SLA-I 
Transcription and Turnover 
5.1. Introduction 
African swine fever virus has previously been shown to modulate MHC class I expression both 
in the cytoplasm and at the surface of infected cells. Observations as to whether expression is 
up-regulated or down-regulated and to what degree depend on a variety of factors including 
whether experiments were performed in vivo or in vitro, the cell type and the isolate of virus 
used for the infection study (Gonzalez-Juarrero et al., 1992b; Vallée et al., 2001; Netherton et 
al., 2006; Hurtado et al., 2011). The results of previous experiments, as well as those 
performed in this project to evaluate the effect of ASFV infection on cell surface expression of 
SLA-I are covered in detail in Chapter 4 of this thesis. The conclusions of Chapter 4 were that 
while the magnitude of the effect varies, ASFV infection does modulate SLA-I expression in 
BMDM in vitro. Two ASFV proteins, EP153R and CD2v have been implicated in this 
modulation; EP153R by Hurtado et al. (2011) and CD2v by the results of Chapter 4. However, 
the mechanisms by which ASFV and these proteins exert their influence on SLA-I expression 
remain unknown. Therefore, the stage of the MHC class I pathway at which ASFV modulates 
expression of SLA-I, from transcription through to turnover of the protein to internalisation of 
molecules from the surface of infected cells was investigated. 
In this chapter, the effect of ASFV infection on mRNA transcript levels of the heavy chain of 
the porcine MHC class I complex, SLA-I, the light chain of the MHC class I complex, β2-
microglobulin (β2M) and housekeeping gene glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), were measured by quantitative reverse transcription PCR (qRT-PCR). 
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Radiolabelling of infected cells with [35S]- Cys/Met gives insight into whether ASFV affects 
SLA-I protein synthesis rate and a combination of flow cytometry and confocal microscopy 
were used to investigate internalisation of SLA-I from the cell surface and track the 
incorporation of new SLA-I molecules at the surface of infected cells. 
5.2. Results 
5.2.1. Using ASFV deletion mutants to investigate the effect of ASFV 
infection, and ASFV proteins EP153R and CD2v, on transcription of SLA-I 
5.2.1.1. Quantitative reverse transcriptase PCR primer and protocol design and 
optimisation 
Primers were designed for quantifying the amount of SLA-I mRNA present in uninfected and 
cells infected with ASFV by quantitative reverse transcriptase PCR (qRT-PCR). The cDNA 
sequences of Sus scrofa (domestic pigs and wild boar) MHC class I antigens 1 through 11 
(SLA-1 to SLA-11) mRNA were obtained from the e!Ensembl (http://www.ensembl.org/) 
database. Ensembl is a joint project between EMBL-EBI and the Wellcome Trust Sanger 
Institute (Flicek et al., 2014). For each locus of SLA-I, cDNA sequences where a protein 
product has been confirmed (as listed under a separate “Protein ID” accession number) were 
selected, rather than those with no confirmed protein product (listed as “No protein product”). 
The exception to this was the locus for SLA-3, which was important to include in the alignment 
as one of the three classical SLA-I genes (see Chapter 1.2.3.2). For some loci, the sequences of 
more than one splice variant were available. A maximum of three splice variants were added 
for each locus to avoid disproportionate weight being given to the sequences of loci with the 
most splice variants. The number of splice variants, Ensembl accession numbers and transcript 
length for each locus are listed in table 5.1. 
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Table 5.1: Loci of SLA-I for design of qRT-PCR primer to quantify changes in SLA-I 
transcription. 
Loci of SLA-I and their splice variants for which sequences were obtained from the Ensembl database 
and aligned using the AlignX tool of Vector NTI in order to design primers for quantification of 
changes in SLA-I transcription resulting from infection with ASFV. 
SLA-I locus Splice variant Ensembl accession number Transcript 
length (bp) 
SLA-1 a ENSSSCT00000001334 1533 
SLA-1 b ENSSSCT00000036412 1467 
SLA-2 a ENSSSCT00000035227 513 
SLA-3 a ENSSSCT00000035587 1767 
SLA-3 b ENSSSCT00000001325 1733 
SLA-3 c ENSSSCT00000001326 1700 
SLA-5 a ENSSSCT00000001329 1813 
SLA-5 b ENSSSCT00000001330 1526 
SLA-6 a ENSSSCT00000001525 1429 
SLA-6 b ENSSSCT00000001327 1153 
SLA-6 c ENSSSCT00000001527 1090 
SLA-7 a ENSSSCT00000001524 1293 
SLA-7 b ENSSSCT00000035331 1206 
SLA-7 c ENSSSCT00000001336 1194 
SLA-11 a ENSSSCT00000001457 1421 
SLA-11 b ENSSSCT00000035848 920 
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Figure 5.1: Alignment of cDNA sequences from SLA-I loci and primers for qRT-PCR.  
The cDNA sequences of six loci of the SLA-I gene and their splice variants were aligned using the 
AlignX tool of Vector NTI in order to identify regions suitable for design of primers for qRT-PCR. 
The forward primer (SLA-I_qPCR_fwd) was designed to cover the most highly-conserved of the 
exon-exon junctions; that between exon 2 and exon 3, with the reverse primer (SLA-I_qPCR_rev) 
designed to cover a highly conserved region further downstream within exon 3, for a total amplified 
product length of 131 bp. Regions covered by the primers are highlighted in magenta. 
178 
 
The SLA-I loci cDNA sequences were aligned using the AlignX tool of Vector NTI. The 
junction of exon 2 and exon 3 was judged to be the most conserved across SLA-I loci, and so 
the forward primer was designed to cover this junction to prevent amplification of genomic 
DNA. The site for the reverse primer was selected in a highly conserved region 104 bp 
downstream from this exon-exon junction giving an expected amplified region of 131 bp. Both 
primers were based on the consensus sequence of the aligned loci, and were completely 
conserved across SLA-1, SLA-3, SLA-5 and SLA-7. SLA-2 is a short locus starting in the 
region of exon 4 of the other longer loci, and no cDNA sequence with an identified protein 
transcript was found in the database for SLA-4 or SLA-8, so these three loci were thus 
excluded from this consensus sequence. SLA-9 and SLA-10 were not found in the Ensembl 
database. Figure 5.1 shows a section of the alignment of SLA-1, SLA-3, SLA-5, SLA-6, 
SLA-7 and SLA-11 cDNA (with splice variants) covering the junction between exon 2 and 
exon 3, and indicating the binding sites of both SLA-I forward and reverse primers.  
Variation from the consensus was seen in SLA-6 and SLA-11, meaning that mRNA from these 
loci would not be detected using the designed primers, but these are non-classical loci (see 
Chapter 1.2.3.2) not shown to be recognized by CD8+ T-cells and as such could be excluded 
from this study into effect of ASFV on transcription of classical SLA-I loci. 
In parallel with the infection experiments described in Chapter 4.2.4 where changes in surface 
SLA-I expression were measured by flow cytometry, BMDM were infected at MOI = 2 for 16 
hours with ASFV Benin 97/1, Benin 97/1 ΔCD2v, Malawi Lil 20-1, Malawi Lil 20-1 ΔCD2v, 
Malawi Lil 20-1::CD2v revertant, NH/P68 parental, NH/P68 Rec 4 and NH/P68 Rec 34 plus 
mock-infected cells and cells stimulated with recombinant porcine IFN-γ at 0.25 μg.ml-1
.
 
mRNA was extracted from the BMDM as described in Chapter 2.5.1 and reverse transcription 
performed  to create cDNA from the mRNA samples as described in Chapter 2.5.2.  
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qRT-PCR conditions for the cDNA template and SLA-I, β2M and GAPDH primers were 
optimised following the guidelines provided by the manufacturers of the qPCR master mixes 
used. Two types of SYBR Green PCR master mix were used, SYBR GreenER qPCR SuperMix 
Universal (Invitrogen-Life Technologies) and SYBR Select Master Mix (Applied Biosystems-
Life Technologies). For both, separate optimisation dilution chequerboards were performed to 
determine optimum primer concentrations for amplification using cDNA template from mock-
infected BMDM.  
Primers for qRT-PCR amplification of β2M and GAPDH were designed by E. Fishbourne 
(2011) as part of a previous study into the effects of ASFV infection on host gene transcription. 
Optimal concentrations were determined for these primers when used with SYBR Select 
Master Mix. The sequences of primer sets for the amplification of mRNA from the genes for 
SLA-I, GAPDH and β2M, along with amplicon length, optimal primer concentration with the 
two SYBR Green master mixes and annealing temperature are listed in table 5.2.  
5.2.1.2. Strategy for normalisation of q-PCR results 
GAPDH and β2M are often chosen as housekeeping genes for use in normalising results of 
qRT-PCR analyses of other target genes, as these genes are expressed in all nucleated cells, and 
in most cases, expression remains stable through various treatments. ASFV has been shown to 
exert an effect on the expression of a number of host genes, including housekeeping genes such 
as GAPDH and β2M. Fishbourne (2011) evaluated five common housekeeping genes; β-actin, 
cyclophilin A, hypoxanthine-guanine phosphoribosyltransferase (HPRT), β2M and GAPDH 
for their suitability in normalising qRT-PCR of mRNA from cells infected with ASFV 
OURT88/3. The study found an unacceptable degree of variation in expression between 
infected and uninfected cells, although this was least pronounced in transcript levels of 
GAPDH mRNA. Ultimately, Fishbourne (2011) did not use any of these housekeeping genes 
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Table 5.2: Primers for qRT-PCR of SLA-I, GAPDH  and β2M. 
The sequences of forward (F) and reverse (R) primers used for qRT-PCR analysis of transcription levels 
of the genes for SLA-I, GAPDH and β2M, along with accession numbers, amplicon size and optimal 
primer concentration with either SYBR GreenER qRT-PCR SuperMix Universal or SYBR Select 
Master Mix and annealing temperature. 
Gene  
Accession  
Number  Primers  
Amplicon  
Size (bp)  
Primer concentration  
by PCR master mix 
(μM) 
Annealing  
Temp 
(⁰C)  
SYBR 
GreenER 
SYBR 
Select 
SLA-I See table 5.1 
F:   
R: 
GCGAGGCCGGGTCTCACACC 
TGAACGAGGACCTGCGCT 131 
25 
25 
20 
20 60 
β2M  NM_213978  
F:   
R: 
AGAAGATGAACGCGGAGCAG 
TGCCGGTTAGTGGTCTCGAT  173  n/a 
20 
40 60  
GAPDH  AF017079  
F:  
R:  
TCAACGACCACTTTGTCAAGC 
TGGTGGTCCAGGGGCTCTTA  118  n/a 
30 
30 60  
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for normalisation of qRT-PCR results, but instead normalised each infected sample to its 
corresponding within-animal mock infected sample across a range of samples from different 
animals. A similar reasoning was employed in Chapter 4 of this thesis, where all SLA-I 
expression data from flow cytometry experiments is represented as fold-change in expression 
from the within-animal mock infected sample due to high between-animal variation. As 
described previously (Fishbourne, 2011), due to variation in transcript levels of housekeeping 
genes between infected and uninfected cells, it was decided that qRT-PCR Ct results would be 
normalised to Ct values of mock-infected samples rather than of housekeeping genes. 
However, since Ct values are transformed on a log scale, the Ct value of each within-animal 
mock infected sample has the potential to exert a strong influence on its corresponding within-
animal ASFV-infected or IFN-γ-stimulated samples, and any mock-infected sample not of 
optimal quality (and with a higher Ct value than average) could disproportionately skew all the 
results from an entire animal. For this reason, all Ct values were instead normalised to the 
mean of all mock-infected samples across all animals, using the equation: 
	ΔCt  Ct	
  Ct				 			
 
With fold-change in mRNA transcription from the mean of mock-infected samples calculated 
as: 
log 2 
Analyses of levels of GAPDH and β2M mRNA transcripts by qRT-PCR were included as a 
comparison of the effect of ASFV-infection on gene transcription levels between different 
genes instead of as housekeeping genes for normalising SLA-I qRT-PCR results. GAPDH was 
selected since it was the gene shown by Fishbourne (2011) to be least affected by ASFV 
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infection, and β2M was selected as it forms the light chain of the MHC class I complex. 
Transcript levels of β2M are predicted to be affected by ASFV infection in a similar manner to 
transcript levels of SLA-I since the regulatory sequence of the β2M gene is often co-regulated 
with MHC class I genes, and contains sequences similar to those found in the upstream 
regulatory complex region I of MHC class I. Transcription of both MHC class I and β2M genes 
have been shown to be up-regulated by stimulation with IFN-γ through transcription factor 
NFκB signalling (Blanar et al., 1989; Johnson & Pober, 1990; Boehm et al., 1997; van den 
Elsen et al., 1998). 
After the RNA samples from ASFV-infected and control BMDM were collected and converted 
to cDNA in a reverse transcription reaction, the primer optimisations were complete and the 
strategy for data normalisation and analysis was in place, analysis of samples was carried out. 
All cDNA samples were incubated in separate reaction mixes with SYBR Green PCR master 
mix and primers for SLA-I, GAPDH or β2M, and amplifications performed using a Stratagene 
Mx3005P instrument (Agilent Technologies). 
5.2.1.3. Investigating the effect of ASFV infection on transcript levels of SLA-I 
mRNA 
As observed in Chapter 4.2.4, in which changes in surface expression of SLA-I were evaluated 
by flow cytometry (figure 4.7-B), there was a high degree of variability between samples from 
BMDM harvested from different animals. Comparing the results using cells from eight 
animals, changes in transcript levels were highly variable for SLA-I (figure 5.2), β2M (figure 
5.3) and GAPDH (figure 5.4) following infection with all eight isolates of ASFV and 
stimulation with IFN-γ. Within each treatment, both down-regulation and up-regulation of 
SLA-I mRNA levels were observed between animals with the exception of cells infected with 
ASFV Malawi Lil 20-1 and its recombinants Malawi Lil 20-1 ΔCD2v and 
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Figure 5.2: Transcription rates of SLA-I in BMDM infected with ASFV. 
Changes in transcription rates of SLA-I genes as determined by reverse transcription and qRT-PCR 
of mRNA extracted from BMDM infected with eight isolates of ASFV at MOI=2 or stimulated with 
IFN-γ at 0.25 μg.ml-1 for 16 hours, expressed as a fold change in expression from mean values of the 
mock-infected samples from all animals. Fold change in expression calculated as log 2-ΔCt where 
ΔCt = Ctsample - Ctmean of all mock-infected samples. Error bars depict standard deviation. Replicates per 
treatment: Mock-infected, n = 8; NH/P68, n = 7; NH/P68 Rec 34, n = 6; NH/P68 Rec 4, n = 6; Benin 
97/1, n = 8; Benin 97/1 ΔCD2v, n = 7; Malawi Lil 20-1, n = 4; Malawi Lil 20-1 ΔCD2v, n = 4; 
Malawi Lil 20-1 rev, n = 4; IFN-γ, n = 6. Data were collected over nine experiments. 
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Figure 5.3: Transcription rates of β2M in BMDM infected with ASFV. 
Changes in transcription rates of the β2M gene as determined by reverse transcription and qRT-PCR 
of mRNA extracted from BMDM infected with eight isolates of ASFV at MOI=2 or stimulated with 
IFN-γ at 0.25 μg.ml-1 for 16 hours, expressed as a fold change in expression from mean values of the 
mock-infected samples from all animals. Fold change in expression calculated as log 2-ΔCt where 
ΔCt = Ctsample - Ctmean of all mock-infected samples. Error bars depict standard deviation. Replicates per 
treatment: Mock-infected, n = 6; NH/P68, n = 4; NH/P68 Rec 34, n = 4; NH/P68 Rec 4, n = 4; Benin 
97/1, n = 6; Benin 97/1 ΔCD2v, n = 6; Malawi Lil 20-1, n = 4; Malawi Lil 20-1 ΔCD2v, n = 4; 
Malawi Lil 20-1 rev, n = 4; IFN-γ, n = 4. Data were collected over six experiments. 
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Figure 5.4: Transcription rates of GAPDH in BMDM infected with ASFV. 
Changes in transcription rates of the GAPDH gene as determined by reverse transcription and qRT-
PCR of mRNA extracted from BMDM infected with eight isolates of ASFV at MOI=2 or stimulated 
with IFN-γ at 0.25 μg.ml-1 for 16 hours, expressed as a fold change in expression from mean values 
of the mock-infected samples from all animals. Fold change in expression calculated as log 2-ΔCt 
where ΔCt = Ctsample - Ctmean of all mock-infected samples. Error bars depict standard deviation. Replicates per 
treatment: Mock-infected, n = 6; NH/P68, n = 4; NH/P68 Rec 34, n = 4; NH/P68 Rec 4, n = 4; Benin 
97/1, n = 6; Benin 97/1 ΔCD2v, n = 6; Malawi Lil 20-1, n = 4; Malawi Lil 20-1 ΔCD2v, n = 4; 
Malawi Lil 20-1 rev, n = 4; IFN-γ, n = 4. Data were collected over six experiments. 
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Table 5.3: Analysis of changes in SLA-I transcription in ASFV-infected BMDM.  
Tukey’s multiple comparisons test one-way ANOVA of SLA-I transcription in BMDM infected with 
ASFV or stimulated with IFN-γ, with fold change in transcription measured as log 2-ΔCt where 
ΔCt = Ctsample - Ctmean of all mock-infected samples, as measured by qRT-PCR, with comparisons of all 
isolates and treatments to mock, and within-isolate comparison of parental and mutant strains. 
Tukey's multiple comparisons test Mean 
Diff. 
95% CI of diff. Summary Adjusted 
P Value 
Mock vs. NH/P68 parental 0.451 -1.998 to 2.899 ns 0.9998 
Mock vs. NH/P68 Rec 4 0.383 -2.172 to 2.938 ns > 0.9999 
Mock vs. NH/P68 Rec 34 0.281 -2.274 to 2.836 ns > 0.9999 
Mock vs. Benin 97/1 0.523 -1.843 to 2.888 ns 0.9991 
Mock vs. Benin 97/1 ∆CD2v 0.653 -1.796 to 3.101 ns 0.9964 
Mock vs. Malawi Lil 20-1 2.103 -0.794 to 5.000 ns 0.3462 
Mock vs. Malawi Lil 20-1 ∆CD2v 1.015 -1.883 to 3.912 ns 0.9752 
Mock vs. Malawi Lil 20-1 rev 1.049 -1.848 to 3.946 ns 0.9692 
Mock vs. IFN-γ -0.040 -2.595 to 2.515 ns > 0.9999 
NH/P68 parental vs. NH/P68 Rec 4 -0.068 -2.700 to 2.564 ns > 0.9999 
NH/P68 parental vs. NH/P68 Rec 34 -0.170 -2.802 to 2.462 ns > 0.9999 
NH/P68 Rec 4 vs. NH/P68 Rec 34 -0.102 -2.833 to 2.630 ns > 0.9999 
Benin 97/1 vs. Benin 97/1 ∆CD2v 0.130 -2.318 to 2.579 ns > 0.9999 
Malawi Lil 20-1 vs. Malawi Lil 20-1 ∆CD2v -1.088 -4.434 to 2.257 ns 0.9848 
Malawi Lil 20-1 vs. Malawi Lil 20-1 rev -1.054 -4.399 to 2.292 ns 0.9879 
Malawi Lil 20-1 ∆CD2v vs. Malawi Lil 20-1 rev 0.035 -3.311 to 3.380 ns > 0.9999 
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Table 5.4: Analysis of changes in β2M transcription in ASFV-infected BMDM.  
Tukey’s multiple comparisons test one-way ANOVA of β2M transcription in BMDM infected with 
ASFV or stimulated with IFN-γ, with fold change in transcription measured as log 2-ΔCt where 
ΔCt = Ctsample - Ctmean of all mock-infected samples, as measured by qRT-PCR, with comparisons of all isolates 
and treatments to mock, and within-isolate comparison of parental and mutant strains. 
Tukey's multiple comparisons test Mean 
Diff. 
95% CI of diff. Summary Adjusted 
P Value 
Mock vs. NH/P68 parental 0.179 -4.452 to 4.809 ns > 0.9999 
Mock vs. NH/P68 Rec 4 0.081 -4.550 to 4.712 ns > 0.9999 
Mock vs. NH/P68 Rec 34 -0.360 -4.991 to 4.271 ns > 0.9999 
Mock vs. Benin 97/1 -0.199 -4.341 to 3.943 ns > 0.9999 
Mock vs. Benin 97/1 ∆CD2v -0.051 -4.193 to 4.091 ns > 0.9999 
Mock vs. Malawi Lil 20-1 -0.551 -5.182 to 4.080 ns > 0.9999 
Mock vs. Malawi Lil 20-1 ∆CD2v -0.385 -5.016 to 4.246 ns > 0.9999 
Mock vs. Malawi Lil 20-1 rev 0.244 -4.387 to 4.875 ns > 0.9999 
Mock vs. IFN-γ -0.277 -4.908 to 4.354 ns > 0.9999 
NH/P68 parental vs. NH/P68 Rec 4 -0.097 -5.170 to 4.976 ns > 0.9999 
NH/P68 parental vs. NH/P68 Rec 34 -0.539 -5.612 to 4.534 ns > 0.9999 
NH/P68 Rec 4 vs. NH/P68 Rec 34 -0.442 -5.515 to 4.631 ns > 0.9999 
Benin 97/1 vs. Benin 97/1 ∆CD2v 0.148 -3.994 to 4.290 ns > 0.9999 
Malawi Lil 20-1 vs. Malawi Lil 20-1 ∆CD2v 0.166 -4.907 to 5.239 ns > 0.9999 
Malawi Lil 20-1 vs. Malawi Lil 20-1 rev 0.795 -4.278 to 5.868 ns > 0.9999 
Malawi Lil 20-1 ∆CD2v vs. Malawi Lil 20-1 rev 0.629 -4.444 to 5.702 ns > 0.9999 
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Table 5.5: Analysis of changes in GAPDH transcription in ASFV-infected BMDM.  
Tukey’s multiple comparisons test one-way ANOVA of GAPDH transcription in BMDM infected with 
ASFV or stimulated with IFN-γ, with fold change in transcription measured as log 2-ΔCt where 
ΔCt = Ctsample - Ctmean of all mock-infected samples, as measured by qRT-PCR, with comparisons of all isolates 
and treatments to mock, and within-isolate comparison of parental and mutant strains. 
Tukey's multiple comparisons test Mean 
Diff. 
95% CI of diff. Summary Adjusted 
P Value 
Mock vs. NH/P68 parental 0.462 -2.442 to 3.366 ns > 0.9999 
Mock vs. NH/P68 Rec 4 0.535 -2.369 to 3.439 ns 0.9998 
Mock vs. NH/P68 Rec 34 0.473 -2.432 to 3.377 ns > 0.9999 
Mock vs. Benin 97/1 0.015 -2.583 to 2.613 ns > 0.9999 
Mock vs. Benin 97/1 ∆CD2v 0.016 -2.581 to 2.614 ns > 0.9999 
Mock vs. Malawi Lil 20-1 -0.221 -3.125 to 2.683 ns > 0.9999 
Mock vs. Malawi Lil 20-1 ∆CD2v -0.216 -3.120 to 2.689 ns > 0.9999 
Mock vs. Malawi Lil 20-1 rev 0.892 -2.012 to 3.796 ns 0.9879 
Mock vs. IFN-γ 0.216 -2.688 to 3.120 ns > 0.9999 
NH/P68 parental vs. NH/P68 Rec 4 0.073 -3.109 to 3.254 ns > 0.9999 
NH/P68 parental vs. NH/P68 Rec 34 0.010 -3.171 to 3.192 ns > 0.9999 
NH/P68 Rec 4 vs. NH/P68 Rec 34 -0.062 -3.244 to 3.119 ns > 0.9999 
Benin 97/1 vs. Benin 97/1 ∆CD2v 0.001 -2.596 to 2.599 ns > 0.9999 
Malawi Lil 20-1 vs. Malawi Lil 20-1 ∆CD2v 0.005 -3.176 to 3.187 ns > 0.9999 
Malawi Lil 20-1 vs. Malawi Lil 20-1 rev 1.113 -2.069 to 4.294 ns 0.9712 
Malawi Lil 20-1 ∆CD2v vs. Malawi Lil 20-1 rev 1.107 -2.074 to 4.289 ns 0.9720 
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Malawi Lil 20-1 ::CD2v revertant. In these three treatments a consistent decrease in SLA-I 
mRNA levels was observed compared to mock-infected cells. (figure 5.2).  
Of the three host genes investigated, changes in transcription of SLA-I appeared to be the most 
variable by treatment (figure 5.2), with changes in transcript levels of β2M showing more 
uniformity (figure 5.3) and changes in transcript levels of GAPDH showing the least deviation 
from mock-infected across treatments (figure 5.4). However, despite these apparent trends, 
one-way ANOVA analysis of the log 2-ΔCt values for each gene showed no statistically 
significant difference in mRNA expression between treatments for SLA-I (table 5.3), β2M 
(table 5.4) or GAPDH (table 5.5). 
BMDM harvested from seven animals were used for both the qRT-PCR and the flow 
cytometry analysis of surface SLA-I expression experiments. The two sets of data obtained 
from these seven animals can therefore be paired to allow a comparison between changes in 
SLA-I mRNA levels and surface expression of SLA-I in cells from individual animals, as 
shown in figure 5.5. Changes in surface expression of SLA-I are plotted on the left axis, 
expressed as a fold change from mock-infected cells of each individual animal. On the right 
axis is the log2 fold change compared to the average of all mock-infected treatments of SLA-I 
mRNA levels.  The central red line represents no change from mock-infected cells for both 
data sets. From figure 5.5, it appears that there is no direct correlation between changes in 
transcript levels and surface expression of SLA-I. For some data sets up-regulation of both 
transcription and surface expression was observed (e.g. Animal 11 NHP/68 Rec 34 and 
Animal 3 Benin 97/1), for some there is little change in either surface expression or mRNA 
levels compared to mock-infected, (e.g. Animal 13 Malawi Lil-20-1 ΔCD2v), and for other 
animals up-regulation of surface SLA-I but down-regulation of transcript level was observed 
(e.g. Animal 12 Benin 97/1) or vice versa (e.g. Animal 3 NH/P68 parental). However, changes 
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Figure 5.5: Comparison between SLA-I mRNA transcription and surface expression. 
For seven of the experiments investigating changes in surface SLA-I expression and SLA-I mRNA 
transcription, the BMDM used were harvested from the same animals and it was possible to match 
seven results from figure 4.7 and figure 5.2. Each animal was assigned a colour and fold changes in 
SLA-I surface expression () are matched to fold changes in SLA-I mRNA transcription (). The red 
line represents no change from mock-infected cells.   
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in transcript level are not necessarily translated into changes in protein level at the same time 
point since other factors including protein stability may have an important effect. 
No significant changes in SLA-I transcription were identified at the 16 hpi time-point analysed 
in BMDM infected with eight isolates of ASFV to explain the changes seen in surface SLA-I 
expression. Therefore, investigations continued into whether ASFV infection affects SLA-I 
protein translation and turnover.  
5.2.2. Investigating effect of ASFV on the synthesis and turnover of SLA-I  
5.2.2.1. Determination of total protein synthesis levels  
To investigate whether changes in surface SLA-I expression are a result of changes in SLA-I 
synthesis and turnover, a [35S]-Cys/Met radiolabelling experiment was performed.  Matured 
BMDM were infected with ASFV Benin 97/1 or Benin 97/1 ΔCDv at MOI = 5, mock-infected 
or stimulated with recombinant porcine IFN-γ at 0.25 μg.ml-1 for up to 16 hours. During the 
infection period, cells were radiolabelled from 2-6 hpi, 4-8 hpi, 8-12 hpi or 12-16 hpi. A 4-hour 
radiolabelling period was shown in preliminary experiments to allow a sufficient quantity of 
the [35S]-Cys/Met to be incorporated for adequate detection after immunoprecipitation of 
SLA-I.  One hour after infection or treatment with IFN-γ the media containing virus or IFN-γ 
was removed and replaced with fresh media. For the 2-6 hpi samples, cysteine/methionine-free 
media was added to starve the cells for one hour. At two hours post-infection, the 2-6 hpi 
sample cells were radiolabelled with EXPRE35S35S Protein Labeling Mix [35S] at 1.5 MBq.ml-1 
for four hours before cell lysates were harvested at 6 hpi. Further sets of cells were 
radiolabelled in the same manner at 4, 8 and 12 hours post-infection and harvested at 8, 12 and 
16 hpi respectively. In Chapter 4.2.3 total protein synthesis levels, as represented by uptake of 
[35S]-Cys/Met and measured by scintillation counting, were analysed and normalised to cell 
counts to investigate changes in total protein synthesis per cell over a 16-hour course of 
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B 
Figure 5.6: Tracking the effects of ASFV infection on SLA-I synthesis by pulse-chase. 
(A) Autoradiograph of BMDM infected with ASFV Benin 97/1 or ASFV Benin 97/1 ΔCD2v at 
MOI = 2, stimulated with 0.25 μg.ml-1 IFN-γ or mock-infected were pulsed with 1.5 MBq.ml-1 of 
[35S]-cysteine/methionine for 4 hours at 2, 4, 8 and 12 hpi, then immunoprecipitated from cell lysates 
with anti-SLA-I antibody. (B) Coomassie stain of BMDM infected with ASFV Benin 97/1 or ASFV 
Benin 97/1 ΔCD2v at MOI = 2, stimulated with 0.25 μg.ml-1 IFN-γ or mock-infected  for 16 hours as 
a total protein comparison for the expression levels observed in the radiolabelling experiment.  
193 
 
  
Figure 5.7: Densitometric quantification of effects of ASFV infection on SLA-I synthesis.  
The intensity of the bands on the autoradiography gel in figure 5.6-A was analysed using 
myImageAnalysis software, with global background correction to compensate for different 
background levels between lanes. A linear regression analysis found no significant changes over 
time for individual treatments, although IFN-γ appears to show a trend for band intensity to increase 
over the time course. Mean band intensity across the time course was analysed by one-way 
ANOVA, and SLA-I synthesis levels in cells stimulated with IFN-γ was found to be significantly 
different (p = 0.0019) from synthesis levels in cells infected with Benin 97/1. Data are from a single 
experiment in this preliminary study. 
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infection with ASFV. As seen in figure 4.5, stimulation with IFN-γ causes a 20% up-regulation 
of total protein synthesis while infection with ASFV Benin 97/1 caused an 11% increase. 
Therefore, to ensure that results were not skewed by overall changes in protein synthesis or 
increased cell death induced by ASFV infection or IFN-γ stimulation, total amount of 
radiolabelled protein in the cell lysates was standardised based on scintillation counts before 
immunoprecipitation of SLA-I. The standardised samples were then immunoprecipitated with 
anti-SLA-I antibody and separated by SDS-PAGE as described in Chapter 2.6.2.7. Proteins 
were detected by autoradiography as seen in figure 5.6-A. A single band was detected in all 
SLA-I immunoprecipitated samples at ~45 kDa, corresponding to the predicted molecular 
weight of SLA-I, while no band was seen in the sample incubated with non-specific anti-V5 
epitope tag antibody as an immunoprecipitation control. As a total protein loading control, the 
standardised cell lysates, without an immunoprecipitation step, were separated by SDS-PAGE 
and the gels stained with Coomassie blue (figure 5.6-B). Consistent levels of staining were 
observed across all samples confirming that the amount of protein loaded was approximately 
the same in all samples. 
The intensities of the bands on the autoradiography gel in figure 5.6-A were analysed using 
myImageAnalysis software (Thermo Scientific, USA). First, the software was allowed to 
automatically detect bands. Next, identically proportioned squares were defined directly above 
each band and designated as the background for the band to allow compensation for different 
background levels between lanes. The intensity of each band was corrected against the 
background intensity by the software resulting in a global background corrected density value 
for each sample. These values are represented in figure 5.7, which shows changes in SLA-I 
synthesis as detected by incorporation of [35S]-Cys/Met over each of the 4 hour labelling 
periods during the 16-hour course of the experiment. IFN-γ appears to show a trend for band 
intensity to increase over the time course (representing an increase in SLA-I synthesis)
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Table 5.6: Linear regression analysis of densitometric quantification of the effect of ASFV 
infection on SLA-I synthesis.   
A linear regression analysis was performed on global background correlated density values of SLA-I 
synthesis in BMDM infected with ASFV Benin 97/1, mock-infected or stimulated with 0.25 μg.ml-1 
IFN-γ over four [35S] pulses of four hours each to cover a 16 hour time course, as detected by 
autoradiography and subjected to densitometry, and depicted in figure 5.7. 
Treatment Slope Summary P value 
Benin 97/1 221.9 ± 199.8 ns 0.3823 
Benin 97/1 ∆CD2v 216.5 ± 144.7 ns 0.2732 
IFN-γ 492.4 ± 428.9 ns 0.3698 
Mock-infected 567.6 ± 488.0 ns 0.3648 
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Table 5.7: One-way ANOVA of densitometric quantification of the effect of ASFV infection on 
SLA-I synthesis.  
Tukey’s multiple comparisons test one-way ANOVA of mean global background correlated density of 
SLA-I synthesis in BMDM infected with ASFV Benin 97/1, mock-infected or stimulated with 
0.25 μg.ml-1 IFN-γ over 16 hours, as detected by autoradiography and subjected to densitometry. 
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Summary Adjusted P 
Value 
Mock vs. Benin 97/1 3513 -914.2 to 7940 ns 0.1396 
Mock vs. Benin 97/1 ∆CD2v 485.6 -3942 to 4913 ns 0.9875 
Mock vs. IFN-γ -3737 -8164 to 690.4 ns 0.1094 
Benin 97/1 vs. Benin 97/1 ∆CD2v -3027 -7455 to 1400 ns 0.2307 
Benin 97/1 vs. IFN-γ -7250 -11677 to -2823 ** 0.0019 
Benin 97/1 ∆CD2v vs. IFN-γ -4223 -8650 to 204.8 ns 0.0633 
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and infection with ASFV Benin appears to show a slight trend for band intensity to decrease 
(representing a decrease in SLA-I synthesis) in comparison to the changes in synthesis 
observed in mock-infected cells. However, a linear regression analysis performed between time 
points found no significant difference for any of the treatments (table 5.6). Since this linear 
regression found no significant difference between time points, the mean global background 
corrected density for each treatment across the 16 hour experiment was calculated and a one-
way ANOVA performed on the mean values (table 5.7). The mean density for the SLA-I 
immunoprecipitated band from cells stimulated with IFN-γ was found to be significantly 
different (p = 0.0019) from the mean density for cells infected with Benin 97/1, but no further 
significant difference was found between treatments.  
In this breakdown of a 16-hour infection into a series of 4-hour pulses, changes in SLA-I 
synthesis as measured by uptake of [35S]-Cys/Met revealed no significant increase in synthesis 
of SLA-I in cells infected with ASFV Benin or Benin ΔCD2v, or stimulated with IFN-γ. The 
raw data does suggest an increase in SLA-I at later time point in cells stimulated with IFN-γ, 
and further replicates of this study may show this increase to be significant. The results 
presented suggest that the increased surface expression of SLA-I observed in BMDM infected 
with ASFV Benin 97/1 compared to mock-infected and infection with ASFV Benin ΔCD2v 
(figure 4.7) is not result of increased SLA-I synthesis. Further experiments were carried out to 
determine if increased surface SLA-I expression results from a change in the turnover of SLA-I 
molecules recycled from the surface of infected cells. 
5.2.3. Internalisation of SLA-I molecules from the cell surface in infected 
BMDM 
An up-regulation of SLA-I at the surface of infected cells may be due to an inhibition of 
internalisation of SLA-I molecules from the surface of infected cells, an increased 
incorporation of new molecules at the cell surface or a combination of the two. A dual-
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labelling method was employed to track the internalisation of SLA-I molecules from the cell 
surface over the course of ASFV infection, and to measure the incorporation of new SLA-I 
molecules. 
Matured BMDM were incubated with anti-SLA-I antibody conjugated to Zenon Alexa Fluor 
488 secondary antibody prior to infection with ASFV NH/P68, Benin 97/1, Benin 97/1 
ΔCD2v, Malawi Lil 20-1 or Malawi Lil 20-1 ΔCD2v at MOI = 2, or stimulation with 
recombinant porcine IFN-γ at 0.25 μg.ml-1. At 0, 4, 8, 12 and 16 hours post-infection, cells 
were fixed and harvested. Once the time course was complete, cells were labelled a second 
time with anti-SLA-I antibody, this time conjugated to Zenon Alexa Fluor 647 secondary 
antibody. Expression of both Alexa Fluor 488- and Alexa Fluor 647-labelled SLA-I was 
analysed by flow cytometry with gating for macrophages/monocytes. Cells were also labelled 
for viral protein VP30, but expression of VP30 was very low in the early time points, meaning 
that counts of VP30 positive-gated cells were too low (< 1000) for a reliable analysis. Because 
of this, all cells gated as macrophages were included in the analysis without gating for infected 
cells.  
Total SLA-I labelling at 0 hpi, as calculated by combining the median fluorescent intensities 
(MFI) of initial SLA-I 488 label plus final SLA-I 647 label, was used as the value against 
which all MFI values were normalised. Figure 5.8 shows changes in SLA-I at the cell surface 
across all treatments over 16 hours; the green line indicates the SLA-I:Alexa Fluor 488 label 
initially added to cells before treatment. Internalisation of SLA-I from the surface would be 
shown by a decrease in the detection of this label over the course of the experiment. New 
SLA-I molecules incorporated at the cell surface over the 16 hours are represented by the red 
line of SLA-I:Alexa Fluor 647 and the combined relative MFI value of both labels is 
represented by the blue line of total SLA-I.  
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G SLA-I-Alexa Fluor 488 (initial label) 
SLA-I-Alexa Fluor 647 (final label) 
Total SLA-I labelling 
Figure 5.8: Internalisation of SLA-I molecules from the surface of BMDM over 16 hours – flow cytometry 
SLA-I molecules on the surface of BMDM were labelled with anti-SLA-I antibody conjugated to Zenon Alexa Fluor 488 
secondary antibody (initial label, plotted in green) before infection with A) ASFV Benin 97/1, B) ASFV Benin 97/1 ΔCD2v, C) 
ASFV Malawi Lil 20-1, D) ASFV Malawi Lil 20-1 ΔCD2v, E) ASFV NH/P68, F) treated with IFN-γ or G) mock-infection. At 
the end of the time-course, the cells were labelled with anti-SLA-I antibody conjugated to Zenon Alexa Fluor 647 secondary 
antibody (final label, plotted in red) to distinguish between SLA-I molecules which were present on the surface at the start of 
the experiment and those newly incorporated at each time point. Initial and final SLA-I expression were analysed by flow 
cytometry with gating for macrophages. Relative median fluorescence intensity was calculated as a proportion of total (initial 
plus final) labelling at zero hours. Linear regression slopes are shown for each line, with (*) indicating lines with significantly 
different slopes and intercepts. Error bars depict standard deviation. Replicates per time point: Mock-infected, n = 3; NH/P68, 
n = 2; Benin 97/1, n = 3; Benin 97/1 ΔCD2v, n = 3; Malawi Lil 20-1, n = 2; Malawi Lil 20-1 ΔCD2v, n = 2; IFN-γ, n = 4. Data 
were collected over six experiments. 
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Table 5.8: Linear regression analysis of changes in surface SLA-I expression over 16 hours.  
A linear regression analysis was performed on internalisation of SLA-I from the cell surface (SLA-I 488  initial label), incorporation of new SLA-I molecules 
(SLA-I 647 final label) and the sum of all SLA-I expression (SLA-I total label) tracked across a 16-hour time course of BMDM infected with ASFV 
Benin 97/1, Benin 97/1 ΔCD2v, Malawi Lil 20-1, Malawi Lil 20-1 ΔCD2v or NH/P68, mock-infected or stimulated with 0.25 μg.ml-1 IFN-γ, as depicted in 
figure 5.8. 
Treatment SLA-I 488 initial label SLA-I 647 final label SLA-I total label 
 
Slope Summary P value Slope Summary P value Slope Summary P value 
Benin 97/1 0.0038 ± 0.0068 ns 0.5879 0.0138 ± 0.0062 * 0.0444 0.0192 ± 0.0100 ns 0.0779 
Benin 97/1 ∆CD2v 0.0066 ± 0.0089 ns 0.4743 0.0066 ± 0.0055 ns 0.2545 0.0138 ± 0.0068 ns 0.0647 
Malawi Lil 20-1 -0.0136 ± 0.0079 ns 0.1230 0.0160 ± 0.0102 ns 0.1568 0.0024 ± 0.0098 ns 0.8137 
Malawi Lil 20-1∆CD2v -0.0125 ± 0.0047 * 0.0300 0.0019 ± 0.0084 ns 0.8280 -0.0109 ± 0.0096 ns 0.2881 
NH/P68 -0.0210 ± 0.0083 * 0.0345 0.0020 ± 0.0031 ns 0.5366 -0.0190 ± 0.0107 ns 0.1139 
IFN-γ -0.0099 ± 0.0061 ns 0.1236 0.0897 ± 0.0191 *** 0.0002 0.0913 ± 0.0205 *** 0.0003 
Mock-infected -0.0131 ± 0.0089 ns 0.1667 0.0093 ± 0.0081 ns 0.2697 -0.0037 ± 0.0119 ns 0.7628 
201 
 
A linear regression analysis was performed on changes in SLA-I expression, and internalisation 
of SLA-I from the cell surface was found to be significant in cells infected with ASFV 
Malawi Lil 20-1 ΔCD2v (p = 0.0300) (figure 5.8-D) and NH/P68 (p = 0.0345) (figure 5.8-E). 
A significant increase in the incorporation of new SLA-I molecules at the cell surface was seen 
in cells infected with ASFV Benin 97/1 (p = 0.0444) (figure 5.8-A) and cells stimulated with 
IFN-γ (p = 0.0002) (figure 5.8-F). However, only the IFN-γ treatment showed an overall 
significant increase in total surface SLA-I over the time course (p = 0.0003) (figure 5.8-F). No 
significant internalisation of initial SLA-I or incorporation of new molecules was observed in 
cells infected with ASFV Benin 97/1 ΔCD2v (figure 5.8-B), Malawi Lil 20-1 (figure 5.8-C) or 
mock-infected cells (figure 5.8-G). 
Further investigation into internalisation of SLA-I from the cell surface was performed by 
confocal microscopy, to allow visualisation of changes in localisation of SLA-I over the 16 
hour infection time course. Matured BMDM were incubated with anti-SLA-I antibody and then 
infected with ASFV Benin 97/1 at MOI = 4 or mock infected for 16 hours. Immediately after 
initial labelling with anti-SLA-I antibody, 0 hpi time-point samples were fixed in 4% PFA and 
stored at 4°C while the reminder of the cells were incubated at 37°C for 16 hours. The 
remaining cells were then fixed, all samples permeabilised with 0.2% TritonX-100 and 
incubated with Alexa Fluor 488 secondary antibody to complete labelling of the “initial” SLA-I 
molecules. Samples were then either labelled a second time with anti-SLA-I antibody plus 
Alexa Fluor 568 secondary antibody for labelling of the “final” SLA-I molecules, or labelled 
with anti-CD203a, a surface marker of macrophages, plus Alexa Fluor 568 secondary antibody. 
Cells infected with ASFV Benin 97/1 were also labelled with antibodies against viral structural 
proteins J13L or VP72, both of which are expressed in the viral replication factories of infected 
cells (Sun et al., 1996; Cobbold & Wileman, 1998). At 0 hpi, before SLA-I internalisation was 
tracked, both the “initial” (shown in green) and “final” (shown in red) labels of SLA-I are 
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Figure 5.9: Internalisation of SLA-I molecules from the surface of BMDM over 16 hours - immunofluorescence. 
SLA-I molecules on the surface of BMDM were incubated with anti-SLA-I antibody (“SLA-I initial”, green) and then mock-infected (A, B, D, E) or 
infected with ASFV Benin 97/1 at MOI = 4 (C, F). The localisation of SLA-I before internalisation was captured by immediately fixing the 0 hpi 
time-point samples (A, D). At 16 hpi, the remaining samples were fixed (B, C, E, F) and all samples permeabilised with 0.2% TritonX-100 prior to 
labelling the anti-SLA-I antibody with Alexa Fluor 488 secondary antibody. Cells were then stained again with anti-SLA-I antibody to label 
molecules newly incorporated on the cell surface (“SLA-I final”, red) (A, B, C), or macrophage surface marker CD203a (red) (D, E, F) and Alexa 
Fluor 568 secondary antibody. Infected cells were also labelled with an antibody against viral proteins VP72 or J13L and Alexa Fluor 647 secondary 
antibody as a marker of infection (white). Coverslips were mounted with Vectashield plus DAPI nuclear stain (blue). Cells infected with ASFV are 
indicated with arrows (C, F). 
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localised at the cell surface (figure 5.9-A). This is confirmed by the localisation of “initial” 
SLA-I together with macrophage surface marker CD203a at 0 hpi (shown in red in figure 
5.9-D). At 16 hpi, most of the “initial” SLA-I is still seen to be located at the cell surface, 
both in mock-infected (figure 5.9-B,E) and cells infected with ASFV Benin 97/1 (figure 5.9-
C,F), with no obvious labelling of SLA-I within the cytoplasm. The level of expression of 
SLA-I on the cell surface can be seen to vary between cells in all treatments, but there is no 
apparent difference in expression of SLA-I on the cell surface, either that tracked over 16 
hours (shown in green) or newly-incorporated molecules (shown in red) between uninfected 
and infected cells (indicated with arrows in figure 5.9-C,F), with most of the detected SLA-I 
expressed on the cell surface.  
5.3. Discussion 
In Chapter 4, it was shown that cell surface expression of SLA-I was up-regulated in BMDM 
infected with virulent ASFV isolates Benin 97/1 and Malawi Lil 20-1 while no significant up-
regulation was observed in cells infected with non-virulent isolate ASFV NH/P68 (figure 
4.7). In order to explore the mechanisms for these changes in surface expression of SLA-I, 
the effect of ASFV on the transcription, translation and internalisation of SLA-I was 
investigated. 
Quantitative PCR of cDNA obtained from a reverse transcription reaction was used to 
evaluate of the effect of ASFV infection on transcription of SLA-I genes. Primers were 
designed to amplify a 131 bp fragment of SLA-I from alleles SLA-1, SLA-3, SLA-5 and 
SLA-7 cDNA (figure 5.1, table 5.2). qRT-PCR analysis of mRNA extracted from BMDM 
infected with ASFV NH/P68 parental, NH/P68 Rec 4, NH/P68 Rec 34, Benin 97/1, Benin 
97/1 ΔCD2v, Malawi Lil 20-1 or Malawi Lil 20-1 ΔCD2v, or stimulated with IFN-γ found no 
significant difference in SLA-I transcript levels between any of these treatments and mock-
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infected cells, (figure 5.2, table 5.3). The same samples were further analysed by qRT-PCR 
with primers designed to amplify cDNA of the light chain of SLA-I, β2M (figure 5.3) or 
housekeeping gene GAPDH (figure 5.4), and no significant difference in transcription of 
these two genes was found between treatments (table 5.4, table 5.5). Despite no significant 
difference being observed in mRNA expression levels for β2M and GAPDH, and these two 
genes being frequently used in other studies as housekeeping genes for normalisation of qRT-
PCR, it was decided that expression levels in response to ASFV infection were still too 
variable for either of these genes to be used as housekeeping genes to normalise the SLA-I 
transcription data obtained in this study without the results being skewed to an unacceptable 
degree (figure 5.3, figure 5.4). For this reason, Ct results for all three genes were normalised 
to the mean Ct value of all mock-infected samples. 
While it might be expected that SLA-I and β2M transcription would be significantly up-
regulated by stimulation of BMDM with IFN-γ (Blanar et al., 1989; Johnson & Pober, 1990; 
Boehm et al., 1997; van den Elsen et al., 1998), measuring transcript levels at a single 16-
hour time point may not accurately represent changes in SLA-I transcription over the course 
of an ASFV infection or other treatment, as a lag may occur between changes in transcript 
levels and detection of the associated changes in protein levels at the cell surface. 
Additionally, changes in transcript levels may oscillate through the course of the infection 
due to feedback mechanisms. Preliminary studies into changes in SLA-I transcript levels at 4, 
8 and 16 hpi showed no significant changes over the three time points (data not shown) but 
further time-course studies should be carried out at a range of infection time points to confirm 
this. Another reason changes in transcript levels are so variable between animals is that the 
use of primary cells harvested from newly-weaned pigs without fully developed immune 
systems may mean that immune responses observed are not always as strong as might 
otherwise be anticipated. An investigation could be carried out to detect the presence of the 
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cell-surface receptors for IFN-γ, IFNGR1 and IFNGR2 (Schroder et al., 2004), by flow 
cytometry to evaluate the level of activating signals from pro-inflammatory cytokines 
received and whether it correlated to the level of the immune response observed. 
Matched pairing of qRT-PCR and flow cytometry data from BMDM harvested from seven 
pigs revealed no overall correlation between changes in SLA-I transcription and surface 
SLA-I expression. While data pairs for some pigs were both up-regulated (figure 5.5: 
Animal 11 NHP/68 Rec 34 and Animal 3 Benin 97/1) or unchanged from mock (figure 5.5: 
Animal 13 Malawi Lil-20-1 ΔCD2v), in other data sets up-regulation of transcript levels was 
paired with down-regulation of surface expression or vice versa (figure 5.5: Animal 12 Benin 
97/1 and Animal 3 NH/P68 parental), with no consistent pattern across treatments. Since the 
limiting factor in up-regulation of MHC class I antigen presentation is the availability of 
peptides to load onto MHC class I molecules within the peptide loading complex in the ER 
(Neefjes et al., 2011) (see Chapter 1.2.3), it is not unfeasible that increased surface 
expression of SLA-I may be observed while not observing a similar increase in SLA-I gene 
transcription. As previously mentioned, there may also be a lag between observed changes in 
gene transcript levels and changes in protein expression, which may explain why surface 
SLA-I expression and transcript levels in individual animals do not correlate when cells for 
flow cytometry and RNA for qRT-PCR were both harvested at the same time at 16 hpi. 
Additionally, when analysing samples by flow cytometry, gating for infected cells was 
applied to eliminate the influence of uninfected cells on SLA-I expression patterns. No such 
means of isolating infected cells was possible prior to extraction of RNA, and with an 
average infection rate of 40-50%, responses to ASFV infection in SLA-I RNA transcript 
levels may be underestimated by qRT-PCR. 
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Since changes at the level of transcription were not shown to correlate with the changes in 
SLA-I expression seen at the cell surface, the effect of ASFV infection on SLA-I protein 
synthesis was investigated by measuring changes in incorporation of [35S]-Cys/Met over four 
labelling periods of 4 hours each in a 16-hour ASFV infection study. Immunoprecipitation of 
radiolabelled SLA-I revealed no significant change in SLA-I synthesis between BMDM 
infected with ASFV Benin 97/1 and Benin 97/1 ΔCD2v or stimulated with IFN-γ with 
measurements at 6, 8, 12 and 16 hours post-infection across a 16-hour time course, although 
the raw data suggests an increase in SLA-I protein synthesis in samples treated with IFN-γ 
(figure 5.6-A, table 5.6).  
Statistical analysis of mean values of SLA-I protein synthesis as determined by incorporation 
of [35S]-Cys/Met across 16 hours found a significant difference in synthesis between BMDM 
infected with ASFV Benin 97/1 and cells stimulated with IFN-γ. The cells infected with 
ASFV Benin 97/1 yielded the lowest mean expression of SLA-I, and cells stimulated with 
IFN-γ yielded the highest mean expression of SLA-I (table 5.7). In the flow cytometry study, 
a highly significant increase in surface SLA-I expression was observed in cells stimulated 
with IFN-γ over mock-infected cells, indicating that the apparent increase in protein synthesis 
may translate to an increase in surface expression of SLA-I in stimulated cells. However, 
while infection with ASFV Benin 97/1 caused the greatest increase in surface SLA-I 
expression of any treatment in the flow cytometry study (table 4.2), in this study no 
significant increase in SLA-I synthesis was detected, and mean levels of synthesis over 16 
hours were the lowest of all treatments (table 5.7) 
Combining the results of SLA-I transcription, translation and surface expression, no clear 
correlation emerges between transcription rates and cell surface expression of SLA-I across 
all ASFV isolates tested. In particular, in cells infected with ASFV Benin 97/1 neither 
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transcription nor synthesis of SLA-I protein was seen to increase on infection, although 
surface expression was highly significantly up-regulated. A possible explanation for this is 
that internalisation of SLA-I molecules from the cell surface is inhibited in cells infected with 
ASFV Benin 97/1. This could result in the cell surface being populated with SLA-I molecules 
presenting “self” peptide fragments as a means of diluting the molecules presenting “non-
self” peptide antigens of viral origin, and decreasing the probability of a CTL receptor 
binding with an SLA-I molecule presenting a viral antigen. 
MHC class I molecules loaded with an antigenic peptide will remain stable at the cell surface 
for 4 to 18 hours, dependent on cell type, with the differences in internalisation rates between 
cell types being poorly understood. (Hansen et al., 2000; Mahmutefendić et al., 2007; van 
Kasteren et al., 2014). Modulation of MHC class I internalisation is a reported mechanism of 
avoiding host cell detection of viral infection via MHC class I antigen presentation. For 
example KSHV proteins K3 and K5 induce polyubiquitylation of MHC class I molecules and 
their internalisation from the cell surface (Vossen et al., 2002; Petersen et al., 2003; Hansen 
& Bouvier, 2009) as a means of directly down-regulating MHC class I molecules which may 
be presenting viral peptides.  
To investigate whether ASFV might modulate the internalisation of SLA-I, SLA-I molecules 
were labelled at the cell surface before being tracked by flow cytometry for 16 hours in cells 
infected with ASFV NH/P68, Benin 97/1, Benin 97/1 ΔCD2v, Malawi Lil 20-1 or Malawi Lil 
20-1 ΔCD2v, stimulated with IFN-γ or mock-infected. At each time point across the 16 
hours, newly incorporated SLA-I molecules were also labelled to compare the rate of 
internalisation vs incorporation of new molecules (figure 5.8). Across the treatments, a 
significant rate of internalisation of “initial” SLA-I from the surface over 16 hours was 
observed in cells infected with ASFV NH/P68 (figure 5.8-E) and ASFV Malawi Lil 20-1 
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ΔCD2v (figure 5.8-D), although there was no significant decrease in total surface SLA-I (sum 
of “initial” plus “final” levels) over the time course in either of these treatments. This 
suggests that CD2v, at least in these two isolates, may play a role in preventing 
internalisation of SLA-I. As suggested above, this may serve to dilute the “non-self” signal of 
presented viral peptides within the “self” signal of host peptides presented by SLA-I 
molecules retained at the cell surface. Significant increases in newly incorporated SLA-I at 
the cell surface were observed in cells infected with ASFV Benin 97/1 (figure 5.8-A) and 
cells stimulated with IFN-γ (figure 5.8-F), but only cells stimulated with IFN-γ displayed a 
significant increase in total surface SLA-I. Further studies with more replicates are required 
to confirm whether internalisation of SLA-I from the surface of ASFV-infected cells is 
significantly affected by infection with ASFV, or whether differences observed between 
treatments are due to between-animal variation. The lack of internalisation of MHC class I 
molecules observed in the results of Chapter 5 are unusual for a DNA virus, and the reasons 
for no internalisation being observed in cells infected with ASFV may bear further 
investigation in the future. 
While flow cytometry studies into internalisation provide quantitative data on changes in 
levels of surface SLA-I in a population of cells, they do not provide information on relative 
localisation of SLA-I or allow investigations into changes in expression within individual 
cells. Confocal microscopy was used to track the internalisation of surface SLA-I in 
individual cells over 16 hours and look for changes in relative localisation of internalised 
molecules in ASFV-infected cells relative to mock-infected cells. Surface expression appears 
to be stable over 16 hours in both ASFV-infected and mock-infected cells, with little 
internalisation observed (figure 5.9-B,C,E,F). Further, tracking the internalisation of SLA-I 
and incorporation of new molecules over 16 hours revealed no noticeable difference in the 
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localisation of either internalised or newly incorporated molecules in mock-infected cells and 
cells infected with ASFV Benin 97/1 (figure 5.9-C,F).  
5.4. Conclusions 
Levels of SLA-I mRNA are not significantly affected by ASFV infection and changes in 
surface expression of SLA-I do not appear to be correlated with changes in transcript levels 
of SLA-I mRNA in BMDM infected with any of the ASFV isolates tested. Synthesis of 
SLA-I protein was not shown be significantly affected in BMDM infected with ASFV 
Benin 97/1 or Benin 97/1 ΔCD2v but significantly lower levels of synthesised protein were 
detected in cells infected with ASFV Benin 97/1 compared to cells stimulated with IFN-γ. 
SLA-I appears stable at the surface of BMDM over 16 hours, with significant levels of 
internalisation observed only in cells infected with ASFV NH/P68 and Malawi ΔCD2v, and a 
significant increase in new molecules at the cell surface in cells infected with ASFV 
Benin 97/1 or stimulated with IFN-γ. 
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Chapter 6 
6 Expression, Localisation and Processing Of ASFV Proteins 
EP153R and CD2v and Their Effect on MHC Class I 
6.1. Introduction 
In previous chapters the effect of infection with ASFV on host MHC class I expression was 
examined, and it was concluded that while ASFV infection does modulate MHC class I 
expression, this modulation is variable and depends on the virus isolate and cell type infected. 
Previous work by Hurtado et al. (2011) implicated ASFV C-type lectin protein EP153R in 
the modulation of MHC class I expression. Naturally attenuated field isolate ASFV NH/P68, 
lacks functional genes EP153R and EP402R (encoding CD2v), while a recombinant of  
NH/P68, NH/P68 Rec 34, has a modified restored gene for CD2v and recombinant NH/P68 
Rec 4 has the same modified restored gene for CD2v plus a restored intact gene for EP153R 
(Duarte, 2000; Rowlands et al., 2009). In Chapter 4, these two recombinant virus isolates 
were used to investigate the effect of EP153R on SLA-I expression in infected cells. No 
significant difference was detected in SLA-I surface expression by flow cytometry in cells 
infected with the two recombinants or parental NH/P68, suggesting that EP153R did not 
modulate SLA-I expression in infected cells. Despite these results, this protein has previously 
been implicated in the modulation of MHC class I (Hurtado et al., 2011).  
CD2v was shown to exert an influence on SLA-I expression in the results described in 
Chapter 4. Lower expression of SLA-I was observed on the surface of BMDM cells infected 
with a mutant of virulent isolate ASFV Benin 97/1 from which the CD2v gene had been 
deleted (ASFV Benin 97/1 ΔCD2v) than those infected with the wild-type isolate. However, 
while the expression and localisation of CD2v have been previously documented (Kay-
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Jackson et al., 2004; Goatley & Dixon, 2011) (see Chapter 1.3.2), little work has been done 
to characterise the expression or localisation of EP153R. 
Galindo et al. (2000) cloned EP153R into an expression plasmid and synthesised the protein 
in a rabbit reticulocyte system, yielding a modified product of ∼50ikDa. On treatment with 
Proteinase K, a slightly smaller fragment of just less than 50 kDa was produced, suggesting 
that a small portion of the N-terminal end of the protein is susceptible to the action of 
proteinases. However, in Galindo et al.’s study, EP153R was expressed under the T7 
promoter of the expression vector in an uninfected system. As such, it is possible that the 
EP153R protein maybe processed differently when expressed in ASFV-infected cells. Using 
an antibody raised against a synthetic peptide of EP153R to label Western blots of lysates of 
Vero cells infected with BA71V, Galindo et al. (2000) again observed a band at 50 kDa in 
untreated samples, and 18 kDa in samples treated with tunicamycin.  
To date, only one other study has investigated the expression of EP153R in transfected cell 
cultures. As part of Hurtado et al.’s (2011) work on the effect of EP153R on MHC class I 
expression, they published confocal microscopy images showing localisation of an EGFP-
EP153R fusion protein to the ER in uninfected transiently transfected Vero cells. 
Surprisingly, however, since their protein modelling work in the same paper proposes that 
EP153R directly binds to SLA-I, they did not publish any images showing the relative 
localisation of EP153R and SLA-I. 
Using flow cytometry, Hurtado et al. (2011) also demonstrated that expression of 
MHC class I at the surface of IPAM (porcine macrophage-derived cells) or Jurkat (human 
leukaemia T-cell line) cells transfected with a plasmid expressing EP153R and stimulated 
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with PMA and ionomycin was significantly lower than in cells which were untransfected or 
transfected with a control plasmid. 
In this chapter, the expression and localisation of EP153R in transiently transfected ASFV-
infected and mock-infected cells was investigated and the effect of N-terminal mutations in 
the EP153R gene was studied. Finally, the effect of EP153R on surface SLA-I expression 
was investigated in uninfected cells through flow cytometry of transiently transfected Max 
cells.  
6.2. Results 
6.2.1. Expression and processing of EP153R 
6.2.1.1. Cloning EP153R with epitope tags in an expression vector 
To investigate the expression and cellular localisation of EP153R in cells infected with 
ASFV, the EP153R gene was amplified from ASFV Georgia 2007/1 genomic DNA and 
cloned into a pcDNA3 expression vector (Invitrogen-Life Technologies) under control of its 
cognate ASFV promoter, using the cloning procedure described in Chapter 2.5.5 (figure 6.1). 
This construct was designated ASFV-EP153R-HA-pcDNA3. Since the exact promoter 
sequences of ASFV genes are unknown, the forward primer of the region to be cloned was 
designed to bind 100 bp upstream of the EP153R start codon. The reverse primer included the 
sequence of an HA epitope tag to be cloned into the gene construct upstream of the stop 
codon. Once the construct was assembled, its sequence was confirmed to be correct as 
described in Chapter 2.5.5.3. 
In order to investigate the localisation and expression of EP153R in uninfected cells, a 
synthetic gene for EP153R was purchased from Eurofins (Luxembourg), codon-optimised for 
expression in mammalian (porcine) cells, also with an HA epitope tag at the 3′ end. The gene 
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Figure 6.1: Map of EP153R and HA epitope tag cloned under ASFV promoter in 
expression vector pcDNA3. 
Map of construct ASFV-EP153R-HA-pcDNA3. The EP153R gene and C-terminal HA 
epitope tag were cloned into the multiple cloning site of pcDNA3 (Invitrogen-Life 
Technologies) using HindIII and XhoI restriction sites. The ampicillin resistance gene and 
CMV promoter region are also highlighted. The gene for EP153R was cloned with its 
cognate ASFV promoter, meaning that expression would be driven off this promoter 
instead of the CMV promoter of pcDNA3. 
ASFV-EP153R-HA-pcDNA3
5986 bp
Ampicillin resistance
Multiple cloning site
EP153R
HA tag
CMV promoter
ASFV promoter
XhoI (1544)
HindIII (912)
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Figure 6.2: Map of EP153R and HA epitope tag cloned under CMV/β-actin promoter in 
expression vector pTriEx-1.1 
Map of construct CMV-EP153R(pig)-HA-pTriEx. The EP153R gene and C-terminal HA epitope 
tag were cloned into the multiple cloning site of pTriEx-1.1 (Novagen-EMD Millipore, Germany) 
using PstI and HindIII restriction sites. The ampicillin resistance gene and CMV enhancer region 
and β-actin promoter region are also highlighted. The gene for EP153R was cloned without its 
cognate ASFV promoter, meaning that expression would be driven off the CMV/β-actin promoter 
of pTriEx-1.1. 
CMV-EP153R(pig)-HA-pTriEx
5787 bp
CMV enhancer region
Multiple cloning site
Ampicillin resistance
Chicken actin promoter
EP153R
HA epitope tag
PstI (2389)
HindIII (2895)
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was delivered within the company’s backbone vector, pEX-A, and cloned as in Chapter 2.5.5 
into pTriEx-1.1 (Novagen-EMD Millipore, Germany) (figure 6.2) with the correct sequence 
confirmed. This construct was designated CMV-EP153R(pig)-HA-pTriEx. 
The gene for CD2v from ASFV Malawi Lil 20-1 was cloned by L. Goatley (TPI) for previous 
studies into the localisation of CD2v (Goatley & Dixon, 2011), with an N-terminal V5 
epitope tag and a C-terminal HA epitope tag, under both its cognate ASFV promoter into 
pcDNA3 and under the β-actin/CMV promoter of pTriEx-1.1. 
6.2.2. Expression and post-translational modification of EP153R 
When newly synthesised proteins are translated and transported into the ER, a 14-sugar 
precursor molecule comprised of N-acetylglucosamine (GlcNAc), mannose and glucose is 
linked to asparagine residues by the enzyme oligosaccharyl transferase. During protein 
movement through the ER, into the Golgi and then into the trans-Golgi vesicular transport 
network, this oligosaccharide undergoes further processing. Proteins which have undergone 
initial glycosylation in the ER but not progressed to the Golgi are susceptible to 
endoglycosidase H (EndoH), which deglycosylates mannose glycoproteins. Proteins which 
have been processed beyond the ER and Golgi become resistant to EndoH as the enzyme 
alpha-mannosidase II removes two mannose subunits in the Golgi. Peptide-N-glycosidase F 
(PNGaseF) cleaves the innermost GlcNAc from asparagine residues, thus removing all N-
linked glycosylations from glycoproteins at all stages of the vesicular transport pathway. 
Treatment with EndoH and PNGaseF allows investigation into N-linked glycosylations 
undergone by proteins during post-translational modification. The level of susceptibility to 
EndoH further provides information into how far through the vesicular transport pathway a 
glycosylated protein has been processed.  
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When cloning of the EP153R constructs was complete, expression and post-translational 
modifications were tested by transient transfection of Vero and Max cells. Cells transfected 
with the plasmid expressing EP153R under its cognate ASFV promoter were infected; Vero 
cells with ASFV BA71V and Max cells with ASFV attenuated Uganda, at MOI = 2 at 4-6 
hours post-transfection. Both ASFV-infected and uninfected cells were harvested at ~24 
hours post transfection. In order to investigate post-translational modification of the 
expressed EP153R glycoprotein, cells were treated overnight with 1 µg.ml-1 tunicamycin to 
inhibit N-linked glycosylation, or the cell lysates were treated with EndoH or PNGaseF (New 
England Biolabs). The molecular weights of expressed EP153R protein within the cell lysates 
were then analysed by SDS-PAGE and Western blot as described in Chapter 2.6.2. 
Membranes were incubated with an antibody against the HA epitope tag, followed by a 
species-specific secondary antibody conjugated to HRP. Bands were detected on addition of a 
chemifluorescent substrate and exposure to X-ray film. A separate Western blot of the cell 
lysates was incubated with an antibody against γ-tubulin as a protein loading control. 
EP153R expressed in both Max and Vero cells was detected as at least two bands differing 
slightly in molecular weight at around 38 kDa. These may represent two forms of the protein 
with slightly different post-translational modifications (figure 6.3, figure 6.4: lanes 1 & 2). 
The predicted unmodified size of EP153R is 18 kDa, and a band of this size was also 
observed in all treatments of both cell types (figure 6.3, figure 6.4: lanes 2 - 8), except 
untreated infected cells transfected with a plasmid expressing EP153R under its cognate 
ASFV promoter, where EP153R appears to be fully processed (figure 6.3, figure 6.4: lane 1).  
EP153R also appears to undergo further modifications resulting in a form of around 
50-60 kDa in size in both infected and uninfected cells. In Vero cells the 50-60 kDa form was 
not detected as strongly as the 38 kDa form (figure 6.3: lanes 1, 2, 5 & 6) while in Max cells 
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Figure 6.3: Expression and post-translational modification of EP153R in Vero cells 
Western blot of Vero cells transiently transfected with a plasmid expressing ASFV-EP153R-HA-
pcDNA3 and infected with ASFV BA71V (ASFV) or uninfected cells transiently transfected with 
CMV-EP153R(pig)-HA-pTriEx (β-actin/CMV), treated with tunicamycin, EndoH or PNGaseF to 
evaluate post-translational modifications. EP153R expressed from ASFV-EP153R-HA-pcDNA3 is 
under control of its cognate ASFV promoter which was cloned into the expression vector along with 
the gene, while expression from CMV-EP153R(pig)-HA-pTriEx is under control of the β-actin/CMV 
promoter region within the pTriEx expression vector. 
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Figure 6.4: Expression and post-translational modification of EP153R in Max cells 
Western blot of Max cells transiently transfected with ASFV-EP153R-HA-pcDNA3 and infected with 
ASFV attenuated Uganda (ASFV) or uninfected cells transiently transfected with CMV-EP153R(pig)-
HA-pTriEx (β-actin/CMV), treated with tunicamycin, EndoH or PNGaseF to evaluate post-
translational modifications. EP153R expressed from ASFV-EP153R-HA-pcDNA3 is under control of 
its cognate ASFV promoter which was cloned into the expression vector along with the gene, while 
expression from CMV-EP153R(pig)-HA-pTriEx is under control of the β-actin/CMV promoter region 
within the pTriEx expression vector. 
. 
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both forms were detected in approximately equal proportions (figure 6.4: lanes 1, 2, 5 & 6).  
EP153R expressed in both cell types and in infected and uninfected cells treated with 
tunicamycin was ~18 kDa in size, as expected from the predicted unmodified size (figure 6.3, 
figure 6.4: lanes 3 & 4). The bands seen in EP153R treated with EndoH (figure 6.3, figure 
6.4: lanes 5 & 6) and PNGaseF (figure 6.3, figure 6.4: lanes 7 & 8) were slightly larger, at 
around 20 kDa, since these enzymes do not completely cleave all post-translational 
glycosylations. The 50-60 kDa form of EP153R was detected in Vero and Max cells treated 
with EndoH, weakly in Vero cells (figure 6.3: lanes 5 & 6) and more strongly in Max cells 
(figure 6.4: lanes 5 & 6), signifying that the protein in this band is resistant to cleavage by 
EndoH. In Vero cells the 50-60 kDa band detected in ASFV-infected cells treated with 
EndoH (figure 6.3: lane 5) was stronger than the band detected in uninfected cells (figure 6.4: 
lane 6). This indicates that in ASFV-infected Vero cells a higher proportion of expressed 
EP153R protein does not remain within the ER but is processed further in the vesicular 
transport pathway.  
A notable detail of the Western blots of EP153R expressed in both infected and uninfected 
Vero and Max cells is the size difference between EP153R expressed in infected cells and 
uninfected cells across all treatments. In tunicamycin, EndoH and PNGaseF treated cells, as 
well as untreated cells, EP153R expressed from its cognate ASFV promoter is approximately 
2 kDa smaller than EP153R expressed from the β-actin/CMV promoter of pTriEx-1.1 (figure 
6.3, figure 6.4). 
As discussed in Chapter 1.3.2, the expression of CD2v in both infected and uninfected cells 
has previously been documented, and expression studies by Western blot were not repeated 
here. Briefly, in uninfected cells, CD2v remains intact and a full-length protein of 105 to 
110 kDa is expressed. In infected cells, CD2v is cleaved by an unknown mechanism to 
222 
 
produce an N-terminal fragment containing the extracellular domain of 63 kDa and a 
C-terminal cytoplasmic fragment of 26 kDa. These fragments are detected in addition to the 
full-length protein (Kay-Jackson et al., 2004; Goatley & Dixon, 2011). 
6.2.3. Localisation of EP153R in infected and uninfected cells 
Max and Vero cells were transiently transfected with a plasmid expressing EP153R under its 
cognate ASFV promoter and the β-actin/CMV promoter of pTriEx-1.1 in order to establish 
the localisation of EP153R in ASFV-infected and uninfected cells by indirect 
immunofluorescence viewed by confocal microscopy. Cells transfected with a plasmid 
expressing EP153R under its cognate ASFV promoter were infected; Vero cells with ASFV 
BA71V and Max cells with ASFV attenuated Uganda, at MOI = 2 at 4-6 hours post-
transfection. Both ASFV-infected and uninfected cells were fixed at ~24 hours post 
transfection (18-20 hpi). Cells were labelled for the C-terminal HA epitope tag of the 
EP153R constructs, as well as for cellular markers for the ER, Golgi and both internal and 
surface SLA-I. Since pigs are the natural hosts of ASFV, wherever possible, images of 
EP153R localisation are from Max (porcine kidney) cells.  
In uninfected Max cells, EP153R was seen to localise with the ER (figure 6.5-A), but not the 
Golgi (figure 6.5-B) or with internal SLA-I (figure 6.5-C). No expression of EP153R was 
detected on the cell surface of uninfected Max or Vero cells. In Max cells transiently 
transfected with a plasmid expressing EP153R under its cognate ASFV promoter and infected 
with ASFV attenuated Uganda, EP153R was not seen to localise with the ER (figure 6.6-A), 
Golgi (figure 6.6-B) or internal SLA-I (figure 6.6-C), but appeared to be expressed in a 
punctate labelling pattern throughout the cytoplasm and on cellular membranes. In surface-
labelled cells, EP153R was seen to localise at the cell surface along with SLA-I (figure 
6.6-D). 
223 
 
   
Figure 6.5: Localisation of C-terminus of EP153R expressed from β-actin/CMV promoter in 
uninfected cells. 
Max cells grown on coverslips were transfected with CMV-EP153R(pig)-HA-pTriEx (C-EH) and at 
~24 hours post-transfection, fixed in 4% PFA and permeabilised with 0.2% TritonX-100. The HA 
epitope tag on the C-terminal end (shown in green) was detected with an anti-HA:Alexa Fluor 488 
conjugated antibody. Cellular markers for the (A) ER (ERp60), (B) Golgi (GM130) and (C) SLA-I 
(JM1E3) (all shown in red) were labelled with primary antibodies, followed by appropriate species- or 
IgG-specific Alexa Fluor 568 secondary antibodies. Coverslips were mounted with VectaSheild plus 
DAPI mounting medium and visualized by confocal microscopy.  
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Figure 6.6: Localisation of C-terminus of EP153R expressed from ASFV promoter in ASFV-
infected cells  
Max cells grown on coverslips were transfected with ASFV-EP153R-HA-pcDNA3 (A-EH) and 
infected with ASFV attenuated Uganda. At ~24 hours post-transfection and 18 hpi, cells were fixed in 
4% PFA and (A, B, C) permeabilised with 0.2% TritonX-100 or (D) surface labelled. The HA epitope 
tag on the C-terminal end (shown in green) was detected with an anti-HA:Alexa Fluor 488 conjugated 
antibody or an anti-HA primary antibody followed by a species-specific Alexa Fluor 488 secondary 
antibody. Cellular markers for the (A) ER (ERp60), (B) Golgi (GM130) and (C, D) SLA-I (JM1E3) 
(all shown in red) were labelled with primary antibodies, followed by appropriate species- or IgG-
specific Alexa Fluor 568 secondary antibodies. Coverslips were mounted with VectaSheild plus DAPI 
mounting medium and visualized by confocal microscopy. 
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6.2.4. Localisation of CD2v in infected and uninfected cells. 
Previous studies into the localisation of CD2v have shown that in uninfected cells, full-length 
CD2v co-localises with markers for the Golgi, while in cells infected with ASFV, protein 
with an N-terminal epitope tag (full length and/or N-terminal extracellular fragment) localises 
to virus factories and co-localises with markers for the Golgi while proteins with a C-terminal 
epitope tag (full-length and/or C-terminal cytoplasmic fragment) is expressed throughout the 
cytoplasm in a punctate labelling pattern suggesting distribution in vesicles. Both the 
N-terminal fragment and full-length CD2v protein have been shown to be expressed at the 
cell surface (Goatley & Dixon, 2011). However, no investigations were carried out into the 
localisation of CD2v relative to MHC class I molecules. Here, Max and Vero cells were 
transiently transfected with a plasmid expressing epitope-tagged CD2v under its cognate 
ASFV promoter or the β-actin/CMV promoter of pTriEx-1.1 and fixed at ~24 hours post-
transfection. Max cells transfected with a plasmid expressing CD2v under its cognate ASFV 
promoter were infected with ASFV attenuated Uganda at MOI = 2 at 4-6 hours post-
transfection. Cells were labelled for the C-terminal HA epitope tag of the CD2v constructs in 
uninfected cells and both the N-terminal V5 and C-terminal HA epitope tags in ASFV-
infected cells, together with cellular markers for internal and surface SLA-I, as well as the ER 
and Golgi.   
As previously seen, in uninfected Max and Vero cells, CD2v co-localised with markers for 
the Golgi (figure 6.7-B), and not the ER (figure 6.7-A) or internal SLA-I (figure 6.7-C), 
although in contrast to Goatley and Dixon (2011) no surface expression was seen (figure 
6.7-D) in surface-labelled cells. In Max cells transfected with a plasmid expressing CD2v 
expressed under its cognate ASFV promoter and infected with ASFV attenuated Uganda, 
antibodies against the C-terminal cytoplasmic tag were not observed to co-localise with the 
ER (figure 6.8-A), the Golgi (figure 6.8-B), internal SLA-I (figure 6.8-C) or on the 
227 
 
membrane with surface SLA-I (figure 6.8-D). Antibodies against the N-terminal tag did not 
localise with internal SLA-I (figure 6.9-C) but were detected at the plasma membrane with 
SLA-I in surface-labelled cells (figure 6.8-D). Again in contrast to the findings of Goatley 
and Dixon (2011), antibodies against the N-terminal tag showed localisation with markers for 
the ER (figure 6.9-A) rather than the Golgi (figure 6.9-B). This difference may be a result of 
this study infecting Max cells with ASFV attenuated Uganda, while Goatley and Dixon 
(2011) infected Vero cells with ASFV BA71V. However, in both studies, the same CD2v 
constructs were used with the EP402R gene cloned from ASFV Malawi Lil 20-1 genomic 
DNA. In all permeabilised internally-labelled cells, the intensity of labelling for the N-
terminal tag of CD2v appeared higher around virus factories than other locations (figure 
6.9-A,B,C). 
6.2.1. Using dual-tagged EP153R and N-terminal mutants to investigate 
processing and ER retention of EP153R 
The results of Chapter 6.2.2 showed that EP153R expressed in ASFV-infected cells runs at an 
apparent lower molecular weight on SDS-PAGE compared to EP153R expressed in 
uninfected cells, suggesting that EP153R may undergo additional processing in ASFV-
infected cells. Since the EP153R protein was successfully detected with antibodies against a 
C-terminal tag, this suggests that no processing occurs at the C-terminal end of the protein, 
and the lower molecular weight form detected may result from a cleavage at the N-terminus 
of EP153R. Further, this cleavage might disrupt the putative ER retention motifs at the 
N-terminal end of EP153R (see Chapter 3.2.2, figure 3.2), which would explain the 
differential localisation of EP153R at the cell surface in ASFV-infected cells but 
predominantly in the ER in uninfected cells (see  Chapter 6.2.3). 
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Figure 6.7: Localisation of C-terminus of CD2v expressed from β-actin/CMV promoter in 
uninfected cells. 
Vero (A, B) and Max (C, D) cells grown on coverslips were transfected with CMV-V5-CD2v-HA-
pTriEx and at ~24 hours post-transfection, fixed in 4% PFA and (A, B, C) permeabilised with 0.2% 
TritonX-100 or (D) surface labelled. The HA epitope tag on the C-terminal end (shown in green) was 
detected an anti-HA:Alexa Fluor 488 conjugated antibody or an anti-HA primary antibody followed 
by a species-specific Alexa Fluor 488 secondary antibody. Cellular markers for the (A) ER (ERp60), 
(B) Golgi (βCOP) and (C, D) SLA-I (JM1E3) (all shown in red) were labelled with primary 
antibodies, followed by appropriate species- or IgG-specific Alexa Fluor 568 secondary antibodies. 
Coverslips were mounted with VectaSheild plus DAPI mounting medium and visualized by confocal 
microscopy.  
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Figure 6.8: Localisation of C-terminus of CD2v expressed from ASFV promoter in ASFV-
infected cells  
Max cells grown on coverslips were transfected with ASFV-V5-CD2v-HA-pcDNA and infected with 
ASFV attenuated Uganda. At ~24 hours post-transfection and 18 hpi, cells were fixed in 4% PFA and 
(A, B, C) permeabilised with 0.2% TritonX-100 or (D) surface labelled. The HA epitope tag on the 
C-terminal end (shown in green) was detected with an anti-HA:Alexa Fluor 488 conjugated antibody. 
Cellular markers for the (A) ER (ERp60), (B) Golgi (GM130) and (C, D) SLA-I (JM1E3) (all shown 
in red) were labelled with primary antibodies, followed by appropriate species- or IgG-specific Alexa 
Fluor 568 secondary antibodies. Coverslips were mounted with VectaSheild plus DAPI mounting 
medium and visualized by confocal microscopy. 
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Figure 6.9: Localisation of N-terminus of CD2v expressed from ASFV promoter in ASFV-
infected cells  
Max cells grown on coverslips were transfected with ASFV-V5-CD2v-HA-pcDNA and infected with 
ASFV attenuated Uganda. At ~24 hours post-transfection and 18 hpi, cells were fixed in 4% PFA and 
(A, B, C) permeabilised with 0.2% TritonX-100 or (D) surface labelled. The V5 epitope tag on the 
N-terminal end (shown in green) was detected by labelling with an anti-V5 primary antibody followed 
by a species- or IgG-specific Alexa Fluor 488 secondary antibody. Cellular markers for the (A) ER 
(ERp60), (B) Golgi (GM130) and (C, D) SLA-I (JM1E3) (all shown in red) were labelled with 
primary antibodies, followed by appropriate species- or IgG-specific Alexa Fluor 568 secondary 
antibodies. Coverslips were mounted with VectaSheild plus DAPI mounting medium and visualized 
by confocal microscopy. 
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6.2.1.1. Using dual-tagged EP153R constructs to investigate processing of 
EP153R in infected cells 
In order to investigate whether EP153R undergoes processing in infected cells the EP153R 
gene was cloned into expression vectors with epitope tags at both the N-terminal and 
C-terminal end. If processing of EP153R at the N-terminus caused a fragment of 
approximately 2 kDa to be cleaved, this fragment would be unlikely to be stable and would 
be expected to be degraded within the cytoplasm. However, if the fragment was stable in 
infected cells, it would be difficult to detect directly by Western blot due to its small size but 
might be detected by immunofluorescence. A combination of V5, FLAG and HA epitope tags 
were cloned at either end of EP153R under its cognate ASFV promoter and the β-actin/CMV 
promoter of pTriEx-1.1 or CMV promoter of pcDNA3. The FLAG tag was used in order to 
also allow co-transfection with V5-CD2v-HA constructs to investigate whether EP153R and 
CD2v may co-localise. 
6.2.1.2. Using deletion mutants to investigate potential ER retention di-lysine 
motifs in EP153R 
The cytoplasmic end of EP153R contains three di-lysine motifs downstream from the amino 
terminus at Lys5-Lys6, Lys13-Lys14 and Lys18-Lys20
. 
Di-lysine motifs have been shown to 
function as ER retention motifs in type I transmembrane proteins. In soluble proteins residing 
in the lumen of the ER the KDEL motif is associated with ER retention (Nilsson et al., 1989; 
Jackson et al., 1990) and in type II transmembrane proteins, di-arginine motifs serve the same 
function (Teasdale & Jackson, 1996). However, despite being a type II transmembrane 
protein, EP153R does not contain any di-arginine motifs, so it was decided to investigate 
whether the di-lysine motifs may function to retain EP153R in the ER in uninfected cells, as 
seen in figure 6.5-A. Synthetic genes for N-terminal mutants of EP153R were purchased 
from Eurofins with the first 5, 13 or 19 amino acids deleted from the N-terminal end of 
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EP153R, which would eliminate the Lys5-Lys6, the Lys5-Lys6 and Lys13-Lys14 or all three of 
the di-lysine motifs. These genes were then cloned into pTriEx1.1 expression vector. 
Additionally, mutants were purchased and cloned with di-arginine motifs or di-alanine motifs 
substituted for all three di-lysine motifs. Di-arginine motifs were chosen since the ER 
retention motif for type II transmembrane proteins is a di-arginine motif and both arginine 
and lysine are polar basic amino acids, meaning that neither side chain nor main chain 
interactions should be affected by the substitution. Alanine was selected since it is a neutral 
amino acid and eliminates side-chain interactions without altering the conformation of the 
main chain by introducing steric or electrostatic effects. 
6.2.1.1. Expression of dual-tagged and N-terminal mutant EP153R constructs 
The dual-tagged and mutant EP153R constructs were analysed by sequencing the inserts 
within the plasmids to confirm that cloning had been successful. Vero and Max cells were 
then transiently transfected with these plasmid constructs to analyse the size of the expressed 
proteins by Western blot and their localisation by indirect immunofluorescence viewed by 
confocal microscopy as described previously in this chapter. For ease of identification of 
constructs as they are discussed, the different promoters under which they have been cloned, 
the epitope tags added and mutations made are highlighted in different colours in the 
abbreviations for each construct. A list of all EP153R constructs, including their epitope tags, 
backbone expression vector, whether the gene was codon-optimised for expression in 
mammalian (porcine) cells, whether expression of epitope tags was detected by Western blot 
and/or immunofluorescence, and the key to the colours used in the construct abbreviation, is 
given in table 6.1. 
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Table 6.1: Epitope-tagged and mutant EP153R constructs cloned into expression vectors. 
List of gene constructs cloned into expression vectors listing abbreviations as used in figures, promoter under which gene is expressed, expression vector, 
whether gene has been codon optimised for expression in pigs, N- and C-terminal epitope tags and whether expression of these constructs has been detected 
using antibodies against these epitope tags by indirect immunofluorescence or Western blot.  = strong expression,  = weak expression,  = no expression 
detected. 
 
     Detected by: 
 
    Epitope tag: Immuno-
fluorescence 
Western blot 
Construct name Abbreviation Promoter Vector Codon-
optimised N C N C N C 
Single-tagged constructs:           
ASFV-EP153R-HA-pcDNA3 A-EH Cognate ASFV pcDNA3 no none HA n/a  n/a  
CMV-EP153R(pig)-HA-pTriEx 
(also referred to as EP153R (Georgia)) 
C-EH β-actin/CMV pTriEx-1.1 yes none HA n/a  n/a  
CMV-EP153R(pig)-FLAG-pTriEx C-EF β-actin/CMV pTriEx-1.1 yes none FLAG n/a  n/a  
Dual-tagged constructs:           
ASFV-FLAG-EP153R-V5-pcDNA3 A-FEV Cognate ASFV pcDNA3 no FLAG V5     
CMV-FLAG-EP153R-HA-pcDNA3 C-FEH β-actin/CMV pcDNA3 no FLAG HA     
CMV-FLAG-EP153R-V5-pcDNA3 C-FEV β-actin/CMV pcDNA3 no FLAG V5     
CMV-V5-EP153R(pig)-HA-pTriEx C-VEH β-actin/CMV pTriEx-1.1 yes V5 HA     
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     Detected by: 
 
    Epitope tag: Immuno-
fluorescence 
Western blot 
Construct name Abbreviation Promoter Vector Codon-
optimised N C N C N C 
N-terminal mutants:           
CMV-EP153R(-5aa)-HA-pTriEx C-EH(-5aa) β-actin/CMV pTriEx-1.1 yes none HA n/a  n/a  
CMV-EP153R(-13aa)-HA-pTriEx C-EH(-13aa) β-actin/CMV pTriEx-1.1 yes none HA n/a  n/a  
CMV-EP153R(-19aa)-HA-pTriEx C-EH(-19aa) β-actin/CMV pTriEx-1.1 yes none HA n/a  n/a  
CMV-EP153R(KK-AA)-HA-pTriEx C-EH(AA) β-actin/CMV pTriEx-1.1 yes none HA n/a  n/a  
CMV-EP153R(KK-RR)-HA-pTriEx C-EH(RR) β-actin/CMV pTriEx-1.1 yes none HA n/a  n/a  
CMV-V5-EP153R(KK-AA)-pTriEx C-VE(AA) β-actin/CMV pTriEx-1.1 yes V5 none  n/a  n/a 
CMV-V5-EP153R(KK-RR)-pTriEx C-VE(RR) β-actin/CMV pTriEx-1.1 yes V5 none  n/a  n/a 
CMV-V5-EP153R(KK-AA)-HA-pTriEx C-VEH(AA) β-actin/CMV pTriEx-1.1 yes V5 HA     
CMV-V5-EP153R(KK-RR)-HA-pTriEx C-VEH(RR) β-actin/CMV pTriEx-1.1 yes V5 HA     
Expression of EP153R from different isolates:          
CMV-EP153R(pig)-HA-pTriEx (Georgia) 
 
EP153R 
(Georgia) 
β-actin/CMV pTriEx-1.1 yes none HA  
 
 
 
CMV-EP153R(pig)-HA-pTriEx (Benin) EP153R 
(Benin) 
β-actin/CMV pTriEx-1.1 yes none HA  
 
 
 
 
238 
 
   
239 
 
   
Figure 6.10: Western blotting showing expression of dual-tagged and N-terminal deletion 
mutant EP153R. 
Vero and Max cells were transiently transfected with the constructs expressing dual-tagged or 
mutant forms of EP153R. Cells, and cells transfected with a plasmid expressing EP153R under its 
cognate ASFV promoter (A-EH and A-FEV) were infected with ASFV BA71V (Vero cells) or 
ASFV attenuated Uganda (Max cells) at MOI = 2 at 4-6 hours post-transfection. At ~24 hours post-
infection the cells were harvested and lysates run on SDS-PAGE followed by Western blotting, with 
membranes incubated with antibodies against the HA, V5 and FLAG epitope tags of the EP153R 
constructs as indicated on the figure. The key to the abbreviated names of the constructs appears 
within the text and in table 6.1. 
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6.2.1.1.1 Detection and localisation of dual-tagged EP153R by Western blot 
and immunofluorescence 
Of the dual-tagged wild-type EP153R constructs listed in table 6.1, in only one, ASFV-
FLAG-EP153R-V5-pcDNA3 [A-FEV(1) and A-FEV(2)]  was expression of both the N-
terminal (FLAG) and C-terminal (V5) epitope tag detected by Western blot in both Max 
(infected with ASFV attenuated Uganda) and Vero cells (infected with ASFV BA71V), as 
seen in figure 6.10. However, expression levels of the N-terminal FLAG tag appeared much 
lower than expression levels of the C-terminal V5 tag. In the homologous construct with 
expression from the β-actin/CMV promoter, CMV-FLAG-EP153R-V5-pcDNA3 (C-FEV), 
expression of the C-terminal V5 tag was detected in Max cells, but not the N-terminal FLAG 
tag, and the V5 epitope tag expression detected was much lower than that seen for ASFV-
FLAG-EP153R-V5-pcDNA3 (A-FEV) (figure 6.10). No expression of either tag was 
detected for dual-tagged constructs CMV-FLAG-EP153R-HA-pcDNA3 (C-FEH) (figure 
6.10) and CMV-V5-EP153R(pig)-HA-pTriEx (C-VEH) (figure 6.11). Possibly the 
combination of an N-terminal tag and a C-terminal HA tag interfere with the stability of 
EP153R. 
Similarly, investigation of the expression of EP153R dual-tagged constructs by 
immunofluorescence showed strongest expression of the ASFV-FLAG-EP153R-V5-pcDNA3 
(A-FEV) protein, as detected via labelling of its C-terminal V5 tag (figure 6.12-A,B,D,E). 
Expression of the N-terminal FLAG tag was also detected (figure 6.12-A,C,E), though at 
lower levels than the C-terminal V5 tag. Figure 6.12-E shows the C-terminal V5 tag and N-
terminal FLAG tag in greyscale to facilitate a direct comparison of expression levels. The 
higher levels of background noise (speckles in the image) and low signal-to-noise ratio in the 
image of the signal detected for the N-terminal FLAG tag demonstrate the higher gain setting 
of the confocal microscope on the 568 channel than the 488 channel of the C-terminal V5 tag  
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Figure 6.11: Western blotting showing expression of dual-tagged and N-terminal 
substitution mutant EP153R. 
Vero and Max cells were transiently transfected with the constructs expressing dual-tagged 
EP153R and EP153R with N-terminal substitutions of di-alanine and di-arginine for the di-
lysine repeats. At ~24 hours post-infection the cells were the cells harvested and lysates run 
on SDS-PAGE followed by Western blotting, with membranes incubated with antibodies 
against the epitope tags of the EP153R constructs. The key to the abbreviated names of the 
constructs appears within the text and in table 6.1. 
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Figure 6.12: Localisation of N- and C-terminus of dual-tagged EP153R expressed from ASFV 
promoter in ASFV-infected cells  
Max cells grown on coverslips were transfected with ASFV-FLAG-EP153R-V5-pcDNA3 (A-FEV) 
and infected with ASFV attenuated Uganda. At ~24 hours post-transfection and 18 hours post-
infection, cells were fixed in 4% PFA and (A, B, E) permeabilised with 0.2% TritonX-100 or (C) 
surface labelled. The V5 and FLAG epitope tags (shown in green in (B-D) and both green and red in 
(A)) were detected by labelling with an anti-V5 or anti-FLAG antibody followed by a species- or IgG-
specific Alexa Fluor 488 or 568 secondary antibody. In (E) both the C-terminal V5 tag and N-terminal 
FLAG tag from (A) are shown in greyscale to allow easier comparison of relative expression. Cellular 
markers for the (B, C) ER (ERp60 or PDI) and (D) SLA-I (JM1E3) (all shown in red) were labelled 
with primary antibodies, followed by appropriate species- or IgG-specific Alexa Fluor 568 secondary 
antibodies. Coverslips were mounted with VectaSheild plus DAPI mounting medium and visualized 
by confocal microscopy. 
E 
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when this image was captured. Both the higher signal-to-noise ratio of the C-terminal V5 tag 
image and the more intense labelling demonstrate a higher detection of this tag by 
immunofluorescence, indicating greater levels of expression. Despite differences in 
expression levels, the N-terminal FLAG tag and the C-terminal V5 tag appear to co-localise 
(figure 6.12-A). ASFV-FLAG-EP153R-V5-pcDNA3 (A-FEV) shows the same cytoplasmic 
localisation as that of ASFV-EP153R-HA-pcDNA3 (A-EH) (as seen in figure 6.6-A) in 
permeabilised cells co-labelled for the ER (figure 6.12-B). In surface-labelled cells, both 
ASFV-FLAG-EP153R-V5-pcDNA3 (A-FEV) (figure 6.12-D) and ASFV-EP153R-HA-
pcDNA3 (A-EH) (figure 6.6-D), as detected by their C-terminal epitope tags, are seen on the 
plasma membrane with surface SLA-I.  
Although both N-terminal and C-terminal epitope tags were not detected by 
immunofluorescence for any other dual-tagged EP153R construct, the C-terminal V5 tag of 
CMV-FLAG-EP153R-V5-pcDNA3 (C-FEV) (figure 6.13-A) and the N-terminal V5 tag of 
CMV-V5-EP153R(pig)-HA-pTriEx (C-VEH) (figure 6.13-C) were seen to localise with the 
ER in the same manner as CMV-EP153R(pig)-HA-pTriEx (C-EH) (figure 6.5-A), and CMV-
FLAG-EP153R-V5-pcDNA3 (C-FEV) did not localise with internal SLA-I (figure 6.13-B). 
6.2.1.1.2 Detection and localisation of N-terminal mutants of EP153R by 
Western blot and immunofluorescence 
Three EP153R N-terminal deletion mutants, CMV-EP153R(-5aa)-HA-pTriEx (C-EH(-5aa)), 
CMV-EP153R(-13aa)-HA-pTriEx (C-EH(-13aa)) and CMV-EP153R(-19aa)-HA-pTriEx 
(C-EH(-19aa)), were investigated for expression of their C-terminal HA epitope tag in 
transiently transfected Vero and Max cells by Western blot. Very low levels of expression of 
CMV-EP153R(-13aa)-HA-pTriEx (C-EH(-13aa)) were detected in Vero cell lysates. Protein 
expression was not detected for any other deletion mutant construct (figure 6.10). As a result 
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Figure 6.13: Localisation of N- and C-terminus of dual-tagged EP153R expressed from 
β-actin/CMV promoter 
Max cells grown on coverslips were transfected with (A,B) CMV-FLAG-EP153R-V5-pcDNA3 
(C-FEV) or (C) CMV-V5-EP153R(pig)-HA-pTriEx (C-VEH). At ~24 hours post-transfection cells 
were fixed in 4% PFA and permeabilised with 0.2% TritonX-100. The V5 epitope tags (shown in 
green) were detected by labelling with an anti-V5 antibody followed by a species- or IgG-specific 
Alexa Fluor 488 secondary antibody. Cellular markers for the (A,C) ER (ERp60) and (B) SLA-I 
(JM1E3) (all shown in red) were labelled with primary antibodies, followed by appropriate species- or 
IgG-specific Alexa Fluor 568 secondary antibodies. Coverslips were mounted with VectaSheild plus 
DAPI mounting medium and visualized by confocal microscopy. 
A 
B 
C 
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Figure 6.14: Localisation of EP153R with N-terminal mutations expressed from β-actin/CMV 
promoter 
Max cells grown on coverslips were transfected with (A,B) CMV-V5-EP153R(KK-RR)-HA-pTriEx 
(C-VEH(RR)) or (C) CMV-EP153R(-5aa)-HA-pTriEx (C-EH(-5aa)). At ~24 hours post-transfection 
cells were fixed in 4% PFA and permeabilised with 0.2% TritonX-100. The V5 or HA epitope tags 
(shown in green) were detected by labelling with an anti-HA:Alexa Fluor 488 conjugated antibody or 
an anti-V5 primary antibody followed by a species- or IgG-specific Alexa Fluor 488 secondary 
antibody. A cellular marker for the ER (ERp60) (shown in red) was labelled with primary antibody, 
followed by appropriate species-specific Alexa Fluor 568 secondary antibody. Coverslips were 
mounted with VectaSheild plus DAPI mounting medium and visualized by confocal microscopy. 
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of this failure to detect expression, mutants with specific amino acid substitutions were also 
cloned. In these mutants the three di-lysine motifs were replaced with di-alanine or di-
arginine repeats, with either a single N-terminal V5 epitope tag [CMV-V5-EP153R(KK-AA)-
pTriEx (C-VE(AA)) and CMV-V5-EP153R(KK-RR)-pTriEx (C-VE(RR))], a single 
C-terminal HA epitope tag [CMV-EP153R(KK-AA)-HA-pTriEx (C-EH(AA)) and CMV-
EP153R(KK-RR)-HA-pTriEx (C-EH(RR))], or both [CMV-V5-EP153R(KK-AA)-HA-
pTriEx (C-VEH(AA)) and CMV-V5-EP153R(KK-RR)-HA-pTriEx (C-VEH(RR))]. No 
expression of any of these mutants was detected by Western blotting for constructs 
containing either epitope tag in transiently transfected Vero and Max cells. Expression of 
CMV-EP153R(pig)-HA-pTriEx (C-EH), which was included as a transfection control, was 
detected (figure 6.11). 
When investigating the expression of N-terminal mutants of EP153R by 
immunofluorescence, expression of EP153R from only two constructs was detected in 
transiently transfected Max cells. Both CMV-V5-EP153R(KK-RR)-HA-pTriEx 
(C-VEH(RR)), as detected by labelling of its N-terminal V5 epitope tag (figure 6.14-A,B), 
and CMV-EP153R(-5aa)-HA-pTriEx (C-EH(-5aa)), as detected with labelling of its C-
terminal HA epitope tag, (figure 6.14-C), localised with markers for the ER in the same 
manner as their wild-type homologues CMV-V5-EP153R(pig)-HA-pTriEx (C-VEH) (figure 
6.13-C) and CMV-EP153R(pig)-HA (figure 6.5-A), respectively. 
A consolidated table of detected expression of EP153R constructs, including dual-tagged and 
N-terminal mutant constructs, by Western blot and immunofluorescence is given in table 6.1. 
This table confirms that detection of constructs by their N-terminal or C-terminal epitope tags 
was consistent by both detection methods, and identifies in which EP153R constructs 
expression was not detected by either one or both epitope tags. 
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6.2.1. Measuring induced changes in surface expression of SLA-I in cells 
transiently transfected with plasmids expressing EP153R and CD2v 
In Hurtado et al.’s (2011) study into the effects of EP153R on modulation of MHC class I, it 
was found that when cells, transiently or stably transfected with a plasmid expressing 
EP153R (cloned from tissue culture adapted isolate ASFV BA71V), were stimulated with 
PMA and ionomycin (PMA/ion), a lower subsequent up-regulation of MHC class I was seen 
than in cells transfected with an expression vector control. They concluded that EP153R 
played a role in preventing an up-regulation of MHC class I in PMA/ion-stimulated cells.  
To expand on these results, Max cells were transiently transfected with a plasmid expressing 
EP153R cloned from ASFV Georgia 2007/1 (EP153R (Georgia)) (identified previously in 
this chapter as CMV-EP153R(pig)-HA-pTriEx) and Benin 97/1 (EP153R (Benin)). The gene 
cloned from ASFV Benin 97/1 was codon-optimised for expression in mammalian cells, and 
cloned into pTriEx-1.1 under the plasmid’s β-actin/CMV promoter and with a C-terminal HA 
epitope tag in the same manner as EP153R (Georgia). Cells were also transfected with 
plasmids containing the gene for ASFV protein VP30 cloned with an HA epitope tag, as well 
as an expression plasmid control in order to investigate changes in surface SLA-I as detected 
by flow cytometry. VP30 was included as a control for two reasons; firstly, the construct 
included an HA epitope tag to allow gating for transfected cells, which is not possible when 
using an empty expression vector as a control into the effect of transfection on SLA-I 
expression. And secondly, VP30 has not been implicated in having any direct effect on the 
immune response in individual cells and so served as a control into the effect of transfecting 
Max cells with plasmids expressing ASFV proteins. 
Six hours post-transfection batches of cells were stimulated with 25 ng.ml-1 PMA (Santa Cruz 
Biotechnology, USA) and 1 μg.ml-1 ionomycin (Cayman Chemical, USA) or 0.25 μg.ml-1 
recombinant porcine IFN-γ (R&D Systems) or were not stimulated. At ~24 hours post-
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transfection cells were harvested, fixed in 4% PFA and labelled with antibodies against the 
HA epitope tag and SLA-I. Surface expression of SLA-I was analysed by flow cytometry 
with gating for single cells. SLA-I levels in cells transfected with plasmids expressing 
HA-tagged protein constructs were also gated for transfected cells as determined by detection 
of the HA epitope tag. 
In unstimulated cells transfected with plasmids expressing EP153R (Georgia) and 
EP153R (Benin), VP30, or pTriEx and pcDNA3 transfection controls, there was no statistical 
difference between treatments and no significant increase in SLA-I expression between any 
treatment and the untransfected mock control (figure 6.15-A, table 6.2).  
In cells stimulated with PMA/ion, surface SLA-I expression increased significantly when 
analysed by one-way ANOVA in cells transfected with a plasmid expressing 
EP153R (Georgia) (mean fold increase = 2.0 ± 0.28; p < 0.0001), VP30 (mean fold 
increase = 1.7 ± 0.16; p < 0.0001) and untransfected stimulated cells (mean fold 
increase = 2.0 ± 0.27; p < 0.0001) compared to untransfected unstimulated cells.  However, 
surface SLA-I expression in cells transfected with a plasmid expressing EP153R (Benin) was 
not significantly up-regulated from the untreated/untransfected mock (mean fold 
increase = 1.4 ± 0.25), but instead was significantly lower than expression in the 
untransfected stimulated treatment (p = 0.0047). Surface SLA-I expression in cells 
transfected with a plasmid expressing EP153R (Benin) was also significantly lower than 
expression in cells transfected with a plasmid expressing EP153R (Georgia) (p = 0.0023) 
(figure 6.15-B, table 6.2). 
Cells stimulated with IFN-γ showed a similar pattern of surface SLA-I expression to those 
stimulated with PMA/ion. Cells transfected with a plasmid expressing EP153R (Georgia) 
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Figure 6.15: Effect of ASFV proteins on surface SLA-I expression in Max cells. 
Investigating changes in surface SLA-I expression in Max cells transiently transfected with 
plasmids expressing ASFV proteins EP153R from ASFV Georgia 2007 (EP153R (Geo)) and 
EP153R from ASFV Benin 2007/1 (EP153R (Ben)), plus VP30 as a control for an irrelevant ASFV 
protein transfection control either (A) unstimulated or stimulated with (B) PMA/ion or (C) IFN-γ. 
SLA-I expression is represented as fold-change from untransfected/untreated cells (untransf’d 
(mock)), as measured by flow cytometry. All samples were gated for single cells, and samples 
containing cells transfected with plasmids expressing ASFV proteins with HA tags were also gated 
for transfected cells, as detected by positive expression of the HA tag. The top row of black * 
indicates treatments with significantly different SLA-I expression from untransfected/untreated 
cells by one-way ANOVA, while the bottom row of black * indicates treatments with significantly 
different SLA-I expression from (B) untransfected controls stimulated with PMA/ion and (C) 
untransfected controls stimulated with IFN-γ. The row of red * indicate statistically different 
SLA-I expression between cells transfected with plasmids expressing the three ASFV proteins; 
EP153R from ASFV Georgia 2007, EP153R (Benin) and VP30. Error bars depict standard 
deviation. Replicates per treatment: n = 4. Data were collected over four experiments.  
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Table 6.2: Analysis of the effect of transfection with ASFV proteins on surface SLA-I expression 
in Max cells. 
Tukey’s multiple comparisons test one-way ANOVA of SLA-I expression in Max cells transiently 
transfected with ASFV proteins EP153R (Georgia) and EP153R (Benin), plus VP30 as an ASFV 
protein transfection control, with and without stimulation with IFN-γ or PMA/ion (as relative to 
untransfected/untreated cells), measured by flow cytometry. All samples were gated for single cells, 
and samples containing cells transfected with plasmids expressing ASFV proteins with HA tags were 
also gated for transfected cells, as detected by positive expression of the HA tag. 
Tukey's multiple comparisons test Mean 
Diff. 
95% CI of diff. Summary Adjusted P 
Value 
Untransf'd vs. Untransf'd IFN-γ -2.099 -2.581 to -1.618 **** < 0.0001 
Untransf'd vs. Untransf'd PMA -0.963 -1.445 to -0.482 **** < 0.0001 
Untransf'd vs. EP153R (Geo) -0.401 -0.882 to 0.081 ns 0.2150 
Untransf'd vs. EP153R (Geo) IFN-γ -1.063 -1.544 to -0.582 **** < 0.0001 
Untransf'd vs. EP153R (Geo) PMA -0.991 -1.472 to -0.510 **** < 0.0001 
Untransf'd vs. EP153R (Ben) -0.088 -0.570 to 0.393 ns > 0.9999 
Untransf'd vs. EP153R (Ben) IFN-γ -0.522 -1.004 to -0.041 * 0.0204 
Untransf'd vs. EP153R (Ben) PMA -0.381 -0.862 to 0.101 ns 0.2888 
Untransf'd vs. VP30 -0.298 -0.792 to 0.197 ns 0.7257 
Untransf'd vs. VP30 IFN-γ -1.156 -1.650 to -0.662 **** < 0.0001 
Untransf'd vs. VP30 PMA -0.749 -1.243 to -0.254 **** < 0.0001 
Untransf'd vs. pTriEx -0.228 -0.709 to 0.254 ns 0.9382 
Untransf'd vs. pcDNA3 -0.184 -0.666 to 0.297 ns 0.9890 
Untransf'd IFN-γ vs. EP153R (Geo) IFN-γ 1.036 0.555 to 1.517 **** < 0.0001 
Untransf'd IFN-γ vs. EP153R (Ben) IFN-γ 1.577 1.096 to 2.058 **** < 0.0001 
Untransf'd IFN-γ vs. VP30 IFN-γ 0.943 0.449 to 1.438 **** < 0.0001 
Untransf'd IFN-γ vs. pTriEx 1.872 1.390 to 2.353 **** < 0.0001 
Untransf'd IFN-γ vs. pcDNA3 1.915 1.434 to 2.396 **** < 0.0001 
Untransf'd PMA vs. EP153R (Geo) PMA -0.028 -0.509 to 0.454 ns > 0.9999 
Untransf'd PMA vs. EP153R (Ben) PMA 0.583 0.102 to 1.064 ** 0.0047 
Untransf'd PMA vs. VP30 PMA 0.215 -0.280 to 0.709 ns 0.9680 
Untransf'd PMA vs. pTriEx 0.736 0.255 to 1.217 **** < 0.0001 
Untransf'd PMA vs. pcDNA3 0.779 0.298 to 1.260 **** < 0.0001 
EP153R (Geo) vs. EP153R (Ben) 0.312 -0.169 to 0.794 ns 0.6157 
EP153R (Geo) vs. VP30 0.103 -0.392 to 0.597 ns > 0.9999 
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Tukey's multiple comparisons test Mean 
Diff. 
95% CI of diff. Summary Adjusted P 
Value 
EP153R (Geo) vs. pTriEx 0.173 -0.308 to 0.655 ns 0.9937 
EP153R (Geo) vs. pcDNA3 0.217 -0.264 to 0.698 ns 0.9575 
EP153R (Geo) IFN-γ vs. EP153R (Ben) IFN-γ 0.541 0.059 to 1.022 * 0.0133 
EP153R (Geo) IFN-γ vs. VP30 IFN-γ -0.093 -0.587 to 0.402 ns > 0.9999 
EP153R (Geo) IFN-γ vs. pcDNA3 0.879 0.398 to 1.360 **** < 0.0001 
EP153R (Geo) PMA vs. EP153R (Ben) PMA 0.611 0.129 to 1.092 ** 0.0023 
EP153R (Geo) PMA vs. VP30 PMA 0.242 -0.252 to 0.737 ns 0.9201 
EP153R (Geo) PMA vs. pTriEx 0.764 0.282 to 1.245 **** < 0.0001 
EP153R (Geo) PMA vs. pcDNA3 0.807 0.326 to 1.288 **** < 0.0001 
EP153R (Ben) vs. pTriEx -0.139 -0.620 to 0.342 ns 0.9993 
EP153R (Ben) vs. pcDNA3 -0.096 -0.571 to 0.386 ns > 0.9999 
EP153R (Ben) IFN-γ vs. VP30 IFN-γ -0.634 -1.128 to -0.139 ** 0.0019 
EP153R (Ben) IFN-γ vs. pTriEx 0.295 -0.186 to 0.776 ns 0.7021 
EP153R (Ben) IFN-γ vs. pcDNA3 0.338 -0.143 to 0.819 ns 0.4834 
EP153R (Ben) PMA vs. VP30 PMA -0.368 -0.863 to 0.126 ns 0.3839 
EP153R (Ben) PMA vs. pTriEx 0.153 -0.328 to 0.634 ns 0.9981 
EP153R (Ben) PMA vs. pcDNA3 0.196 -0.285 to 0.678 ns 0.9808 
VP30 vs. pTriEx 0.070 -0.424 to 0.565 ns > 0.9999 
VP30 vs. pcDNA3 0.114 -0.381 to 0.608 ns > 0.9999 
VP30 IFN-γ vs. pTriEx 0.929 0.434 to 1.423 **** < 0.0001 
VP30 IFN-γ vs. pcDNA3 0.972 0.477 to 1.466 **** < 0.0001 
VP30 PMA vs. pTriEx 0.521 0.027 to 1.016 * 0.0286 
VP30 PMA vs. pcDNA3 0.565 0.070 to 1.059 * 0.0108 
pTriEx vs. pcDNA3 0.043 -0.438 to 0.525 ns > 0.9999 
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(mean fold increase = 2.1 ± 0.56; p < 0.0001), VP30 (mean fold increase = 2.2 ± 0.51; 
p < 0.0001) and untransfected stimulated cells (mean fold increase = 3.1 ± 0.64; p < 0.0001) 
expressed significantly higher levels of surface SLA-I than the untransfected unstimulated 
cells. Surface SLA-I expression was also significantly increased in cells transfected with a 
plasmid expressing EP153R (Benin) (mean fold increase = 1.5 ± 0.18; p = 0.0204), but this 
up-regulation was lower than that seen in the other transfected cell treatments. Additionally, 
surface SLA-I expression in cells transfected with a plasmid expressing EP153R (Benin) was 
significantly lower than in cells transfected with a plasmid expressing EP153R (Georgia) 
(p = 0.0133) and VP30 (p = 0.0019). All three treatments where cells were transfected with 
plasmids expressing ASFV proteins; EP153R (Benin) (p < 0.0001), EP153R (Georgia) 
(p < 0.0001) and VP30 (p < 0.0001) showed a significantly lower expression of surface 
SLA-I than untransfected stimulated cells (figure 6.15-C, table 6.2). 
6.3. Discussion 
In cells infected with ASFV, EP153R was detected in a punctate staining pattern throughout 
the cytoplasm and also localised on the plasma membrane with SLA-I. Expression of 
EP153R on the plasma membrane was expected as it is a transmembrane protein and thought 
to be involved in immune evasion as well as stabilising CD2v in its function of mediating 
haemadsorption of erythrocytes to infected macrophages (Rodríguez et al., 1993; Borca et al., 
1998; Galindo et al., 2000) (see Chapter 1.3.3.3.1). One of the reasons for cloning EP153R 
with FLAG tag epitope tags under both its cognate ASFV promoter and the CMV promoter 
of the expression vectors was to allow co-transfection of cells with EP153R with a FLAG 
epitope tag and CD2v constructs ASFV-V5-CD2v-HA-pcDNA3 or CMV-V5-CD2v-HA-
pTriEx, to investigate whether EP153R and CD2v co-localise. However expression of 
EP153R and CD2v together was not detected in co-transfected cells. Possibly transfection 
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rates were not sufficiently high to achieve this although a more subtle effect of co-expressing 
both proteins cannot be excluded. 
While both EP153R and SLA-I were seen to be expressed at the plasma membrane in ASFV-
infected cells (figure 6.6-D), this labelling does not confirm actual interaction of the two 
proteins. Additionally, no localisation of EP153R with SLA-I was seen in the cytoplasm of 
either ASFV-infected (figure 6.6-C) or uninfected cells (figure 6.5-C). Thus, the results of 
immunofluorescent visualisation of the localisation of EP153R and SLA-I in both ASFV-
infected and uninfected cells do not support a model for EP153R binding directly to SLA-I. 
Further work would be required to determine if EP153R interacts with SLA-I at the cell 
surface. In Chapter 3.2.4 Hurtado et al.’s (2011) proposed model of EP153R binding directly 
to SLA-I was discussed, including reasons why this model may not be viable, and a potential 
function of EP153R was proposed in terms of the similarity of its C-type lectin domain to the 
Clec2 sub-family of NK cell receptors.  
Similarly, CD2v was not observed to co-localise with SLA-I within the cytoplasm of infected 
(figure 6.8-C, figure 6.9-C) or uninfected cells (figure 6.7-C). Although the N-terminal 
extracellular fragment of CD2v is expressed at the plasma membrane of ASFV-infected cells 
(figure 6.9-D), it was not possible to confirm if CD2v and SLA-I interact at the cell surface. 
Thus, while the results of Chapter 4 suggest that CD2v plays a role in the modulation of 
surface SLA-I expression in ASFV-infected cells, this seems unlikely to be the result of a 
direct interaction between CD2v and SLA-I. 
Investigations into the expression and post-translational modifications of EP153R in infected 
and uninfected Max and Vero cells revealed that EP153R expressed in ASFV-infected cells 
was around 2 kDa smaller than the protein expressed in uninfected cells, including samples 
from cells incubated with tunicamycin, or treated with EndoH and PNGaseF. Since this 
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difference in protein size was detected in cells treated with tunicamycin, which inhibits 
protein glycosylation and transport beyond the ER, this indicates that any modifications to 
EP153R occur within the ER rather than at a later stage of the protein secretory pathway. The 
size difference between the two forms of the EP153R protein would translate to 
approximately 20 amino acids (figure 6.3, figure 6.4). In addition, in uninfected cells, 
EP153R localised in the ER with no detectable surface expression (figure 6.5-A), while in 
infected cells, localisation was seen in a punctate pattern throughout the cytoplasm (figure 
6.6-A,B,C) and at the surface (figure 6.6-D). A possibility for this difference in localisation is 
that processing of EP153R in infected cells results in cleavage of an ER retention motif. An 
alternative explanation could be that EP153R undergoes different post-translational 
modification in uninfected and ASFV-infected cells.  
EP153R was successfully detected by both Western blot and immunofluorescence using a 
C-terminal epitope tag, which indicated that any cleavage must take place at the N-terminal 
end. Galindo et al. (2000) had previously suggested that a small portion of the N-terminal end 
of EP153R expressed in a rabbit reticulocyte transcription/translation system is susceptible to 
the action of proteinases.  
There are three di-lysine motifs, which is an ER retention motif usually associated with type I 
transmembrane proteins, within the first 20 amino acids at the N-terminal end of EP153R, at 
positions Lys5-Lys6, Lys13-Lys14 and Lys18-Lys20. In type II transmembrane proteins such as 
EP153R, the ER retention motif has been shown to be di-arginine. However, if the difference 
in size between EP153R in infected and uninfected cells observed by Western blot (figure 
6.3, figure 6.4) was due to an N-terminal cleavage of around 20 amino acids, this would 
equate with the removal of all three putative di-lysine ER retention motifs. Thus, this 
cleavage would allow EP153R to be transported through the secretory pathway to the cell 
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surface. Therefore, despite the di-lysine motif not being a typical ER retention motif of 
type II transmembrane proteins, it was decided to investigate whether these motifs had an ER 
retention function in uninfected cells by creating constructs with one, two or all three of these 
motifs deleted. Expression from these deletion mutant constructs was poor, with expression 
of only the 13 amino acid deletion mutant weakly detected by Western blot (figure 6.10). By 
immunofluorescence, only the 5 amino acid deletion mutant was seen to be expressed, also 
very weakly, and this mutant of EP153R was observed to co-localise with markers for the ER 
(figure 6.14-C), the same as the wild-type protein in uninfected cells (figure 6.5-A). 
The lack of expression of the EP153R deletion mutants lead to speculation that the deletions 
were affecting the stability of the protein, and so new mutants were designed and cloned with 
all three di-lysine motifs substituted with di-arginine, since arginine has the same charge and 
hydrophobicity and the ER retention motif for type II transmembrane proteins is a di-arginine 
motif. The di-lysine residues were also substituted by di-alanine as a neutral amino acid. 
These substitution mutants were cloned with single N- or C-terminal epitope tags or with dual 
tags to try to maximise the chances of expression being detected. As was the case for the 
deletion mutants of EP153R, expression was not readily detected, with only one of the 
constructs, CMV-V5-EP153R(KK-RR)-HA-pTriEx (C-VEH(RR)), being detected by 
immunofluorescence of its N-terminal V5 tag. Localisation of this mutant was with markers 
for the ER, as seen in both the C-terminal single-tagged CMV-EP153R(pig)-HA-pTriEx 
(C-EH) (figure 6.5-A) and dual-tagged CMV-V5-EP153R(pig)-HA-pTriEx (C-VEH) (figure 
6.13-C) wild-type constructs of EP153R expressed in uninfected cells. Localisation of this di-
arginine mutant to the ER suggests that the substitution of di-lysine for di-arginine has not 
disrupted any motifs causing the protein to be retained within the ER. However, since the di-
arginine mutant is also an ER retention motif, and arginine has the same charge and 
hydrophobicity as lysine, it is not unexpected that no change in localisation was seen. Since 
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expression of the di-alanine substitution mutant was not detected, and only the 5 amino acid 
EP153R deletion mutant was expressed in which only one of the three di-lysine repeats was 
deleted, conclusions cannot be drawn as to whether or not the three di-lysine motifs at the 
N-terminal end of EP153R play a role in its retention to the ER in uninfected cells.  
To ascertain whether the N-terminal cytoplasmic end was cleaved from EP153R in ASFV-
infected cells, dual-tagged constructs were cloned. The reasoning was that if cleavage was 
occurring, either only the C-terminal epitope tag would be detected when EP153R was 
expressed in ASFV-infected cells, or in the same manner as CD2v, two separate fragments 
would be detected by Western blot and the two tags would localise differently by 
immunofluorescence. Since the difference in size between EP153R in ASFV-infected and 
uninfected cells is so small (~ 2 kDa), it seemed probable that any cleavage product would be 
too small to remain stable on its own and may be degraded. Therefore it was predicted that 
both tags would be detected in uncleaved EP153R expressed in uninfected cells while in 
ASFV-infected cells, where EP153R had undergone additional processing, only the 
C-terminal tag would be detected. On investigating the expression of dual-tagged EP153R 
constructs in both ASFV-infected and uninfected cells, however, the results varied depending 
both on the epitope tag and its position.  
In uninfected Max cells, the C-terminal V5 epitope tag of dual-tagged EP153R construct 
CMV-FLAG-EP153R-V5-pcDNA3 (C-FEV) was detected by Western blot (figure 6.10) and 
immunofluorescence (figure 6.13-A,B). The N-terminal V5 epitope tag of CMV-V5-
EP153R(pig)-HA-pTriEx (C-VEH) was detected by immunofluorescence (figure 6.13-C) but 
not by Western blot (figure 6.11). However, their corresponding C-terminal HA tag and N-
terminal FLAG tags, respectively, were not detected by either method, and no expression of 
CMV-FLAG-EP153R-HA-pcDNA3 (C-FEH) was detected. 
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The only construct where both N- and C-terminal EP153R expression was detected was 
ASFV-FLAG-EP153R-V5-pcDNA3 (A-FEV), where both the N-terminal FLAG tag and 
C-terminal V5 tag were detected both by Western blot (figure 6.10) and immunofluorescence 
(figure 6.12). The fragments detected through labelling of the N-terminal FLAG tag and the 
C-terminal V5 tag by Western blot were approximately the same size, and the labelled tags 
co-localised by immunofluorescence. This suggests that these tags were both present on an 
intact full-sized protein which localised in infected cells in punctate staining throughout the 
cytoplasm and at the cell surface. However, expression of the C-terminal V5 tag was 
considerably stronger than that of the N-terminal FLAG tag both by Western blot and 
immunofluorescence. It is possible that labelling for the V5 tag detected both a full-length 
form of EP153R, and a form where the FLAG tag and some of the N-terminus had been 
cleaved. As such, detection of both epitope tags and their co-localisation does not preclude 
the theory that the N-terminal end of EP153R undergoes additional processing or cleavage in 
ASFV-infected cells. When EP153R is detected at around 38 kDa by Western blot, there are 
at least two bands detected close together at this size in all constructs, suggesting different 
modified forms of the protein. These may be forms which have undergone differential 
processing of their N-terminal ends. 
The variation in expression of dual-tagged and mutant EP153R constructs resulting from 
changes to their amino termini and to different combinations of epitope tags suggests that 
EP153R as expressed by these constructs may be unstable, and that the addition of epitope 
tags changes either folding or stability of the protein. For example, the FLAG-EP153R-V5 
form seems particularly stable, especially in ASFV-infected cells, while no constructs with a 
C-terminal FLAG tag were ever detected, suggesting this form is highly unstable. Despite 
some conformations of EP153R and epitope tags not being detected by Western blot or 
immunofluorescence, the expressed size and localisation patterns of EP153R detected by 
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these methods were constant across ASFV-infected cells and uninfected cells when 
expression was successfully detected. 
While the potential N-terminal processing of EP153R in ASFV-infected cells has been 
suggested here as a reason for differences in localisation and size of EP153R between 
infected and uninfected cells, other explanations should be considered. Different post-
translational modifications such as phosphorylation, acetylation, methylation, ubiquitination 
and sumoylation may account for the size difference observed. Additionally, the association 
of another virus protein or host protein induced by viral infection may be required for cell 
surface transport of EP153R, accounting for its cell surface localisation only being observed 
in ASFV-infected cells. 
Hurtado et al.’s (2011) study found that in human and mouse cells transfected with a plasmid 
expressing EP153R from ASFV BA71V (genotype I), up-regulation of surface MHC class I 
expression resulting from stimulation with PMA/ion was reduced when compared with 
stimulated cells transfected with an expression vector control. From this they concluded that 
EP153R inhibits up-regulation of MHC class I in infected cells. They constructed mutants of 
EP153R and further concluded that the C-type lectin extracellular domain was required, and 
that the RGD motif within this domain was essential to this function. As a control, they used 
an empty expression vector, but did not include unstimulated cells as a baseline of MHC 
class I expression.  
In an extension of this study, Max cells were transfected with plasmid vectors expressing 
EP153R from ASFV Benin 97/1 (genotype I) and ASFV Georgia 2007 (genotype II) as well 
as viral protein VP30. While pcDNA3 and pTriEx were also included as unstimulated 
transfection controls, a plasmid expressing VP30 was included since firstly, this construct 
was cloned with an HA tag to allow gating for transfected cells only, which was not possible 
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for the empty vectors, and secondly, as an ASFV protein, it would provide a measure of the 
effect that transfection with a plasmid expressing a viral protein not predicted to directly 
influence SLA-I expression could exert indirectly. As for Hurtado et al.’s (2011) study, a 
significant reduction in up-regulation of SLA-I in response to stimulation with PMA/ion was 
seen in cells transfected with a plasmid expressing EP153R (Benin). However, in cells 
transfected with plasmids expressing EP153R (Georgia) and VP30 there was no significant 
reduction in SLA-I up-regulation in response to stimulation with PMA/ion compared to 
stimulated untransfected cells.  
In cells stimulated with IFN-γ a similar pattern was observed; transfection with plasmids 
expressing all three ASFV proteins lead to a significant reduction of up-regulation in 
response to stimulation compared to controls. This reduction was greatest in cells transfected 
with the plasmid expressing EP153R (Benin), and there was no significant difference 
between the level of reduction seen in cells transfected with plasmids expressing EP153R 
(Georgia) or VP30. Thus, while these results concur with those of Hurtado et al. (2011) in 
that up-regulation of MHC class I in cells stimulated with PMA/ion is inhibited in cells 
transfected with EP153R from an isolate of ASFV in genotype I, the results suggest that same 
is not necessarily true of cells transfected with a plasmid expressing EP153R from other 
isolates or genotypes of ASFV. Additionally, up-regulation of MHC class I expression in 
response to stimulation with IFN-γ is also reduced in cells transfected with a plasmid 
expressing another viral protein (VP30) not associated with modulation of host MHC class I 
expression. From this, is can be reasoned that while EP153R from ASFV genotype I isolates 
does appear to play a role in modulation of host MHC class I expression, this effect is not 
universal across ASFV isolates. Some level of this reduction of MHC class I expression 
appears to be induced by transfecting stimulated cells with a plasmid expressing a protein of 
viral origin. Transfection of a plasmid containing viral DNA may trigger cytoplasmic DNA 
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sensors within the transfected cell, possibly via binding of STING to plasmid or viral DNA 
(Abe et al., 2013). The immune response induced by cytoplasmic DNA sensors includes the 
production of type I IFNs and pro-inflammatory cytokines (Yoneyama & Fujita, 2010). 
However, since type I IFNs and pro-inflammatory cytokines stimulate up-regulation of MHC 
class I expression (Zhou, 2009), they would probably have a synergistic rather than 
antagonistic effect on the stimulation of MHC class I by PMA/ion. Further work would be 
required to establish how transfection with a plasmid expressing VP30 caused a decrease in 
the MHC class I response to PMA/ion stimulation. However, expression of the viral protein 
encoded by the plasmid appears more likely than the presence of cytosolic viral or plasmid 
DNA to interfere with the induction of MHC class I through stimulation with pro-
inflammatory cytokines. 
6.4. Conclusions 
Viral C-type lectin protein EP153R expressed in ASFV-infected cells was shown to localise 
at the cell surface and in a punctate pattern through the cytoplasm. In contrast, in uninfected 
cells EP153R was shown to localise within the ER and no expression was detected at the 
plasma membrane. Neither EP153R nor CD2v appeared to co-localise with SLA-I in the 
cytoplasm. Further work would be required to determine if the proteins interact with SLA-I at 
the plasma membrane. Both the fully modified and deglycosylated forms of EP153R 
expressed in ASFV-infected cells are ~ 2 kDa smaller than EP153R expressed in uninfected 
cells. This difference in size is observed in cells treated with tunicamycin, which prevents 
protein transport from the ER. This indicates that the modification in ASFV-infected cells 
occurs within the ER. Investigations into whether the processing undergone in ASFV-
infected cells involved the cleavage of three putative ER retention motif di-lysine motifs at 
the N-terminal end of EP153R under conditions of ASFV infection did not yield conclusive 
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results. However, higher observed expression of the C-terminal V5 epitope tag of dual-tagged 
ASFV-FLAG-EP153R-V5-pcDNA3 (A-FEV) than the N-terminal FLAG epitope tag lends 
support to the hypothesis that the N-terminal end of EP153R may undergo some level of 
cleavage or processing in ASFV-infected cells.  
Transfection of Max cells with EP153R from ASFV Benin 97/1, a genotype I isolate, lead to 
significantly reduced up-regulation of SLA-I in response to stimulation with PMA/ion, but no 
significant reduction was seen in cells transfected with a plasmid expressing EP153R from 
ASFV Georgia 2007, an isolate from genotype II. In cells stimulated with IFN-γ, transfection 
with EP153R from ASFV Georgia 2007 and ASFV Benin 97/1 both lead to a significant 
reduction in up-regulation of SLA-I, though this reduction was stronger in cells transfected 
with a plasmid expressing EP153R from ASFV Benin 97/1. There was no significant 
difference in the reduction of SLA-I up-regulation between cells transfected with a plasmid 
expressing ASFV transfection control protein VP30 and EP153R from ASFV Georgia 2007 
on stimulation with either PMA/ion or IFN-γ.  
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Chapter 7 
7 Discussion and Future Work 
The MHC class I antigen presentation pathway alerts cells of the immune system to infection 
via presentation of viral antigens on the surface of infected cells. In response, viruses have 
evolved various methods of overcoming detection by the MHC class I through down-
regulation of all stages of the pathway. Thus, a vital part of understanding the effect of a virus 
on host immune response in order to develop effective vaccines and antivirals is an 
understanding of how the virus may modulate expression of MHC class I molecules at the 
cell surface. The aims of this project were to expand on current knowledge of the effect of 
ASFV infection on modulation of host MHC class I expression and to investigate the role of 
two viral proteins, EP153R and CD2v, in this modulation. This was achieved by firstly using 
flow cytometry to investigate changes in surface expression of the porcine MHC class I 
molecule, SLA-I, on infection with three isolates of ASFV, as well as mutants and 
recombinants of these isolates with or without intact genes for EP153R and CD2v. Secondly, 
the stage of the SLA-I antigen presentation pathway affected by ASFV infection was 
explored by employing qRT-PCR to investigate changes in transcription of SLA-I genes, 
radiography to measure changes in protein synthesis, and flow cytometry and 
immunofluorescence were used to study rates of internalisation of SLA-I molecules from the 
plasma membrane. Finally, bioinformatics and expression vector constructs were used to 
characterise the function, localisation and expression dynamics of EP153R. Functional motifs 
in EP153R and host or viral proteins with similarities in sequence were identified using 
amino acid sequence search databases available from international research institutes. A 
protein structure modelling tool which utilises these same databases was used to predict the 
3D structure of EP153R and the position of crucial domains within this structure. Plasmids 
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expressing EP153R allowed investigations into the cellular expression and localisation of the 
protein in uninfected and ASFV-infected cells, and also the effect of EP153R on SLA-I 
expression in isolation from other ASFV proteins.   
7.1. Furthering investigations into the effect of ASFV on expression of 
SLA-I 
A paper published shortly after this project began steered its direction into the investigation 
of the role of viral C-type lectin protein EP153R in the modulation of host MHC class I. 
Hurtado et al. (2011) showed that EP153R, and in particular its C-type lectin domain, 
inhibited the up-regulation of MHC class I in response to both stimulation with PMA and 
ionomycin and infection with ASFV. This paper proposed that EP153R binds directly to 
SLA-I, and by doing so prevents up-regulation of surface expression in response to infection. 
The authors did not, however, suggest the mechanism by which up-regulation was inhibited 
after binding, nor did they provide evidence such as observed co-localisation in confocal 
microscopy images or immunoprecipitation studies to confirm that this binding takes place. 
As such, Hurtado et al.’s (2011) study left scope for further investigations into whether 
EP153R does in fact bind SLA-I, and at what stage of the MHC class I antigen presentation 
pathway modulation of expression takes place. 
In addition to advancing the results of Hurtado et al.’s (2011) study on EP153R, the work 
carried out in this thesis aimed to advance knowledge of the overall effect of ASFV on 
SLA-I. Previous studies did not provide a cohesive conclusion on how infection with ASFV 
affects SLA-I expression as results varied by ASFV isolate tested and cell type infected 
(Gonzalez-Juarrero et al., 1992b; Vallée et al., 2001; Netherton et al., 2006; Hurtado et al., 
2011). 
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7.2. Developing a protocol for investigating the effects of ASFV on 
SLA-I expression 
Investigations into the effect of ASFV on host cell processes are routinely carried out in bone 
marrow derived macrophages (BMDM) since these cells can be harvested in sufficient 
quantities for more complex experiments. Macrophages have been shown to require 3-5 days 
of maturation in order to increase susceptibility to infection with ASFV, and levels of SLA-I 
expression at the surface of macrophages has also been shown to depend on time spent in 
culture (Gonzalez-Juarrero et al., 1992b; McCullough et al., 1997). Before beginning 
investigations into the effect of ASFV on host SLA-I expression, in Chapter 4.2.1 optimal 
times for BMDM maturation and ASFV infection time were established for maximum 
expression of SLA-I in BMDM and differentiation of expression between treatments. SLA-I 
expression in uninfected BMDM was found to peak at five days of maturation time in culture. 
In Chapter 4.2.2 surface expression of SLA-I in ASFV-infected cells was found to be 
maximal at 16 hours post-infection, and beyond this time point cell death became a 
compounding factor in experiments. For these reasons, the majority of work carried out in 
this thesis was performed on BMDM matured for 5 days post-harvest, infected for 16 hours 
with ASFV. Standardising cell culture conditions and length of infection also allowed direct 
comparison of results from different experimental methods such as flow cytometry, 
immunofluorescence and radiography. 
The two principal methods used in this thesis to investigate changes in expression of host and 
viral proteins are flow cytometry and immunofluorescence with observation by confocal 
microscopy. Changes in levels of protein expression as a result of ASFV infection are readily 
quantified by flow cytometry. Additionally, the application of gating allows control over 
which cells within a population are analysed, for example, ASFV-infected cells only. 
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Although results obtained from confocal microscopy are not as readily quantified, this 
method has the advantage that changes in protein expression in individual cells can be 
visualised, and infected cells can be identified by labelling of viral proteins.  
7.2.1. Using mutant isolates of ASFV to investigate the role of EP153R in 
modulation of SLA-I expression 
Preliminary experiments were carried out in which changes in SLA-I surface expression were 
measured by flow cytometry in BMDM infected with naturally attenuated field isolate ASFV 
NH/P68, in which the gene for EP153R is disrupted. Two recombinants of this isolate were 
also used in the infection studies, and in one of these, ASFV NH/P68 Rec 4, the gene for 
EP153R is restored. No significant difference was seen in levels of surface SLA-I expression 
between cells infected with ASFV NH/P68 and NH/P68 Rec 4 (Chapter 4.2.4). Additionally, 
when Vero cells were infected with tissue culture adapted isolate BA71V with an intact wild-
type gene for EP153R and a mutant with the gene for EP153R deleted in Chapter 4.2.7, there 
was again no detected difference in SLA-I expression at the surface of cells infected with 
either isolate. These isolates were the only ones available for which a parental and 
recombinant existed, one with an intact gene for EP153R and one without. Further 
investigations into the localisation and expression of EP153R using expression vectors 
transfected into uninfected and ASFV-infected cells were carried out as described in Chapter 
6.2.1 as another means of determining if this protein does play a role in modulation of SLA-I 
expression.  
The results of Chapter 4.2.4  suggested that instead of EP153R, viral protein CD2v may have 
a role in modulating cell surface expression of SLA-I. Continuing experiments into the effect 
of ASFV infection on SLA-I included studying the role of CD2v using virulent ASFV 
isolates Benin 97/1 and Malawi Lil 20-1, and ΔCD2v deletion mutants of these isolates.  
 268 
 
7.2.2. Using mutant isolates of ASFV to investigate the role of CD2v in 
modulation of SLA-I expression 
The ASFV gene EP402R is directly downstream from EP153R, and encodes viral protein 
CD2v which is essential for haemadsorption of red blood cells around ASFV-infected 
macrophages (Rodríguez et al., 1993; Borca et al., 1998; Goatley & Dixon, 2011). It has been 
proposed that EP153R also plays a role in this process by acting as a stabilising molecule in 
the interaction between CD2v on the surface of infected cells and its ligand in erythrocytes 
(Galindo et al., 2000). Non-haemadsorbing isolate ASFV NH/P68 has a disrupted gene for 
CD2v as well as for EP153R. In both recombinant NH/P68 Rec 4, and in another 
recombinant, NH/P68 Rec 34, EP402R is partially restored, expressing a form of CD2v with 
a deletion of its C-terminal end and modified form of the region up to the C-terminal end, 
abrogating the proline-rich repeats of wild-type CD2v.  
While using ASFV NH/P68 and NH/P68 Rec 4 to investigate the role of EP153R in the 
modulation of SLA-I, ASFV NH/P68 Rec 34 was also included as a control. However, in a 
preliminary study using BMDM from three pigs it was observed that expression of SLA-I 
was significantly higher in cells infected with ASFV NH/P68, which did not express CD2v, 
than those infected with NH/P68 Rec 4 and NH/P68 Rec 34, both of which expressed the 
modified form of CD2v. This implicated CD2v in modulation of SLA-I expression at the cell 
surface. To further investigate this, two virulent ASFV isolates were used in further infection 
studies; ASFV Benin 97/1 and Malawi Lil 20-1, as well as deletion mutants of these isolates, 
ASFV Benin 97/1 ΔCD2v and Malawi Lil 20-1 ΔCD2v which lacked the EP402R gene but 
had an intact gene for EP153R. SLA-I expression in BMDM (Chapter 4.2.4) and PBMC 
(Chapter 4.2.6) primary cell cultures harvested from a number of pigs and infected with 
ASFV NH/P68, ASFV Benin 97/1 and Malawi Lil 20-1 and their mutants/recombinants were 
analysed by flow cytometry. The results of these studies showed that modulation of SLA-I 
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expression on the surface of cells infected with ASFV varies significantly dependent of the 
virus isolate, the cell type infected, and the individual animal from which cells are harvested. 
A significant difference was seen in surface SLA-I expression between BMDM infected with 
virulent wild-type isolate ASFV Benin 97/1 and deletion mutant Benin 97/1 ΔCD2v, 
suggesting that CD2v does play a role in modulation of SLA-I expression. With the inclusion 
of more replicates, no statistically significant difference in surface SLA-I expression was 
seen between cells infected with ASFV NH/P68 and its recombinants, NH/P68 Rec 4 and 
NH/P68 Rec 34, although there is a trend for surface expression of SLA-I to be lower in cells 
infected with recombinants ASFV NH/P68 Rec 4 and NH/P68 Rec 34 than in cells infected 
with parental NH/P68. As discussed previously, the form of CD2v expressed by these 
recombinants lacks the proline-rich repeats in the cytoplasmic domain of wild-type CD2v. 
These proline-rich repeats have been shown to be necessary and sufficient for the binding of 
CD2v to host adaptor protein mAbp1 (Kay-Jackson et al., 2004). Protein mAbp1 is predicted 
to interact with transport vesicles while they are loaded at the Golgi, preventing premature 
release of these vesicles before they are correctly loaded with proteins for transport to the cell 
surface (Larbolette et al., 1999). The proposed function of CD2v when bound to mAbp1 is 
the modulation of protein transport to the surface of ASFV-infected cells (Kay-Jackson et al., 
2004). As such, differences in surface SLA-I expression observed between cells infected with 
isolates of ASFV expressing or not expressing intact wild-type CD2v may be caused by the 
role of CD2v in maintaining vesicular transport in ASFV-infected cells rather than a direct 
effect on SLA-I. This role of CD2v would result in higher expression of proteins, including 
SLA-I, at the surface of cells infected with isolates of ASFV with an intact gene for CD2v. 
Future work to confirm this hypothesis would include infecting BMDM with ASFV 
Benin 97/1 and deletion mutant Benin 97/1 ΔCD2v, and then tracking differences in transport 
of cellular proteins which have previously been shown to still be transported to the surface of 
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ASFV-infected cells, such as cell surface markers CD45, CD203a and CD163 (Lithgow et 
al., 2014). 
Subsequent to the variation in surface SLA-I modulation observed between the infection 
experiments, investigations were initiated into studying the mechanism by which ASFV 
modulates SLA-I, with an aim of elucidating the reason for the variation in expression of 
SLA-I observed following infection with different ASFV isolates. 
7.2.3. Studies on the transcription, synthesis and internalisation of SLA-I in 
ASFV-infected cells 
To investigate how infection with different ASFV isolates may modulate cell surface 
expression of SLA-I, transcript levels of SLA-I mRNA for SLA-1, SLA-3, SLA-5 and SLA-7 
were examined by qPCR. Synthesis of new SLA-I proteins was assessed by [35S] 
radiolabelling and internalisation of SLA-I from the cell surface was investigated by both 
flow cytometry and immunofluorescence.  
Up-regulation of MHC class I transcription as a result of infection occurs in response to 
transcription factor NFκB signalling, stimulated by IFN-γ (Blanar et al., 1989; Johnson & 
Pober, 1990; Boehm et al., 1997; van den Elsen et al., 1998). A number of viruses have been 
shown to encode proteins which interfere with this up-regulation. Some virus proteins 
directly inhibit transcription of components of the MHC class I pathway, including the heavy 
chain, such as protein E1A of human oncogenic adenovirus 12 (Ad12). Other viruses 
including HCMV and MCMV may disrupt the IFN-γ-induced up-regulation of genes, thus 
indirectly inhibiting up-regulation of MHC class I gene transcription (Othman & Yusof, 
2012). In Chapter 5.2.1.3, no significant changes in SLA-I mRNA transcripts were observed 
in BMDM infected with ASFV isolates Benin 97/1, Malawi Lil 20-1, NH/P68 or any 
mutants/recombinants of these isolates at 16 hpi. Additionally, changes in SLA-I mRNA 
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transcripts did not correlate with changes observed in cell surface expression of SLA-I in 
response to ASFV infection when results from cells from the same animal were compared. 
This suggests that modulation of SLA-I expression by ASFV does not occur at the level of 
transcription of SLA-I genes, but further experiments are required which cover a range of 
time points to fully investigate any effect of ASFV on levels of SLA-I transcripts over the 
course of infection. 
Another means by which viruses modulate expression of MHC class I is by targeting MHC 
class I molecules for degradation by the proteasome or lysosomes. For example, MCMV 
proteins US2 and US11 cause rapid degradation of newly-synthesised MHC class I heavy 
chains by translocating them from the ER into the cytosol, where they are deglycosylated and 
degraded by the proteasome, while MCMV protein Gp48 and equine herpesvirus type 1 
(EHV-1) protein pUL56 bind MHC class I molecules and redirect their transport into 
lysosomes (Vossen et al., 2002; Hewitt, 2003; Huang et al., 2014).  
The results from Chapter 4.2.4 indicated that of the ASFV isolates used, Benin 97/1 caused 
the greatest up-regulation of surface SLA-I expression, to levels similar to those induced by 
the SLA-I up-regulation control, IFN-γ. There was also a significant difference between 
SLA-I expression levels in cells infected with ASFV Benin 97/1 and Benin 97/1 ΔCD2v. 
Rates of SLA-I protein synthesis were therefore focussed on comparing infections with 
ASFV Benin 97/1 and Benin 97/1 ΔCD2v, and stimulation of SLA-I expression with IFN-γ. 
The results of Chapter 4.2.3 demonstrated that infection with ASFV Benin 97/1 did not cause 
an overall decrease in protein synthesis in BMDM. To investigate changes in SLA-I 
synthesis, a preliminary investigation entailed radiolabelling cells for different 4 hour 
intervals over 16 hours and detection of radiolabelled SLA-I by immunoprecipitation, 
followed by gel electrophoresis and autoradiography. This revealed no significant change in 
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synthesis of SLA-I in response to infection with ASFV Benin 97/1or Benin 97/1 ΔCD2v over 
the 16 hours of the experiment (Chapter 5.2.2). As expected, the raw data indicated an 
increase in the incorporation of [35S]-labelled SLA-I over 16 hours in cells stimulated with 
IFN-γ. These results indicate that there was no overall increase in SLA-I protein synthesised 
in cells infected with these isolates of ASFV during the course of the infection. However, 
high between-animal variation in SLA-I expression was observed in response to infection 
with ASFV in other experiments performed. Therefore this result is not considered 
conclusive and further repeats of this experiment are required. As an additional experiment, 
the protocol could be modified to a pulse-chase, with the [35S] labelling removed after each 
pulse period as before, but instead of cells being harvested, they would be further incubated 
in a chase to the 16-hour time-point to allow turnover of the newly synthesised SLA-I. This 
would provide valuable information on the stability and turnover of SLA-I in ASFV-infected 
cells.   
The final stage of exploring at what stage of the MHC class I pathway modulation by ASFV 
occurs was to investigate internalisation of SLA-I from the plasma membrane. Increased 
expression of MHC class I at the surface of an infected cell could be due to a down-
regulation of internalisation of MHC class I, diluting the signal of “non-self” peptides 
presented to CTLs amongst the “self” peptides. A decrease in surface expression might be 
caused by targeting of surface MHC class I molecules for internalisation and either 
sequestration in the trans-Golgi network or entry into the late endosomal pathway. KSHV 
proteins K3 and K5, and HIV-1 protein Nef, both cause internalisation of surface 
MHC class I via clathrin-mediated endocytosis. However, while K3 and K5 target 
MHC class I to the endosomal pathway for degradation, Nef causes the MHC class I 
molecules to be sequestered in the trans-Golgi network (Hewitt, 2003; Hansen & Bouvier, 
2009).  
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An experimental protocol was designed to evaluate the rates of incorporation of new SLA-I 
molecules at the surface of ASFV-infected cells and the internalisation of existing molecules 
from the surface over the course of a 16-hour infection. The results of Chapter 5.2.3 showed 
that both the internalisation of existing molecules and incorporation of new molecules at the 
cell surface continued in the same steady state as mock-infected cells in cells infected with 
ASFV isolates Benin 97/1, Benin 97/1 ΔCD2v and Malawi Lil 20-1. In BMDM infected with 
ASFV NH/P68 and Malawi Lil 20-1 ΔCD2v a significant increase in internalisation of SLA-I 
from the cell surface was observed. Incorporation of new SLA-I molecules increased over 16 
hours at the surface of cells stimulated with IFN-γ and cells infected with ASFV Benin 97/1. 
Further replicates of these experiments would better establish the validity of this observation.  
Confocal microscopy showed differences in levels of SLA-I expression in individual infected 
cells. The factors that influenced this were not further investigated but might be related to 
differences in the activation state of infected macrophages or stage of the virus replication 
cycle at which cells were fixed. However, immunofluorescence revealed no changes in 
localisation of internalised SLA-I to suggest sequestration of the internalised molecules in 
ASFV-infected cells compared with mock-infected cells. 
The results obtained from these investigations into the effect of ASFV on SLA-I surface 
expression, transcription, synthesis and internalisation have shown that infection with ASFV 
does exert an influence on SLA-I expression at the surface of infected cells, dependent on 
ASFV isolate and cell type used for the infection study. They also show that ASFV protein 
CD2v appears to play a role, though possibly indirectly, on this modulation. Transcript levels 
of SLA-I mRNA, extracted at the same 16 hpi time point as surface SLA-I expression was 
measured by flow cytometry, indicated that transcription is not the point at which SLA-I 
expression is modulated. Preliminary work suggests that synthesis of new SLA-I molecules is 
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not affected by infection with ASFV Benin 97/1, although further work is required to draw 
definite conclusions on this. Finally, increases in SLA-I at the plasma membrane have been 
shown to be the result of the incorporation of new SLA-I molecules rather than due to a 
down-regulation of internalisation of SLA-I from the plasma membrane in ASFV-infected 
cells. 
These infection studies have provided important new information into the modulation of 
SLA-I expression by ASFV, and the potential role of CD2v in this modulation. However, 
infection studies did not yield data on the function of EP153R or its effect on SLA-I 
expression. As such, characterisation of viral protein EP153R and its role in SLA-I 
modulation was conducted by use of EP153R constructs cloned into expression vectors. 
7.3. Localisation, processing and stability of EP153R 
Previous work into the localisation and processing of EP153R described it to be located 
within the ER in uninfected Vero cells (Hurtado et al., 2011), and to be expressed as a 
50 kDa glycoprotein or an 18 kDa unmodified product in Vero cells infected with ASFV 
BA71V (Galindo et al., 2000). EP153R was cloned into expression vectors with a C-terminal 
HA epitope tag to enable antibodies against this tag to be used for studies into its localisation 
and processing in infected and uninfected cells. The localisation of EP153R relative to a 
range of cellular markers in uninfected transiently transfected Max and Vero cells as shown 
in Chapter 6.2.3 confirmed Hurtado et al.’s (2011) observation that EP153R localised with 
markers for the ER, with no expression detected on the cell surface. Observations were 
extended to determine the localisation and expression of EP153R in ASFV-infected cells. In 
contrast to the results observed in uninfected cells, in Max and Vero cells transiently 
transfected with plasmids expressing EP153R under control of its own promoter and infected 
with tissue-culture adapted stains of ASFV, EP153R localised in a punctate pattern 
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throughout the cytoplasm and on cellular membranes including the plasma membrane. 
Additionally, a size difference was observed between EP153R expressed in infected and 
uninfected cells. Experiments carried out with EndoH, PNGaseF and tunicamycin treatments 
resulted in an observed decrease in mobility of EP153R, confirming that the protein is 
glycosylated. However, in all treatments, the EP153R protein expressed in ASFV-infected 
cells ran with a mobility suggesting it was 2 kDa smaller than the form expressed in 
uninfected cells (Chapter 6.2.2). This analysis indicated that EP153R undergoes additional 
processing in ASFV-infected cells. The largest form of EP153R detected was approximately 
60 kDa and this was resistant to EndoH, indicating that it had progressed through the 
secretory pathway beyond the trans-Golgi network. A greater amount of this form of the 
protein was detected in Max cells compared to Vero and in infected compared to uninfected 
cells. Therefore, these results were consistent with data from confocal microscopy showing a 
greater localisation of EP153R beyond the ER in infected cells.  
The results on the localisation and size difference of EP153R in infected compared to 
uninfected cells suggested that in infected cells cleavage of EP153R close to the N-terminus 
may remove an ER localisation signal and result in transport of the protein through the 
secretory pathway to the cell surface. Three di-lysine motifs are present close to the N-
terminus and were investigated as possible ER retentions motifs. Investigations into whether 
differences in localisation of EP153R between ASFV-infected and uninfected cells was due 
to these putative dilysine ER retention motifs did not yield results as mutant forms of 
EP153R with N-terminal deletion or substitution mutations were not successfully expressed. 
As a further method to investigate whether the N-terminal of EP153R is cleaved or processed 
in infected cells, dual-tagged constructs were cloned into expression vectors. 
Immunofluorescence and Western blot studies of their expression in Chapter 6.2.1 showed 
that dual-tagging seems to confer instability on EP153R constructs since in only one 
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construct, ASFV-FLAG-EP153R-V5-pTriEx, were both N- and C-terminal tags successfully 
detected. From expression of this dual-tagged construct it appears that both the N- and 
C-termini of EP153R co-localise in infected cells, but that the C-terminal tag is more highly 
expressed, suggesting that an intact protein is expressed and then undergoes processing which 
abrogates detection of the N-terminal tag. A future study would include tunicamycin 
treatment of cells transfected with ASFV-FLAG-EP153R-V5-pTriEx and infected with 
ASFV, followed by analysis by Western blot. If N-terminal processing of EP153R occurs, 
labelling of the C-terminal V5 tag would be expected to detect two bands with a 2 kDa 
difference between them, representing both a full length and a processed form of the protein, 
while labelling for the N-terminal FLAG tag would detect only the full-length form. The 
shorter processed form would be unlikely to be successfully detected. This processing of 
EP153R is likely be important to its function in ASFV-infected cells, and is probably carried 
out by an enzyme encoded or induced by the virus.  
The level of instability in EP153R indicated by variable detection of dual-tagged protein 
constructs suggests that it may require another protein either as a chaperone or to form a 
heterodimer in order to function in ASFV-infected cells. The C-type lectin domain of 
EP153R is similar to those of the NK cell receptor family of proteins, all of which exist as 
homo- or heterodimers (Sawicki et al., 2001; Natarajan et al., 2002; Bartel et al., 2013). This 
lends credence to the theory that EP153R may require another protein, either or host of viral 
origin, to stabilise it within a heterodimer. Hurtado et al.’s (2011) model of EP153R shows 
the molecule as a homodimer. The apparent instability of EP153R observed in this study 
suggests that it does not form a homodimer, but this cannot be precluded as the epitope tags 
may interfere with its ability to successfully dimerise.  
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Future work into the function of EP153R should include bait-prey studies such as yeast two-
hybrid or avidity-based extracellular interaction screening (AVEXIS) to identify any binding 
partner of EP153R. A proteomics approach could also be considered, with EP153R and its 
host or viral binding partner co-immunoprecipitated, and the bound peptides identified by 
mass spectrometry. 
Additionally, future work into the processing of EP153R could include a radiolabelling 
experiment where both ASFV-infected and uninfected cells are transiently transfected with 
EP153R and then labelled with [35S] for time points of a few minutes up to 20 min to try to 
determine if EP153R undergoes processing rather than additional post-translational 
modification, and the point at which this occurs in infected cells. Some preliminary work was 
carried out with time points from 20 min to 1 hour, but full processing of EP153R was found 
to have occurred by 20 min. Treatment of ASFV-infected cells transfected with EP153R with 
a range of protease inhibitors could also indicate if processing of the protein is carried out by 
a virus-induced protease. 
EP153R was postulated by Hurtado et al. (2011) to directly bind SLA-I in its function of 
modulating expression of SLA-I. In Chapter 6.2.3, immunofluorescence studies with markers 
for SLA-I did not find EP153R to localise with SLA-I in the cytoplasm of infected or 
uninfected cells. Both proteins are expressed on the surface of ASFV-infected cells, but it 
could not be determined if they co-localise. These results make it seem unlikely that EP153R 
and SLA-I bind to one another. The localisation of CD2v was also investigated relative to 
localisation of SLA-I in Chapter 6.2.4, and as for EP153R, no co-localisation was detected 
either in the cytoplasm or on the plasma membrane of either infected or uninfected cells. This 
adds weight to the theory that while CD2v exerts an influence on the expression of SLA-I, 
this influence is not due to direct action of CD2v on SLA-I molecules. 
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7.4. Using transfection studies to investigate the effect of EP153R on 
expression of SLA-I 
Hurtado et al. (2011) reported that EP153R caused a reduction in up-regulation of MHC 
class I expression in response to stimulation with PMA and ionomycin and infection with 
ASFV. The results of Chapter 6.2.1 showed a similar significant reduction in up-regulation of 
SLA-I in cells transiently transfected with EP153R cloned from ASFV Benin 97/1 and 
stimulated with PMA and ionomycin or IFN-γ, but conversely found that this effect was not 
significant in cells transfected with EP153R cloned from ASFV Georgia 2007/1. Moreover, 
some inhibition of SLA-I up-regulation was observed in stimulated cells transfected with a 
plasmid expressing viral protein VP30, which is not predicted to exert any influence on 
SLA-I expression. This indicates that while EP153R does appear to inhibit the up-regulation 
of SLA-I in response to cytokine stimulation in uninfected cells, the scale of the influence 
exerted depends on the ASFV isolate from which EP153R was cloned. Moreover, at least part 
of this influence appears to result from transfection of cells with an ASFV protein, instead of 
being a direct effect of EP153R itself. Future work could include cloning the same genes for 
EP153R and VP30 into a plasmid without a mammalian promoter to drive transcription of the 
gene, and a version of the gene for VP30 without a translation initiation codon so the gene 
would be transcribed but not translated efficiently. This could unravel if an expressed ASFV 
protein is required to reduce the levels of SLA-I at the cell surface of cytokine-stimulated 
cells, or if this reduction is a result of AT-rich viral DNA within the plasmid or transcripts of 
the gene being detected by cytoplasmic DNA sensors. 
As discussed above, the processing and localisation of EP153R differ between ASFV-
infected and uninfected cells, which has implications for how effectively it is able to perform 
its function in uninfected cells. Studies of EP153R in isolation from other ASFV proteins 
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have value in terms of results being more straightforward to interpret without compounding 
viral factors, and any effect seen can be directly attributed to EP153R without the possibility 
that another ASFV gene may also be exerting an influence. However, no absolute 
conclusions on the localisation, processing or function of viral genes should be drawn without 
further confirmation in an infected cell system. 
This project was designed to investigate the role of viral protein EP153R in terms of its 
predicted role in host immune evasion and the possibility of its importance in development of 
rationally attenuated vaccines and anti-virals against ASFV. Suggestions have been made in 
the preceding sections for future work to continue investigations into both the 
characterisation of EP153R and the effect of ASFV infection on SLA-I. However, the results 
of this thesis have cast some doubt on Hurtado et al.’s (2011) theory that EP153R exerts a 
direct influence on expression of host SLA-I. Perhaps the most important suggestion for 
future work, in this case, may be to broaden the investigation into the function of EP153R, 
basing future studies on the similarity of the C-type lectin domain of EP153R to ligands of 
host NK cell activating receptors and the implication of this similarity. 
7.5. EP153R and host NK cell receptor ligand Clec2B 
Bioinformatic investigations into the amino acid sequence of EP153R in Chapter 3.2.2 
revealed that it is highly variable across isolates. However, the C-type lectin domain is more 
conserved than the cytoplasmic domain and the first 16 amino acids of the C-type lectin 
domain particularly are highly conserved across isolates. This region was found to have a 
high similarity to the C-type lectin domains of the NK cell receptor C-type lectin family, and 
in particular Clec2B (AICL) (Chapter 3.2.3). Clec2B is expressed on the surface of infected 
monocytes and functions as the cell surface ligand of activating NK cell receptor NKp80, 
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stimulating the secretion of pro-inflammatory cytokines IFN-γ and TNF-α (Welte et al., 
2006; Bartel et al., 2013).  
A strategy employed by other viruses, and herpesviruses in particular, to avoid the combined 
innate immune response of MHC class I presentation of “non-self” antigens and NK cell 
activation by “missing self” is to combine down-regulation of MHC class I with a down-
regulation of NK cell activating receptor ligands. This evasion response may be further 
enhanced by expression of an MHC class I homologue to reinforce both evasion strategies. 
MHC class I presentation of viral antigens on the cell surface is down-regulated by KSHV 
via the expression of a viral ligase encoded by genes K3 and K5 which targets MHC class I 
molecules for ubiquitinylation and lysosomal degradation (Ishido et al., 2000; Lodoen & 
Lanier, 2005; Thomas et al., 2008). The product of the K5 gene also targets NK cell receptor 
activating ligands, including Clec2B, for lysosomal degradation (Thomas et al., 2008). 
MCMV encodes at least three proteins which have been identified as down-regulating 
expression of ligands of activating NK cell receptor NKG2D (Jonjic et al., 2008). Other 
viruses encode homologues of MHC class I molecules on the surface of infected cells, such 
as HCMV protein UL18, which serves as another means of avoiding both CTL recognition of 
viral antigens presented by MHC class I molecules and the activation of NK cell killing due 
to the absence of MHC class I on the cell surface (Kim et al., 2008; Wilkinson et al., 2008). 
The similarity of the extracellular C-type lectin domain of EP153R to NK cell activating 
receptor ligand Clec2B might suggest that the function of EP153R involves evasion of NK 
cell activation in response to ASFV infection. One possibility is that EP153R acts as a decoy 
for binding of NK cell activating receptor NKp80, although this is not a strategy which has 
previously been reported as a method of host immune evasion in large DNA viruses. EP153R 
is apparently unstable as a monomer or homodimer when transfected into uninfected cell 
culture systems, suggesting that it requires another ASFV protein or a host protein not 
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expressed in cell culture lines for stability. EP153R may bind to Clec2B, which is expressed 
on the surface of activated monocytes and macrophages (Welte et al., 2006; Bartel et al., 
2013), forming an inactive heterodimer such as that depicted in figure 3.9 of Chapter 3.2.4, 
instead of the active Clec2B homodimer. The methods of identifying the binding partner of 
EP153R suggested in Chapter 7.3 would shed light on whether this is the case. The role of 
EP153R as a means of evading NK cell killing in ASFV infection has not been investigated 
in this thesis for reasons already discussed. However, the data presented here suggests it is 
worth prioritising in future studies into the function of the protein.  
7.6. Final conclusions 
This project has yielded new information on the effect of infection with ASFV on the 
expression of SLA-I both at the cell surface and within the cytoplasm of infected cells. The 
extent of modulation of SLA-I on infection with ASFV appears to vary depending on the 
isolate of ASFV and cell type used in the infection study, and high between-animal variation 
is seen in the primary cell cultures used for infection studies with field isolates of ASFV. 
Transcript levels of SLA-I mRNA were not seen to be affected by ASFV infection at 16 hpi, 
but analysis of further time points is required. A preliminary study indicated that synthesis of 
new SLA-I molecules is not up-regulated by infection with ASFV Benin 97/1 or 
Benin 97/1 ΔCD2v, although given the high levels of between-animal variation observed in 
other experiments, further replicates are required to confirm this conclusion. Internalisation 
of SLA-I from the plasma membrane was significantly up-regulated by infection with two 
ASFV isolates, NH/P68 and Malawi ΔCD2v, both of which lack an intact gene for viral 
protein CD2v. In experiments into the effect of ASFV infection on levels of SLA-I 
expression at the cell surface, CD2v was implicated in up-regulation of SLA-I expression, 
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possibly via binding to host adaptor protein mAbp1 and maintaining vesicular transport 
through host organelle rearrangements induced by ASFV infection.  
Viral C-type lectin protein EP153R was shown to exhibit differential localisation and 
processing in uninfected cells and cells infected with ASFV, with an additional stage of 
processing probably occurring at the N-terminal end of EP153R in cells infected with ASFV. 
EP153R shows signs of instability when expressed in transiently transfected cells, and may 
exist as a heterodimer with another ASFV or host protein in its natural state. There is 
potential for a substantial body of future work to be carried out into the function of EP153R 
in ASFV infection, with the most promising direction for research in investigating the 
relevance of the similarity of its C-type lectin domain to that of Clec2B, the host cell ligand 
of activating NK cell receptor NKp80. 
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